prednisolone has been researched along with Rheumatoid Arthritis in 1151 studies
Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.
prednisolone : A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the effect of 2 years of add-on prednisolone 5 mg/day on body weight and composition in patients with active rheumatoid arthritis (RA) aged 65+ and the relation with disease activity." | 9.69 | Changes in body weight and body composition in patients with active rheumatoid arthritis aged 65+ treated with 2-year low-dose add-on prednisolone in the randomised double-blind placebo-controlled GLORIA trial. ( Boers, M; Bos, R; Emmering, J; Eshuis, S; Güler-Yüksel, M; Human, A; Kok, MR; Kuijper, M; Molenaar, E; Reimann, F, 2023) |
| "The GLORIA (Glucocorticoid LOw-dose in RheumatoId Arthritis) pragmatic double-blind randomised trial compared 2 years of prednisolone, 5 mg/day, to placebo in patients aged 65+ with active RA." | 9.51 | Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial. ( Allaart, CF; Baudoin, P; Boers, M; Bos, R; Buttgereit, F; Cutolo, M; Da Silva, JA; Griep, EN; Hartman, L; Klaasen, R; Klausch, LT; Kok, MR; Lems, WF; Masaryk, P; Opris-Belinski, D; Paolino, S; Raterman, HG; Schilder, AM; Szekanecz, Z, 2022) |
| "In active early rheumatoid arthritis (RA), glucocorticoids are often used for bridging, due to the delayed action of methotrexate." | 9.51 | The Efficacy of Short-Term Bridging Strategies With High- and Low-Dose Prednisolone on Radiographic and Clinical Outcomes in Active Early Rheumatoid Arthritis: A Double-Blind, Randomized, Placebo-Controlled Trial. ( Baraliakos, X; Boeddeker, S; Braun, J; Christoph, HJ; Fendler, C; Igelmann, M; Klaassen-Mielke, R; Klink, C; Krause, D; Mai, A; Menne, HJ; Ose, C; Rau, R; Rudolf, H; Saracbasi-Zender, E; Schade-Brittinger, C; Schmid, A; Schmitz, E; Sonuc, N; Timmesfeld, N; Trampisch, HJ; Trampisch, U; Wassenberg, S, 2022) |
| "The GLORIA placebo-controlled trial found a favorable balance of benefit and harm for two years of prednisolone (5 mg/day) as add-on treatment for rheumatoid arthritis (RA) patients aged 65+." | 9.51 | Cost-effectiveness and cost-utility of add-on, low-dose prednisolone in patients with rheumatoid arthritis aged 65+: The pragmatic, multicenter, placebo-controlled GLORIA trial. ( Boers, M; Bos, R; Buttgereit, F; Coupé, V; Cutolo, M; Da Silva, J; El Alili, M; Hartman, L; Kok, MR; Lems, WF; Masaryk, P; Opris, D; Paolino, S; Szekanecz, Z, 2022) |
| "This study aimed to evaluate the short-term effectiveness and safety profiles of baricitinib and explore factors associated with improved short-term effectiveness in patients with rheumatoid arthritis (RA) in clinical settings." | 9.34 | Predictors for clinical effectiveness of baricitinib in rheumatoid arthritis patients in routine clinical practice: data from a Japanese multicenter registry. ( Asai, S; Hanabayashi, M; Hirano, Y; Ishiguro, N; Ishikawa, H; Kanayama, Y; Kaneko, A; Kato, T; Kobayakawa, T; Kojima, T; Nishiume, T; Sobue, Y; Suzuki, M; Takahashi, N; Terabe, K; Watanabe, T; Yabe, Y; Yokota, Y; Yoshioka, Y, 2020) |
| "Cross-sectional study in 42 patients with rheumatoid arthritis (29 women, aged 36-86 years) treated with 5 mg prednisolone/day, who had received prednisolone for ≥6 months (median: 66, range: 6-444 months)." | 9.24 | Adrenal insufficiency is seen in more than one-third of patients during ongoing low-dose prednisolone treatment for rheumatoid arthritis. ( Baslund, B; Borresen, SW; Feldt-Rasmussen, U; Friis-Hansen, L; Hansen, A; Hetland, ML; Hilsted, L; Klose, M; Locht, H; Lydolph, MC; Rasmussen, ÅK, 2017) |
| "5 mg/week, sulfasalazine 2 g/day, with initial prednisolone 60 mg/day) after 26 weeks in patients with early active rheumatoid arthritis (RA)." | 9.20 | Intensive combination treatment regimens, including prednisolone, are effective in treating patients with early rheumatoid arthritis regardless of additional etanercept: 1-year results of the COBRA-light open-label, randomised, non-inferiority trial. ( Boers, M; den Uyl, D; Kerstens, P; Lems, WF; Nurmohamed, M; ter Wee, MM; van Schaardenburg, D; Voskuyl, AE, 2015) |
| "Treatment with initial high-dose prednisolone and a combination of methotrexate (MTX) and sulfasalazine (SSZ) according to the COBRA regimen (Dutch acronym for combinatietherapie bij reumatoide artritis, 'combination therapy for rheumatoid arthritis'), has repeatedly been demonstrated to be very effective in early rheumatoid arthritis (RA)." | 9.20 | Initial high-dose prednisolone combination therapy using COBRA and COBRA-light in early rheumatoid arthritis. ( Boers, M; Lems, WF; Rasch, LA; van Tuyl, LH, 2015) |
| "To examine the long-term effects of early low-dose prednisolone use in patients with rheumatoid arthritis (RA) on cardiovascular (CV) morbidity and mortality." | 9.19 | Low-dose prednisolone treatment of early rheumatoid arthritis and late cardiovascular outcome and survival: 10-year follow-up of a 2-year randomised trial. ( Ajeganova, S; Hafström, I; Svensson, B, 2014) |
| "To analyse if predictors of radiographic progression differ between patients treated with or without prednisolone in early rheumatoid arthritis (RA)." | 9.19 | Rheumatoid factor and anti-CCP do not predict progressive joint damage in patients with early rheumatoid arthritis treated with prednisolone: a randomised study. ( Boonen, A; Engvall, IL; Hafström, I; Rönnelid, J; Svensson, B; van der Heijde, D, 2014) |
| "To conduct aphase II study to determine the efficacy and safety of BMS945429 in patients with active rheumatoid arthritis and an inadequate response to methotrexate." | 9.16 | A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate. ( Dimic, A; Liu, Y; Mease, P; Raskina, T; Shalamberidze, L; Smith, J; Strand, V; Xu, LA, 2012) |
| "To determine whether low-dose prednisolone affects body composition and bone mineral density (BMD) in patients with rheumatoid arthritis (RA), also considering inflammation and physical disability." | 9.15 | Treatment with low-dose prednisolone is associated with altered body composition but no difference in bone mineral density in rheumatoid arthritis patients: a controlled cross-sectional study. ( Brismar, K; Engvall, IL; Hafström, I; Tengstrand, B, 2011) |
| "To identify predictors of response to methotrexate (MTX) in early rheumatoid arthritis (RA)." | 9.15 | Predictors of response to methotrexate in early DMARD naive rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial. ( Bratt, J; Ernestam, S; Geborek, P; Petersson, IF; Saevarsdottir, S; Seddighzadeh, M; van Vollenhoven, RF; Wallin, H, 2011) |
| "Bucillamine (Buc), developed in Japan, is a disease-modifying antirheumatic drug (DMARD) which has been used to treat numerous patients with rheumatoid arthritis (RA) in Japan and Korea with favorable results." | 9.14 | A comparative study of the effects of bucillamine and salazosulfapyridine in the treatment of rheumatoid arthritis. ( Abe, M; Kinoshita, M; Nakajima, M; Ohara, H; Ueda, N, 2009) |
| "To investigate the effects of vitamin K2 (Vit K2) alone or in combination with etidronate and risedronate on bone loss, osteoclast induction, and inflammation in patients with rheumatoid arthritis (RA)." | 9.13 | Osteoclast inhibitory effects of vitamin K2 alone or in combination with etidronate or risedronate in patients with rheumatoid arthritis: 2-year results. ( Morishita, M; Nagashima, M; Takahashi, H; Takenouchi, K; Wauke, K, 2008) |
| "Bucillamine (Buc) is a disease-modifying antirheumatic drug (DMARD) developed in Japan, which has been used as one of the first-line DMARDs for the treatment of rheumatoid arthritis (RA) in Japan." | 9.12 | Efficacy profile of bucillamine in rheumatoid arthritis patients in a large observational cohort study, IORRA. ( Hara, M; Inoue, E; Iwatani, M; Kamatani, N; Nakajima, A; Nakamura, T; Tomatsu, T; Yamanaka, H, 2006) |
| "This pilot study aimed to determine if an elemental diet could be used to treat patients with active rheumatoid arthritis and to compare its effect to that of oral prednisolone." | 9.12 | Is rheumatoid arthritis a disease that starts in the intestine? A pilot study comparing an elemental diet with oral prednisolone. ( Mayberry, JF; Nightingale, JM; Oldham, R; Podas, T; Roy, S; Sheehan, NJ, 2007) |
| "The optimal methotrexate dose differs between rheumatoid arthritis (RA) patients, and dose-escalation strategies also differ among rheumatologists." | 9.12 | Influence of methotrexate dose on its efficacy and safety in rheumatoid arthritis patients: evidence based on the variety of prescribing approaches among practicing Japanese rheumatologists in a single institute-based large observational cohort (IORRA). ( Hara, M; Inoue, E; Kamatani, N; Nakajima, A; Tanaka, E; Taniguchi, A; Terai, C; Tomatsu, T; Yamanaka, H, 2007) |
| "To determine the influence of low-dose prednisolone on atherosclerosis, endothelial function, and risk factors for atherosclerosis in patients with early rheumatoid arthritis (RA)." | 9.12 | Effects of low-dose prednisolone on endothelial function, atherosclerosis, and traditional risk factors for atherosclerosis in patients with rheumatoid arthritis--a randomized study. ( Deneberg, S; Frostegård, J; Hafström, I; Jogestrand, T; Rohani, M; Wörnert, M, 2007) |
| "The aim of this study was to compare the pain relief and tolerability of SKI306X and celecoxib in patients with RA." | 9.12 | Assessment of comparative pain relief and tolerability of SKI306X compared with celecoxib in patients with rheumatoid arthritis: a 6-week, multicenter, randomized, double-blind, double-dummy, phase III, noninferiority clinical trial. ( Baek, HJ; Cha, HS; Jung, HG; Kang, SW; Kim, HA; Koh, EM; Lee, CK; Lee, EY; Lee, YJ; Song, YW; Suh, Y; Yoo, B, 2007) |
| "To evaluate the efficacy and safety of tacrolimus (FK506) in patients with active rheumatoid arthritis (RA) exhibiting resistance to disease modifying antirheumatic drug (DMARD) therapy, and to determine the optimal dosage." | 9.11 | Efficacy and safety of tacrolimus (FK506) in treatment of rheumatoid arthritis: a randomized, double blind, placebo controlled dose-finding study. ( Abe, T; Hara, M; Hashimoto, H; Irimajiri, S; Kondo, H; Sugawara, S; Uchida, S, 2004) |
| "A double blind, randomised, controlled trial over 12 weeks in 143 patients with active rheumatoid arthritis, comparing budesonide 3 mg daily, budesonide 9 mg daily, prednisolone 7." | 9.11 | A randomised placebo controlled 12 week trial of budesonide and prednisolone in rheumatoid arthritis. ( Bjorck, E; Book, C; Bowman, S; Byron, M; Cox, N; Field, M; Hällgren, R; Kanerud, L; Kirwan, JR; Leirisalo-Repo, M; Malaise, M; Mielants, H; Mohammad, A; Palmer, R; Persson, T; Petersson, IF; Ringertz, B; Sheldon, P; Simonsson, M; Snowden, N; Van den Bosch, F; Wollheim, F, 2004) |
| "To evaluate the effect of low dose oral prednisolone in early rheumatoid arthritis on disease activity over two years." | 9.11 | Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial. ( Capell, HA; Hampson, R; Hunter, JA; Larkin, J; Madhok, R; Morrison, E; Poon, FW; Porter, D; Thomson, EA, 2004) |
| "To our knowledge, this is the first double-blind randomized study to show that disease-related loss of hand bone density in rheumatoid arthritis can be decelerated by prednisolone." | 9.11 | Reduced loss of hand bone density with prednisolone in early rheumatoid arthritis: results from a randomized placebo-controlled trial. ( Haugeberg, G; Kirwan, JR; Kvien, TK; Strand, A, 2005) |
| "To assess the efficacy of low-dose prednisolone on joint damage and disease activity in patients with early rheumatoid arthritis (RA)." | 9.11 | Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial. ( Albertsson, K; Boonen, A; Hafström, I; Keller, C; Svensson, B; van der Heijde, D, 2005) |
| "To assess the effect of 5 mg/day prednisolone on disease progression in patients with early rheumatoid arthritis (RA) receiving standardized disease-modifying antirheumatic drug (DMARD) therapy." | 9.11 | Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial. ( Rau, R; Steinfeld, P; Wassenberg, S; Zeidler, H, 2005) |
| "To assess the efficacy, safety, and optimal dose of tacrolimus monotherapy in patients with rheumatoid arthritis (RA)." | 9.10 | Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging study. ( Baldassare, A; Block, JA; Calabrese, L; Caldwell, J; Dietz, F; Fleischmann, MR; Furst, DE; Harris, RE; Hurd, E; Kaine, J; Matsumoto, A; Moreland, LW; Rutstein, J; Saag, K; Sack, M; Satoi, Y; Schiff, M; Schnitzer, T; Senter, RG; Sherrer, Y; Stamler, DA; Stein, CM; Wiesenhutter, C; Yocum, D, 2002) |
| "To study benefits and skeletal side effects of carefully monitored prednisolone treatment in patients with active rheumatoid arthritis." | 9.09 | A randomised trial of differentiated prednisolone treatment in active rheumatoid arthritis. Clinical benefits and skeletal side effects. ( Borch, A; Florescu, A; Hansen, M; Hansen, TM; Kluger, E; Podenphant, J; Stoltenberg, M; Sørensen, SF, 1999) |
| "Data analysis from a randomized clinical trial with 155 rheumatoid arthritis (RA) patients; median age 50 yr, early and active disease (diagnosis < 2 yr); one group treated with a combination of sulphasalazine (SSZ; 2000 mg/day), methotrexate (MTX; 7." | 9.09 | Bone turnover, joint damage and bone mineral density in early rheumatoid arthritis treated with combination therapy including high-dose prednisolone. ( Boers, M; Geusens, P; Markusse, HM; te Koppele, JM; van der Laan, WH; van der Linden, S; Verhoeven, AC, 2001) |
| "The aim of this study was to evaluate the efficiency of radiation synovectomy with rhenium-186 in rheumatoid arthritis." | 9.08 | Radiosynoviorthesis with rhenium-186 in rheumatoid arthritis: a prospective study of three treatment regimens. ( Becker, W; Göbel, D; Gratz, S; von Rothkirch, T; Willert, HG, 1997) |
| "Assessment of the cost-effectiveness and cost-utility of early intervention in rheumatoid arthritis (RA) patients, with combined step-down prednisolone, methotrexate and sulphasalazine, compared to sulphasalazine alone." | 9.08 | Cost-effectiveness and cost-utility of combination therapy in early rheumatoid arthritis: randomized comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone. COBRA Trial Group. Combinatietherapie Bij Reumat ( Bibo, JC; Boers, M; Engel, GL; van der Linden, S; Verhoeven, AC, 1998) |
| "To evaluate the therapeutic efficacy of 46 weeks of treatment with cyclosporine (5 mg/kg/day) in patients with rheumatoid arthritis (RA)." | 9.07 | Radiologic evidence of disease modification in rheumatoid arthritis patients treated with cyclosporine. Results of a 48-week multicenter study comparing low-dose cyclosporine with placebo. Norwegian Arthritis Study Group. ( Førre, O, 1994) |
| "A study of methotrexate (MTX) pharmacokinetics with and without prednisolone was performed in 33 patients with rheumatoid arthritis." | 9.07 | Is there an interaction between low doses of corticosteroids and methotrexate in patients with rheumatoid arthritis? A pharmacokinetic study in 33 patients. ( Acquaviva, PC; Catalin, J; Durand, A; Lafforgue, P; Monjanel-Mouterde, S, 1993) |
| "Altogether 53 patients (31 women, 22 men) with definite rheumatoid arthritis were randomly divided into groups of 5-6 patients and treated for one day only with one of the following non-steroidal anti-inflammatory drugs (NSAIDs): acetylsalicylic acid, carprofen, diclofenac, indomethacin, naproxen, proquazone, timegadine, tolfenamic acid or paracetamol, and with prednisolone, in recommended doses." | 9.06 | Effects of non-steroidal anti-inflammatory drugs and prednisolone on synovial fluid white cells, prostaglandin E2, leukotriene B4 and cyclic AMP in patients with rheumatoid arthritis. ( Isomäki, H; Nissilä, M; Seppälä, E; Vapaatalo, H; Wuorela, H, 1990) |
| "Pulse methylprednisolone therapy has dramatic effects on clinical and immunological parameters of disease activity in patients with rheumatoid arthritis." | 9.06 | Pulse steroid therapy in rheumatoid arthritis: can equivalent doses of oral prednisolone give similar clinical results to intravenous methylprednisolone? ( Ahern, MJ; Roberts-Thomson, PJ; Smith, MD, 1988) |
| "A study of pirprofen (rengasil) combined with small doses of corticosteroids in 93 patients with rheumatoid arthritis during a double blind multicentre testing showed good and satisfactory therapeutic results in 60%." | 9.06 | [Study of pirprofen (rengasil) combined with maintenance doses of corticosteroids in rheumatoid arthritis in a double-blind multicenter trial]. ( Alekberova, ZS; Kobaladze, SG; Pokryshkin, VI; Taletene, IP; Trofimova, TM, 1986) |
| "A multicenter double-blind study was carried out in patients with rheumatoid arthritis (RA) by comparing treatment with a novel immunomodulator, lobenzarit, disodium 4-chloro-2, 2'-iminodibenzoate, with an inert placebo." | 9.05 | A multicenter double-blind controlled study of lobenzarit, a novel immunomodulator, in rheumatoid arthritis. ( Abe, C; Honma, M; Horiuchi, Y; Kageyama, T; Mizushima, Y; Ofuji, T; Ogawa, N; Shichikawa, K; Shiokawa, Y; Yoshizawa, H, 1984) |
| "Forty-one patients with rheumatoid arthritis (RA) maintained on low dose prednisolone (mean 5." | 9.05 | The timing of prednisolone dosage and its effect on morning stiffness in rheumatoid arthritis. ( Binder, A; De Silva, M; Hazleman, BL, 1984) |
| "Twelve patients with rheumatoid arthritis took low dosage prednisolone, mean 5." | 9.05 | Time of day of prednisolone administration in rheumatoid arthritis. ( Knapp, MS; Kowanko, IC; Mahoney, PG; Pownall, R; Swannell, AJ, 1982) |
| " Two oral corticosteroids, prednisolone (8 mg/day) and betamethasone (1 mg/day) have been compared in terms of efficacy and adrenal suppressive activity when used in chronic oral dosage in rheumatoid arthritis." | 9.05 | A pharmacological and clinical comparison of prednisolone and betamethasone in rheumatoid arthritis. ( Al-Shakarchi, H; Bird, HA; Dixon, JS; Lowe, JR; Marwah, RJ; Pickup, ME; Wright, V, 1982) |
| "Indomethacin, 100 mg orally, was compared with prednisolone, 5 mg, as addititional therapy at night, in a two-week, double-blind, between-patient study in twenty-four in-patients with rheumatoid arthritis." | 9.04 | Indomethacin or prednisolone at night in rheumatoid arthritis? ( Murthy, MH; Rhymer, AR; Wright, V, 1978) |
| "A double-blind trial of prednisolone in patients with rheumatoid arthritis using doses of zero, 3 mg and 5 mg is reported." | 9.04 | The effect of low doses of prednisolone compared with placebo on function and on the hypothalamic pituitary adrenal axis in patients with rheumatoid arthritis. ( Chamberlain, MA; Keenan, J, 1976) |
| "In a controlled trial including 80 patients suffering from different stages of rheumatoid arthritis it was demonstrated that D-penicillamine therapy favourably influences the clinical course of the disease as compared to a control group treated with antirheumatic drugs." | 9.04 | [Long term treatment of rheumatoid arthritis. Experiences with D-penicillamine in comparison with gold and immunosuppressive drugs (author's transl)]. ( Gutmann, W; Scheiffarth, F; Warnatz, H, 1975) |
| "The ability of azathioprine to reduce the corticosteroid requirements of patients with severe rheumatoid arthritis was tested under double-blind conditions against placebo." | 9.03 | Azathioprine in rheumatoid arthritis. ( Barnes, CG; Currey, HL; Dunne, JF; Hazleman, BL; Mason, M; Strickland, ID, 1969) |
| "To determine whether short-term, oral low dose prednisolone (< or = 15 mg daily) is superior to placebo and non-steroidal anti-inflammatory drugs in patients with rheumatoid arthritis." | 8.80 | Meta-analysis of short-term low dose prednisolone versus placebo and non-steroidal anti-inflammatory drugs in rheumatoid arthritis. ( Gøtzsche, PC; Johansen, HK, 1998) |
| "We describe a case of a 57-year-old white woman treated for rheumatoid arthritis (RA) with tofacitinib 10mg daily (started one year ago) and prednisolone 5mg daily." | 8.12 | Takotsubo Syndrome in a Rheumatoid Arthritis Patient Under Tofacitinib: A Case Report. ( Bernardes, M; Costa, L; Garcia, S; Martins, E; Pimenta, S; Terroso, G, 2022) |
| "A 78-year-old woman with rheumatoid arthritis on TNF-α inhibitor, methotrexate and prednisolone presented with severe but unspecific symptoms such as leg weakness, shivering, bifrontal headache, nausea and staggering." | 7.96 | [Neurological symptoms in a patient on anti-TNF therapy, methotrexate and prednisolone for rheumatoid arthritis]. ( Bach, M; Baerwald, C; Schob, S, 2020) |
| " Here, we describe a case of tubercular osteomyelitis in an old fused hip of a patient with RA who received prednisolone, salazosulfapyridine (SASP), and low-dose methotrexate (MTX)." | 7.96 | Tuberculosis osteomyelitis in an old fused hip; activated by prednisolone, salazosulfapyridine, and low-dose methotrexate therapy in a patient with rheumatoid arthritis. ( Fukushi, JI; Ishitani, EI; Katsuki, I; Matsubara, H; Okada, F; Sonoda, Y, 2020) |
| "Prednisolone (PD) is extremely effective for treating rheumatoid arthritis (RA)." | 7.91 | Co-Delivery of Prednisolone and Curcumin in Human Serum Albumin Nanoparticles for Effective Treatment of Rheumatoid Arthritis. ( Li, C; Li, H; Lin, Y; Tang, C; Yan, F; Zhong, Z; Zhou, M, 2019) |
| "This study aimed to evaluate the relationships between concomitant biologic disease-modifying anti-rheumatic drugs (DMARDs) and prednisolone administration and blood tacrolimus exposure or serum CYP3A4/5-related markers in rheumatoid arthritis (RA) patients without severe disease activity." | 7.91 | Relationships between concomitant biologic DMARDs and prednisolone administration and blood tacrolimus exposure or serum CYP3A4/5-related markers in rheumatoid arthritis patients. ( Kawakami, J; Naito, T; Ogawa, N; Ohshiro, J; Sato, H; Suzuki, M; Torikai, E, 2019) |
| "This investigation was aimed to explore the targeting potential of folate conjugated double liposomes (fDLs) bearing combination of synergistic drugs (Prednisolone and Methotrexate) for effective management of the rheumatoid arthritis (RA)." | 7.91 | Folate Conjugated Double Liposomes Bearing Prednisolone and Methotrexate for Targeting Rheumatoid Arthritis. ( Agrawal, GP; Jain, A; Jain, SK; Panda, PK; Saraf, S; Tiwari, A; Verma, A, 2019) |
| "Eighteen rheumatoid arthritis patients who had not taken prednisolone for >6 months (non-glucocorticoid (GC) users), 18 rheumatoid arthritis patients taking continuous oral prednisolone (6." | 7.85 | Opposing effects of rheumatoid arthritis and low dose prednisolone on arginine metabolomics. ( Burt, MG; Drake, SM; Mangelsdorf, BL; Mangoni, AA; Radhakutty, A; Rowland, A; Smith, MD; Thompson, CH, 2017) |
| "Arterial stiffness is not affected by low dose prednisolone per se, but is negatively associated with peripheral insulin sensitivity." | 7.85 | Low dose prednisolone and insulin sensitivity differentially affect arterial stiffness and endothelial function: An open interventional and cross-sectional study. ( Burt, MG; Greenfield, JR; Mangelsdorf, BL; Petersons, CJ; Poljak, A; Smith, MD; Thompson, CH, 2017) |
| "Methotrexate (MTX) is the cornerstone of rheumatoid arthritis (RA) treatment." | 7.81 | Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: A retrospective analysis of real-world data from the St. Gallen cohort. ( Haile, SR; Müller, RB; Schiff, MH; von Kempis, J, 2015) |
| "We encountered a disseminated sporotrichosis patient with polyarthritis and progressive skin ulcers, who had been previously treated with prednisolone, tocilizmab, tacrolims, and cyclophosphamide under the diagnosis of rheumatoid arthritis in another hospital." | 7.78 | A case of disseminated sporotrichosis treated with prednisolone, immunosuppressants, and tocilizumab under the diagnosis of rheumatoid arthritis. ( Goto, D; Goto, M; Hayashi, T; Horikoshi, M; Ito, S; Matsumoto, I; Sumida, T; Takano, Y; Umeda, N; Yamaguchi, T, 2012) |
| "A 66-year-old woman with seropositive rheumatoid arthritis (RA) and latent tuberculosis infection developed minimal-change nephrotic syndrome following the initiation of anti-tuberculosis chemoprophylaxis with isoniazid." | 7.77 | Minimal-change nephrotic syndrome associated with isoniazid in anti-tuberculosis chemoprophylaxis for a patient with rheumatoid arthritis. ( Arizono, K; Matsushita, Y; Mori, S, 2011) |
| "The objective of this study was to assess the usefulness of tacrolimus (TAC) for rheumatoid arthritis (RA) patients." | 7.76 | Efficacy and safety of tacrolimus in 101 consecutive patients with rheumatoid arthritis. ( Inoue, E; Kaneko, H; Kitahama, M; Koseki, Y; Momohara, S; Okamoto, H; Taniguchi, A; Yamanaka, H, 2010) |
| " We treated a patient who developed polymyositis (PM) following the treatment of RA with leflunomide." | 7.75 | Leflunomide-induced polymyositis in a patient with rheumatoid arthritis. ( Nagashima, M; Ochi, S; Taniguchi, K, 2009) |
| "To evaluate if remission induced by low-dose prednisolone during the first 2 years of rheumatoid arthritis (RA) in the BARFOT glucocorticoid (GC) study had a sustained effect on radiological damage for a total of 4 years." | 7.75 | Remission achieved after 2 years treatment with low-dose prednisolone in addition to disease-modifying anti-rheumatic drugs in early rheumatoid arthritis is associated with reduced joint destruction still present after 4 years: an open 2-year continuation ( Albertsson, K; Boonen, A; Hafström, I; Landewé, R; Svensson, B; van der Heijde, D, 2009) |
| "Leflunomide is an immunomodulating agent with proven efficacy in rheumatoid arthritis." | 7.74 | Leflunomide-induced toxic epidermal necrolysis in a patient with rheumatoid arthritis. ( Baaj, M; El Haouri, M; Hadri, L; Hassikou, H; Safi, S; Tabache, F, 2008) |
| "To evaluate the potential of using prednisolone phosphate (PSLP)-containing 3,5-dipentadecyloxybenzamidine hydrochloride (TRX-20) liposomes to treat rheumatoid arthritis (RA), we examined their ability to bind human fibroblast-like synovial (HFLS) cells and their effects in these cells." | 7.74 | Prednisolone phosphate-containing TRX-20 liposomes inhibit cytokine and chemokine production in human fibroblast-like synovial cells: a novel approach to rheumatoid arthritis therapy. ( Hagiwara, H; Harigai, T; Ishizuka, T; Kaneda, S; Kimura, J; Ogawa, Y, 2007) |
| " The disease appeared during low-dose oral methotrexate (MTX) therapy for rheumatoid arthritis." | 7.74 | Massive myelinolytic leukoencephalopathy in a patient medicated with low-dose oral methotrexate for rheumatoid arthritis: an autopsy report. ( Harigaya, Y; Igeta, Y; Itoh, H; Nakazato, Y; Sasaki, N; Yokoo, H, 2007) |
| "To compare antibody responses to 23-valent pneumococcal vaccine (Pneumovax) in controls and patients with established rheumatoid arthritis (RA) treated with TNF blockers, methotrexate (MTX) or a combination of both." | 7.73 | Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. ( Geborek, P; Jönsson, G; Kapetanovic, MC; Saxne, T; Sjöholm, A; Truedsson, L, 2006) |
| "To assess adrenal function with respect to the presence or absence of steroid therapy, we investigated differences in the blood levels of adrenocorticotropic hormone (ACTH) and dehydroepiandrosterone sulfate (DHEAS) in relation to steroid (prednisolone) administration in 123 patients with rheumatoid arthritis (RA)." | 7.73 | Adrenocorticotropic hormone and dehydroepiandrosterone sulfate levels of rheumatoid arthritis patients treated with glucocorticoids. ( Komatsubara, Y; Ochi, T; Toyosaki-Maeda, T; Yonenobu, K; Yukioka, K; Yukioka, M, 2006) |
| "To study which factors are associated with longterm methotrexate (MTX) use in rheumatoid arthritis (RA)." | 7.72 | Longterm observational study of methotrexate use in a Dutch cohort of 1022 patients with rheumatoid arthritis. ( Bernelot Moens, HJ; Haagsma, CJ; Hoekstra, M; Kruijsen, MW; van de Laar, MA, 2003) |
| "We report a patient with rheumatoid arthritis (RA) who developed malignant lymphoma of the diffuse large B-cell type in the right submandibular region shortly after initiation of oral methotrexate (MTX)." | 7.72 | Malignant lymphoma associated with rheumatoid arthritis, developing shortly after initiation of oral methotrexate. ( Gono, T; Hoshi, K; Ikeda, S; Matsuda, M; Shikama, N; Shimojima, Y; Tokuda, T; Yamamoto, K, 2004) |
| "A 63-year-old woman had D-penicillamine-induced pemphigus with a high index value of circulating autoantibodies against desmoglein 1." | 7.72 | D-penicillamine-induced pemphigus successfully treated with combination therapy of mizoribine and prednisolone. ( Hirokawa, H; Izu, K; Sugita, K; Tokura, Y, 2004) |
| "The synthesis, activity and mass of LPL in adipose tissue were studied in patients with rheumatoid arthritis (RA) treated with prednisolone (PSL) (PSL-treated group) and untreated patients with osteoarthritis (untreated group)." | 7.71 | Active-dimeric form of lipoprotein lipase increases in the adipose tissue of patients with rheumatoid arthritis treated with prednisolone. ( Kidani, T; Masuno, H; Matsuda, Y; Okuda, H; Sakayama, K; Takubo, N; Yamamoto, H, 2002) |
| "To study pharmacokinetics of prednisolone in patients with rheumatoid arthritis (RA)." | 7.71 | [Pharmacokinetic of prednisolone in patients with rheumatoid arthritis]. ( Chekalin, AF; Nesterov, SL; Rossokhin, VF; Shishkanov, SF, 2002) |
| "To compare patterns and time trends of initial disease-modifying antirheumatic drugs (DMARDs) and prednisolone prescriptions for patients with rheumatoid arthritis (RA) by the rheumatologists at King Chulalongkorn Memorial Hospital, Bangkok, Thailand over a 15-year period, as well as their side effects." | 7.70 | Initial disease modifying antirheumatic drugs and prednisolone prescriptions for patients with rheumatoid arthritis: a 15-year study. ( Akkasilpa, S; Deesomchok, U; Osiri, M, 2000) |
| "We compared lymphocyte-suppressive potencies of prednisolone and methylprednisolone in rheumatoid arthritis (RA)." | 7.70 | Comparative study of lymphocyte-suppressive potency between prednisolone and methylprednisolone in rheumatoid arthritis. ( Abe, H; Hayashi, T; Hirano, T; Homma, M; Oka, K; Tahara, K; Takanashi, H; Takekoshi, T; Tsuboi, N; Urata, Y, 2000) |
| "To determine daily production of nitric oxide (NO) measured as urinary nitrate excretion, and the effect of prednisolone in patients with rheumatoid arthritis (RA)." | 7.69 | Urinary nitrate excretion is increased in patients with rheumatoid arthritis and reduced by prednisolone. ( Fauler, J; Frölich, JC; Stichtenoth, DO; Zeidler, H, 1995) |
| " Though the treatment with prednisolone and dipyridamole against nephrotic syndrome and amyloidosis due to RA was not effective, cyclophosphamide, which was added after tapering of prednisolone, was able to induce remission of nephrotic syndrome after two years." | 7.69 | Combined treatment with cyclophosphamide and prednisolone can induce remission of nephrotic syndrome in a patient with renal amyloidosis, associated with rheumatoid arthritis. ( Hiromura, K; Kanai, H; Maezawa, A; Mitsuhashi, H; Naruse, T; Tsukada, Y; Yano, S, 1994) |
| "D-penicillamine, an agent still used in the treatment of rheumatoid arthritis (RA) may produce inflammatory myopathy or myositis." | 7.69 | D-penicillamine-induced myositis in rheumatoid arthritis. ( Chappel, R; Willems, J, 1996) |
| "The possible association of leukotriene B4 (LTB4)-like activity with the development of active rheumatoid arthritis was studied in 25 children with the disease and in 15 normal subjects." | 7.69 | Increased serum leukotriene B4 level in the active stage of rheumatoid arthritis in children. ( Ercan, ZS; Firat, S; Gürsel, T, 1997) |
| "In a patient suffering from rheumatoid arthritis, we report the first simultaneous occurrence of two side effects of low-dose methotrexate: an acute megaloblastic anaemia and a pneumonitis." | 7.68 | Concurrent acute megaloblastic anaemia and pneumonitis: a severe side-effect of low-dose methotrexate therapy during rheumatoid arthritis. ( Bolla, G; Disdier, P; Harle, JR; Verrot, D; Weiller, PJ, 1993) |
| "The sex hormones dehydroepiandrosterone sulphate (DHEAS), oestradiol, and sex hormone binding globulin (SHBG) were measured in 185 postmenopausal women (aged 45-65 years) with rheumatoid arthritis (RA) and related to assessments of bone mineral density at the spine and proximal femur." | 7.68 | Depressed levels of dehydroepiandrosterone sulphate in postmenopausal women with rheumatoid arthritis but no relation with axial bone density. ( Hall, GM; Perry, LA; Spector, TD, 1993) |
| "A 40 year old woman with rheumatoid arthritis developed pure red cell aplasia after treatment with D-penicillamine 500 mg/day." | 7.68 | Pure red cell aplasia caused by D-penicillamine treatment of rheumatoid arthritis. ( Kahn, Y; Tishler, M; Yaron, M, 1991) |
| "A patient with rheumatoid arthritis-associated interstitial pneumonitis, treated with prednisolone, developed mild colitis due to Clostridium difficile in association with the use of cefotaxime (CTX)." | 7.67 | Cefotaxime-associated diarrhea and Clostridium difficile. ( Funada, H; Hattori, K; Ishizaki, T; Kuroda, T; Nakamura, S, 1984) |
| "A patient with rheumatoid arthritis and collagenous colitis apparently responding to sulfasalazine and prednisolone enemas is reported." | 7.67 | Collagenous colitis: possible response to sulfasalazine and local steroid therapy. ( Farah, DA; Lee, FD; McLay, A; Mills, PR; Russell, RI, 1985) |
| "Pulse prednisolone hemisuccinate therapy (500 mg given intravenously on three occasions over two weeks) has been combined with either intramuscular sodium aurothiomalate or azathioprine in an assessment of 30 patients with rheumatoid arthritis." | 7.67 | A comparison of prednisolone with azathioprine and prednisolone with intramuscular gold in rheumatoid arthritis. ( Arnold, S; Astbury, G; Bird, HA; Dixon, JS; Häntzschel, H; Krüger, W; Otto, W; Seidel, W; Winiecki, P; Wright, V, 1988) |
| "Methylprednisolone pulse therapy is often used in patients with severe rheumatoid arthritis (RA)." | 7.67 | Comparison of methylprednisolone (1 g i.v.) with prednisolone (1 g orally) in rheumatoid arthritis: a pharmacokinetic and clinical study. ( Boutagy, J; Brooks, PM; Cosh, D; Donovan, S; McCredie, M; Needs, CJ; Smith, M, 1988) |
| "The pharmacokinetic profile of a single 10 mg oral dose of prednisolone was studied in three groups of six patients with rheumatoid arthritis (RA), polymyalgia rheumatica (PMR) and bronchial asthma (BA) who were already receiving steroid therapy." | 7.67 | Prednisolone pharmacokinetics in patients with rheumatoid arthritis, polymyalgia rheumatica and asthma. ( Astbury, C; Bird, HA; Dixon, JS; Taggart, AJ, 1986) |
| "The effects of a single dose of 5 and 10 mg of prednisolone on the kinetics of lymphocytes and T lymphocyte subsets were investigated in patients suffering from active rheumatoid arthritis." | 7.66 | The effect of low doses of prednisolone on the traffic of T helper-inducer cells in rheumatoid arthritis. ( Delanghe, J; Hermanns, P; Vansteenkiste, M; Verbruggen, G; Veys, EM, 1982) |
| "Plasma prednisolone levels were measured in parallel with clinical and laboratory assessments in seven patients with rheumatoid arthritis on single daily doses of prednisolone which were reduced at weekly intervals from 10 mg." | 7.66 | Plasma levels and response to prednisolone therapy in rheumatoid arthritis. ( Chakraborty, J; De Silva, M; English, J; Hazleman, BL; Marks, V, 1983) |
| "Eight patients with rheumatoid arthritis received an intra-articular injection of either 50 mg or 100 mg of prednisolone acetate into the knee joint." | 7.66 | Plasma steroid levels after intra-articular injection of prednisolone acetate in patients with rheumatoid arthritis. ( Chakraborty, J; English, J; Gibson, T; Marks, V; Reeback, JS, 1980) |
| "Azathioprine has been shown to reduce the steroid requirements of patients with severe rheumatoid arthritis." | 7.65 | Further experience with azathioprine in rheumatoid arthritis. ( Chaput de Saintonge, DM; Harris, J; Jessop, JD, 1971) |
| "Although glucocorticoids are widely used in the treatment of patients with early rheumatoid arthritis, the best dosage of glucocorticoids with regards to efficacy and safety is not known." | 6.79 | Comparison of the efficacy and safety of two starting dosages of prednisolone in early active rheumatoid arthritis (CORRA): study protocol for a randomized controlled trial. ( Baraliakos, X; Braun, J; Klaassen-Mielke, R; Krause, D; Trampisch, HJ; Trampisch, US, 2014) |
| "Treatment with prednisolone at both dosages reduced CRP levels significantly." | 6.77 | Metabolic effects of high-dose prednisolone treatment in early rheumatoid arthritis: balance between diabetogenic effects and inflammation reduction. ( Bijlsma, JW; den Uyl, D; Diamant, M; Dijkmans, BA; Hoes, JN; Lems, WF; Nurmohamed, MT; van Raalte, DH, 2012) |
| "Mizoribine (MZR) is an immunosuppressant that inhibits nucleic acid metabolism and is a relatively safe disease-modifying anti-rheumatic drug (DMARD)." | 6.75 | Efficacy and safety of mizoribine by one single dose administration for patients with rheumatoid arthritis. ( Aramaki, T; Arima, K; Eguchi, K; Fujikawa, K; Ichinose, K; Ida, H; Iwamoto, N; Kamachi, M; Kawakami, A; Kawashiri, SY; Nakamura, H; Origuchi, T; Tamai, M; Tsukada, T; Ueki, Y, 2010) |
| "To determine whether intermittent rather than daily administration of D-penicillamine (D-Pen) would effectively reduce the incidence of adverse effects without significantly diminishing the clinical benefits." | 6.67 | Intermittent treatment with D-penicillamine is effective in lower doses and with fewer adverse effects in patients with rheumatoid arthritis. ( Akahoshi, T; Hakoda, M; Kamatani, N; Kashiwazaki, S; Taniguchi, A, 1994) |
| "Fifty RA patients receiving prednisolone and prednisolone combined with retabolil were examined." | 6.66 | [Experimental substantiation of the treatment of patients with rheumatoid arthritis with prednisolone and its combination with retabolil (clinico-experimental study)]. ( Bagirova, VV; Iaglinskiĭ, VA; Kriukov, AP, 1986) |
| "Glucocorticoids are used in the treatment of rheumatoid arthritis since many decades." | 5.72 | [Low dosed prednisolone in older patients with rheumatoid arthritis]. ( van der Goes, MC, 2022) |
| "This post hoc analysis used data from a placebo-controlled, phase 3 trial (RAJ4) of peficitinib in patients with rheumatoid arthritis and inadequate response to methotrexate." | 5.69 | Post hoc analysis of clinical characteristics of patients with radiographic progression in a Japanese phase 3 trial of peficitinib and methotrexate treatment (RAJ4). ( Fukuda, M; Izutsu, H; Kaneko, Y; Kato, D; Rokuda, M; Takeuchi, T; Tanaka, Y; van der Heijde, D, 2023) |
| "In the Glucocorticoid Low-dose Outcome in Rheumatoid Arthritis (GLORIA) study, 451 RA patients ≥65 years of age were randomized to 2 years 5 mg/day prednisolone or placebo." | 5.69 | Development of prediction models to select older RA patients with comorbidities for treatment with chronic low-dose glucocorticoids. ( Boers, M; Buttgereit, F; Cutolo, M; da Silva, JAP; Hartman, L; Heymans, MW; Lems, WF; Masaryk, P; Opris-Belinski, D; Szekanecz, Z; van der Heijde, DMFM; Voshaar, MJH, 2023) |
| "To investigate the effect of 2 years of add-on prednisolone 5 mg/day on body weight and composition in patients with active rheumatoid arthritis (RA) aged 65+ and the relation with disease activity." | 5.69 | Changes in body weight and body composition in patients with active rheumatoid arthritis aged 65+ treated with 2-year low-dose add-on prednisolone in the randomised double-blind placebo-controlled GLORIA trial. ( Boers, M; Bos, R; Emmering, J; Eshuis, S; Güler-Yüksel, M; Human, A; Kok, MR; Kuijper, M; Molenaar, E; Reimann, F, 2023) |
| "The randomised placebo-controlled GLORIA (Glucocorticoid LOw-dose in RheumatoId Arthritis) trial evaluated the benefits and harms of prednisolone 5 mg/day added to standard care for 2 years in patients aged 65+ years with rheumatoid arthritis (RA)." | 5.69 | Three-month tapering and discontinuation of long- term, low-dose glucocorticoids in senior patients with rheumatoid arthritis is feasible and safe: placebo-controlled double blind tapering after the GLORIA trial. ( Allaart, CF; Almayali, AAH; Baudoin, P; Boers, M; Bos, R; Buttgereit, F; Cutolo, M; Da Silva, JA; Griep, E; Hartman, L; Klaasen, R; Kok, MR; Lems, W; Masaryk, P; Opris, D; Raterman, HG; Smulders, Y; Szekanecz, Z; Ter Wee, MM, 2023) |
| "The GLORIA (Glucocorticoid LOw-dose in RheumatoId Arthritis) pragmatic double-blind randomised trial compared 2 years of prednisolone, 5 mg/day, to placebo in patients aged 65+ with active RA." | 5.51 | Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial. ( Allaart, CF; Baudoin, P; Boers, M; Bos, R; Buttgereit, F; Cutolo, M; Da Silva, JA; Griep, EN; Hartman, L; Klaasen, R; Klausch, LT; Kok, MR; Lems, WF; Masaryk, P; Opris-Belinski, D; Paolino, S; Raterman, HG; Schilder, AM; Szekanecz, Z, 2022) |
| "In active early rheumatoid arthritis (RA), glucocorticoids are often used for bridging, due to the delayed action of methotrexate." | 5.51 | The Efficacy of Short-Term Bridging Strategies With High- and Low-Dose Prednisolone on Radiographic and Clinical Outcomes in Active Early Rheumatoid Arthritis: A Double-Blind, Randomized, Placebo-Controlled Trial. ( Baraliakos, X; Boeddeker, S; Braun, J; Christoph, HJ; Fendler, C; Igelmann, M; Klaassen-Mielke, R; Klink, C; Krause, D; Mai, A; Menne, HJ; Ose, C; Rau, R; Rudolf, H; Saracbasi-Zender, E; Schade-Brittinger, C; Schmid, A; Schmitz, E; Sonuc, N; Timmesfeld, N; Trampisch, HJ; Trampisch, U; Wassenberg, S, 2022) |
| "The GLORIA placebo-controlled trial found a favorable balance of benefit and harm for two years of prednisolone (5 mg/day) as add-on treatment for rheumatoid arthritis (RA) patients aged 65+." | 5.51 | Cost-effectiveness and cost-utility of add-on, low-dose prednisolone in patients with rheumatoid arthritis aged 65+: The pragmatic, multicenter, placebo-controlled GLORIA trial. ( Boers, M; Bos, R; Buttgereit, F; Coupé, V; Cutolo, M; Da Silva, J; El Alili, M; Hartman, L; Kok, MR; Lems, WF; Masaryk, P; Opris, D; Paolino, S; Szekanecz, Z, 2022) |
| "Prednisolone was subsequently administered instead of chemotherapy; however, multiple masses, including in the spine (case 1), and severe icterus with liver dysfunction (case 2) were exacerbated within a few months." | 5.46 | The aggressive clinical courses of Hodgkin lymphoma primarily diagnosed as methotrexate-induced non-specific lymphoproliferative disorder in patients with rheumatoid arthritis. ( Amano, K; Anan-Nemoto, T; Higashi, M; Kimura, Y; Kizaki, M; Momose, S; Okuyama, A; Tabayashi, T; Takahashi, Y; Tamaru, JI; Tanaka, Y; Tokuhira, M; Tomikawa, T; Watanabe, R, 2017) |
| "The aim of this study was to evaluate the effect of treatment with methotrexate (MTX), by itself or combined with other non-biological disease-modifying antirheumatic drugs (DMARDs) (methotrexate, MTX with prednisolone, MTX with leflunomide, MTX with chloroquine, and MTX with sulfasalazine) on clinimetric outcomes in a retrospective cohort with a 6-month follow-up and under a Treat to Target (T2T) approach." | 5.42 | Treatment of rheumatoid arthritis with methotrexate alone and in combination with other conventional DMARDs using the T2T strategy. A cohort study. ( Castro, C; de la Hoz-Valle, J; Palomino, A; Sánchez, G; Santos-Moreno, PI; Villarreal, L, 2015) |
| "Current treatment of rheumatoid arthritis includes systemic administration of glucocorticoids." | 5.42 | [(18)]F FDG PET/CT imaging to monitor the therapeutic effect of liposome-encapsulated prednisolone in experimental rheumatoid arthritis. ( Boerman, OC; Gerrits, D; Laverman, P; Metselaar, JM; Storm, G; van der Geest, T; van Lent, PL, 2015) |
| "Prednisolone treatment was strongly associated with negative TST, adjusted odds ratio (AOR) 0." | 5.37 | Prednisolone treatment affects the performance of the QuantiFERON gold in-tube test and the tuberculin skin test in patients with autoimmune disorders screened for latent tuberculosis infection. ( Bélard, E; Brylov, A; Hetland, ML; Jensen, FK; Nordgaard-Lassen, I; Ravn, P; Ruhwald, M; Semb, S; Soborg, B; Thomsen, H; Werlinrud, AM, 2011) |
| " Dose was raised until a final dosage of 30 mg/week." | 5.37 | [Autoimmune pancreatitis associated with rheumatoid arthritis: successful combination therapy with steroids and methotrexate]. ( Boltuch-Sherif, J; Erlacher, L; Horvath-Mechtler, B; Kowalski-Bodzenta, J; Mustak, M, 2011) |
| "Mizoribine has been recognized to have an acceptable toxicity profile compared with other immunosuppressants." | 5.35 | A sudden onset of diabetic ketoacidosis and acute pancreatitis after introduction of mizoribine therapy in a patient with rheumatoid arthritis. ( Ebihara, K; Mori, S, 2008) |
| "To assess the incidence and severity of disease modifying antirheumatic drug (DMARD)-induced adverse effects (AE) in patients with rheumatoid arthritis (RA) taking/not taking glucocorticoids (GC)." | 5.35 | Low-dose prednisolone in rheumatoid arthritis: adverse effects of various disease modifying antirheumatic drugs. ( Arnold, S; Baerwald, CG; Häntzschel, H; Malysheva, OA; Pierer, M; Wagner, U; Wahle, M, 2008) |
| " The results highlight the efficacy and safety of active conventional treatment based on methotrexate combined with corticosteroids, with nominally better results for abatacept, in treatment naive early rheumatoid arthritis." | 5.34 | Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial. ( Baecklund, E; Bakland, G; Brodin, E; Cagnotto, G; Ellingsen, T; Faustini, F; Grondal, G; Grøn, KL; Gudbjornsson, B; Haavardsholm, EA; Heiberg, MS; Hendricks, O; Hetland, ML; Hultgård Ekwall, AK; Husmark, T; Hyldstrup, LH; Hørslev-Petersen, K; Just, SA; Kapetanovic, M; Krabbe, S; Lampa, J; Larsson, P; Laurberg, TB; Lend, K; Lindqvist, J; Ljoså, MA; Lorenzen, T; Nordström, D; Nurmohamed, M; Olsen, IC; Olsson, ÅR; Rizk, M; Rudin, A; Söderbergh, A; Sokka-Isler, T; Stevens, DJ; Tuompo, R; Twisk, J; Uhlig, T; Uhrenholt, L; van Vollenhoven, R; Vedder, D; Østergaard, M, 2020) |
| "This study aimed to evaluate the short-term effectiveness and safety profiles of baricitinib and explore factors associated with improved short-term effectiveness in patients with rheumatoid arthritis (RA) in clinical settings." | 5.34 | Predictors for clinical effectiveness of baricitinib in rheumatoid arthritis patients in routine clinical practice: data from a Japanese multicenter registry. ( Asai, S; Hanabayashi, M; Hirano, Y; Ishiguro, N; Ishikawa, H; Kanayama, Y; Kaneko, A; Kato, T; Kobayakawa, T; Kojima, T; Nishiume, T; Sobue, Y; Suzuki, M; Takahashi, N; Terabe, K; Watanabe, T; Yabe, Y; Yokota, Y; Yoshioka, Y, 2020) |
| " We studied the efficacy of cyclophosphamide (CYC) combined with prednisolone (PSL) in amyloidotic patients who had serum amyloid A (SAA) 1." | 5.32 | Efficacy of cyclophosphamide combined with prednisolone in patients with AA amyloidosis secondary to rheumatoid arthritis. ( Baba, S; Nakamura, T; Shono, M; Tomoda, K; Tsukano, M; Yamamura, Y, 2003) |
| "Histopathologic diagnosis was bronchiolitis obliterans organizing pneumonia (BOOP)." | 5.32 | Bronchiolitis obliterans organizing pneumonia associated with sulfasalazine in a patient with rheumatoid arthritis. ( Apaydin, D; Aydin, O; Ozer, C; Ozgür, E; Sahin, G; Ulubaş, B, 2004) |
| "Kynurenine analysis was performed by HPLC." | 5.32 | Kynurenine and neopterin levels in patients with rheumatoid arthritis and osteoporosis during drug treatment. ( Darlington, LG; Forrest, CM; Kennedy, A; Stone, TW; Stoy, N, 2003) |
| " Therapeutic studies were performed for up to 8 weeks of dosing with prednisolone, methotrexate, 3 nonsteroidal antiinflammatory drugs (celecoxib, diclofenac, and indomethacin), a p38 MAPK inhibitor, SB242235, and human soluble TNF receptor (sTNFR; etanercept) and murine sTNFR fusion proteins." | 5.32 | Characterization of pristane-induced arthritis, a murine model of chronic disease: response to antirheumatic agents, expression of joint cytokines, and immunopathology. ( Bush, K; Life, P; Morgan, R; Patten, C; Rioja, I; Trill, J; Wooley, P, 2004) |
| "A diagnosis of autoimmune hemolytic anemia (AIHA) was made on the basis of the laboratory findings." | 5.31 | [A case of rheumatoid arthritis associated with autoimmune hemolytic anemia due to weekly low-dose methotrexate therapy]. ( Kurosaka, D; Ozawa, Y; Tajima, N; Yokoyama, T; Yoshida, K, 2000) |
| "Ninety-nine patients with early, DMARD-naive RA were treated with a triple combination of csDMARDs and prednisolone and randomized to double-blind receipt of infusions of either IFX (the Finnish Rheumatoid Arthritis Combination Therapy Trial [FIN-RACo] + IFX) or placebo (FIN-RACo + placebo) during the first 6 months." | 5.30 | Early Targeted Combination Treatment With Conventional Synthetic Disease-Modifying Antirheumatic Drugs and Long-Term Outcomes in Rheumatoid Arthritis: Ten-Year Follow-Up Results of a Randomized Clinical Trial. ( Hannonen, P; Julkunen, H; Kaipiainen-Seppänen, O; Kauppi, MJ; Kautiainen, H; Koski, J; Laasonen, L; Leirisalo-Repo, M; Malmi, T; Möttönen, T; Rantalaiho, V; Sandström, T; Uutela, T; Yli-Kerttula, T, 2019) |
| "Pentoxifylline was also reported to possess therapeutic properties in 50% of severe refractory RA in an open study." | 5.30 | [Remission induction after pentoxifylline treatment in a patient with rheumatoid arthritis]. ( Ichikawa, Y; Ishii, O; Kase, C; Moriuchi, E; Ohya, S; Yamada, H; Yamasaki, K, 1997) |
| "Pentosidine is an advanced glycation endproduct formed by glycosylation and oxidation." | 5.30 | Pentosidine in synovial fluid in osteoarthritis and rheumatoid arthritis: relationship with disease activity in rheumatoid arthritis. ( Chen, JR; Inoue, T; Kushida, K; Miyamoto, S; Suzuki, M; Takahashi, M, 1998) |
| "Lactoferrin is a multifunctional immunoregulatory protein, stored in specific granules of neutrophil granulocytes, from which it is released following cell activation." | 5.30 | Increased levels of lactoferrin in synovial fluid but not in serum from patients with rheumatoid arthritis. ( Afeltra, A; Bonomo, L; Caccavo, D; Di Monaco, C; Ferri, GM; Galeazzi, M; Guido, F; Sebastiani, GD, 1999) |
| "Cross-sectional study in 42 patients with rheumatoid arthritis (29 women, aged 36-86 years) treated with 5 mg prednisolone/day, who had received prednisolone for ≥6 months (median: 66, range: 6-444 months)." | 5.24 | Adrenal insufficiency is seen in more than one-third of patients during ongoing low-dose prednisolone treatment for rheumatoid arthritis. ( Baslund, B; Borresen, SW; Feldt-Rasmussen, U; Friis-Hansen, L; Hansen, A; Hetland, ML; Hilsted, L; Klose, M; Locht, H; Lydolph, MC; Rasmussen, ÅK, 2017) |
| "Eighteen subjects with rheumatoid arthritis who had not taken oral glucocorticoids for ≥6 months were studied before and after prednisolone 6 mg/day for 7 days to determine the acute effects of prednisolone." | 5.22 | Effect of acute and chronic glucocorticoid therapy on insulin sensitivity and postprandial vascular function. ( Burt, MG; Drake, SM; Heilbronn, LK; Jenkins, AB; Mangelsdorf, BL; Radhakutty, A; Samocha-Bonet, D; Smith, MD; Thompson, CH, 2016) |
| "5 mg/week, sulfasalazine 2 g/day, with initial prednisolone 60 mg/day) after 26 weeks in patients with early active rheumatoid arthritis (RA)." | 5.20 | Intensive combination treatment regimens, including prednisolone, are effective in treating patients with early rheumatoid arthritis regardless of additional etanercept: 1-year results of the COBRA-light open-label, randomised, non-inferiority trial. ( Boers, M; den Uyl, D; Kerstens, P; Lems, WF; Nurmohamed, M; ter Wee, MM; van Schaardenburg, D; Voskuyl, AE, 2015) |
| "Treatment with initial high-dose prednisolone and a combination of methotrexate (MTX) and sulfasalazine (SSZ) according to the COBRA regimen (Dutch acronym for combinatietherapie bij reumatoide artritis, 'combination therapy for rheumatoid arthritis'), has repeatedly been demonstrated to be very effective in early rheumatoid arthritis (RA)." | 5.20 | Initial high-dose prednisolone combination therapy using COBRA and COBRA-light in early rheumatoid arthritis. ( Boers, M; Lems, WF; Rasch, LA; van Tuyl, LH, 2015) |
| "Early, intensive treatment of rheumatoid arthritis (RA) with the combination of (initially high dose) prednisolone, methotrexate and sulfasalazine (COBRA therapy) considerably lowers disease activity and suppresses radiological progression, but is infrequently prescribed in daily practice." | 5.19 | A non-inferiority trial of an attenuated combination strategy ('COBRA-light') compared to the original COBRA strategy: clinical results after 26 weeks. ( Boers, M; den Uyl, D; Dijkmans, B; Kerstens, P; Lems, W; Nurmohamed, M; Raterman, H; ter Wee, M; van Dillen, N; van Schaardenburg, D; Voskuyl, A, 2014) |
| "To examine the long-term effects of early low-dose prednisolone use in patients with rheumatoid arthritis (RA) on cardiovascular (CV) morbidity and mortality." | 5.19 | Low-dose prednisolone treatment of early rheumatoid arthritis and late cardiovascular outcome and survival: 10-year follow-up of a 2-year randomised trial. ( Ajeganova, S; Hafström, I; Svensson, B, 2014) |
| "To analyse if predictors of radiographic progression differ between patients treated with or without prednisolone in early rheumatoid arthritis (RA)." | 5.19 | Rheumatoid factor and anti-CCP do not predict progressive joint damage in patients with early rheumatoid arthritis treated with prednisolone: a randomised study. ( Boonen, A; Engvall, IL; Hafström, I; Rönnelid, J; Svensson, B; van der Heijde, D, 2014) |
| "Early treatment of patients with rheumatoid arthritis (RA) with combination treatment starting with methotrexate, sulfasalazine, hydroxychloroquine and prednisolone (FIN-RACo strategy) is superior to monotherapy." | 5.17 | Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study). ( Blåfield, H; Hannonen, PJ; Ilva, K; Julkunen, HA; Kaipiainen-Seppänen, O; Karjalainen, A; Kauppi, MJ; Kautiainen, H; Korpela, M; Laasonen, L; Leirisalo-Repo, M; Luosujärvi, R; Luukkainen, R; Moilanen, E; Möttönen, T; Paimela, L; Puolakka, K; Uutela, T, 2013) |
| "To conduct aphase II study to determine the efficacy and safety of BMS945429 in patients with active rheumatoid arthritis and an inadequate response to methotrexate." | 5.16 | A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate. ( Dimic, A; Liu, Y; Mease, P; Raskina, T; Shalamberidze, L; Smith, J; Strand, V; Xu, LA, 2012) |
| "To determine whether low-dose prednisolone affects body composition and bone mineral density (BMD) in patients with rheumatoid arthritis (RA), also considering inflammation and physical disability." | 5.15 | Treatment with low-dose prednisolone is associated with altered body composition but no difference in bone mineral density in rheumatoid arthritis patients: a controlled cross-sectional study. ( Brismar, K; Engvall, IL; Hafström, I; Tengstrand, B, 2011) |
| "To identify predictors of response to methotrexate (MTX) in early rheumatoid arthritis (RA)." | 5.15 | Predictors of response to methotrexate in early DMARD naive rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial. ( Bratt, J; Ernestam, S; Geborek, P; Petersson, IF; Saevarsdottir, S; Seddighzadeh, M; van Vollenhoven, RF; Wallin, H, 2011) |
| "A two-armed randomized trial of patients with early rheumatoid arthritis (RA) treated by either combination therapy (sulfasazaline, methotrextate, prednisolone) or monotherapy (sulfasazaline)." | 5.14 | Relapse-remission and remission-relapse switches in rheumatoid arthritis patients were modeled by random effects. ( Berkhof, J; Boers, M; Knol, DL; Rijmen, F; Twisk, JW; Uitdehaag, BJ, 2009) |
| "Bucillamine (Buc), developed in Japan, is a disease-modifying antirheumatic drug (DMARD) which has been used to treat numerous patients with rheumatoid arthritis (RA) in Japan and Korea with favorable results." | 5.14 | A comparative study of the effects of bucillamine and salazosulfapyridine in the treatment of rheumatoid arthritis. ( Abe, M; Kinoshita, M; Nakajima, M; Ohara, H; Ueda, N, 2009) |
| "To investigate the effects of vitamin K2 (Vit K2) alone or in combination with etidronate and risedronate on bone loss, osteoclast induction, and inflammation in patients with rheumatoid arthritis (RA)." | 5.13 | Osteoclast inhibitory effects of vitamin K2 alone or in combination with etidronate or risedronate in patients with rheumatoid arthritis: 2-year results. ( Morishita, M; Nagashima, M; Takahashi, H; Takenouchi, K; Wauke, K, 2008) |
| "To investigate the influence of anti-tumour necrosis factor antibody treatment (anti-TNF) with adalimumab on levels of myoglobin (degradation marker) and IGF1 in patients with rheumatoid arthritis with and without prednisolone treatment." | 5.12 | Anti-TNF antibody treatment improves glucocorticoid induced insulin-like growth factor 1 (IGF1) resistance without influencing myoglobin and IGF1 binding proteins 1 and 3. ( Atzeni, F; Cutolo, M; Sarzi-Puttini, P; Schölmerich, J; Straub, RH, 2006) |
| "Bucillamine (Buc) is a disease-modifying antirheumatic drug (DMARD) developed in Japan, which has been used as one of the first-line DMARDs for the treatment of rheumatoid arthritis (RA) in Japan." | 5.12 | Efficacy profile of bucillamine in rheumatoid arthritis patients in a large observational cohort study, IORRA. ( Hara, M; Inoue, E; Iwatani, M; Kamatani, N; Nakajima, A; Nakamura, T; Tomatsu, T; Yamanaka, H, 2006) |
| "This study evaluates the value of contrast-enhanced pulse-inversion harmonic imaging (PIHI) to detect synovial vascularization and thus the therapeutic effects of prednisolone treatment on the inflammation in finger joints in rheumatoid arthritis (RA)." | 5.12 | Power Doppler sonography and pulse-inversion harmonic imaging in evaluation of rheumatoid arthritis synovitis. ( Aletaha, D; Kainberger, F; Kapral, T; Krestan, C; Schueller, G; Schueller-Weidekamm, C, 2007) |
| "This pilot study aimed to determine if an elemental diet could be used to treat patients with active rheumatoid arthritis and to compare its effect to that of oral prednisolone." | 5.12 | Is rheumatoid arthritis a disease that starts in the intestine? A pilot study comparing an elemental diet with oral prednisolone. ( Mayberry, JF; Nightingale, JM; Oldham, R; Podas, T; Roy, S; Sheehan, NJ, 2007) |
| "The optimal methotrexate dose differs between rheumatoid arthritis (RA) patients, and dose-escalation strategies also differ among rheumatologists." | 5.12 | Influence of methotrexate dose on its efficacy and safety in rheumatoid arthritis patients: evidence based on the variety of prescribing approaches among practicing Japanese rheumatologists in a single institute-based large observational cohort (IORRA). ( Hara, M; Inoue, E; Kamatani, N; Nakajima, A; Tanaka, E; Taniguchi, A; Terai, C; Tomatsu, T; Yamanaka, H, 2007) |
| "To determine the influence of low-dose prednisolone on atherosclerosis, endothelial function, and risk factors for atherosclerosis in patients with early rheumatoid arthritis (RA)." | 5.12 | Effects of low-dose prednisolone on endothelial function, atherosclerosis, and traditional risk factors for atherosclerosis in patients with rheumatoid arthritis--a randomized study. ( Deneberg, S; Frostegård, J; Hafström, I; Jogestrand, T; Rohani, M; Wörnert, M, 2007) |
| "The aim of this study was to compare the pain relief and tolerability of SKI306X and celecoxib in patients with RA." | 5.12 | Assessment of comparative pain relief and tolerability of SKI306X compared with celecoxib in patients with rheumatoid arthritis: a 6-week, multicenter, randomized, double-blind, double-dummy, phase III, noninferiority clinical trial. ( Baek, HJ; Cha, HS; Jung, HG; Kang, SW; Kim, HA; Koh, EM; Lee, CK; Lee, EY; Lee, YJ; Song, YW; Suh, Y; Yoo, B, 2007) |
| "In the Finnish Rheumatoid Arthritis Combination Therapy trial, 195 patients with recent-onset RA were randomly assigned to receive either combination therapy with DMARDs (sulfasalazine, methotrexate, hydroxychloroquine) plus prednisolone or single therapy with a DMARD with or without prednisolone." | 5.11 | Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: a five-year randomized followup trial. ( Blåfield, H; Hakala, M; Hannonen, P; Julkunen, H; Kautiainen, H; Korpela, M; Leirisalo-Repo, M; Luukkainen, R; Möttönen, T; Paimela, L; Puolakka, K; Vuori, K, 2004) |
| "To evaluate the efficacy and safety of tacrolimus (FK506) in patients with active rheumatoid arthritis (RA) exhibiting resistance to disease modifying antirheumatic drug (DMARD) therapy, and to determine the optimal dosage." | 5.11 | Efficacy and safety of tacrolimus (FK506) in treatment of rheumatoid arthritis: a randomized, double blind, placebo controlled dose-finding study. ( Abe, T; Hara, M; Hashimoto, H; Irimajiri, S; Kondo, H; Sugawara, S; Uchida, S, 2004) |
| "A double blind, randomised, controlled trial over 12 weeks in 143 patients with active rheumatoid arthritis, comparing budesonide 3 mg daily, budesonide 9 mg daily, prednisolone 7." | 5.11 | A randomised placebo controlled 12 week trial of budesonide and prednisolone in rheumatoid arthritis. ( Bjorck, E; Book, C; Bowman, S; Byron, M; Cox, N; Field, M; Hällgren, R; Kanerud, L; Kirwan, JR; Leirisalo-Repo, M; Malaise, M; Mielants, H; Mohammad, A; Palmer, R; Persson, T; Petersson, IF; Ringertz, B; Sheldon, P; Simonsson, M; Snowden, N; Van den Bosch, F; Wollheim, F, 2004) |
| "To evaluate the effect of low dose oral prednisolone in early rheumatoid arthritis on disease activity over two years." | 5.11 | Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial. ( Capell, HA; Hampson, R; Hunter, JA; Larkin, J; Madhok, R; Morrison, E; Poon, FW; Porter, D; Thomson, EA, 2004) |
| "In the Finnish Rheumatoid Arthritis Combination Therapy trial, 195 patients with recent-onset RA were randomized to receive either a combination of disease-modifying antirheumatic drugs (DMARDs) with prednisolone or a single DMARD with or without prednisolone for 2 years." | 5.11 | Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial. ( Ahonen, J; Forsberg, S; Hakala, M; Hannonen, P; Järvinen, P; Kautiainen, H; Korpela, M; Leirisalo-Repo, M; Möttönen, T; Puolakka, K, 2005) |
| "To our knowledge, this is the first double-blind randomized study to show that disease-related loss of hand bone density in rheumatoid arthritis can be decelerated by prednisolone." | 5.11 | Reduced loss of hand bone density with prednisolone in early rheumatoid arthritis: results from a randomized placebo-controlled trial. ( Haugeberg, G; Kirwan, JR; Kvien, TK; Strand, A, 2005) |
| "To assess the efficacy of low-dose prednisolone on joint damage and disease activity in patients with early rheumatoid arthritis (RA)." | 5.11 | Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial. ( Albertsson, K; Boonen, A; Hafström, I; Keller, C; Svensson, B; van der Heijde, D, 2005) |
| "To assess the effect of 5 mg/day prednisolone on disease progression in patients with early rheumatoid arthritis (RA) receiving standardized disease-modifying antirheumatic drug (DMARD) therapy." | 5.11 | Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial. ( Rau, R; Steinfeld, P; Wassenberg, S; Zeidler, H, 2005) |
| "To assess the efficacy, safety, and optimal dose of tacrolimus monotherapy in patients with rheumatoid arthritis (RA)." | 5.10 | Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging study. ( Baldassare, A; Block, JA; Calabrese, L; Caldwell, J; Dietz, F; Fleischmann, MR; Furst, DE; Harris, RE; Hurd, E; Kaine, J; Matsumoto, A; Moreland, LW; Rutstein, J; Saag, K; Sack, M; Satoi, Y; Schiff, M; Schnitzer, T; Senter, RG; Sherrer, Y; Stamler, DA; Stein, CM; Wiesenhutter, C; Yocum, D, 2002) |
| "Twenty two patients with rheumatoid arthritis received a total of 29 treatments with five different combinations of rituximab (RTX), cyclophosphamide (CP), and/or high dose prednisolone (PR) on an open basis as follows; cohort I: RTX 1400 mg/m(2), CP 750x2+PR; cohort II: RTX 300-700 mg/m(2), -CP+/-PR); cohort III: RTX 600-700 mg/m(2), CP 750x2+PR; cohort IV: RTX 1200 mg/m(2), CP 750x2-PR; cohort V: RTX 500 mg/m(2), CP 750x2+PR." | 5.10 | Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. ( Cambridge, G; Edwards, JC; Leandro, MJ, 2002) |
| "The Combinatietherapie Bij Reumatoide Artritis (COBRA) trial demonstrated that step-down combination therapy with prednisolone, methotrexate, and sulfasalazine (SSZ) was superior to SSZ monotherapy for suppressing disease activity and radiologic progression of rheumatoid arthritis (RA)." | 5.10 | COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. ( Boers, M; Boonen, A; Dijkmans, BA; Jacobs, P; Landewé, RB; Markusse, HM; Peeters, AJ; van de Laar, MA; van Denderen, JC; van der Heijde, DM; van der Linden, S; Verhoeven, AC; Westedt, ML; Westhovens, R, 2002) |
| "In the FIN-RACo (FINnish Rheumatoid Arthritis Combination therapy) trial, 195 patients with recent-onset RA (median duration 6 months) were randomly assigned to receive either 1) a combination of DMARDs (sulfasalazine, methotrexate, hydroxychloroquine, and prednisolone) or 2) a single DMARD with or without prednisolone." | 5.10 | Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. ( Franzen, P; Gripenberg-Gahmberg, M; Hannonen, P; Helve, T; Ilonen, J; Kaipiainen-Seppänen, O; Kautiainen, H; Korpela, M; Koski, J; Laasonen, L; Leirisalo-Repo, M; Möttönen, T; Myllykangas-Luosujärvi, R; Nissilä, M, 2002) |
| "To study benefits and skeletal side effects of carefully monitored prednisolone treatment in patients with active rheumatoid arthritis." | 5.09 | A randomised trial of differentiated prednisolone treatment in active rheumatoid arthritis. Clinical benefits and skeletal side effects. ( Borch, A; Florescu, A; Hansen, M; Hansen, TM; Kluger, E; Podenphant, J; Stoltenberg, M; Sørensen, SF, 1999) |
| "To evaluate MRI for assessment of inflammation, destruction and prognosis in rheumatoid arthritis (RA), 26 RA patients, randomized to disease-modifying anti-rheumatic drug (DMARD) therapy alone or in combination with oral prednisolone, were followed for one year with contrast-enhanced MRI of the dominant wrist (months zero, three, six and 12), conventional radiography and clinical and biochemical examinations." | 5.09 | [Magnetic resonance imaging as a marker of inflammation, destruction and prognosis in rheumatoid arthritis wrists]. ( Gideon, P; Hansen, MS; Jensen, KE; Klarlund, M; Lorenzen, I; Ostergaard, M; Stoltenberg, MB, 2000) |
| "Data analysis from a randomized clinical trial with 155 rheumatoid arthritis (RA) patients; median age 50 yr, early and active disease (diagnosis < 2 yr); one group treated with a combination of sulphasalazine (SSZ; 2000 mg/day), methotrexate (MTX; 7." | 5.09 | Bone turnover, joint damage and bone mineral density in early rheumatoid arthritis treated with combination therapy including high-dose prednisolone. ( Boers, M; Geusens, P; Markusse, HM; te Koppele, JM; van der Laan, WH; van der Linden, S; Verhoeven, AC, 2001) |
| "In patients with early, active rheumatoid arthritis, prednisolone (7." | 5.08 | The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. ( Kirwan, JR, 1995) |
| "26 patients with rheumatoid arthritis were randomly divided into two equal groups and allocated to low doses of prednisolone at either 2." | 5.08 | The timing of glucocorticoid administration in rheumatoid arthritis. ( Arvidson, NG; Gudbjörnsson, B; Hällgren, R; Larsson, A, 1997) |
| "The aim of this study was to evaluate the efficiency of radiation synovectomy with rhenium-186 in rheumatoid arthritis." | 5.08 | Radiosynoviorthesis with rhenium-186 in rheumatoid arthritis: a prospective study of three treatment regimens. ( Becker, W; Göbel, D; Gratz, S; von Rothkirch, T; Willert, HG, 1997) |
| "The scheme 'Combination therapy in rheumatoid arthritis' (COBRA) in early rheumatoid arthritis (RA) involves administration of not only sulfasalazine but also prednisolone and methotrexate during the first six months." | 5.08 | [Combination therapy in early rheumatoid arthritis: the COBRA study]. ( Boers, M; van der Linden, S; Verhoeven, AC, 1997) |
| "To determine the effects of low-dose prednisolone on joint tissue metabolism in early rheumatoid arthritis (RA)." | 5.08 | Changes in biochemical markers of joint tissue metabolism in a randomized controlled trial of glucocorticoid in early rheumatoid arthritis. ( Kirwan, JR; Salisbury, C; Sharif, M; Taylor, DJ, 1998) |
| "Prednisolone reduced the progression of joint destruction over 2 yr in early, active rheumatoid arthritis." | 5.08 | Joint destruction after glucocorticoids are withdrawn in early rheumatoid arthritis. Arthritis and Rheumatism Council Low Dose Glucocorticoid Study Group. ( Hickling, P; Jacoby, RK; Kirwan, JR, 1998) |
| "Assessment of the cost-effectiveness and cost-utility of early intervention in rheumatoid arthritis (RA) patients, with combined step-down prednisolone, methotrexate and sulphasalazine, compared to sulphasalazine alone." | 5.08 | Cost-effectiveness and cost-utility of combination therapy in early rheumatoid arthritis: randomized comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone. COBRA Trial Group. Combinatietherapie Bij Reumat ( Bibo, JC; Boers, M; Engel, GL; van der Linden, S; Verhoeven, AC, 1998) |
| "To evaluate the therapeutic efficacy of 46 weeks of treatment with cyclosporine (5 mg/kg/day) in patients with rheumatoid arthritis (RA)." | 5.07 | Radiologic evidence of disease modification in rheumatoid arthritis patients treated with cyclosporine. Results of a 48-week multicenter study comparing low-dose cyclosporine with placebo. Norwegian Arthritis Study Group. ( Førre, O, 1994) |
| "A study of methotrexate (MTX) pharmacokinetics with and without prednisolone was performed in 33 patients with rheumatoid arthritis." | 5.07 | Is there an interaction between low doses of corticosteroids and methotrexate in patients with rheumatoid arthritis? A pharmacokinetic study in 33 patients. ( Acquaviva, PC; Catalin, J; Durand, A; Lafforgue, P; Monjanel-Mouterde, S, 1993) |
| "Altogether 53 patients (31 women, 22 men) with definite rheumatoid arthritis were randomly divided into groups of 5-6 patients and treated for one day only with one of the following non-steroidal anti-inflammatory drugs (NSAIDs): acetylsalicylic acid, carprofen, diclofenac, indomethacin, naproxen, proquazone, timegadine, tolfenamic acid or paracetamol, and with prednisolone, in recommended doses." | 5.06 | Effects of non-steroidal anti-inflammatory drugs and prednisolone on synovial fluid white cells, prostaglandin E2, leukotriene B4 and cyclic AMP in patients with rheumatoid arthritis. ( Isomäki, H; Nissilä, M; Seppälä, E; Vapaatalo, H; Wuorela, H, 1990) |
| "Pulse methylprednisolone therapy has dramatic effects on clinical and immunological parameters of disease activity in patients with rheumatoid arthritis." | 5.06 | Pulse steroid therapy in rheumatoid arthritis: can equivalent doses of oral prednisolone give similar clinical results to intravenous methylprednisolone? ( Ahern, MJ; Roberts-Thomson, PJ; Smith, MD, 1988) |
| "A study of pirprofen (rengasil) combined with small doses of corticosteroids in 93 patients with rheumatoid arthritis during a double blind multicentre testing showed good and satisfactory therapeutic results in 60%." | 5.06 | [Study of pirprofen (rengasil) combined with maintenance doses of corticosteroids in rheumatoid arthritis in a double-blind multicenter trial]. ( Alekberova, ZS; Kobaladze, SG; Pokryshkin, VI; Taletene, IP; Trofimova, TM, 1986) |
| "A multicenter double-blind study was carried out in patients with rheumatoid arthritis (RA) by comparing treatment with a novel immunomodulator, lobenzarit, disodium 4-chloro-2, 2'-iminodibenzoate, with an inert placebo." | 5.05 | A multicenter double-blind controlled study of lobenzarit, a novel immunomodulator, in rheumatoid arthritis. ( Abe, C; Honma, M; Horiuchi, Y; Kageyama, T; Mizushima, Y; Ofuji, T; Ogawa, N; Shichikawa, K; Shiokawa, Y; Yoshizawa, H, 1984) |
| "Forty-one patients with rheumatoid arthritis (RA) maintained on low dose prednisolone (mean 5." | 5.05 | The timing of prednisolone dosage and its effect on morning stiffness in rheumatoid arthritis. ( Binder, A; De Silva, M; Hazleman, BL, 1984) |
| "Twelve patients with rheumatoid arthritis took low dosage prednisolone, mean 5." | 5.05 | Time of day of prednisolone administration in rheumatoid arthritis. ( Knapp, MS; Kowanko, IC; Mahoney, PG; Pownall, R; Swannell, AJ, 1982) |
| " Two oral corticosteroids, prednisolone (8 mg/day) and betamethasone (1 mg/day) have been compared in terms of efficacy and adrenal suppressive activity when used in chronic oral dosage in rheumatoid arthritis." | 5.05 | A pharmacological and clinical comparison of prednisolone and betamethasone in rheumatoid arthritis. ( Al-Shakarchi, H; Bird, HA; Dixon, JS; Lowe, JR; Marwah, RJ; Pickup, ME; Wright, V, 1982) |
| "Indomethacin, 100 mg orally, was compared with prednisolone, 5 mg, as addititional therapy at night, in a two-week, double-blind, between-patient study in twenty-four in-patients with rheumatoid arthritis." | 5.04 | Indomethacin or prednisolone at night in rheumatoid arthritis? ( Murthy, MH; Rhymer, AR; Wright, V, 1978) |
| "A double-blind trial of prednisolone in patients with rheumatoid arthritis using doses of zero, 3 mg and 5 mg is reported." | 5.04 | The effect of low doses of prednisolone compared with placebo on function and on the hypothalamic pituitary adrenal axis in patients with rheumatoid arthritis. ( Chamberlain, MA; Keenan, J, 1976) |
| "In a controlled trial including 80 patients suffering from different stages of rheumatoid arthritis it was demonstrated that D-penicillamine therapy favourably influences the clinical course of the disease as compared to a control group treated with antirheumatic drugs." | 5.04 | [Long term treatment of rheumatoid arthritis. Experiences with D-penicillamine in comparison with gold and immunosuppressive drugs (author's transl)]. ( Gutmann, W; Scheiffarth, F; Warnatz, H, 1975) |
| " On the basis of its good local compatibility in relapsing effusions of the large articulations, mostly of the knee-joints, which appeared in the course of a chronic progressive rheumatoid arthritis of Bechterew's disease, cyclophosphamide was applied intraarticularly and was compared with the results after injections of prednisolone." | 5.04 | [Practical experiences in the intra-articular treatment of chronic rheumatic diseases]. ( Häntzschel, H; Otto, W; Reinelt, D, 1975) |
| "The ability of azathioprine to reduce the corticosteroid requirements of patients with severe rheumatoid arthritis was tested under double-blind conditions against placebo." | 5.03 | Azathioprine in rheumatoid arthritis. ( Barnes, CG; Currey, HL; Dunne, JF; Hazleman, BL; Mason, M; Strickland, ID, 1969) |
| "5 mg/day prednisone) in the treatment of rheumatoid arthritis is still controversial." | 4.90 | Glucocorticoid treatment in rheumatoid arthritis. ( Rau, R, 2014) |
| "This is a case of a 65-year-old man with seropositive erosive rheumatoid arthritis (RA), well controlled on methotrexate, sulfasalazine, low-dose prednisolone and monthly infusions of tocilizumab." | 4.89 | C reactive protein may not be reliable as a marker of severe bacterial infection in patients receiving tocilizumab. ( Bari, SF; Khan, A; Lawson, T, 2013) |
| "The effect of low dose corticosteroids, equivalent to 15 mg prednisolone daily or less, in patients with rheumatoid arthritis has been questioned." | 4.82 | Short-term low-dose corticosteroids vs placebo and nonsteroidal antiinflammatory drugs in rheumatoid arthritis. ( Gotzsche, PC; Johansen, HK, 2003) |
| "The effect of low dose corticosteroids, equivalent to 15 mg prednisolone daily or less, in patients with rheumatoid arthritis has been questioned." | 4.82 | Short-term low-dose corticosteroids vs placebo and nonsteroidal antiinflammatory drugs in rheumatoid arthritis. ( Gotzsche, PC; Johansen, HK, 2004) |
| "We report about a patient with polyarticular rheumatoid arthritis taking methotrexat and 5 mg prednisolone who developed in the course of a RA flare a septic arthritis in the right shoulder." | 4.81 | [Listeria arthritis in chronic polyarthritis during low dose prednisolone and methotrexate therapy. Case report and review of the literature]. ( Becker-Capeller, D; Braun, MG; Polnau, U; van den Boom, H, 2001) |
| "The effect of low dose corticosteroids, equivalent to 15 mg prednisolone daily or less, in patients with rheumatoid arthritis has been questioned." | 4.81 | Short-term low-dose corticosteroids vs placebo and nonsteroidal antiinflammatory drugs in rheumatoid arthritis. ( Gotzsche, PC; Johansen, HK, 2001) |
| "The effectiveness of low dose corticosteroids, equivalent to 15 mg prednisolone daily or less, in patients with rheumatoid arthritis has been questioned." | 4.81 | Short-term low-dose corticosteroids vs placebo and nonsteroidal antiinflammatory drugs in rheumatoid arthritis. ( Gotzsche, PC; Johansen, HK, 2002) |
| "To determine whether short-term, oral low dose prednisolone (< or = 15 mg daily) is superior to placebo and non-steroidal anti-inflammatory drugs in patients with rheumatoid arthritis." | 4.80 | Meta-analysis of short-term low dose prednisolone versus placebo and non-steroidal anti-inflammatory drugs in rheumatoid arthritis. ( Gøtzsche, PC; Johansen, HK, 1998) |
| "Combination therapy with methotrexate may be the newest standard to which future therapies for rheumatoid arthritis are compared." | 4.80 | Rheumatoid arthritis: new developments in the use of existing therapies. ( O'Dell, JR; Scott, DL, 1999) |
| "The effect of low dose corticosteroids, equivalent to 15 mg prednisolone daily or less, in patients with rheumatoid arthritis has been questioned." | 4.80 | Short-term low-dose corticosteroids vs placebo and nonsteroidal antiinflammatory drugs in rheumatoid arthritis. ( Gotzsche, PC; Johansen, HK, 2000) |
| "We conducted post hoc analyses of two cohorts that included a total of 280 Japanese women, 105 of whom had AIRDs and had been taking bisphosphonate (BP) and prednisolone (PSL) and 175 of whom had rheumatoid arthritis (RA)." | 4.31 | Risks of femoral localized periosteal thickening in patients with autoimmune inflammatory rheumatic diseases. ( Abe, A; Endo, N; Hasegawa, E; Ishikawa, H; Ito, S; Kazama, JJ; Kobayashi, D; Kondo, N; Kuroda, T; Kurosawa, Y; Nakatsue, T; Narita, I; Sato, H; Takai, C; Wakamatsu, A, 2023) |
| " In this case report, based on the efficacy of baricitinib in patients with rheumatoid arthritis (RA) and CEP, we aimed to show that the administration of Janus kinase (JAK) inhibitors, when RA is complicated by an allergic disease, can stabilize the disease state and help avoid the adverse effects of long-term systemic glucocorticoid administration." | 4.31 | A case of chronic eosinophilic pneumonia associated with rheumatoid arthritis in glucocorticoid-free remission with JAK inhibitor: A case report. ( Hashiramoto, A; Yamane, T, 2023) |
| "A morning standard dose of 250 mcg tetracosactide (Synacthen test) was given in 25 consecutive patients (13 rheumatoid arthritis, 2 psoriatic arthritis, 5 systemic lupus erythematosus, 2 dermatomyositis, 1 systemic sclerosis, 2 temporal arteritis) at the time of relapse upon small reductions (1-2 mg daily) of low prednisolone dose (<7." | 4.12 | Impaired adrenal cortex reserve in patients with rheumatic and musculoskeletal diseases who relapse upon tapering of low glucocorticoid dose. ( Filippa, MG; Panopoulos, S; Sfikakis, PP; Spanos, E; Spanos, G; Tektonidou, MG; Yavropoulou, MP, 2022) |
| "We describe a case of a 57-year-old white woman treated for rheumatoid arthritis (RA) with tofacitinib 10mg daily (started one year ago) and prednisolone 5mg daily." | 4.12 | Takotsubo Syndrome in a Rheumatoid Arthritis Patient Under Tofacitinib: A Case Report. ( Bernardes, M; Costa, L; Garcia, S; Martins, E; Pimenta, S; Terroso, G, 2022) |
| "A 78-year-old woman with rheumatoid arthritis on TNF-α inhibitor, methotrexate and prednisolone presented with severe but unspecific symptoms such as leg weakness, shivering, bifrontal headache, nausea and staggering." | 3.96 | [Neurological symptoms in a patient on anti-TNF therapy, methotrexate and prednisolone for rheumatoid arthritis]. ( Bach, M; Baerwald, C; Schob, S, 2020) |
| " Hypocomplementemic urticarial vasculitis improved after CZP was discontinued and the dose of oral prednisolone was increased." | 3.96 | Development of hypocomplementemic urticarial vasculitis during certolizumab pegol treatment for rheumatoid arthritis: A case report. ( Horai, Y; Ishikawa, H; Iwanaga, N; Izumi, Y; Kawakami, A; Matsuoka, Y; Miura, S, 2020) |
| " Here, we describe a case of tubercular osteomyelitis in an old fused hip of a patient with RA who received prednisolone, salazosulfapyridine (SASP), and low-dose methotrexate (MTX)." | 3.96 | Tuberculosis osteomyelitis in an old fused hip; activated by prednisolone, salazosulfapyridine, and low-dose methotrexate therapy in a patient with rheumatoid arthritis. ( Fukushi, JI; Ishitani, EI; Katsuki, I; Matsubara, H; Okada, F; Sonoda, Y, 2020) |
| " A 40-year-old man with a history of rheumatoid arthritis treated with prednisolone, Disease-Modifying Anti-Rheumatic Drugs (DMARDs), and biologic agents was admitted with chief complaints of fever, chills, malaise, myalgia, and dyspnea." | 3.96 | COVID-19 pandemic and biological therapy in rheumatologic disorders: how to deal with? ( Ahmadinejad, Z; Assari, R; Ayoobi Yazdi, N; Javanshayani, P; Khalili Afousi, H; Mazloomi, SH; Ziaee, V, 2020) |
| " After a meningeal biopsy, we redefined the diagnosis to rheumatoid meningitis (RM), and the patient showed remarkable improvement with prednisolone administration." | 3.91 | Rheumatoid meningitis can present MRI findings that mimic chronic subdural haematoma. ( Shinde, A; Suenaga, T; Yagita, K, 2019) |
| "Prednisolone (PD) is extremely effective for treating rheumatoid arthritis (RA)." | 3.91 | Co-Delivery of Prednisolone and Curcumin in Human Serum Albumin Nanoparticles for Effective Treatment of Rheumatoid Arthritis. ( Li, C; Li, H; Lin, Y; Tang, C; Yan, F; Zhong, Z; Zhou, M, 2019) |
| " She responded to intensive immunosuppressive therapy consisting of prednisolone, tacrolimus, and MTX with a parallel reduction of proteinuria." | 3.91 | Membranous nephropathy caused by rheumatoid arthritis. ( Hayashi, J; Honda, K; Iida, A; Inaba, T; Iyoda, M; Shibata, T; Tachibana, S; Wada, Y, 2019) |
| "This study aimed to evaluate the relationships between concomitant biologic disease-modifying anti-rheumatic drugs (DMARDs) and prednisolone administration and blood tacrolimus exposure or serum CYP3A4/5-related markers in rheumatoid arthritis (RA) patients without severe disease activity." | 3.91 | Relationships between concomitant biologic DMARDs and prednisolone administration and blood tacrolimus exposure or serum CYP3A4/5-related markers in rheumatoid arthritis patients. ( Kawakami, J; Naito, T; Ogawa, N; Ohshiro, J; Sato, H; Suzuki, M; Torikai, E, 2019) |
| "This investigation was aimed to explore the targeting potential of folate conjugated double liposomes (fDLs) bearing combination of synergistic drugs (Prednisolone and Methotrexate) for effective management of the rheumatoid arthritis (RA)." | 3.91 | Folate Conjugated Double Liposomes Bearing Prednisolone and Methotrexate for Targeting Rheumatoid Arthritis. ( Agrawal, GP; Jain, A; Jain, SK; Panda, PK; Saraf, S; Tiwari, A; Verma, A, 2019) |
| "Eighteen rheumatoid arthritis patients who had not taken prednisolone for >6 months (non-glucocorticoid (GC) users), 18 rheumatoid arthritis patients taking continuous oral prednisolone (6." | 3.85 | Opposing effects of rheumatoid arthritis and low dose prednisolone on arginine metabolomics. ( Burt, MG; Drake, SM; Mangelsdorf, BL; Mangoni, AA; Radhakutty, A; Rowland, A; Smith, MD; Thompson, CH, 2017) |
| " She had a 7-year history of rheumatoid arthritis (RA), which had been treated with methotrexate (MTX) and prednisolone." | 3.85 | Biopsy-proven case of Epstein-Barr virus (EBV)-associated vasculitis of the central nervous system. ( Anei, R; Asanome, A; Hasebe, N; Kamada, K; Kano, K; Katayama, T; Miyokawa, N; Nishihara, H; Saito, M; Saito, T; Sawada, J; Takahashi, K; Takeguchi, S, 2017) |
| "Arterial stiffness is not affected by low dose prednisolone per se, but is negatively associated with peripheral insulin sensitivity." | 3.85 | Low dose prednisolone and insulin sensitivity differentially affect arterial stiffness and endothelial function: An open interventional and cross-sectional study. ( Burt, MG; Greenfield, JR; Mangelsdorf, BL; Petersons, CJ; Poljak, A; Smith, MD; Thompson, CH, 2017) |
| " Rheumatoid vasculitis was diagnosed, and the patient began treatment with prednisolone and methotrexate, which improved his condition." | 3.83 | Recurrent Stenosis of the Ileum Caused by Rheumatoid Vasculitis. ( Aihara, H; Furukawa, NE; Naito, Y; Tago, M; Yamashita, S, 2016) |
| " Balb/c mice were divided into two groups: collagen antibody-induced arthritis (CAIA) and CAIA treated with prednisolone, the latter reflecting an established treatment in human rheumatoid arthritis." | 3.81 | Quantifying not only bone loss, but also soft tissue swelling, in a murine inflammatory arthritis model using micro-computed tomography. ( Cantley, M; Crotti, TN; Dharmapatni, AA; Haynes, DR; Marino, V; Perilli, E; Smith, MD, 2015) |
| " We present a case of postoperative polyarthritis with high inflammatory markers, which responded to a course of prednisolone." | 3.81 | Acute postoperative inflammatory polyarthritis associated with a lone IgM cardiolipin antibody. ( Chua, I; Jawad, A, 2015) |
| "Methotrexate (MTX) is the cornerstone of rheumatoid arthritis (RA) treatment." | 3.81 | Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: A retrospective analysis of real-world data from the St. Gallen cohort. ( Haile, SR; Müller, RB; Schiff, MH; von Kempis, J, 2015) |
| "To reveal how often patients with rheumatoid arthritis (RA) or any of other connective tissue diseases (CTDs) who take prednisolone (PSL) manifest postprandial hyperglycemia, and to evaluate the effects of divided daily dose administration of PSL, and of acarbose and nateglinide, on RA patients." | 3.80 | Early diagnosis and treatment of steroid-induced diabetes mellitus in patients with rheumatoid arthritis and other connective tissue diseases. ( Chino, Y; Goto, D; Hayashi, T; Ito, S; Kondo, Y; Matsumoto, I; Ogishima, H; Sugihara, M; Sumida, T, 2014) |
| " He presented with a high level of serum vascular endothelial growth factor (VEGF) and RS3PE syndrome-like pitting edema in the extremities, which improved following treatment with low-dose prednisolone." | 3.80 | Anti-citrullinated protein antibody-positive rheumatoid arthritis associated with RS3PE syndrome-like symptoms and an elevated serum vascular endothelial growth factor level in a patient with myasthenia gravis. ( Honda, M; Horai, Y; Ichinose, K; Kawakami, A; Kawashiri, SY; Motomura, M; Nakamura, H; Nakashima, Y; Nishino, A; Origuchi, T; Suzuki, T; Tamai, M, 2014) |
| "A 73-year-old woman with rheumatoid arthritis treated with methotrexate and prednisolone was admitted with dyspnea and ground-glass opacity on chest CT." | 3.80 | Deterioration of the immune response induced by sulfamethoxazole-trimethoprim in a rheumatoid arthritis patient with Pneumocystis jirovecii pneumonia. ( Gochi, M; Ishiguro, T; Miyahara, Y; Shimizu, Y; Sugita, Y; Takayanagi, N; Yanagisawa, T, 2014) |
| " A current user of 5mg prednisolone had a 30%, 46% or 100% increased risk of serious infection when used continuously for the last 3 months, 6 months or 3 years, respectively, compared to a non-user." | 3.78 | Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case-control analysis. ( Abrahamowicz, M; Beauchamp, ME; Bernatsky, S; Dixon, WG; Ray, DW; Suissa, S; Sylvestre, MP, 2012) |
| "We encountered a disseminated sporotrichosis patient with polyarthritis and progressive skin ulcers, who had been previously treated with prednisolone, tocilizmab, tacrolims, and cyclophosphamide under the diagnosis of rheumatoid arthritis in another hospital." | 3.78 | A case of disseminated sporotrichosis treated with prednisolone, immunosuppressants, and tocilizumab under the diagnosis of rheumatoid arthritis. ( Goto, D; Goto, M; Hayashi, T; Horikoshi, M; Ito, S; Matsumoto, I; Sumida, T; Takano, Y; Umeda, N; Yamaguchi, T, 2012) |
| "A 66-year-old woman with seropositive rheumatoid arthritis (RA) and latent tuberculosis infection developed minimal-change nephrotic syndrome following the initiation of anti-tuberculosis chemoprophylaxis with isoniazid." | 3.77 | Minimal-change nephrotic syndrome associated with isoniazid in anti-tuberculosis chemoprophylaxis for a patient with rheumatoid arthritis. ( Arizono, K; Matsushita, Y; Mori, S, 2011) |
| "The objective of this study was to assess the usefulness of tacrolimus (TAC) for rheumatoid arthritis (RA) patients." | 3.76 | Efficacy and safety of tacrolimus in 101 consecutive patients with rheumatoid arthritis. ( Inoue, E; Kaneko, H; Kitahama, M; Koseki, Y; Momohara, S; Okamoto, H; Taniguchi, A; Yamanaka, H, 2010) |
| " We treated a patient who developed polymyositis (PM) following the treatment of RA with leflunomide." | 3.75 | Leflunomide-induced polymyositis in a patient with rheumatoid arthritis. ( Nagashima, M; Ochi, S; Taniguchi, K, 2009) |
| "In this study, we investigated the effect of the antitumor necrosis factor alpha (anti-TNF-alpha) antibody, infliximab, combined with methotrexate (MTX) and MTX alone on the serum levels of interleukin (IL)-23 and IL-17 in rheumatoid arthritis (RA) patients." | 3.75 | Infliximab treatment reduces the serum levels of interleukin-23 in patients with rheumatoid arthritis. ( Kageyama, Y; Kato, N; Kobayashi, H, 2009) |
| "We attempted to determine what baseline variables are responsible for the efficacy of tacrolimus at 6 months in Japanese patients with rheumatoid arthritis (RA)." | 3.75 | Prediction of DAS28-CRP remission in patients with rheumatoid arthritis treated with tacrolimus at 6 months by baseline variables. ( Aoyagi, K; Aramaki, T; Arima, K; Eguchi, K; Fujikawa, K; Furuyama, M; Ida, H; Iwamoto, N; Kamachi, M; Kawakami, A; Kawashiri, SY; Matsuoka, N; Mizokami, A; Nakamura, H; Nakashima, M; Origuchi, T; Tamai, M; Ueki, Y; Yamasaki, S, 2009) |
| "To evaluate if remission induced by low-dose prednisolone during the first 2 years of rheumatoid arthritis (RA) in the BARFOT glucocorticoid (GC) study had a sustained effect on radiological damage for a total of 4 years." | 3.75 | Remission achieved after 2 years treatment with low-dose prednisolone in addition to disease-modifying anti-rheumatic drugs in early rheumatoid arthritis is associated with reduced joint destruction still present after 4 years: an open 2-year continuation ( Albertsson, K; Boonen, A; Hafström, I; Landewé, R; Svensson, B; van der Heijde, D, 2009) |
| "Leflunomide is an immunomodulating agent with proven efficacy in rheumatoid arthritis." | 3.74 | Leflunomide-induced toxic epidermal necrolysis in a patient with rheumatoid arthritis. ( Baaj, M; El Haouri, M; Hadri, L; Hassikou, H; Safi, S; Tabache, F, 2008) |
| "To evaluate the potential of using prednisolone phosphate (PSLP)-containing 3,5-dipentadecyloxybenzamidine hydrochloride (TRX-20) liposomes to treat rheumatoid arthritis (RA), we examined their ability to bind human fibroblast-like synovial (HFLS) cells and their effects in these cells." | 3.74 | Prednisolone phosphate-containing TRX-20 liposomes inhibit cytokine and chemokine production in human fibroblast-like synovial cells: a novel approach to rheumatoid arthritis therapy. ( Hagiwara, H; Harigai, T; Ishizuka, T; Kaneda, S; Kimura, J; Ogawa, Y, 2007) |
| " The disease appeared during low-dose oral methotrexate (MTX) therapy for rheumatoid arthritis." | 3.74 | Massive myelinolytic leukoencephalopathy in a patient medicated with low-dose oral methotrexate for rheumatoid arthritis: an autopsy report. ( Harigaya, Y; Igeta, Y; Itoh, H; Nakazato, Y; Sasaki, N; Yokoo, H, 2007) |
| "The Combinatietherapie Bij Reumatoide Artritis (COBRA) trial has proved that combination therapy with prednisolone, methotrexate and sulphasalazine is superior to sulphasalazine monotherapy in suppressing disease activity and radiological progression of early rheumatoid arthritis (RA)." | 3.74 | Why are Dutch rheumatologists reluctant to use the COBRA treatment strategy in early rheumatoid arthritis? ( Boers, M; Dijkmans, BA; Lems, WF; Plass, AM; van Tuyl, LH; Voskuyl, AE, 2007) |
| "We report a case of rheumatoid arthritis (RA) complicated by myelodysplastic syndrome (MDS) successfully treated by tacrolimus." | 3.74 | Successful treatment using tacrolimus plus corticosteroid in a patient with RA associated with MDS. ( Funauchi, M; Kinoshita, K; Nagare, Y; Nozaki, Y; Urase, F, 2008) |
| "To ascertain changes in axial bone mineral in premenopausal women with severe rheumatoid arthritis (RA) treated with and without prednisolone (PRED), we conducted a two-year follow-up study of axial bone mineral density (BMD) and bone mineral content (BMC)." | 3.74 | Changes in bone mineral density in premenopausal women with rheumatoid arthritis during a two-year follow-up. ( Hakala, M; Hämäläinen, H; Järvenpää, S; Kaarela, K; Kauppi, M; Kotaniemi, A; Kröger, H, 2007) |
| " She had a history of rheumatoid arthritis (RA) for 26 years, and had been taking methotrexate and prednisolone." | 3.74 | [Case of malignant lymphoma associated with rheumatoid arthritis]. ( Kono, T; Noguchi, T; Nohara, J; Sakaguchi, Y; Terada, Y, 2008) |
| "A 63-year-old woman with active rheumatoid arthritis (RA) had been treated with methotrexate and prednisolone." | 3.74 | Reversible infliximab-related lymphoproliferative disorder associated with Epstein-Barr virus in a patient with rheumatoid arthritis. ( Komatsuda, A; Nimura, T; Sawada, K; Wakui, H, 2008) |
| "We describe a 54-year-old woman with rheumatoid arthritis (RA), who developed acute respiratory failure 2 weeks after cessation of 6-week treatment with leflunomide." | 3.73 | Leflunomide induced acute interstitial pneumonia. ( Adachi, D; Akiba, H; Akiyama, Y; Hirano, M; Mimura, T; Takeishi, M, 2005) |
| " We report on a patient with rheumatoid arthritis treated with etanercept for 2 years, in addition to methotrexate and prednyliden, who developed fulminant pneumococcal pneumonia with rapid progression to fatal acute respiratory distress syndrome (ARDS) and septic shock." | 3.73 | Lethal acute respiratory distress syndrome during anti-TNF-alpha therapy for rheumatoid arthritis. ( Beiderlinden, M; Peters, J; Zimmer, C, 2006) |
| "To compare antibody responses to 23-valent pneumococcal vaccine (Pneumovax) in controls and patients with established rheumatoid arthritis (RA) treated with TNF blockers, methotrexate (MTX) or a combination of both." | 3.73 | Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. ( Geborek, P; Jönsson, G; Kapetanovic, MC; Saxne, T; Sjöholm, A; Truedsson, L, 2006) |
| "To assess adrenal function with respect to the presence or absence of steroid therapy, we investigated differences in the blood levels of adrenocorticotropic hormone (ACTH) and dehydroepiandrosterone sulfate (DHEAS) in relation to steroid (prednisolone) administration in 123 patients with rheumatoid arthritis (RA)." | 3.73 | Adrenocorticotropic hormone and dehydroepiandrosterone sulfate levels of rheumatoid arthritis patients treated with glucocorticoids. ( Komatsubara, Y; Ochi, T; Toyosaki-Maeda, T; Yonenobu, K; Yukioka, K; Yukioka, M, 2006) |
| " He was subsequently diagnosed with rheumatoid arthritis and prescribed 20 mg methotrexate weekly, 3 mg/kg ciclosporin daily and 5 mg prednisolone daily." | 3.73 | Lupus anticoagulant and ischemic myocardial microangiopathy in rheumatoid arthritis. ( Alivernini, S; De Santis, M; Ferraccioli, G; Loperfido, F; Verrillo, A; Zoli, A, 2006) |
| "To study which factors are associated with longterm methotrexate (MTX) use in rheumatoid arthritis (RA)." | 3.72 | Longterm observational study of methotrexate use in a Dutch cohort of 1022 patients with rheumatoid arthritis. ( Bernelot Moens, HJ; Haagsma, CJ; Hoekstra, M; Kruijsen, MW; van de Laar, MA, 2003) |
| "To investigate the mechanisms underlying glucocorticoid (GC) resistance in rheumatoid arthritis (RA), we evaluated the suppressive effects of prednisolone (PSL) or methylprednisolone (MPSL) on the blastogenesis of peripheral blood mononuclear cells (PBMC)." | 3.72 | Role of mRNA expression of transcription factors in glucocorticoid sensitivity of peripheral blood mononuclear cells and disease state in rheumatoid arthritis. ( Abe, H; Hayashi, T; Hirano, T; Niitsuma, T; Oka, K; Onda, K; Rimbara, E; Tahara, K; Takanashi, H; Tsuboi, N, 2004) |
| "We report a patient with rheumatoid arthritis (RA) who developed malignant lymphoma of the diffuse large B-cell type in the right submandibular region shortly after initiation of oral methotrexate (MTX)." | 3.72 | Malignant lymphoma associated with rheumatoid arthritis, developing shortly after initiation of oral methotrexate. ( Gono, T; Hoshi, K; Ikeda, S; Matsuda, M; Shikama, N; Shimojima, Y; Tokuda, T; Yamamoto, K, 2004) |
| " We report a case of a 61-year-old man with seronegative rheumatoid arthritis and fibrosing alveolitis on long-term prednisolone who presented with a number of tender, red, subcutaneous nodules on his upper arms and a pustule on his left cheek." | 3.72 | Disseminated cutaneous infection with Mycobacterium chelonae in a patient with steroid-dependent rheumatoid arthritis. ( Lamb, SR; Merchant, W; Stables, GI, 2004) |
| "A 63-year-old woman had D-penicillamine-induced pemphigus with a high index value of circulating autoantibodies against desmoglein 1." | 3.72 | D-penicillamine-induced pemphigus successfully treated with combination therapy of mizoribine and prednisolone. ( Hirokawa, H; Izu, K; Sugita, K; Tokura, Y, 2004) |
| "The synthesis, activity and mass of LPL in adipose tissue were studied in patients with rheumatoid arthritis (RA) treated with prednisolone (PSL) (PSL-treated group) and untreated patients with osteoarthritis (untreated group)." | 3.71 | Active-dimeric form of lipoprotein lipase increases in the adipose tissue of patients with rheumatoid arthritis treated with prednisolone. ( Kidani, T; Masuno, H; Matsuda, Y; Okuda, H; Sakayama, K; Takubo, N; Yamamoto, H, 2002) |
| "It is known and has been repeatedly demonstrated that low doses of prednisone or prednisolone (10 mg daily or 5 mg bid) will control most of the inflammatory features of early polyarticular rheumatoid arthritis (Table 2)." | 3.71 | Resolved: Low-dose prednisone is indicated as a standard treatment in patients with rheumatoid arthritis. ( Conn, DL, 2001) |
| "While being treated with corticosteroids and methotrexate for rheumatoid arthritis, a 63-year-old man developed livid nodules on his lower arms, hands and feet, as well as fever, necrotizing skin ulcers and rupture of a finger extensor tendon." | 3.71 | [Skin nodules and ulcers of the limbs in a patient with rheumatoid arthritis]. ( Böcher, W; Galle, PR; Märker-Hermann, E, 2002) |
| "To study pharmacokinetics of prednisolone in patients with rheumatoid arthritis (RA)." | 3.71 | [Pharmacokinetic of prednisolone in patients with rheumatoid arthritis]. ( Chekalin, AF; Nesterov, SL; Rossokhin, VF; Shishkanov, SF, 2002) |
| "A 75-year old man with rheumatoid arthritis developed bronchiolitis obliterans organizing pneumonia (BOOP), which responded to treatment with prednisolone (1 mg/kg/d) and cyclophosphamide (100 mg/d)." | 3.70 | Bronchiolitis obliterans organizing pneumonia in a patient with rheumatoid arthritis. ( Billey, T; Farny, M; Lassoued, S; Olivier, P; Pommepuy, I, 1998) |
| " She had been treated with prednisolone for a long time, and had renal amyloidosis secondary to RA." | 3.70 | Cryptococcal pleural effusion in a patient with chronic renal failure receiving long-term corticosteroid therapy for rheumatoid arthritis. ( Fukuchi, M; Hori, T; Kobayashi, M; Mizushima, Y, 1998) |
| "Estimate the contribution of monocytes/macrophages to the disease process in rheumatoid arthritis (RA), by measuring the serum levels of the leucocyte-derived granular proteins: lysozyme, myeloperoxidase (MPO), lactoferrin and human neutrophil lipocalin (HNL)." | 3.70 | Serum lysozyme: a potential marker of monocyte/macrophage activity in rheumatoid arthritis. ( Arvidson, NG; Gudbjörnsson, B; Hâkansson, L; Hällgren, R; Torsteinsdóttir, I; Venge, P, 1999) |
| " The course of the disease and the shape of the lesions strongly suggested involvement of rheumatoid vasculitis; oral administration of prednisolone was effective." | 3.70 | Rheumatoid arthritis accompanied by colonic lesions. ( Matake, H; Matsui, T; Matsumura, M; Nagahama, T; Sakurai, T; Schlemper, R; Tsuda, S; Yao, T, 2000) |
| "To compare patterns and time trends of initial disease-modifying antirheumatic drugs (DMARDs) and prednisolone prescriptions for patients with rheumatoid arthritis (RA) by the rheumatologists at King Chulalongkorn Memorial Hospital, Bangkok, Thailand over a 15-year period, as well as their side effects." | 3.70 | Initial disease modifying antirheumatic drugs and prednisolone prescriptions for patients with rheumatoid arthritis: a 15-year study. ( Akkasilpa, S; Deesomchok, U; Osiri, M, 2000) |
| "We compared lymphocyte-suppressive potencies of prednisolone and methylprednisolone in rheumatoid arthritis (RA)." | 3.70 | Comparative study of lymphocyte-suppressive potency between prednisolone and methylprednisolone in rheumatoid arthritis. ( Abe, H; Hayashi, T; Hirano, T; Homma, M; Oka, K; Tahara, K; Takanashi, H; Takekoshi, T; Tsuboi, N; Urata, Y, 2000) |
| " He had an 11-year history of sero-negative rheumatoid arthritis (Stage III) maintained by daily administration of 10 mg of prednisolone and 300 mg of actarit." | 3.70 | [Eosinophilic meningoencephalitis in a case of rheumatoid arthritis]. ( Higuchi, M; Koyanagi, M; Motomura, S; Sakai, Y; Tsuda, Y, 1998) |
| "To determine daily production of nitric oxide (NO) measured as urinary nitrate excretion, and the effect of prednisolone in patients with rheumatoid arthritis (RA)." | 3.69 | Urinary nitrate excretion is increased in patients with rheumatoid arthritis and reduced by prednisolone. ( Fauler, J; Frölich, JC; Stichtenoth, DO; Zeidler, H, 1995) |
| "30 patients with rheumatoid arthritis were treated with a weekly low dose of Methotrexate for a period of 12 months." | 3.69 | [Low dosage methotrexate treatment in chronic polyarthritis]. ( Knoflach, P; Puchner, R; Roithinger, FX; Steglegger-Friede, B, 1994) |
| " Though the treatment with prednisolone and dipyridamole against nephrotic syndrome and amyloidosis due to RA was not effective, cyclophosphamide, which was added after tapering of prednisolone, was able to induce remission of nephrotic syndrome after two years." | 3.69 | Combined treatment with cyclophosphamide and prednisolone can induce remission of nephrotic syndrome in a patient with renal amyloidosis, associated with rheumatoid arthritis. ( Hiromura, K; Kanai, H; Maezawa, A; Mitsuhashi, H; Naruse, T; Tsukada, Y; Yano, S, 1994) |
| " In four of the patients with rheumatoid arthritis, serum IL-6 levels were measured before and after one week of treatment with prednisolone 15-20 mg daily." | 3.69 | Circadian rhythm of serum interleukin-6 in rheumatoid arthritis. ( Arvidson, NG; Elfman, L; Gudbjörnsson, B; Hällgren, R; Rydén, AC; Tötterman, TH, 1994) |
| "D-penicillamine, an agent still used in the treatment of rheumatoid arthritis (RA) may produce inflammatory myopathy or myositis." | 3.69 | D-penicillamine-induced myositis in rheumatoid arthritis. ( Chappel, R; Willems, J, 1996) |
| " Follicular bronchiolitis was diagnosed from the results of an open-lung biopsy, and prednisolone therapy was started at a dosage of 40 mg/day." | 3.69 | [Follicular bronchiolitis associated with rheumatoid arthritis]. ( Chida, K; Hayakawa, H; Imokawa, S; Iwata, M; Morita, S; Sato, A; Sato, J; Todate, A; Toyoshima, M; Tsukamoto, K, 1996) |
| "The possible association of leukotriene B4 (LTB4)-like activity with the development of active rheumatoid arthritis was studied in 25 children with the disease and in 15 normal subjects." | 3.69 | Increased serum leukotriene B4 level in the active stage of rheumatoid arthritis in children. ( Ercan, ZS; Firat, S; Gürsel, T, 1997) |
| "A 59-year-old woman with diabetes and rheumatoid arthritis was given prednisolone following the diagnosis of rheumatoid lung disease." | 3.68 | [Successful surgery for pulmonary aspergillosis progressing to subacute process]. ( Itoh, Y; Kawaguchi, H; Mukohyama, N; Noguchi, M; Ohshika, H; Senda, Y; Suzuki, M; Torii, Y; Totani, Y; Wakayama, H, 1993) |
| "In a patient suffering from rheumatoid arthritis, we report the first simultaneous occurrence of two side effects of low-dose methotrexate: an acute megaloblastic anaemia and a pneumonitis." | 3.68 | Concurrent acute megaloblastic anaemia and pneumonitis: a severe side-effect of low-dose methotrexate therapy during rheumatoid arthritis. ( Bolla, G; Disdier, P; Harle, JR; Verrot, D; Weiller, PJ, 1993) |
| "The sex hormones dehydroepiandrosterone sulphate (DHEAS), oestradiol, and sex hormone binding globulin (SHBG) were measured in 185 postmenopausal women (aged 45-65 years) with rheumatoid arthritis (RA) and related to assessments of bone mineral density at the spine and proximal femur." | 3.68 | Depressed levels of dehydroepiandrosterone sulphate in postmenopausal women with rheumatoid arthritis but no relation with axial bone density. ( Hall, GM; Perry, LA; Spector, TD, 1993) |
| " Based on her systemic arthralgia, positive RA factor, and characteristic pleural effusion, the diagnosis of rheumatoid pleural effusion was made and prednisolone was administered." | 3.68 | [A case of rheumatoid arthritis accompanied by repeated pleural effusion associated with rapid tapering of steroid]. ( Soejima, R; Sumi, M; Umeki, S, 1993) |
| "A 40 year old woman with rheumatoid arthritis developed pure red cell aplasia after treatment with D-penicillamine 500 mg/day." | 3.68 | Pure red cell aplasia caused by D-penicillamine treatment of rheumatoid arthritis. ( Kahn, Y; Tishler, M; Yaron, M, 1991) |
| "A patient with rheumatoid arthritis-associated interstitial pneumonitis, treated with prednisolone, developed mild colitis due to Clostridium difficile in association with the use of cefotaxime (CTX)." | 3.67 | Cefotaxime-associated diarrhea and Clostridium difficile. ( Funada, H; Hattori, K; Ishizaki, T; Kuroda, T; Nakamura, S, 1984) |
| "In the course of molecular biological research on patients with classical rheumatoid arthritis (according to ARA criteria), an investigation was carried out on the influence of different doses of prednisolone on semiconservative DNA synthesis, the sedimentation of nucleoids before and after gamma-irradiation and protein synthesis in synovial fluid cells." | 3.67 | [Molecular biology studies of synovial fluid cells of patients with chronic polyarthritis after intra-articular prednisolone medication]. ( Bröll, H, 1984) |
| "Thirty-one patients with rheumatoid arthritis maintained on prednisolone 5 mg daily for an average period of 9." | 3.67 | Prolonged low-dose corticosteroid therapy and osteoporosis in rheumatoid arthritis. ( Hajiroussou, VJ; Webley, M, 1984) |
| "A 60-year-old man with seropositive rheumatoid arthritis developed rapidly progressive dyspnoea and bilateral pulmonary infiltrates on short exposure to 50 mg penicillamine daily." | 3.67 | Diffuse alveolitis on a small dose of penicillamine. ( Chattopadhyay, C; Shettar, SP; Swinson, DR; Wolstenholme, RJ, 1984) |
| "A patient with rheumatoid arthritis and collagenous colitis apparently responding to sulfasalazine and prednisolone enemas is reported." | 3.67 | Collagenous colitis: possible response to sulfasalazine and local steroid therapy. ( Farah, DA; Lee, FD; McLay, A; Mills, PR; Russell, RI, 1985) |
| "Pulse prednisolone hemisuccinate therapy (500 mg given intravenously on three occasions over two weeks) has been combined with either intramuscular sodium aurothiomalate or azathioprine in an assessment of 30 patients with rheumatoid arthritis." | 3.67 | A comparison of prednisolone with azathioprine and prednisolone with intramuscular gold in rheumatoid arthritis. ( Arnold, S; Astbury, G; Bird, HA; Dixon, JS; Häntzschel, H; Krüger, W; Otto, W; Seidel, W; Winiecki, P; Wright, V, 1988) |
| "Methylprednisolone pulse therapy is often used in patients with severe rheumatoid arthritis (RA)." | 3.67 | Comparison of methylprednisolone (1 g i.v.) with prednisolone (1 g orally) in rheumatoid arthritis: a pharmacokinetic and clinical study. ( Boutagy, J; Brooks, PM; Cosh, D; Donovan, S; McCredie, M; Needs, CJ; Smith, M, 1988) |
| "The pharmacokinetic profile of a single 10 mg oral dose of prednisolone was studied in three groups of six patients with rheumatoid arthritis (RA), polymyalgia rheumatica (PMR) and bronchial asthma (BA) who were already receiving steroid therapy." | 3.67 | Prednisolone pharmacokinetics in patients with rheumatoid arthritis, polymyalgia rheumatica and asthma. ( Astbury, C; Bird, HA; Dixon, JS; Taggart, AJ, 1986) |
| "The effects of a single dose of 5 and 10 mg of prednisolone on the kinetics of lymphocytes and T lymphocyte subsets were investigated in patients suffering from active rheumatoid arthritis." | 3.66 | The effect of low doses of prednisolone on the traffic of T helper-inducer cells in rheumatoid arthritis. ( Delanghe, J; Hermanns, P; Vansteenkiste, M; Verbruggen, G; Veys, EM, 1982) |
| "Plasma prednisolone levels were measured in parallel with clinical and laboratory assessments in seven patients with rheumatoid arthritis on single daily doses of prednisolone which were reduced at weekly intervals from 10 mg." | 3.66 | Plasma levels and response to prednisolone therapy in rheumatoid arthritis. ( Chakraborty, J; De Silva, M; English, J; Hazleman, BL; Marks, V, 1983) |
| "The prednisolone sparing effect of benoxaprofen has been examined in only 13 cases of rheumatoid arthritis." | 3.66 | [Prednisolone reduction by benoxaprofen]. ( Mathies, H; Wolff, E, 1982) |
| "The dose-reducing effect of [1-(p-chlorobenzoyl)-5-methoxy-2-methylindol-3-acetoxy[ acetic acid (acemetacin, TV 1322, Rantudil¿) on prednisolon was studied on 22 patients suffering from rheumatoid arthritis." | 3.66 | [Study of the dose-reducing effect of acemetacin on prednisolon (author's transl)]. ( Mathies, H; Wolff, E, 1980) |
| "Eight patients with rheumatoid arthritis received an intra-articular injection of either 50 mg or 100 mg of prednisolone acetate into the knee joint." | 3.66 | Plasma steroid levels after intra-articular injection of prednisolone acetate in patients with rheumatoid arthritis. ( Chakraborty, J; English, J; Gibson, T; Marks, V; Reeback, JS, 1980) |
| "Thirty-two female patients with rheumatoid arthritis were divided into 3 groups and treated for 6 months with prednisolone, depot tetracosactrin, or indomethacin." | 3.66 | Whole body elemental composition during drug treatment of rheumatoid arthritis: a preliminary study. ( Boddy, K; Elliott, AT; Harvey, I; Haywood, JK; Holloway, I; Kennedy, AC; Williams, ED, 1979) |
| "The addition of phenobarbitone in therapeutic dosage to the drug regimen of prednisolone-treated subjects with rheumatoid arthritis produced measurable deterioration in the clinical status of the patients associated with a more rapid clearance of prednisolone from plasma." | 3.65 | Effects of enzyme induction on metabolism of prednisolone. Clinical and laboratory study. ( Brooks, PM; Buchanan, WW; Downie, WW; Grove, M, 1976) |
| "Since for various reasons the Lansbury Index appeared inadequate to define the therapeutic efficacy of antirheumatic compounds, we chose to investigate in our trials the prednisolone saving effect in patients with rheumatoid arthritis." | 3.65 | [Steroid saving effect of naproxen]. ( Mathies, H, 1975) |
| " After their base-line blood levels had been assessed, 3 patients with classical rheumatoid arthritis (according to ARA criteria; American Rheumatism Association) received 500 mg of d-2-(6'-methoxy-2'-naphthyl)-propionic acid (naproxen) daily (in capsules)." | 3.65 | [Effect of naproxen on DNA synthesis and DNA repair of human lymphocytes in in vivo experiments]. ( Tausch, G, 1975) |
| "Thirteen patients with rheumatoid or psoriatic arthritis who had not previously received corticosteroids were treated with prednisolone in a single-dose each morning." | 3.65 | Single daily dose corticosteroid treatment. ( Daly, JR; Glass, D; Myles, AB; Schiller, LF, 1976) |
| "Azathioprine has been shown to reduce the steroid requirements of patients with severe rheumatoid arthritis." | 3.65 | Further experience with azathioprine in rheumatoid arthritis. ( Chaput de Saintonge, DM; Harris, J; Jessop, JD, 1971) |
| " The chemotactic indices in three patients with severe connective tissue disease (seropositive rheumatoid arthritis, systemic lupus erythematosus, and polymyositis) returned to normal after 5 days' treatment with 60 mg of prednisolone per day." | 3.65 | Chemotaxis of polymorphonuclear leukocytes from patients with rheumatoid arthritis. ( Baum, J; Mowat, AG, 1971) |
| "The concentrations of free and protein-bound L-tryptophan were measured in sera from normal subjects, patients with rheumatoid arthritis, pregnant women, and patients with jaundice." | 3.65 | Mode of action of antirheumatic drugs. ( Dawkins, PD; Hamilton, EB; McArthur, JN; Smith, MJ, 1971) |
| " Salicylates are preferred to adrenocortical steroids in the treatment of the ordinary patient with acute rheumatic fever." | 3.64 | NONSPECIFIC ANTI-INFLAMMATORY AGENTS. SOME NOTES ON THEIR PRACTICAL APPLICATION, ESPECIALLY IN RHEUMATIC DISORDERS. ( BOLAND, EW, 1964) |
| "Two examples of hematological toxicity following phenylbutazone therapy are described, one of agranulocytosis and one of aplastic anemia." | 3.64 | HEMATOLOGICAL COMPLICATIONS OF PHENYLBUTAZONE THERAPY: REVIEW OF THE LITERATURE AND REPORT OF TWO CASES. ( CHALMERS, TM; MCCARTHY, DD, 1964) |
| "To appraise the efficiency of complemental antacid administration in preventing and reducing digestive disturbances during prolonged treatment with prednisone and prednisolone, 100 patients with active rheumatoid arthritis who were maintained on combined antacid and prednisone or prednisolone therapy for periods of one year or longer, were studied clinically and roentgenographically." | 3.63 | Effectiveness of antacids in reducing digestive disturbances in patients treated with prednisone and prednisolone. ( BOLAND, EW, 1958) |
| "A total of 170 patients who had been treated for rheumatoid arthritis at our hospital from August 2016 and June 2018, were enrolled as research objects." | 2.90 | Observation of the clinical effect of the combined therapy of zushima tablet and western medicine in the treatment of rheumatoid arthritis and MRI test results. ( Ji, H; Sun, Q; Tang, Z, 2019) |
| " The benefits of glucocorticoids in terms of symptoms and structural damage were confirmed, but the proportion of patients with at least one adverse event of special interest (serious or glucocorticoids-related) was increased by 24%, mostly due to nonsevere infections." | 2.82 | The safety of glucocorticoids in the treatment of inflammatory rheumatic disease: new evidence. ( Boers, M; Buttgereit, F; da Silva, JAP; Luís, M; Saag, K, 2022) |
| " Decreasing glucocorticoid dosage appears important for improving bone metabolism." | 2.82 | Reducing glucocorticoid dosage improves serum osteocalcin in patients with rheumatoid arthritis-results from the TOMORROW study. ( Inui, K; Koike, T; Mamoto, K; Nakamura, H; Okano, T; Sugioka, Y; Tada, M, 2016) |
| "Although glucocorticoids are widely used in the treatment of patients with early rheumatoid arthritis, the best dosage of glucocorticoids with regards to efficacy and safety is not known." | 2.79 | Comparison of the efficacy and safety of two starting dosages of prednisolone in early active rheumatoid arthritis (CORRA): study protocol for a randomized controlled trial. ( Baraliakos, X; Braun, J; Klaassen-Mielke, R; Krause, D; Trampisch, HJ; Trampisch, US, 2014) |
| "Optimal outcome of treatment in rheumatoid arthritis (RA) is early clinical remission to delay joint damage." | 2.79 | Predictors for low disease activity and remission in rheumatoid arthritis patients treated with biological DMARDs. ( Suwannalai, P; Wacharapornin, P, 2014) |
| "Treatment with prednisolone at both dosages reduced CRP levels significantly." | 2.77 | Metabolic effects of high-dose prednisolone treatment in early rheumatoid arthritis: balance between diabetogenic effects and inflammation reduction. ( Bijlsma, JW; den Uyl, D; Diamant, M; Dijkmans, BA; Hoes, JN; Lems, WF; Nurmohamed, MT; van Raalte, DH, 2012) |
| "Early treatment of rheumatoid arthritis (RA) has been shown to retard the development of joint damage for a period of up to 5 years." | 2.75 | Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy trial. ( Blåfield, H; Hannonen, P; Järvenpää, S; Karjalainen, A; Kautiainen, H; Korpela, M; Laasonen, L; Leirisalo-Repo, M; Möttönen, T; Puolakka, K; Rantalaiho, V, 2010) |
| "Mizoribine (MZR) is an immunosuppressant that inhibits nucleic acid metabolism and is a relatively safe disease-modifying anti-rheumatic drug (DMARD)." | 2.75 | Efficacy and safety of mizoribine by one single dose administration for patients with rheumatoid arthritis. ( Aramaki, T; Arima, K; Eguchi, K; Fujikawa, K; Ichinose, K; Ida, H; Iwamoto, N; Kamachi, M; Kawakami, A; Kawashiri, SY; Nakamura, H; Origuchi, T; Tamai, M; Tsukada, T; Ueki, Y, 2010) |
| " More patients completed the first year without unplanned DMARD changes and without dosage adjustment and fewer had DMARD changes due to side effects or inefficacy in the step-down group compared with step-up, whereas the number of adverse events was comparable." | 2.73 | Daily practice effectiveness of a step-down treatment in comparison with a tight step-up for early rheumatoid arthritis. ( Esselens, G; Verschueren, P; Westhovens, R, 2008) |
| " In the future, more selectively acting substances could achieve an uncoupling of desired and adverse effects." | 2.72 | [Safety aspects of the treatment with glucocorticoids for rheumatoid arthritis]. ( Keyßer, G, 2021) |
| "In prednisolone-treated patients there was no correlation between clinical synovitis and change in Larsen score (r=0." | 2.70 | The relationship between soft tissue swelling, joint space narrowing and erosive damage in hand X-rays of patients with rheumatoid arthritis. ( Byron, M; Kirwan, J; Watt, I, 2001) |
| "Oral prednisolone was required by 63 patients." | 2.69 | Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. ( Ahonen, J; Blåfield, H; Forsberg, S; Friman, C; Hakala, M; Hakola, M; Hannonen, P; Ilva, K; Järvinen, P; Julkunen, H; Kautiainen, H; Koota, K; Korpela, M; Laasonen, L; Leirisalo-Repo, M; Luukkainen, R; Möttönen, T; Nissilä, M; Paimela, L; Pälvimäki, I; Piirainen, H; Puolakka, K; Vuori, K; Yli-Kerttula, U, 1999) |
| " The drop-out rate due to adverse events was surprisingly higher in the placebo group (41%) than in the auranofin group (10%) and, as expected, higher due to lack of effect (29 and 16%)." | 2.68 | Auranofin is safe and superior to placebo in elderly-onset rheumatoid arthritis. ( Andrup, O; Brodin, U; Clarke-Jenssen, O; Glennås, A; Karstensen, B; Kvien, TK, 1997) |
| " In April 1995, the microemulsion-based formulation of cyclosporin (Neoral) was introduced based on its increased bioavailability at 'no extra cost'." | 2.68 | Neoral--new cyclosporin for old? ( Scott, DG; Somerville, MF, 1997) |
| "To determine whether intermittent rather than daily administration of D-penicillamine (D-Pen) would effectively reduce the incidence of adverse effects without significantly diminishing the clinical benefits." | 2.67 | Intermittent treatment with D-penicillamine is effective in lower doses and with fewer adverse effects in patients with rheumatoid arthritis. ( Akahoshi, T; Hakoda, M; Kamatani, N; Kashiwazaki, S; Taniguchi, A, 1994) |
| " The employment of a special diet favourably influenced the course of the disease and enabled the dosage of antirheumatic drugs to be reduced, thereby reducing the frequency of side-effects of the drugs." | 2.67 | On the medicinal efficacy of dietetic therapy in patients with rheumatoid arthritis. ( Denissov, LN; Samsonov, MA; Sharafetdinov, Kh, 1992) |
| "Fifty RA patients receiving prednisolone and prednisolone combined with retabolil were examined." | 2.66 | [Experimental substantiation of the treatment of patients with rheumatoid arthritis with prednisolone and its combination with retabolil (clinico-experimental study)]. ( Bagirova, VV; Iaglinskiĭ, VA; Kriukov, AP, 1986) |
| "Erbium 169 was injected into 121 joints and saline water into 80 joints." | 2.64 | Double-blind study of erbium 169 injection (synoviorthesis) in rheumatoid digital joints. ( Aignan, M; Delbarre, F; Gô, AL; Menkes, CJ; Verrier, P, 1977) |
| "These findings led to the diagnosis of allergic bronchopulmonary aspergillosis (ABPA)." | 2.53 | Allergic bronchopulmonary aspergillosis in a patient with rheumatoid arthritis under adalimumab therapy: a case report. ( Kamiya, M; Kawahara, Y; Kawasaki, T; Nakagawa, A; Nonomura, Y; Takagiwa, J, 2016) |
| " Meanwhile, adherence to recommendations on standardized methodologies for registration and report of glucocorticoid adverse events is essential for improving our knowledge and competence in the best management of these important medications." | 2.50 | Safety of low- to medium-dose glucocorticoid treatment in rheumatoid arthritis: myths and reality over the years. ( da Silva, JA; Santiago, T, 2014) |
| "Patients with rheumatoid arthritis are at higher risk for serious infections and death from infection than the general public." | 2.48 | Infections and biologic therapy in rheumatoid arthritis: our changing understanding of risk and prevention. ( Winthrop, KL, 2012) |
| " Toxicity was assessed by number of the patients withdrawn for adverse events (AEs), and the numbers of serious adverse events (SAEs) and AEs." | 2.45 | Safety of medium- to long-term glucocorticoid therapy in rheumatoid arthritis: a meta-analysis. ( Choy, EH; Rachapalli, S; Ravindran, V, 2009) |
| "Most patients were on corticosteroid treatment." | 2.43 | Necrotizing fasciitis in rheumatic diseases. ( Chan, TM; Lau, CS; Mok, MY; Tang, WM; Wong, SY; Wong, WS, 2006) |
| "In the cases of Crohn's disease and rheumatoid arthritis administered anti-TNF-alpha, chemoprophylaxis is necessary for those who show healing of TB despite those who are suspected of having TB infection by a tuberculin test." | 2.42 | [Measures for tuberculosis in compromised hosts--mainly on chemoprophylaxis]. ( Yamagishi, F, 2003) |
| "Older disease modifying agents for treating rheumatoid arthritis were limited by long-term toxicity." | 2.42 | Newer approaches to the treatment of rheumatoid arthritis. ( Finesilver, AG, 2003) |
| "We describe a patient with chronic myelogenous leukemia (CML) and a patient with hairy cell leukemia being effectively treated with alpha-interferon who developed a seropositive chronic polyarthritis formally fulfilling the ACR criteria for rheumatoid arthritis." | 2.40 | [Interferon-alpha-associated polyarthritis. Possible induction of seropositive rheumatoid arthritis by interferon-alpha: two case reports and review of the literature]. ( Einsele, H; Kanz, L; Kötter, I; Mohren, M; Müller, CA, 1999) |
| "Fractures and stress fractures in patients with RA are probably much more common." | 2.39 | [Osteoporosis in collagen diseases]. ( Aritomi, H; Momohara, S, 1994) |
| "Here we report a patient in whom multiple myeloma developed about 30 years after the onset of rheumatoid arthritis." | 2.39 | [A case of rheumatoid arthritis associated with multiple myeloma]. ( Furukawa, H; Inoue, F; Ohno, T, 1996) |
| "The role of corticosteroids in treating rheumatoid arthritis is controversial, but recourse to the available evidence of efficacy should guide patient management decisions." | 2.39 | Low dose corticosteroids in early rheumatoid arthritis. Can these drugs slow disease progression? ( Kirwan, JR; Lim, KK, 1996) |
| " Antirheumatic therapy therefore requires strict adherence to the prescribed indications and careful selection of the specific drug type and dosage regimen." | 2.38 | [Glucocorticoids]. ( Hayashi, T, 1992) |
| " Emphases of the description are general principles of treatment, indications and dosage in systemic and local treatment, side effects, problems of long-term treatment, application of ACTH, the cortisonoid withdrawal syndrome, prophylaxis of therapy complications and references to the reduction of the dose or to the withdrawal of the treatment with cortisonoids." | 2.36 | [Cortisonoids in the therapy of rheumatic diseases]. ( Reinicke, C, 1977) |
| "Prednisolone was less effective in reducing the expression of the TNF-α in the area of plantar joints than the other group." | 1.91 | Immunomodulatory Effects of Combined Nicotinic Acid and Prednisolone in Adjuvant-induced Arthritis. ( Froushani, SMA; Mirzaaghasi, S, 2023) |
| "2 in DAS28-ESR for ≥ 6 months) and discontinuations due to treatment failure in the low dose group, and we compared the incidence of serious adverse events (SAEs) between LD and SD groups." | 1.72 | Rheumatoid arthritis patients initiating rituximab with low number of previous bDMARDs failures may effectively reduce rituximab dose and experience fewer serious adverse events than patients on full dose: a 5-year cohort study. ( Avgoustidis, N; Bertsias, A; Bertsias, G; Flouri, I; Kalogiannaki, E; Kougkas, N; Papalopoulos, I; Repa, A; Sidiropoulos, P, 2022) |
| "Leflunomide treatment failure was defined as failure to achieve remission, the need to add other DMARDs for controlling attacks and disease progression to chronic arthritis during treatment with leflunomide." | 1.72 | Efficacy of leflunomide in the treatment of palindromic rheumatism. ( Esalatmanesh, K; Khabbazi, A; Sadri, M, 2022) |
| "We aimed to study the outcomes of coronavirus disease 2019 (COVID-19) in patients with a history of rheumatoid arthritis (RA) in Iran, where most patients receive corticosteroids and are at high risk for COVID-19 infection." | 1.72 | Outcomes of coronavirus disease 19 patients with a history of rheumatoid arthritis: A retrospective registry-based study in Iran. ( Movassaghi, S; Rostamian, A; Seyyedsalehi, MS; Zargaran, M; Zendehdel, K, 2022) |
| "Glucocorticoids are used in the treatment of rheumatoid arthritis since many decades." | 1.72 | [Low dosed prednisolone in older patients with rheumatoid arthritis]. ( van der Goes, MC, 2022) |
| "Prednisolone was administered to 33% of patients with a median dose of 0 (0-2." | 1.62 | Simplified disease activity index and clinical disease activity index before and during pregnancy correlate with those at postpartum in patients with rheumatoid arthritis. ( Fujita, D; Hata, K; Hiramatsu, Y; Kotani, T; Matsumura, Y; Nakamura, E; Takeuchi, T; Tokai, N; Wada, Y; Yoshikawa, A, 2021) |
| "Thus, the condition was compatible with reactive arthritis." | 1.62 | Reactive arthritis after COVID-19. ( Hermansen, MF; Hønge, BL; Storgaard, M, 2021) |
| " The lower dosage of oral prednisolone was a significant risk factor compared with higher dosage when used." | 1.51 | Oral steroid decreases the progression of joint destruction of large joints in the lower extremities in rheumatoid arthritis. ( Azukizawa, M; Doi, K; Hashimoto, M; Ito, H; Matsuda, S; Mimori, T; Murakami, K; Murata, K; Nishitani, K; Okahata, A; Saito, M; Tanaka, M; Tomizawa, T, 2019) |
| "He developed focal onset motor seizures." | 1.51 | Rheumatoid arthritis presenting as rheumatoid meningitis. ( Bermingham, N; Cronin, S; McKenna, MC; Vaughan, D, 2019) |
| "Clinical examination revealed new-onset paroxysmal atrial fibrillation with symptomatic sinus pauses and worsening mitral regurgitation, which were both resistant to conventional therapies." | 1.51 | Glucocorticoid-sensitive Paroxysmal Atrial Fibrillation, Sick Sinus Syndrome, and Mitral Regurgitation in a Patient with Malignant Rheumatoid Vasculitis. ( Hirata, KI; Mori, S; Morinobu, A; Nakamura, K; Okano, T; Shono, A; Takada, H; Tanaka, H; Yatomi, A, 2019) |
| "To develop an objective, readily measurable pharmacodynamic biomarker of glucocorticoid (GC) activity." | 1.48 | Development of a Molecular Signature to Monitor Pharmacodynamic Responses Mediated by In Vivo Administration of Glucocorticoids. ( Bandyopadhyay, S; Carman, JA; Connolly, S; Fan, L; Furie, R; Goldstine, C; Holloway, D; Hu, Y; Johnsen, A; Kansal, S; Latek, R; Lee, D; Nadler, SG; Shadick, N; Somerville, JE; Townsend, R; Weinblatt, ME, 2018) |
| "Corticosteroids (CSs), used to treat rheumatoid arthritis (RA), confer a risk of adverse events (AEs)." | 1.48 | Safety and efficacy of alternate-day corticosteroid treatment as adjunctive therapy for rheumatoid arthritis: a comparative study. ( Kishimoto, M; Ohde, S; Okada, M; Suda, M; Tsuda, T, 2018) |
| "A 36-year-old woman with RA and generalized myasthenia gravis (MG) developed RM during a remission phase." | 1.48 | Rheumatoid meningitis developed in patient with stable rheumatoid arthritis and myasthenia gravis-detailed analysis of intracranial inflammation using flow cytometry. ( Fujita, Y; Fujita-Nakata, M; Kawai, U; Matsui, M; Nagayama, S; Nakanishi, M; Oono, M; Sanada, M; Uchida, N, 2018) |
| "Prednisolone was subsequently administered instead of chemotherapy; however, multiple masses, including in the spine (case 1), and severe icterus with liver dysfunction (case 2) were exacerbated within a few months." | 1.46 | The aggressive clinical courses of Hodgkin lymphoma primarily diagnosed as methotrexate-induced non-specific lymphoproliferative disorder in patients with rheumatoid arthritis. ( Amano, K; Anan-Nemoto, T; Higashi, M; Kimura, Y; Kizaki, M; Momose, S; Okuyama, A; Tabayashi, T; Takahashi, Y; Tamaru, JI; Tanaka, Y; Tokuhira, M; Tomikawa, T; Watanabe, R, 2017) |
| "Since prednisolone is used to treat rheumatoid arthritis at a dose ≤10 mg/d, the patients were divided based on the prednisolone dose into the groups treated at >10 and ≤10 mg/d, and the onset time was investigated in each group." | 1.46 | Factorial Analysis of Hepatitis B Virus Reactivation-Induced Hepatitis B Using JADER. ( Hara, A; Kizu, J; Matsumoto, K; Yokoyama, Y, 2017) |
| "This study aimed to determine whether the long-term use of biologic agents increases serious infections in elderly patients with rheumatoid arthritis (RA) and to determine the risk factors of serious infections in biologics-treated elderly RA patients." | 1.46 | Long-term use of biologic agents does not increase the risk of serious infections in elderly patients with rheumatoid arthritis. ( Furuta, S; Iwamoto, I; Kagami, SI; Kashiwakuma, D; Kawashima, H; Takahashi, K; Yokota, M, 2017) |
| "Effective treatment for rheumatoid arthritis is hindered by the lack of drugs that selectively target inflamed joints." | 1.46 | pH-sensitive polymeric micelles for targeted delivery to inflamed joints. ( Gong, T; Li, C; Li, H; Li, M; Sun, X; Wang, Q; Zhang, Z; Zhou, M, 2017) |
| " Information on the dosage and timing of GC use was extracted." | 1.43 | Risk of Incident Diabetes Mellitus Associated With the Dosage and Duration of Oral Glucocorticoid Therapy in Patients With Rheumatoid Arthritis. ( Abrahamowicz, M; Beauchamp, ME; Dixon, WG; Michaud, K; Movahedi, M; Pedro, S; Ray, DW, 2016) |
| "When pregnancy was confirmed, TCZ was terminated as soon as possible in all patients." | 1.43 | Tocilizumab and pregnancy: Four cases of pregnancy in young women with rheumatoid arthritis refractory to anti-TNF biologics with exposure to tocilizumab. ( Goto, M; Kaneko, K; Murashima, A; Sugitani, M, 2016) |
| "Individuals with rheumatoid arthritis are at higher risk for infection than the general population, and surgical site infection after spinal surgery in this population can result in clinically significant complications." | 1.43 | Postoperative Surgical Infection After Spinal Surgery in Rheumatoid Arthritis. ( Ebata, S; Haro, H; Koyama, K; Ohba, T, 2016) |
| " Current GC dose of below 5 mg per day (prednisolone equivalent dose) was not associated with an increased risk of death, but a dose-response association was seen for higher dose categories." | 1.43 | Oral glucocorticoid therapy and all-cause and cause-specific mortality in patients with rheumatoid arthritis: a retrospective cohort study. ( Costello, R; Dixon, WG; Lunt, M; Movahedi, M; Pye, SR; Sergeant, JC, 2016) |
| "The aim of this study was to evaluate the effect of treatment with methotrexate (MTX), by itself or combined with other non-biological disease-modifying antirheumatic drugs (DMARDs) (methotrexate, MTX with prednisolone, MTX with leflunomide, MTX with chloroquine, and MTX with sulfasalazine) on clinimetric outcomes in a retrospective cohort with a 6-month follow-up and under a Treat to Target (T2T) approach." | 1.42 | Treatment of rheumatoid arthritis with methotrexate alone and in combination with other conventional DMARDs using the T2T strategy. A cohort study. ( Castro, C; de la Hoz-Valle, J; Palomino, A; Sánchez, G; Santos-Moreno, PI; Villarreal, L, 2015) |
| "Current treatment of rheumatoid arthritis includes systemic administration of glucocorticoids." | 1.42 | [(18)]F FDG PET/CT imaging to monitor the therapeutic effect of liposome-encapsulated prednisolone in experimental rheumatoid arthritis. ( Boerman, OC; Gerrits, D; Laverman, P; Metselaar, JM; Storm, G; van der Geest, T; van Lent, PL, 2015) |
| "pain was -19." | 1.42 | Interplay between patient global assessment, pain, and fatigue and influence of other clinical disease activity measures in patients with active rheumatoid arthritis. ( Egsmose, EL; Madsen, OR, 2015) |
| "The long-term outcome of patients with autoimmune hepatitis (AIH) in Japan has not been well-defined." | 1.38 | Long-term outcome of Japanese patients with type 1 autoimmune hepatitis. ( Abe, M; Ichijo, T; Joshita, S; Katsuyama, Y; Kiyosawa, K; Komatsu, M; Matsumoto, A; Onji, M; Ota, M; Tanaka, E; Tanaka, N; Umemura, T; Yoshizawa, K, 2012) |
| "Kirenol is a major diterpenoid components of Herba Siegesbeckiae, which has been applied for arthritic therapy for centuries." | 1.38 | Kirenol exerts a potent anti-arthritic effect in collagen-induced arthritis by modifying the T cells balance. ( Chen, YY; Fu, HZ; Hu, J; Lu, Y; Qian, RQ; Wang, ZM; Wu, ZW; Xiao, J, 2012) |
| "Prednisolone treatment was strongly associated with negative TST, adjusted odds ratio (AOR) 0." | 1.37 | Prednisolone treatment affects the performance of the QuantiFERON gold in-tube test and the tuberculin skin test in patients with autoimmune disorders screened for latent tuberculosis infection. ( Bélard, E; Brylov, A; Hetland, ML; Jensen, FK; Nordgaard-Lassen, I; Ravn, P; Ruhwald, M; Semb, S; Soborg, B; Thomsen, H; Werlinrud, AM, 2011) |
| " Dose was raised until a final dosage of 30 mg/week." | 1.37 | [Autoimmune pancreatitis associated with rheumatoid arthritis: successful combination therapy with steroids and methotrexate]. ( Boltuch-Sherif, J; Erlacher, L; Horvath-Mechtler, B; Kowalski-Bodzenta, J; Mustak, M, 2011) |
| "Rheumatoid arthritis is not uncommon among Nigerian; and clinical, serologic acumen are necessary for early diagnosis and appropriate referral." | 1.36 | Rheumatoid arthritis among Nigerians: the first 200 patients from a rheumatology clinic. ( Adelowo, OO; Oduenyi, I; Ojo, O; Okwara, CC, 2010) |
| "Prednisolone was tapered to 20 mg/day for 5 months." | 1.36 | Rheumatoid leptomeningitis: radiological alteration of cerebral hypoperfusion and subarachnoid lesions. ( Ikeda, K; Ishikawa, Y; Ito, H; Iwasaki, Y; Kawabe, K; Miura, K; Takazawa, T; Yoshii, Y, 2010) |
| "Mizoribine has been recognized to have an acceptable toxicity profile compared with other immunosuppressants." | 1.35 | A sudden onset of diabetic ketoacidosis and acute pancreatitis after introduction of mizoribine therapy in a patient with rheumatoid arthritis. ( Ebihara, K; Mori, S, 2008) |
| "PD is considered to be a reactive arthritis, which is a different entity from tuberculous arthritis." | 1.35 | A case of Poncet's disease (tuberculous rheumatism). ( Ideguchi, H; Ishigatsubo, Y; Kaneko, T; Ohno, S; Takase, K; Tsukahara, T, 2009) |
| " In the present case, re-epithelization and healthy granulation were induced by the CDS without increasing the dosage of systemic prednisolone." | 1.35 | Case report: a case of pyoderma gangrenosum with intractable leg ulcers treated by allogeneic cultured dermal substitutes. ( Furukawa, F; Kanazawa, N; Kishioka, A; Kuroyanagi, Y; Matsumoto, Y; Nishide, T; Toyozawa, S; Yamamoto, Y, 2008) |
| " There seems to be a boost and extension of the glucocorticoid effect by the combination, without a clear increase of adverse effects, potentially allowing the application of lower dosages." | 1.35 | Innovative combination strategy to enhance effect and diminish adverse effects of glucocorticoids: another promise? ( Bijlsma, JW; Jacobs, JW, 2009) |
| "To assess the incidence and severity of disease modifying antirheumatic drug (DMARD)-induced adverse effects (AE) in patients with rheumatoid arthritis (RA) taking/not taking glucocorticoids (GC)." | 1.35 | Low-dose prednisolone in rheumatoid arthritis: adverse effects of various disease modifying antirheumatic drugs. ( Arnold, S; Baerwald, CG; Häntzschel, H; Malysheva, OA; Pierer, M; Wagner, U; Wahle, M, 2008) |
| " Infliximab was administered by intravenous infusion at a dosage of 3 mg/kg." | 1.34 | The effect of infliximab on chemokines in patients with rheumatoid arthritis. ( Ichikawa, T; Kageyama, Y; Nagano, A; Suzuki, M; Torikai, E, 2007) |
| "To determine whether drugs used in the treatment of rheumatoid arthritis (RA) contribute to the increased risk of respiratory infection or influence its outcome." | 1.34 | Acute lower respiratory tract infections in patients with rheumatoid arthritis. ( Coulson, E; Coyne, P; Hamilton, J; Heycock, C; Kelly, CA; Saravanan, V, 2007) |
| " Patients received a total steroid dosage between 100 and 500 mg of prednisolone." | 1.33 | Serum levels of cartilage oligomeric matrix protein (COMP): a rapid decrease in patients with active rheumatoid arthritis undergoing intravenous steroid treatment. ( Bauer, K; Dunky, A; Feyertag, J; Haberhauer, G; Kittl, EM; Skoumal, M, 2006) |
| " We studied the efficacy of cyclophosphamide (CYC) combined with prednisolone (PSL) in amyloidotic patients who had serum amyloid A (SAA) 1." | 1.32 | Efficacy of cyclophosphamide combined with prednisolone in patients with AA amyloidosis secondary to rheumatoid arthritis. ( Baba, S; Nakamura, T; Shono, M; Tomoda, K; Tsukano, M; Yamamura, Y, 2003) |
| "Histopathologic diagnosis was bronchiolitis obliterans organizing pneumonia (BOOP)." | 1.32 | Bronchiolitis obliterans organizing pneumonia associated with sulfasalazine in a patient with rheumatoid arthritis. ( Apaydin, D; Aydin, O; Ozer, C; Ozgür, E; Sahin, G; Ulubaş, B, 2004) |
| "Kynurenine analysis was performed by HPLC." | 1.32 | Kynurenine and neopterin levels in patients with rheumatoid arthritis and osteoporosis during drug treatment. ( Darlington, LG; Forrest, CM; Kennedy, A; Stone, TW; Stoy, N, 2003) |
| " Therapeutic studies were performed for up to 8 weeks of dosing with prednisolone, methotrexate, 3 nonsteroidal antiinflammatory drugs (celecoxib, diclofenac, and indomethacin), a p38 MAPK inhibitor, SB242235, and human soluble TNF receptor (sTNFR; etanercept) and murine sTNFR fusion proteins." | 1.32 | Characterization of pristane-induced arthritis, a murine model of chronic disease: response to antirheumatic agents, expression of joint cytokines, and immunopathology. ( Bush, K; Life, P; Morgan, R; Patten, C; Rioja, I; Trill, J; Wooley, P, 2004) |
| "Prednisolone use was not associated with increased IMT (0." | 1.31 | Atherosclerosis in rheumatoid arthritis: morphologic evidence obtained by carotid ultrasound. ( Ahn, CW; Choi, HK; In, BH; Lee, HC; Lee, SH; Lee, SK; Nam, CM; Park, YB, 2002) |
| " There was no significant difference between the two genotypes in age, gender, body mass index (BMI), disease duration, disease types, time of glucocorticoid administration and cumulative dosage (P > 0." | 1.31 | Relationship between glucocorticoid-induced osteoporosis and vitamin D receptor genotypes. ( Chen, L; Li, Y; Shen, L; Xu, L; Yu, L, 2002) |
| "In our case, senile osteoporosis was present before the onset of the fracture was recognized on radiographs, and RA and corticosteroid therapy might have further aggravated the porosis, resulting in the destruction of the fossa acetabuli." | 1.31 | A case report of insufficiency fracture of the Fossa acetabuli in a patient with rheumatoid arthritis. ( Nakayama, Y; Ozaki, D; Shirai, Y; Uesaka, S, 2000) |
| "A diagnosis of autoimmune hemolytic anemia (AIHA) was made on the basis of the laboratory findings." | 1.31 | [A case of rheumatoid arthritis associated with autoimmune hemolytic anemia due to weekly low-dose methotrexate therapy]. ( Kurosaka, D; Ozawa, Y; Tajima, N; Yokoyama, T; Yoshida, K, 2000) |
| "Pachymeningitis is a rare complication of rheumatoid arthritis." | 1.31 | Pachymeningitis and optic neuritis in rheumatoid arthritis: successful treatment with cyclophosphamide. ( Ağildere, AM; Altinörs, N; Aydin, P; Benli, S; Demirhan, B; Kart, H; Yücel, AE, 2001) |
| "In addition to patients with RA or MCTD, focal sialadenitis also affects a very high proportion of patients with AS or SpA." | 1.31 | Focal sialadenitis in patients with ankylosing spondylitis and spondyloarthropathy: a comparison with patients with rheumatoid arthritis or mixed connective tissue disease. ( Helenius, I; Helenius, LM; Hietanen, JH; Kautiainen, H; Lappalainen, M; Leirisalo-Repo, M; Lindqvist, C; Paimela, L; Piirainen, H; Suuronen, R, 2001) |
| "They are normal in SLE, systemic sclerosis, and vasculitides as well as in non-rheumatic inflammatory controls, but are significantly increased by steroids." | 1.31 | Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment. ( Damas, P; Franchimont, N; Houssiau, FA; Jaspar, JM; Kaiser, MJ; Malaise, MG; Martin y Porras, M; Ribbens, C, 2002) |
| "We report a case of pulmonary nocardiosis in a 69-year-old man with rheumatoid arthritis who was receiving corticosteroid treatment." | 1.31 | Pulmonary nocardiosis in a patient treated with corticosteroid therapy. ( Endoh, S; Kasai, T; Narushima, M; Ohtsuka, H; Suzuki, H; Tomita, S; Tsuzura, Y; Yamada, M, 2002) |
| "The renal biopsy findings indicated membranous nephropathy." | 1.31 | [An elderly case of ANCA-positive membranous nephropathy]. ( Honda, K; Kawashima, A; Nihei, H; Nitta, K; Onuki, T; Sekine, S; Suganuma, S; Tanaka, Y; Uchida, K; Yumura, W, 2002) |
| "Treatment of interstitial lung disease (ILD) in rheumatoid arthritis (RA) has been controversial." | 1.31 | Successful treatment of progressive rheumatoid interstitial lung disease with cyclosporine: a case report. ( Chang, HK; Park, W; Ryu, DS, 2002) |
| "Renal biopsy showed focal segmental glomerulosclerosis (FSGS)." | 1.30 | [Focal segmental glomerulosclerosis presenting nephrotic syndrome and acute renal failure in a patient with rheumatoid arthritis]. ( Akikusa, B; Matsumura, R; Sueishi, M; Sugiyama, T; Tomioka, H, 1997) |
| "However, bronchiolitis obliterans was suspected because of a low FEV1% (23%)." | 1.30 | [Bronchiolitis obliterans and no radiographic abnormalities in a patient with rheumatoid arthritis]. ( Abe, Y; Arakawa, M; Hasegawa, T; Kagamu, H; Kurashige, K; Nakano, M; Saitoh, Y; Satoh, M; Suzuki, E; Terada, M, 1997) |
| "Pentoxifylline was also reported to possess therapeutic properties in 50% of severe refractory RA in an open study." | 1.30 | [Remission induction after pentoxifylline treatment in a patient with rheumatoid arthritis]. ( Ichikawa, Y; Ishii, O; Kase, C; Moriuchi, E; Ohya, S; Yamada, H; Yamasaki, K, 1997) |
| "We conclude that menopause affects the bone turnover in RA as well as in normal controls." | 1.30 | The effects of menopausal status and disease activity on biochemical markers of bone metabolism in female patients with rheumatoid arthritis. ( Hoshino, H; Inoue, T; Kushida, K; Miura, M; Miyamoto, S; Suzuki, M; Takahashi, M, 1998) |
| "Pentosidine is an advanced glycation endproduct formed by glycosylation and oxidation." | 1.30 | Pentosidine in synovial fluid in osteoarthritis and rheumatoid arthritis: relationship with disease activity in rheumatoid arthritis. ( Chen, JR; Inoue, T; Kushida, K; Miyamoto, S; Suzuki, M; Takahashi, M, 1998) |
| "Rheumatic pleurisy was suspected because of a high serum rheumatoid factor(RF)level and high RF and high rheumatoid arthritis hemagglutination levels in the pleural effusion." | 1.30 | [Rheumatoid nodule diagnosed by thoracoscopy using flexible fiberoptic bronchoscope]. ( Hojyo, T; Kimura, K; Nakata, M; Ryo, H; Sim, J; Toyama, K; Yoshida, M, 1998) |
| "Lactoferrin is a multifunctional immunoregulatory protein, stored in specific granules of neutrophil granulocytes, from which it is released following cell activation." | 1.30 | Increased levels of lactoferrin in synovial fluid but not in serum from patients with rheumatoid arthritis. ( Afeltra, A; Bonomo, L; Caccavo, D; Di Monaco, C; Ferri, GM; Galeazzi, M; Guido, F; Sebastiani, GD, 1999) |
| "Metyrapone treatment increased the surface expression of CD35 and CD49f on eosinophils, but did not affect surface expression on neutrophils." | 1.30 | Enhanced expression of integrins and CD66b on peripheral blood neutrophils and eosinophils in patients with rheumatoid arthritis, and the effect of glucocorticoids. ( Arvidson, NG; Håkansson, L; Hällgren, R; Torsteinsdóttir, I, 1999) |
| "Progression of osteonecrosis is related to a mean maximal day dose of prednisolone in the first month of therapy." | 1.29 | [Corticosteroid therapy and aseptic bone necrosis in patients with rheumatoid arthritis]. ( Ivanova, MM; Tokmachev, IuK; Tsurko, VV, 1995) |
| " In current users (mean daily prednisolone dosage 6." | 1.29 | The effect of rheumatoid arthritis and steroid therapy on bone density in postmenopausal women. ( Doyle, DV; Griffin, AJ; Hall, GM; Hall, ML; Jawad, AS; Spector, TD, 1993) |
| " This is a peculiar case in which the long-term administration of glucocorticoid for rheumatoid arthritis might have concealed Cushing's syndrome, and conversely the increased intrinsic adrenal steroid hormone might have suppressed the activity of the rheumatoid arthritis." | 1.28 | [Cushing's syndrome found during long-term glucocorticoid treatment of rheumatoid arthritis in an elderly woman]. ( Mikami, H; Nakamoto, Y; Ogihara, T; Saeki, S; Tabuchi, Y, 1992) |
| "It was increased in the active cases of systemic lupus erythematosus (SLE) and mixed connective tissue disease (MCTD)." | 1.28 | Serum level of interferon-gamma in autoimmune diseases. ( Funauchi, M; Horiuchi, A; Minoda, M; Sugishima, H, 1991) |
| "A 54-year-old woman under treatment for rheumatoid arthritis was admitted because of aggravation of dyspnea on effort and restrictive pulmonary dysfunction." | 1.28 | [Cellular interstitial pneumonia and follicular bronchiolitis diagnosed by open lung biopsy in a patient with rheumatoid arthritis]. ( Ichijima, K; Iwata, T; Kobashi, Y; Kohri, Y; Mino, M; Nambu, Y; Oida, K; Taguchi, Y; Tomii, K; Yunoki, Y, 1991) |
| "Colchicine treatment increased the SSA of PMN toward normal level in BD patients, and prevented the decrease of SSA in PMN obtained from healthy adults after the stimulation with opsonized zymosan in vitro." | 1.28 | Superoxide scavenging activity of leukocytes in rheumatoid arthritis and Behçet's diseases. ( Arimori, S; Ichikawa, Y; Nakazawa, H; Prónai, L, 1990) |
| "A patient with biopsy proven temporal arteritis/polymyalgia rheumatica and erosive rheumatoid arthritis is presented." | 1.27 | Coexistence of temporal arteritis/polymyalgia rheumatica and rheumatoid arthritis. ( Husby, G; Omdal, R, 1984) |
| " Prednisolone therapy in 22 patients (mean dosage 8 mg/day) was associated with reductions in estrone and testosterone levels; however, DHEAS and femoral BMD were also decreased in RA patients who were not receiving corticosteroids." | 1.27 | Sex hormone status and osteoporosis in postmenopausal women with rheumatoid arthritis. ( Champion, GD; Eisman, JA; Pocock, NA; Sambrook, PN, 1988) |
| " During gradual reduction of the steroid dosage osteocalcin returned to pretreatment values." | 1.27 | Serum osteocalcin in rheumatoid arthritis and other inflammatory arthritides: relation between inflammatory activity and the effect of glucocorticoids and remission inducing drugs. ( Ekenstam, EA; Hällgren, R; Ljunghall, S, 1986) |
| " Prednisolone (mean dosage 8 mg/day) was not associated with significantly increased bone loss in women, whereas higher dosages in men (mean 10." | 1.27 | Determinants of axial bone loss in rheumatoid arthritis. ( Champion, GD; Eberl, S; Eisman, JA; Pocock, NA; Sambrook, PN; Yeates, MG, 1987) |
| " In the dosage used, none of the compounds promoted discernible salt and water retention." | 1.24 | 16a-Methyl corticosteroids; a new series of anti-inflammatory compounds; clinical appraisal of their antirheumatic potencies. ( BOLAND, EW, 1958) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 496 (43.09) | 18.7374 |
| 1990's | 156 (13.55) | 18.2507 |
| 2000's | 247 (21.46) | 29.6817 |
| 2010's | 188 (16.33) | 24.3611 |
| 2020's | 64 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Miner, JN | 2 |
| Ardecky, B | 1 |
| Benbatoul, K | 2 |
| Griffiths, K | 1 |
| Larson, CJ | 1 |
| Mais, DE | 1 |
| Marschke, K | 2 |
| Rosen, J | 2 |
| Vajda, E | 1 |
| Zhi, L | 2 |
| Negro-Vilar, A | 2 |
| Aldridge, J | 1 |
| Lundell, AC | 1 |
| Andersson, K | 1 |
| Mark, L | 1 |
| Lund Hetland, M | 1 |
| Østergaard, M | 2 |
| Uhlig, T | 2 |
| Schrumpf Heiberg, M | 1 |
| Haavardsholm, EA | 2 |
| Nurmohamed, M | 4 |
| Lampa, J | 2 |
| Nordström, D | 2 |
| Hørslev-Petersen, K | 3 |
| Gudbjornsson, B | 6 |
| Gröndal, G | 2 |
| van Vollenhoven, R | 3 |
| Rudin, A | 2 |
| Tanaka, Y | 6 |
| Takeuchi, T | 8 |
| Kato, D | 3 |
| Kaneko, Y | 3 |
| Fukuda, M | 2 |
| Izutsu, H | 2 |
| Rokuda, M | 2 |
| Kasahara, A | 1 |
| Kida, T | 1 |
| Hirano, A | 1 |
| Omura, S | 1 |
| Sofue, H | 1 |
| Sakashita, A | 1 |
| Sagawa, T | 1 |
| Asano, M | 1 |
| Fukui, M | 1 |
| Wada, M | 1 |
| Kohno, M | 2 |
| Kawahito, Y | 1 |
| Lord, AE | 1 |
| Zhang, L | 1 |
| Erickson, JE | 1 |
| Bryant, S | 1 |
| Nelson, CM | 1 |
| Gaudette, SM | 1 |
| Phillips, LA | 1 |
| Schwartz Sterman, AJ | 1 |
| Mitra, S | 1 |
| Luís, M | 1 |
| Boers, M | 37 |
| Saag, K | 2 |
| Buttgereit, F | 7 |
| da Silva, JAP | 3 |
| van der Heijde, D | 8 |
| McKeigue, PM | 1 |
| Porter, D | 3 |
| Hollick, RJ | 1 |
| Ralston, SH | 2 |
| McAllister, DA | 1 |
| Colhoun, HM | 1 |
| Hartman, L | 7 |
| Opris-Belinski, D | 3 |
| Bos, R | 5 |
| Kok, MR | 5 |
| Da Silva, JA | 3 |
| Griep, EN | 1 |
| Klaasen, R | 4 |
| Allaart, CF | 6 |
| Baudoin, P | 2 |
| Raterman, HG | 3 |
| Szekanecz, Z | 4 |
| Masaryk, P | 4 |
| Klausch, LT | 2 |
| Paolino, S | 2 |
| Schilder, AM | 1 |
| Lems, WF | 19 |
| Cutolo, M | 9 |
| Krause, D | 3 |
| Mai, A | 1 |
| Klaassen-Mielke, R | 2 |
| Timmesfeld, N | 1 |
| Trampisch, U | 1 |
| Rudolf, H | 1 |
| Baraliakos, X | 3 |
| Schmitz, E | 1 |
| Fendler, C | 1 |
| Klink, C | 1 |
| Boeddeker, S | 1 |
| Saracbasi-Zender, E | 1 |
| Christoph, HJ | 1 |
| Igelmann, M | 1 |
| Menne, HJ | 1 |
| Schmid, A | 1 |
| Rau, R | 7 |
| Wassenberg, S | 3 |
| Sonuc, N | 1 |
| Ose, C | 1 |
| Schade-Brittinger, C | 1 |
| Trampisch, HJ | 2 |
| Braun, J | 5 |
| Bertsias, A | 1 |
| Avgoustidis, N | 1 |
| Papalopoulos, I | 1 |
| Repa, A | 1 |
| Kougkas, N | 1 |
| Kalogiannaki, E | 1 |
| Bertsias, G | 1 |
| Flouri, I | 1 |
| Sidiropoulos, P | 1 |
| Sadri, M | 1 |
| Esalatmanesh, K | 1 |
| Khabbazi, A | 1 |
| Yavropoulou, MP | 1 |
| Filippa, MG | 1 |
| Panopoulos, S | 1 |
| Spanos, E | 1 |
| Spanos, G | 1 |
| Tektonidou, MG | 1 |
| Sfikakis, PP | 2 |
| Sato, H | 2 |
| Kondo, N | 2 |
| Takai, C | 3 |
| Kurosawa, Y | 1 |
| Hasegawa, E | 2 |
| Wakamatsu, A | 1 |
| Kobayashi, D | 3 |
| Nakatsue, T | 1 |
| Abe, A | 3 |
| Kazama, JJ | 1 |
| Kuroda, T | 2 |
| Ito, S | 6 |
| Ishikawa, H | 5 |
| Endo, N | 2 |
| Narita, I | 2 |
| Hassouna, SS | 1 |
| Sheta, E | 1 |
| Zaki, I | 1 |
| Harby, SA | 1 |
| Allam, EA | 1 |
| Zargaran, M | 1 |
| Movassaghi, S | 1 |
| Seyyedsalehi, MS | 1 |
| Zendehdel, K | 1 |
| Rostamian, A | 1 |
| Ng, KH | 1 |
| Chen, DY | 1 |
| Lin, CH | 1 |
| Chao, WC | 1 |
| Chen, HH | 1 |
| Voshaar, MJH | 2 |
| Heymans, MW | 1 |
| van der Heijde, DMFM | 1 |
| Rasch, LA | 3 |
| Turk, SA | 1 |
| Ter Wee, MM | 6 |
| Kerstens, PJSM | 3 |
| van der Laken, CJ | 1 |
| Nurmohamed, MT | 6 |
| van Schaardenburg, D | 6 |
| van Tuyl, LHD | 3 |
| Voskuyl, AE | 10 |
| Garcia, S | 1 |
| Terroso, G | 1 |
| Martins, E | 1 |
| Pimenta, S | 1 |
| Costa, L | 1 |
| Bernardes, M | 1 |
| Koo, BS | 1 |
| Eun, S | 1 |
| Shin, K | 1 |
| Hong, S | 1 |
| Kim, YG | 1 |
| Lee, CK | 2 |
| Yoo, B | 2 |
| Oh, JS | 1 |
| El Alili, M | 1 |
| Opris, D | 3 |
| Da Silva, J | 1 |
| Coupé, V | 1 |
| Mok, CC | 3 |
| Ho, LY | 3 |
| Tse, SM | 3 |
| Chan, KL | 3 |
| To, CH | 3 |
| Ma, M | 2 |
| Santosa, A | 2 |
| Fong, W | 2 |
| Chew, LC | 2 |
| Low, AH | 2 |
| Law, A | 2 |
| Poh, YJ | 2 |
| Yeo, SI | 2 |
| Leung, YY | 2 |
| Ng, VW | 2 |
| Koh, JZ | 2 |
| Tay, SH | 2 |
| Mak, A | 2 |
| Teng, GG | 2 |
| Xu, C | 2 |
| Tang, JG | 2 |
| Kong, KO | 2 |
| Angkodjojo, S | 2 |
| Goh, WR | 2 |
| Chuah, TY | 2 |
| Roslan, NE | 2 |
| Arkachaisri, T | 2 |
| Teh, KL | 2 |
| Sriranganathan, M | 2 |
| Tan, TC | 2 |
| Phang, KF | 2 |
| Yap, QV | 2 |
| Chan, YH | 2 |
| Cheung, PP | 2 |
| Lahiri, M | 2 |
| Horie, K | 1 |
| Asakura, T | 1 |
| Masuzawa, K | 1 |
| Terai, H | 1 |
| Nakayama, S | 2 |
| Suzuki, Y | 4 |
| van der Goes, MC | 1 |
| Dlamini, ST | 1 |
| Htet, KM | 1 |
| Theint, ECC | 1 |
| Mayadilanuari, AM | 1 |
| Li, WM | 1 |
| Tung, YC | 1 |
| Tu, HP | 1 |
| Yamazaki, K | 1 |
| Kiyomi, A | 1 |
| Imai, S | 1 |
| Sugiyama, K | 1 |
| Tahara, K | 3 |
| Sawada, T | 2 |
| Sugiura, M | 1 |
| Yamane, T | 1 |
| Hashiramoto, A | 1 |
| Shiba, H | 1 |
| Kotani, T | 2 |
| Nagai, K | 1 |
| Hata, K | 2 |
| Yamamoto, W | 1 |
| Yoshikawa, A | 2 |
| Wada, Y | 4 |
| Hiramatsu, Y | 2 |
| Makino, H | 3 |
| Ueda, Y | 1 |
| Onishi, A | 1 |
| Murata, K | 2 |
| Amuro, H | 1 |
| Son, Y | 1 |
| Hara, R | 1 |
| Hirano, T | 4 |
| Ebina, K | 1 |
| Katayama, M | 1 |
| Hashimoto, M | 3 |
| Güler-Yüksel, M | 1 |
| Kuijper, M | 1 |
| Molenaar, E | 1 |
| Emmering, J | 1 |
| Eshuis, S | 1 |
| Human, A | 1 |
| Reimann, F | 1 |
| Xie, W | 2 |
| Huang, H | 2 |
| Zhang, Z | 3 |
| Pisaniello, HL | 1 |
| Lester, S | 1 |
| Russell, O | 1 |
| Black, R | 2 |
| Tieu, J | 1 |
| Richards, B | 1 |
| Barrett, C | 1 |
| Lassere, M | 3 |
| March, L | 2 |
| Buchbinder, R | 2 |
| Whittle, SL | 1 |
| Hill, CL | 2 |
| Almayali, AAH | 1 |
| Griep, E | 1 |
| Lems, W | 3 |
| Smulders, Y | 1 |
| Mirzaaghasi, S | 1 |
| Froushani, SMA | 1 |
| Schattner, A | 1 |
| Nishii, Y | 1 |
| Okamoto, M | 3 |
| Zaizen, Y | 1 |
| Kojima, T | 4 |
| Nouno, T | 1 |
| Naitou-Nishida, Y | 1 |
| Matsuo, N | 2 |
| Takeoka, H | 1 |
| Ishida, M | 1 |
| Nakamura, M | 1 |
| Masuda, T | 2 |
| Tanaka, T | 3 |
| Miyamura, T | 1 |
| Hoshino, T | 1 |
| Yagita, K | 1 |
| Shinde, A | 1 |
| Suenaga, T | 1 |
| Tang, Z | 1 |
| Sun, Q | 1 |
| Ji, H | 1 |
| Kuo, SJ | 1 |
| Hsua, PW | 1 |
| Chien, SY | 1 |
| Huang, CC | 1 |
| Hu, SL | 1 |
| Tsai, CH | 1 |
| Su, CM | 1 |
| Tang, CH | 1 |
| Doi, K | 1 |
| Ito, H | 4 |
| Tomizawa, T | 1 |
| Tanaka, M | 2 |
| Murakami, K | 1 |
| Nishitani, K | 1 |
| Azukizawa, M | 2 |
| Okahata, A | 1 |
| Saito, M | 2 |
| Mimori, T | 3 |
| Matsuda, S | 2 |
| Yan, F | 1 |
| Li, H | 2 |
| Zhong, Z | 1 |
| Zhou, M | 2 |
| Lin, Y | 1 |
| Tang, C | 1 |
| Li, C | 2 |
| Bach, M | 1 |
| Schob, S | 1 |
| Baerwald, C | 1 |
| Horai, Y | 2 |
| Iwanaga, N | 1 |
| Izumi, Y | 2 |
| Matsuoka, Y | 1 |
| Miura, S | 1 |
| Kawakami, A | 6 |
| Kotani, H | 1 |
| Ohtsuka, T | 1 |
| Okada, S | 1 |
| Kusama, M | 1 |
| Taniguchi, T | 1 |
| Fukaya, D | 1 |
| Inoue, T | 3 |
| Kogure, Y | 1 |
| Kajiyama, H | 1 |
| Ishizawa, K | 1 |
| Seto, T | 1 |
| Hasegawa, H | 1 |
| Mimura, T | 3 |
| Okada, H | 1 |
| Higashida-Konishi, M | 1 |
| Izumi, K | 1 |
| Tsukamoto, M | 1 |
| Ohya, H | 1 |
| Takasugi, N | 1 |
| Hama, S | 1 |
| Hayashi, Y | 2 |
| Ushikubo, M | 1 |
| Akiya, K | 1 |
| Kazuhiro, A | 1 |
| Okano, Y | 2 |
| Oshima, H | 1 |
| Holland-Fischer, M | 1 |
| Thomsen, RW | 1 |
| Tarp, U | 1 |
| Nørgaard, M | 1 |
| Fujisawa, J | 1 |
| Okusa, T | 1 |
| Shoji, H | 1 |
| Oguri, S | 1 |
| Nakano, T | 3 |
| Nemoto, T | 1 |
| Lee, H | 1 |
| Otani, H | 1 |
| Nakazono, K | 2 |
| Murasawa, A | 2 |
| Katsuya, H | 1 |
| Kizuka-Sano, H | 1 |
| Yokoo, M | 1 |
| Kidoguchi, K | 1 |
| Yamaguchi, K | 1 |
| Nishioka, A | 1 |
| Ureshino, H | 1 |
| Kubota, Y | 1 |
| Ando, T | 1 |
| Naito, S | 1 |
| Ohshima, K | 1 |
| Kimura, S | 1 |
| Nakamura, E | 1 |
| Matsumura, Y | 1 |
| Tokai, N | 1 |
| Fujita, D | 1 |
| Okada, F | 1 |
| Fukushi, JI | 1 |
| Matsubara, H | 2 |
| Ishitani, EI | 1 |
| Sonoda, Y | 1 |
| Katsuki, I | 1 |
| Nawata, T | 1 |
| Shiragami, K | 1 |
| Matsuura, T | 1 |
| Honda, N | 1 |
| Kubo, M | 1 |
| Kawano, H | 1 |
| Yano, M | 1 |
| Ahmadinejad, Z | 1 |
| Assari, R | 1 |
| Ayoobi Yazdi, N | 1 |
| Mazloomi, SH | 1 |
| Javanshayani, P | 1 |
| Khalili Afousi, H | 1 |
| Ziaee, V | 1 |
| Hetland, ML | 3 |
| Heiberg, MS | 1 |
| Twisk, J | 2 |
| Lend, K | 1 |
| Krabbe, S | 1 |
| Hyldstrup, LH | 1 |
| Lindqvist, J | 1 |
| Hultgård Ekwall, AK | 1 |
| Grøn, KL | 1 |
| Kapetanovic, M | 1 |
| Faustini, F | 1 |
| Tuompo, R | 1 |
| Lorenzen, T | 1 |
| Cagnotto, G | 1 |
| Baecklund, E | 1 |
| Hendricks, O | 1 |
| Vedder, D | 1 |
| Sokka-Isler, T | 1 |
| Husmark, T | 1 |
| Ljoså, MA | 1 |
| Brodin, E | 1 |
| Ellingsen, T | 1 |
| Söderbergh, A | 1 |
| Rizk, M | 1 |
| Olsson, ÅR | 1 |
| Larsson, P | 1 |
| Uhrenholt, L | 1 |
| Just, SA | 1 |
| Stevens, DJ | 1 |
| Laurberg, TB | 1 |
| Bakland, G | 1 |
| Olsen, IC | 1 |
| Takahashi, N | 3 |
| Asai, S | 2 |
| Kobayakawa, T | 1 |
| Kaneko, A | 4 |
| Watanabe, T | 2 |
| Kato, T | 3 |
| Nishiume, T | 1 |
| Yoshioka, Y | 2 |
| Kanayama, Y | 3 |
| Hirano, Y | 3 |
| Hanabayashi, M | 3 |
| Yabe, Y | 3 |
| Yokota, Y | 1 |
| Suzuki, M | 6 |
| Sobue, Y | 2 |
| Terabe, K | 2 |
| Ishiguro, N | 3 |
| Hirata, S | 1 |
| Kohno, H | 1 |
| Watanabe, H | 3 |
| Tokunaga, T | 1 |
| Yoshida, Y | 1 |
| Sugimoto, T | 1 |
| Mokuda, S | 1 |
| Oda, K | 1 |
| Nojima, T | 1 |
| Sugiyama, E | 1 |
| Izuka, S | 1 |
| Kaneko, S | 1 |
| Harada, T | 3 |
| Sakai, H | 2 |
| Takahashi, Y | 3 |
| Yamashita, H | 1 |
| Kaneko, H | 2 |
| Lucassen, MJJ | 1 |
| den Uyl, D | 6 |
| Konijn, NPC | 2 |
| Bultink, IEM | 2 |
| Banerjee, A | 1 |
| Goswami, RP | 1 |
| Chatterjee, M | 1 |
| van Schaik, E | 1 |
| Ramnarain, D | 1 |
| Pouwels, S | 1 |
| Sapart, E | 1 |
| Sokolova, T | 1 |
| de Montjoye, S | 1 |
| Dierckx, S | 1 |
| Nzeusseu, A | 1 |
| Avramovska, A | 1 |
| Durez, P | 1 |
| Hønge, BL | 1 |
| Hermansen, MF | 1 |
| Storgaard, M | 1 |
| Griep-Wentink, HJRM | 1 |
| Bruyn, GAW | 1 |
| Gomes, N | 1 |
| Pinto, RMA | 1 |
| Keyßer, G | 1 |
| Li, G | 1 |
| Hao, Y | 1 |
| Gui, Y | 1 |
| Wang, Y | 1 |
| Deng, X | 1 |
| Zhao, J | 1 |
| Geng, Y | 1 |
| Ji, L | 1 |
| Zhang, X | 1 |
| Song, Z | 1 |
| Takanashi, S | 1 |
| Isoda, K | 1 |
| Akita, S | 1 |
| Hashimoto, J | 1 |
| Ohshima, S | 1 |
| Tokuhira, M | 1 |
| Tabayashi, T | 1 |
| Kimura, Y | 1 |
| Tomikawa, T | 1 |
| Anan-Nemoto, T | 1 |
| Momose, S | 1 |
| Higashi, M | 1 |
| Okuyama, A | 1 |
| Watanabe, R | 1 |
| Amano, K | 4 |
| Tamaru, JI | 1 |
| Kizaki, M | 1 |
| Kiltz, U | 1 |
| von Zabern, C | 1 |
| Heldmann, F | 1 |
| Mintrop, B | 1 |
| Sarholz, M | 1 |
| Dybowski, F | 2 |
| Kalthoff, L | 1 |
| Nakamura, Y | 1 |
| Suzuki, T | 4 |
| Yoshida, T | 3 |
| Yamazaki, H | 2 |
| Kato, H | 1 |
| Son, KM | 1 |
| Lee, SY | 1 |
| Seo, YI | 1 |
| Choi, JE | 1 |
| Kim, HA | 2 |
| Zamani, B | 1 |
| Farshbaf, S | 1 |
| Golkar, HR | 1 |
| Bahmani, F | 1 |
| Asemi, Z | 1 |
| Hara, A | 1 |
| Matsumoto, K | 1 |
| Yokoyama, Y | 2 |
| Kizu, J | 1 |
| Hattori, Y | 2 |
| Kida, D | 2 |
| van der Wijden, LKM | 1 |
| Borresen, SW | 1 |
| Klose, M | 1 |
| Baslund, B | 1 |
| Rasmussen, ÅK | 1 |
| Hilsted, L | 1 |
| Friis-Hansen, L | 1 |
| Locht, H | 1 |
| Hansen, A | 1 |
| Lydolph, MC | 1 |
| Feldt-Rasmussen, U | 1 |
| Radhakutty, A | 3 |
| Mangelsdorf, BL | 4 |
| Drake, SM | 3 |
| Rowland, A | 1 |
| Smith, MD | 6 |
| Mangoni, AA | 1 |
| Thompson, CH | 4 |
| Burt, MG | 4 |
| Klausch, T | 1 |
| Bijlsma, HWJ | 1 |
| Christensen, R | 2 |
| Smulders, YM | 1 |
| Rovenský, J | 1 |
| Szamosi, S | 1 |
| Middelink, LM | 1 |
| Thodou, V | 1 |
| Buechter, M | 1 |
| Manka, P | 1 |
| Gerken, G | 1 |
| Kahraman, A | 1 |
| Hu, Y | 1 |
| Carman, JA | 1 |
| Holloway, D | 1 |
| Kansal, S | 1 |
| Fan, L | 1 |
| Goldstine, C | 1 |
| Lee, D | 1 |
| Somerville, JE | 1 |
| Latek, R | 1 |
| Townsend, R | 1 |
| Johnsen, A | 1 |
| Connolly, S | 1 |
| Bandyopadhyay, S | 1 |
| Shadick, N | 1 |
| Weinblatt, ME | 1 |
| Furie, R | 1 |
| Nadler, SG | 1 |
| Suda, M | 1 |
| Ohde, S | 1 |
| Tsuda, T | 1 |
| Kishimoto, M | 1 |
| Okada, M | 1 |
| Oono, M | 1 |
| Fujita, Y | 3 |
| Uchida, N | 1 |
| Kawai, U | 1 |
| Fujita-Nakata, M | 1 |
| Nakanishi, M | 1 |
| Sanada, M | 1 |
| Nagayama, S | 1 |
| Matsui, M | 1 |
| Gouveia, VM | 1 |
| Lopes-de-Araújo, J | 1 |
| Costa Lima, SA | 1 |
| Nunes, C | 1 |
| Reis, S | 1 |
| Suto, T | 2 |
| Yonemoto, Y | 3 |
| Okamura, K | 3 |
| Sakane, H | 1 |
| Takeuchi, K | 2 |
| Tamura, Y | 2 |
| Kaneko, T | 4 |
| Ayabe, K | 1 |
| Chikuda, H | 1 |
| Beyer, K | 1 |
| Zaura, E | 1 |
| Brandt, BW | 1 |
| Buijs, MJ | 1 |
| Brun, JG | 3 |
| Crielaard, W | 1 |
| Bolstad, AI | 1 |
| Rantalaiho, V | 7 |
| Sandström, T | 1 |
| Koski, J | 2 |
| Hannonen, P | 14 |
| Möttönen, T | 15 |
| Kaipiainen-Seppänen, O | 6 |
| Yli-Kerttula, T | 2 |
| Kauppi, MJ | 3 |
| Uutela, T | 3 |
| Malmi, T | 2 |
| Julkunen, H | 4 |
| Laasonen, L | 7 |
| Kautiainen, H | 16 |
| Leirisalo-Repo, M | 19 |
| Imai, R | 1 |
| Jinta, T | 1 |
| Matsumoto, H | 1 |
| Sato, S | 2 |
| Yashiro-Furuya, M | 1 |
| Matsuoka, N | 2 |
| Asano, T | 1 |
| Kobayashi, H | 2 |
| Migita, K | 4 |
| Valli, A | 1 |
| Ranta, N | 1 |
| Grönholm, A | 1 |
| Silvennoinen, O | 1 |
| Pesu, M | 1 |
| Isomäki, P | 1 |
| Shikuma, A | 1 |
| Uchiyama, H | 1 |
| Shiraishi, J | 1 |
| Oshiro, M | 1 |
| Kawaji, Y | 1 |
| Koshi, N | 1 |
| Lian, BS | 1 |
| Busmanis, I | 1 |
| Lee, HY | 1 |
| McKenna, MC | 1 |
| Vaughan, D | 1 |
| Bermingham, N | 1 |
| Cronin, S | 1 |
| Devaraj, NK | 1 |
| Forslind, K | 2 |
| Eberhardt, K | 1 |
| Svensson, B | 9 |
| Poppelaars, PBM | 1 |
| Sarathchandran, P | 1 |
| Alboudi, A | 1 |
| AlSuwaidi, R | 1 |
| Almadani, AA | 1 |
| Sinnathurai, P | 1 |
| Bartlett, SJ | 1 |
| Halls, S | 1 |
| Hewlett, S | 1 |
| Orbai, AM | 1 |
| Henderson, L | 1 |
| Iida, A | 1 |
| Hayashi, J | 3 |
| Tachibana, S | 1 |
| Inaba, T | 1 |
| Iyoda, M | 1 |
| Honda, K | 2 |
| Shibata, T | 1 |
| Otsuka, M | 1 |
| Koga, T | 2 |
| Sumiyoshi, R | 1 |
| Endo, Y | 1 |
| Tsuji, S | 1 |
| Takatani, A | 1 |
| Shimizu, T | 2 |
| Igawa, T | 1 |
| Kawashiri, SY | 4 |
| Iwamoto, N | 3 |
| Ichinose, K | 4 |
| Tamai, M | 4 |
| Nakamura, H | 6 |
| Origuchi, T | 4 |
| Daisuke, N | 1 |
| Naito, T | 1 |
| Ohshiro, J | 1 |
| Torikai, E | 3 |
| Ogawa, N | 3 |
| Kawakami, J | 1 |
| Ogawa, Y | 2 |
| Oguchi, T | 2 |
| Fujibayashi, T | 2 |
| Takagi, H | 2 |
| Funahashi, K | 2 |
| Hayashi, M | 2 |
| Tsuboi, S | 2 |
| Asai, N | 1 |
| Matsumoto, T | 2 |
| Verma, A | 1 |
| Jain, A | 2 |
| Tiwari, A | 1 |
| Saraf, S | 1 |
| Panda, PK | 1 |
| Agrawal, GP | 1 |
| Jain, SK | 1 |
| Shono, A | 1 |
| Mori, S | 3 |
| Nakamura, K | 2 |
| Yatomi, A | 1 |
| Takada, H | 1 |
| Tanaka, H | 2 |
| Okano, T | 3 |
| Morinobu, A | 1 |
| Hirata, KI | 1 |
| Horikoshi, H | 1 |
| Takada, K | 1 |
| Higuchi, T | 1 |
| Yoshikawa, T | 1 |
| Matsumoto, M | 1 |
| Suzuki, K | 3 |
| Weitoft, T | 2 |
| Øberg, K | 1 |
| Mitani, Y | 1 |
| van den Broek, M | 2 |
| Dirven, L | 1 |
| Kroon, HM | 1 |
| Kloppenburg, M | 1 |
| Ronday, HK | 1 |
| Peeters, AJ | 4 |
| Kerstens, PJ | 5 |
| Huizinga, TW | 4 |
| Stiefelhagen, P | 1 |
| ter Wee, M | 1 |
| Kerstens, P | 3 |
| Voskuyl, A | 1 |
| Raterman, H | 1 |
| van Dillen, N | 1 |
| Dijkmans, B | 1 |
| Lisitsyna, TA | 1 |
| Vel'tishchev, DIu | 1 |
| Gerasimov, AN | 1 |
| Seravina, OF | 1 |
| Kovalevskaia, OB | 1 |
| Zel'tyn', AE | 1 |
| Novikov, AA | 1 |
| Aleksandrova, EN | 1 |
| Tallerova, AV | 1 |
| Kovalenko, LP | 1 |
| Korpela, M | 15 |
| Kauppi, M | 3 |
| Karjalainen, A | 7 |
| Laiho, K | 2 |
| Hakola, M | 2 |
| Peltomaa, R | 1 |
| Ker, KJ | 1 |
| Pan, JY | 1 |
| Lui, NL | 1 |
| Tey, HL | 1 |
| Kristensen, LE | 1 |
| Bliddal, H | 1 |
| Karlsson, JA | 1 |
| Gülfe, A | 1 |
| Saxne, T | 2 |
| Geborek, P | 3 |
| Miyake, H | 1 |
| Fukaya, N | 1 |
| Hirabara, S | 1 |
| Bari, SF | 1 |
| Khan, A | 1 |
| Lawson, T | 1 |
| Kobak, S | 1 |
| Karaarslan, A | 1 |
| Aktakka, Y | 1 |
| Ochi, K | 3 |
| Go, Y | 1 |
| Furuya, T | 3 |
| Ikari, K | 3 |
| Taniguchi, A | 6 |
| Yamanaka, H | 7 |
| Momohara, S | 5 |
| Ogishima, H | 2 |
| Kondo, Y | 4 |
| Sugihara, M | 2 |
| Hayashi, T | 7 |
| Chino, Y | 2 |
| Goto, D | 4 |
| Matsumoto, I | 5 |
| Sumida, T | 5 |
| Puolakka, K | 10 |
| Blåfield, H | 7 |
| Ilva, K | 5 |
| Omata, Y | 1 |
| Hagiwara, F | 2 |
| Nishino, J | 1 |
| Matsudaira, K | 1 |
| Kadono, Y | 1 |
| Juji, T | 1 |
| Mori, T | 1 |
| Nakayama, H | 2 |
| Nagase, Y | 1 |
| Hirose, J | 1 |
| Yasui, T | 1 |
| Matsui, T | 3 |
| Tohma, S | 2 |
| Tanaka, S | 1 |
| Seegobin, SD | 1 |
| Ma, MH | 2 |
| Dahanayake, C | 2 |
| Cope, AP | 2 |
| Scott, DL | 5 |
| Lewis, CM | 1 |
| Scott, IC | 3 |
| Miyagi, R | 1 |
| Ideguchi, H | 2 |
| Soga, T | 1 |
| Yamakawa, Y | 1 |
| Otsuki, H | 1 |
| Niino, H | 1 |
| Shiina, T | 1 |
| Ueda, A | 1 |
| Ishigatsubo, Y | 2 |
| Namekawa, M | 1 |
| Ohtani, K | 2 |
| Watanabe, E | 1 |
| Nakano, I | 1 |
| Ajeganova, S | 1 |
| Hafström, I | 8 |
| Honda, M | 1 |
| Nishino, A | 1 |
| Nakashima, Y | 1 |
| Motomura, M | 2 |
| Wailoo, A | 1 |
| Hernández Alava, M | 1 |
| Ibrahim, F | 1 |
| Santiago, T | 1 |
| Saag, KG | 2 |
| Gochi, M | 1 |
| Takayanagi, N | 2 |
| Ishiguro, T | 1 |
| Miyahara, Y | 2 |
| Yanagisawa, T | 2 |
| Shimizu, Y | 1 |
| Sugita, Y | 2 |
| Engvall, IL | 4 |
| Rönnelid, J | 2 |
| Boonen, A | 9 |
| Krüger, K | 1 |
| Trampisch, US | 1 |
| van Tuyl, LH | 8 |
| Järvenpää, S | 4 |
| Mustila, A | 1 |
| Paimela, L | 7 |
| Santos-Moreno, PI | 1 |
| de la Hoz-Valle, J | 1 |
| Villarreal, L | 1 |
| Palomino, A | 1 |
| Sánchez, G | 1 |
| Castro, C | 1 |
| Perilli, E | 1 |
| Cantley, M | 1 |
| Marino, V | 1 |
| Crotti, TN | 1 |
| Haynes, DR | 1 |
| Dharmapatni, AA | 1 |
| Kanbe, K | 2 |
| Chiba, J | 2 |
| Inoue, Y | 4 |
| Taguchi, M | 2 |
| Iwamatsu, A | 1 |
| Albrecht, K | 2 |
| Callhoff, J | 1 |
| Schneider, M | 1 |
| Zink, A | 1 |
| Wacharapornin, P | 1 |
| Suwannalai, P | 1 |
| Chua, I | 1 |
| Jawad, A | 1 |
| Ishida, O | 1 |
| Inoue, E | 5 |
| Harman, H | 1 |
| Tekeoğlu, İ | 1 |
| Takçı, S | 1 |
| Kamanlı, A | 2 |
| Nas, K | 1 |
| Harman, S | 1 |
| Müller, RB | 1 |
| von Kempis, J | 1 |
| Haile, SR | 1 |
| Schiff, MH | 1 |
| van der Geest, T | 1 |
| Metselaar, JM | 2 |
| Gerrits, D | 1 |
| van Lent, PL | 2 |
| Storm, G | 2 |
| Laverman, P | 1 |
| Boerman, OC | 2 |
| Simões, RG | 1 |
| Maia, H | 1 |
| Egsmose, EL | 1 |
| Madsen, OR | 2 |
| Szeto, MC | 1 |
| Disney, B | 1 |
| Perkins, P | 1 |
| Wood, G | 1 |
| Schotte, H | 2 |
| Schlüter, B | 2 |
| Schmidt, H | 1 |
| Gaubitz, M | 2 |
| Drynda, S | 1 |
| Kekow, J | 1 |
| Willeke, P | 2 |
| Rolls, S | 1 |
| Hyams, C | 1 |
| Sheaff, M | 1 |
| O'Shaughnessy, TC | 1 |
| Yaşar Bilge, NŞ | 1 |
| Kaşifoğlu, N | 1 |
| Kaşifoğlu, T | 1 |
| Şahin, F | 1 |
| Gönüllü, E | 1 |
| Korkmaz, C | 1 |
| Kobayashi, T | 2 |
| Okura, C | 2 |
| Tsushima, Y | 2 |
| Takagishi, K | 2 |
| Haugeberg, G | 2 |
| Hansen, IJ | 1 |
| Soldal, DM | 1 |
| Sokka, T | 1 |
| Tada, M | 1 |
| Inui, K | 1 |
| Sugioka, Y | 1 |
| Mamoto, K | 1 |
| Koike, T | 1 |
| Kuusalo, L | 1 |
| Eklund, KK | 1 |
| Valleala, H | 2 |
| Ishibashi, M | 1 |
| Watanabe, M | 2 |
| Samocha-Bonet, D | 2 |
| Jenkins, AB | 1 |
| Heilbronn, LK | 2 |
| Movahedi, M | 2 |
| Beauchamp, ME | 2 |
| Abrahamowicz, M | 2 |
| Ray, DW | 2 |
| Michaud, K | 1 |
| Pedro, S | 1 |
| Dixon, WG | 3 |
| Takizawa, N | 2 |
| Nomura, A | 1 |
| Gurunathan, S | 1 |
| Parsons, G | 1 |
| Young, G | 1 |
| Porter, A | 1 |
| Elghamaz, A | 1 |
| Senior, R | 1 |
| Nordal, HH | 1 |
| Hordvik, M | 1 |
| Eidsheim, M | 1 |
| Jonsson, R | 1 |
| Halse, AK | 1 |
| Iwata, T | 2 |
| Furu, M | 1 |
| Fujii, T | 2 |
| Ishikawa, M | 1 |
| Hamamoto, Y | 1 |
| Akiyama, H | 1 |
| Kaneko, K | 3 |
| Sugitani, M | 1 |
| Goto, M | 3 |
| Murashima, A | 1 |
| Kamio, Y | 1 |
| Kanazawa, N | 2 |
| Mine, Y | 1 |
| Utani, A | 1 |
| Kabuto, M | 1 |
| Fujimoto, N | 1 |
| Hamaguchi, Y | 1 |
| Ohashi, T | 1 |
| Yamamoto, T | 2 |
| Tago, M | 1 |
| Naito, Y | 1 |
| Aihara, H | 1 |
| Furukawa, NE | 1 |
| Yamashita, S | 1 |
| Oh, EH | 1 |
| Shin, JM | 1 |
| Hong, JH | 1 |
| Kim, JS | 1 |
| Ro, YS | 1 |
| Ko, JY | 1 |
| Koyama, K | 1 |
| Ohba, T | 1 |
| Ebata, S | 1 |
| Haro, H | 1 |
| Kawasaki, T | 1 |
| Kamiya, M | 1 |
| Nakagawa, A | 1 |
| Takagiwa, J | 1 |
| Kawahara, Y | 1 |
| Nonomura, Y | 2 |
| Konijn, NP | 1 |
| van de Ven, PM | 1 |
| Costello, R | 1 |
| Lunt, M | 1 |
| Pye, SR | 1 |
| Sergeant, JC | 1 |
| Saitoh, M | 1 |
| Matsushita, K | 1 |
| Murakawa, Y | 1 |
| Koiwa, M | 1 |
| Goto, S | 1 |
| Takahashi, K | 3 |
| Kamada, T | 1 |
| Takai, S | 1 |
| Elshafie, AI | 1 |
| Elkhalifa, AD | 1 |
| Elbagir, S | 1 |
| Aledrissy, MI | 1 |
| Elagib, EM | 1 |
| Nur, MA | 1 |
| Moxey, J | 1 |
| Morrisroe, K | 1 |
| Romas, E | 1 |
| Anthony, D | 1 |
| Diethelm, M | 1 |
| Brändle, M | 1 |
| Tachibana, M | 1 |
| Syrigos, K | 1 |
| Tsagouli, S | 1 |
| Grapsa, D | 1 |
| Kawashima, H | 1 |
| Kagami, SI | 1 |
| Kashiwakuma, D | 1 |
| Yokota, M | 1 |
| Furuta, S | 1 |
| Iwamoto, I | 1 |
| Kano, K | 1 |
| Katayama, T | 1 |
| Takeguchi, S | 1 |
| Asanome, A | 1 |
| Saito, T | 1 |
| Sawada, J | 1 |
| Anei, R | 1 |
| Kamada, K | 1 |
| Miyokawa, N | 1 |
| Nishihara, H | 1 |
| Hasebe, N | 1 |
| Wang, Q | 1 |
| Li, M | 1 |
| Gong, T | 1 |
| Sun, X | 1 |
| Oh, K | 1 |
| Yabuki, A | 1 |
| Cuppen, BV | 1 |
| Pardali, K | 1 |
| Kraan, MC | 2 |
| Marijnissen, AC | 1 |
| Yrlid, L | 1 |
| Olsson, M | 1 |
| Bijlsma, JW | 5 |
| Lafeber, FP | 1 |
| Fritsch-Stork, RD | 1 |
| Verhoeven, F | 1 |
| Totoson, P | 1 |
| Maguin-Gaté, K | 1 |
| Prigent-Tessier, A | 1 |
| Marie, C | 1 |
| Wendling, D | 1 |
| Moretto, J | 1 |
| Prati, C | 1 |
| Demougeot, C | 1 |
| Arida, A | 1 |
| Protogerou, AD | 1 |
| Konstantonis, G | 1 |
| Fragiadaki, K | 1 |
| Kitas, GD | 3 |
| Petersons, CJ | 1 |
| Poljak, A | 1 |
| Greenfield, JR | 1 |
| Miyanishi, K | 1 |
| Hara, T | 1 |
| Hamada, T | 1 |
| Maekawa, M | 1 |
| Tsurusaki, S | 1 |
| Moro-oka, TA | 1 |
| Kamo, Y | 1 |
| Jingushi, S | 1 |
| Torisu, T | 1 |
| Garnero, P | 3 |
| Dijkmans, BA | 9 |
| Ebihara, K | 1 |
| Shimizu, H | 2 |
| Miyashita, N | 1 |
| Obase, Y | 1 |
| Sugiu, T | 1 |
| Ohue, Y | 1 |
| Mouri, K | 1 |
| Yagi, S | 1 |
| Kobashi, Y | 2 |
| Oka, M | 5 |
| Plass, AM | 3 |
| Hassikou, H | 1 |
| El Haouri, M | 1 |
| Tabache, F | 1 |
| Baaj, M | 1 |
| Safi, S | 1 |
| Hadri, L | 1 |
| Ogata, A | 2 |
| Terabe, F | 1 |
| Nakanishi, K | 1 |
| Kawai, M | 2 |
| Kuwahara, Y | 1 |
| Arimitsu, J | 1 |
| Hagihara, K | 1 |
| Shima, Y | 1 |
| Narazaki, M | 1 |
| Kawase, I | 1 |
| Yaguchi, M | 1 |
| Yaguchi, H | 1 |
| Kucharekova, M | 1 |
| Winnepenninckx, V | 1 |
| Frank, J | 1 |
| Poblete-Gutiérrez, P | 1 |
| Tengstrand, B | 2 |
| Brismar, K | 2 |
| Ohno, S | 1 |
| Takase, K | 1 |
| Tsukahara, T | 1 |
| Pandit, RT | 1 |
| Toyozawa, S | 1 |
| Yamamoto, Y | 2 |
| Nishide, T | 1 |
| Kishioka, A | 1 |
| Matsumoto, Y | 1 |
| Kuroyanagi, Y | 1 |
| Furukawa, F | 1 |
| Yokote, T | 1 |
| Kobayashi, K | 2 |
| Hirata, Y | 1 |
| Hara, S | 3 |
| Akioka, T | 1 |
| Miyoshi, T | 1 |
| Tsuji, M | 1 |
| Takubo, T | 1 |
| Hanafusa, T | 1 |
| Neva, MH | 1 |
| Luukkainen, R | 4 |
| Hannonen, PJ | 2 |
| Berkhof, J | 1 |
| Knol, DL | 1 |
| Rijmen, F | 1 |
| Twisk, JW | 1 |
| Uitdehaag, BJ | 1 |
| Jacobs, JW | 2 |
| Klarenbeek, NB | 1 |
| Nakajima, M | 2 |
| Ueda, N | 1 |
| Ohara, H | 1 |
| Abe, M | 2 |
| Kinoshita, M | 1 |
| Handa, S | 1 |
| Kose, K | 1 |
| Okamoto, Y | 1 |
| Minami, M | 1 |
| Hakala, M | 7 |
| Luosujärvi, R | 2 |
| Kagohashi, K | 1 |
| Satoh, H | 2 |
| Nishimagi, H | 1 |
| Ravindran, V | 1 |
| Rachapalli, S | 2 |
| Choy, EH | 2 |
| Landewé, RB | 2 |
| Han, H | 1 |
| van der Linden, S | 11 |
| van de Laar, M | 1 |
| Westhovens, R | 4 |
| van Denderen, JC | 3 |
| Westedt, ML | 2 |
| Jacobs, P | 3 |
| van de Brink, H | 1 |
| Shimada, K | 1 |
| Kawakami, M | 1 |
| Hayakawa, H | 2 |
| Futami, H | 1 |
| Michishita, K | 1 |
| Takaoka, H | 1 |
| Ikenaka, T | 1 |
| Komiya, A | 1 |
| Sugii, S | 2 |
| Furukawa, H | 2 |
| Ozawa, Y | 2 |
| Ochi, S | 1 |
| Taniguchi, K | 1 |
| Nagashima, M | 3 |
| Ueda-Nakata, R | 1 |
| Miyashita, T | 1 |
| Ezaki, H | 1 |
| Ito, M | 3 |
| Eguchi, K | 4 |
| Angelucci, E | 1 |
| Cesarini, M | 1 |
| Vernia, P | 1 |
| Hienonen-Kempas, T | 1 |
| Biyikoğlu, B | 1 |
| Buduneli, N | 1 |
| Kardeşler, L | 1 |
| Aksu, K | 1 |
| Pitkala, M | 1 |
| Sorsa, T | 1 |
| Tateiwa, T | 1 |
| Shinmura, K | 1 |
| Ko, M | 1 |
| Mibe, J | 1 |
| Yamamoto, K | 2 |
| Kageyama, Y | 3 |
| Kato, N | 1 |
| Wahle, M | 2 |
| Suzuki, J | 1 |
| Goto, H | 1 |
| Aramaki, T | 2 |
| Fujikawa, K | 2 |
| Arima, K | 2 |
| Kamachi, M | 2 |
| Yamasaki, S | 1 |
| Nakashima, M | 1 |
| Mizokami, A | 1 |
| Furuyama, M | 1 |
| Ueki, Y | 3 |
| Ida, H | 2 |
| Aoyagi, K | 1 |
| Ohara, G | 1 |
| Hizawa, N | 1 |
| Ishii, W | 1 |
| Kishida, D | 1 |
| Suzuki, A | 2 |
| Shimojima, Y | 2 |
| Matsuda, M | 5 |
| Hoshii, Y | 1 |
| Ikeda, S | 5 |
| Watanabe, K | 2 |
| Koike, R | 2 |
| Kubota, T | 2 |
| Harigai, M | 2 |
| Iwai, T | 1 |
| Miyasaka, N | 3 |
| Li, WL | 1 |
| Lo, Y | 1 |
| Leung, MH | 1 |
| Wong, WS | 2 |
| Mok, MY | 2 |
| Takeda, Y | 2 |
| Toki, T | 1 |
| Komaba, H | 1 |
| Abe, T | 6 |
| Umezu, M | 1 |
| Joh, K | 1 |
| Fukagawa, M | 1 |
| Inan, AS | 1 |
| Masatlıoglu, S | 1 |
| Ozyurek, SC | 1 |
| Engin, D | 1 |
| Erdem, I | 1 |
| Adelowo, OO | 1 |
| Ojo, O | 1 |
| Oduenyi, I | 1 |
| Okwara, CC | 1 |
| Seitz, CS | 1 |
| Berens, N | 1 |
| Bröcker, EB | 1 |
| Trautmann, A | 1 |
| Isogai, S | 1 |
| Sakurai, T | 3 |
| Nagasaka, K | 1 |
| Hammer, HB | 1 |
| Sveinsson, M | 1 |
| Kongtorp, AK | 1 |
| Kvien, TK | 3 |
| Chen, LA | 1 |
| Su, LH | 1 |
| Chang, YJ | 1 |
| Hsu, YL | 1 |
| Tsai, TH | 1 |
| Kitahama, M | 1 |
| Okamoto, H | 2 |
| Koseki, Y | 2 |
| Francis, S | 1 |
| Block, MJ | 1 |
| Sen, D | 1 |
| Rajbhandary, R | 1 |
| Carlino, A | 1 |
| Anderson, RJ | 1 |
| Schur, PH | 1 |
| Panush, RS | 1 |
| Hirohama, D | 1 |
| Hoshino, J | 1 |
| Yamanouchi, M | 1 |
| Hayami, N | 1 |
| Suwabe, T | 1 |
| Sawa, N | 2 |
| Takemoto, F | 2 |
| Ubara, Y | 2 |
| Ohashi, K | 1 |
| Takaichi, K | 2 |
| Haeusler, U | 1 |
| Wittkaemper, TA | 1 |
| Kisters, K | 1 |
| Godolias, G | 1 |
| Ikeda, K | 2 |
| Takazawa, T | 1 |
| Ishikawa, Y | 1 |
| Miura, K | 1 |
| Yoshii, Y | 1 |
| Kawabe, K | 1 |
| Iwasaki, Y | 1 |
| Tsukada, T | 1 |
| Malipeddi, A | 1 |
| Reddy, VR | 1 |
| Kallarackal, G | 1 |
| Böttcher, A | 1 |
| Guder, E | 1 |
| Just, T | 1 |
| Saevarsdottir, S | 1 |
| Wallin, H | 1 |
| Seddighzadeh, M | 1 |
| Ernestam, S | 2 |
| Petersson, IF | 2 |
| Bratt, J | 1 |
| van Vollenhoven, RF | 1 |
| Ozşahin, M | 1 |
| Ataoğlu, S | 1 |
| Turan, H | 1 |
| Matsushita, Y | 1 |
| Arizono, K | 1 |
| Bélard, E | 1 |
| Semb, S | 1 |
| Ruhwald, M | 1 |
| Werlinrud, AM | 1 |
| Soborg, B | 1 |
| Jensen, FK | 1 |
| Thomsen, H | 1 |
| Brylov, A | 1 |
| Nordgaard-Lassen, I | 1 |
| Ravn, P | 1 |
| Sassa, Y | 1 |
| Kawano, Y | 1 |
| Yamana, T | 1 |
| Mashima, T | 1 |
| Ishibashi, T | 1 |
| Maeda, T | 1 |
| Banno, S | 1 |
| Maeda, S | 1 |
| Naniwa, T | 1 |
| Hayami, Y | 1 |
| Ueda, R | 1 |
| Gatica, H | 2 |
| Aliste, M | 1 |
| Guerrero, J | 1 |
| Goecke, IA | 1 |
| Sahebari, M | 1 |
| Goshayeshi, L | 1 |
| Mirfeizi, Z | 1 |
| Rezaieyazdi, Z | 1 |
| Hatef, MR | 1 |
| Ghayour-Mobarhan, M | 1 |
| Akhlaghi, S | 1 |
| Sahebkar, A | 1 |
| Ferns, GA | 1 |
| Saracino, A | 1 |
| Kelly, R | 1 |
| Liew, D | 1 |
| Chong, A | 1 |
| Maher, JR | 2 |
| Takahata, M | 2 |
| Awad, HA | 2 |
| Berger, AJ | 2 |
| Mustak, M | 1 |
| Boltuch-Sherif, J | 1 |
| Horvath-Mechtler, B | 1 |
| Kowalski-Bodzenta, J | 1 |
| Erlacher, L | 1 |
| Ikonomidis, I | 1 |
| Tzortzis, S | 1 |
| Lekakis, J | 1 |
| Paraskevaidis, I | 1 |
| Dasou, P | 1 |
| Parissis, J | 1 |
| Nikolaou, M | 1 |
| Markantonis, SL | 1 |
| Katsimbri, P | 1 |
| Skarantavos, G | 1 |
| Andreadou, I | 1 |
| Anastasiou-Nana, M | 1 |
| van Raalte, DH | 1 |
| Hoes, JN | 1 |
| Diamant, M | 1 |
| Ikeuchi, H | 1 |
| Umemoto, A | 1 |
| Tsukida, M | 1 |
| Sakurai, N | 1 |
| Maeshima, A | 1 |
| Kuroiwa, T | 2 |
| Hiromura, K | 2 |
| Nojima, Y | 1 |
| Bernatsky, S | 1 |
| Suissa, S | 1 |
| Sylvestre, MP | 1 |
| Mease, P | 1 |
| Strand, V | 1 |
| Shalamberidze, L | 1 |
| Dimic, A | 1 |
| Raskina, T | 1 |
| Xu, LA | 1 |
| Liu, Y | 1 |
| Smith, J | 1 |
| Yoshizawa, K | 1 |
| Matsumoto, A | 2 |
| Ichijo, T | 1 |
| Umemura, T | 1 |
| Joshita, S | 1 |
| Komatsu, M | 1 |
| Tanaka, N | 3 |
| Tanaka, E | 4 |
| Ota, M | 1 |
| Katsuyama, Y | 1 |
| Kiyosawa, K | 1 |
| Onji, M | 1 |
| Becker, H | 1 |
| Pavenstäd, H | 1 |
| Mickholz, E | 1 |
| Wierichs, C | 1 |
| Herenius, MM | 1 |
| Wijbrandts, CA | 1 |
| de Jager, W | 1 |
| Prakken, BJ | 1 |
| Gerlag, DM | 4 |
| Tak, PP | 4 |
| Dragonas, C | 1 |
| Ehrenstein, B | 1 |
| Fleck, M | 1 |
| Byrne, R | 1 |
| Rath, E | 1 |
| Hladik, A | 1 |
| Niederreiter, B | 1 |
| Bonelli, M | 1 |
| Frantal, S | 1 |
| Smolen, JS | 2 |
| Scheinecker, C | 1 |
| Lu, Y | 1 |
| Xiao, J | 1 |
| Wu, ZW | 1 |
| Wang, ZM | 1 |
| Hu, J | 1 |
| Fu, HZ | 1 |
| Chen, YY | 1 |
| Qian, RQ | 1 |
| Julkunen, HA | 1 |
| Moilanen, E | 1 |
| Juneja, SC | 1 |
| Inzana, J | 1 |
| Xing, L | 1 |
| Schwarz, EM | 1 |
| Martínez-Martínez, MU | 1 |
| Martínez-Lozano, J | 1 |
| Abud-Mendoza, C | 1 |
| Yamaguchi, T | 2 |
| Takano, Y | 1 |
| Umeda, N | 2 |
| Horikoshi, M | 2 |
| Hirota, T | 1 |
| Tsuboi, H | 1 |
| Winthrop, KL | 1 |
| van Tuyl, L | 1 |
| Kostense, PJ | 2 |
| Wakabayashi, H | 1 |
| Hasegawa, M | 1 |
| Nishioka, Y | 1 |
| Minami, Y | 1 |
| Nishioka, K | 2 |
| Sudo, A | 1 |
| Sakai, R | 1 |
| Sakai, F | 1 |
| Sugiyama, H | 1 |
| Komano, Y | 1 |
| Akiyama, Y | 2 |
| Kaneko, M | 1 |
| Tokuda, H | 1 |
| Iso, T | 1 |
| Motegi, M | 1 |
| Nakajima, H | 2 |
| Taki, H | 1 |
| Kodama, H | 2 |
| Nawata, Y | 1 |
| Shiozawa, K | 1 |
| Sawada, S | 1 |
| Matsukawa, Y | 1 |
| Okazaki, T | 1 |
| Mukai, M | 2 |
| Iwahashi, M | 1 |
| Saito, K | 1 |
| Nanki, T | 1 |
| Lee, LY | 1 |
| Akhtar, MM | 1 |
| Kirresh, O | 1 |
| Gibson, T | 2 |
| Lerner, UH | 1 |
| Pomirleanu, C | 1 |
| Ancuta, C | 1 |
| Miu, S | 1 |
| Chirieac, R | 1 |
| Neeck, G | 4 |
| Kluter, A | 2 |
| Dotzlaw, H | 2 |
| Eggert, M | 2 |
| Park, YB | 1 |
| Ahn, CW | 1 |
| Choi, HK | 1 |
| Lee, SH | 1 |
| In, BH | 1 |
| Lee, HC | 1 |
| Nam, CM | 1 |
| Lee, SK | 1 |
| Yukioka, M | 2 |
| Komatsubara, Y | 2 |
| Maeda, A | 1 |
| Shichikawa, K | 2 |
| Yukioka, K | 2 |
| Furumitsu, Y | 1 |
| Yamazawa, K | 1 |
| Matsui, H | 1 |
| Sekiya, S | 1 |
| Verbruggen, LA | 1 |
| Versaen, H | 1 |
| Rebmann, V | 1 |
| Duquet, W | 1 |
| De Cock, S | 1 |
| Grosse-Wilde, H | 1 |
| Demanet, C | 1 |
| Furst, DE | 1 |
| Fleischmann, MR | 1 |
| Sherrer, Y | 1 |
| Block, JA | 1 |
| Schnitzer, T | 1 |
| Rutstein, J | 1 |
| Baldassare, A | 1 |
| Kaine, J | 1 |
| Calabrese, L | 1 |
| Dietz, F | 1 |
| Sack, M | 1 |
| Senter, RG | 1 |
| Wiesenhutter, C | 1 |
| Schiff, M | 1 |
| Stein, CM | 1 |
| Satoi, Y | 1 |
| Caldwell, J | 1 |
| Harris, RE | 1 |
| Moreland, LW | 1 |
| Hurd, E | 1 |
| Yocum, D | 1 |
| Stamler, DA | 1 |
| Iwadate, H | 1 |
| Takeda, I | 2 |
| Kanno, T | 2 |
| Kasukawa, R | 2 |
| Kidani, T | 1 |
| Sakayama, K | 1 |
| Masuno, H | 1 |
| Takubo, N | 1 |
| Matsuda, Y | 1 |
| Okuda, H | 1 |
| Yamamoto, H | 1 |
| Leandro, MJ | 2 |
| Edwards, JC | 2 |
| Cambridge, G | 2 |
| Möller, B | 1 |
| Kukoc-Zivojnov, N | 1 |
| Koyama, N | 1 |
| Grapenthin, S | 1 |
| Kessler, U | 1 |
| Klein, SA | 1 |
| Kalina, U | 1 |
| Kaltwasser, JP | 1 |
| Hoelzer, D | 1 |
| Ottmann, OG | 1 |
| Landewé, R | 3 |
| Verhoeven, A | 1 |
| Christgau, S | 1 |
| Geusens, P | 3 |
| Rusch, D | 1 |
| Schmidt, KL | 1 |
| Schulz, M | 1 |
| Pabst, W | 1 |
| Böke, J | 1 |
| Renkawitz, R | 1 |
| Bae, SC | 1 |
| Corzillius, M | 1 |
| Kuntz, KM | 1 |
| Liang, MH | 1 |
| Gotzsche, PC | 5 |
| Johansen, HK | 7 |
| Schnabel, A | 1 |
| Gross, WL | 1 |
| Ichikawa, Y | 8 |
| Li, Y | 1 |
| Xu, L | 1 |
| Shen, L | 1 |
| Yu, L | 1 |
| Chen, L | 1 |
| Yildiz, M | 1 |
| Erdogan, O | 1 |
| Aktoz, M | 1 |
| Gul, C | 1 |
| Ozbay, G | 1 |
| Yee, CS | 1 |
| Filer, A | 1 |
| Pace, A | 1 |
| Douglas, K | 1 |
| Situnayake, D | 1 |
| Rowe, IF | 1 |
| Nishikawa, N | 1 |
| Hoshi, K | 2 |
| Straub, RH | 4 |
| Pongratz, G | 1 |
| Schölmerich, J | 4 |
| Kees, F | 1 |
| Schaible, TF | 1 |
| Antoni, C | 1 |
| Kalden, JR | 1 |
| Lorenz, HM | 1 |
| Kasumoto, H | 1 |
| Izumi, M | 1 |
| Shirai, K | 1 |
| Miyagawa, K | 1 |
| Itahana, R | 1 |
| Nishikage, H | 1 |
| Hiraoka, K | 1 |
| Nakanishi, T | 1 |
| Takamitsu, Y | 1 |
| Seriolo, B | 1 |
| Craviotto, C | 1 |
| Pizzorni, C | 1 |
| Sulli, A | 1 |
| Fransen, J | 1 |
| Stucki, G | 1 |
| Chamot, AM | 1 |
| Gerster, JC | 1 |
| Langenegger, T | 1 |
| Seitz, M | 1 |
| Michel, BA | 1 |
| Evans, R | 1 |
| Ehrenstein, MR | 1 |
| Salden, M | 1 |
| Bodman-Smith, M | 1 |
| Webster, AD | 1 |
| Balabanova, RM | 1 |
| SPIES, TD | 1 |
| STONE, RE | 1 |
| GARCIA LOPEZ, G | 1 |
| DIAZ TELLECHEA, CM | 1 |
| LOPEZ TOCA, R | 1 |
| REBOREDO, A | 1 |
| SUAREZ, RM | 1 |
| HART, FD | 1 |
| CLARK, CJ | 1 |
| GOLDING, JR | 1 |
| BOLAND, EW | 8 |
| NEUSTADT, DH | 3 |
| MCCLENDON, R | 1 |
| OLASH, FA | 1 |
| BEST, M | 1 |
| ROSEN, PS | 1 |
| CARTER, AJ | 1 |
| DAUPHINEE, JA | 1 |
| GORNALL, AG | 1 |
| OGRYZLO, MA | 1 |
| FISHER, M | 1 |
| GOLZ, G | 1 |
| HESS, EV | 2 |
| MACPHERSON, ME | 2 |
| WARTER, PJ | 2 |
| PHILIPS, VK | 2 |
| ROTHERMICH, NO | 3 |
| FRANCE, O | 3 |
| LOSADA, M | 3 |
| DE MATTEIS, F | 1 |
| SALOMONE, P | 1 |
| WITTICH, FW | 1 |
| TILLIS, HH | 2 |
| ABLARD, G | 1 |
| DRY, J | 1 |
| LARCAN, A | 1 |
| DORDICK, JR | 1 |
| TARNOPOLSKY, S | 1 |
| GAMP, A | 2 |
| BOPP, A | 1 |
| BRANDT, H | 1 |
| STOLZER, BL | 1 |
| BARR, JH | 1 |
| EISENBEIS, CH | 1 |
| WECHSLER, RL | 1 |
| MARGOLIS, HM | 1 |
| DZIUBA, K | 1 |
| LIDDLE, GW | 1 |
| PAYNE, RW | 2 |
| SHETLAR, MR | 1 |
| HELLBAUM, AA | 1 |
| ISHMAEL, WK | 1 |
| STOEBER, E | 2 |
| CRAIN, DC | 1 |
| KEHOE, JA | 1 |
| BERTHOUD, E | 1 |
| DENTAND, A | 1 |
| ALBRECHT, D | 1 |
| ZUMKELLER, R | 1 |
| TEDESCHI, G | 1 |
| MONTGOMERY, DA | 2 |
| ROBINSON, RG | 2 |
| BILKA, PJ | 3 |
| MELBY, JC | 1 |
| EDGCOMB, JH | 1 |
| KENDALL, PH | 1 |
| ROSENBERG, EF | 2 |
| CAPLAN, PS | 1 |
| WEST, HF | 7 |
| ZUCKNER, J | 3 |
| MACHEK, O | 1 |
| CACIOLO, C | 1 |
| AHERN, AM | 1 |
| RAMSEY, R | 1 |
| MASTURZO, A | 1 |
| GEDDA, PO | 1 |
| MORITZ, U | 1 |
| SCHIAVETTI, A | 1 |
| NUNES, CV | 1 |
| HARNAGEL, EE | 1 |
| BERTRAND, J | 2 |
| RIFFAT, G | 2 |
| LORAS, B | 2 |
| RONDELET, J | 2 |
| MIEHLKE, K | 1 |
| THURIGEN, G | 1 |
| MURDOCH, WR | 2 |
| WILL, G | 2 |
| McMAHON, FG | 1 |
| GORDON, ES | 1 |
| COHEN, A | 1 |
| GOLDMAN, J | 1 |
| KANENSON, WL | 1 |
| TURNER, R | 1 |
| ROSE, I | 1 |
| COKE, H | 1 |
| GAUDIN, G | 1 |
| GOMEZ CARPIO, M | 1 |
| COHEN, H | 1 |
| MASSAD, F | 1 |
| HUSCHKE, U | 1 |
| KOELLE, G | 1 |
| NEBO, F | 1 |
| SPILBORGHS, G | 1 |
| LENG-LEVY, J | 1 |
| DAVID-CHAUSSE, J | 1 |
| SAGARDILUZ, J | 1 |
| LASSERRE, M | 1 |
| WOODBURY, JF | 1 |
| BIECHL, A | 1 |
| JANKOWIAK, J | 1 |
| ANSELL, BM | 1 |
| BERNSTEIN, RE | 1 |
| GAULT, NL | 1 |
| CARDOE, N | 1 |
| THOMPSON, M | 2 |
| RAMSEY, RH | 2 |
| BUDD, JJ | 1 |
| BARCELO, P | 2 |
| SANTAMARIA, A | 1 |
| CURRIE, JP | 1 |
| McNICOL, GW | 1 |
| GLICK, EN | 1 |
| BUCHAN, JF | 1 |
| TEGNER, W | 1 |
| TEICHMANN, W | 1 |
| LAHDESMAKI, K | 1 |
| HARTFALL, SJ | 1 |
| WALKER, WC | 2 |
| WRIGHT, V | 7 |
| ROHWEDDER, HJ | 1 |
| WHEELDON, T | 1 |
| KOVACS, L | 1 |
| KOSZTOLNYIK, J | 1 |
| TAKACS, B | 1 |
| GAAL, K | 1 |
| PANTLITSCHKO, L | 1 |
| WOOD, EA | 1 |
| NEWBOULD, BB | 1 |
| HEATHER, AJ | 1 |
| RUGGIERO, HA | 1 |
| GORDON, MK | 1 |
| PEREIRA, OM | 1 |
| DE REZENDE, JE | 1 |
| SERVERDUPUY, JM | 1 |
| BARKER, SA | 1 |
| BAYYUK, SH | 1 |
| BRIMACOMBE, JS | 1 |
| HAWKINS, CF | 1 |
| STACEY, M | 1 |
| KLARE, V | 1 |
| FOURNIE, A | 1 |
| SCHWARTZ, W | 1 |
| MARUYAMA, R | 1 |
| TAKENOUE, T | 1 |
| GOTO, K | 1 |
| SCHLESINGER, B | 1 |
| SCHMID, J | 1 |
| FORSSMAN, O | 1 |
| KORSGREN, M | 1 |
| NORDH, B | 1 |
| PAULSEN, F | 1 |
| DEANDRADE, JR | 2 |
| MCCORMICK, JN | 1 |
| HILL, AG | 1 |
| STRANDBERG, B | 1 |
| TREADWELL, BL | 1 |
| SEVER, ED | 1 |
| SAVAGE, O | 3 |
| COPEMAN, WS | 1 |
| FRANDSEN, E | 1 |
| PEETERS, EG | 1 |
| KUSHKII, RO | 1 |
| FOKINA, AA | 1 |
| FILIMONOVA, MV | 1 |
| SVADKOVSKII, BS | 1 |
| MOSCHIDIS, C | 1 |
| MCCARTHY, DD | 1 |
| CHALMERS, TM | 1 |
| SIEGENTHALER, W | 1 |
| SIEGENTHALER, G | 1 |
| BONER, A | 1 |
| DULTSIN, MS | 1 |
| SIGIDIN, IaA | 3 |
| ZHELEZNOVA, AI | 1 |
| PEREZ GALDOS, I | 1 |
| FERNANDEZDELVALLADO, P | 1 |
| GIJONBANOS, J | 1 |
| BELTRANGUTIERREZ, J | 1 |
| MANTECAFERNANDEZ, O | 1 |
| GRAYZEL, EF | 1 |
| LONGSON, D | 1 |
| SILTZBACH, LE | 1 |
| CORCOS, JM | 1 |
| SOLER-BECHARA, J | 1 |
| MAYER, K | 1 |
| FREYBERG, RH | 1 |
| GOLDSTEIN, R | 1 |
| JAFFE, I | 1 |
| SVANTESSON, H | 1 |
| CEBON, L | 1 |
| GARRACHONAGUADO, J | 1 |
| SAUER, H | 2 |
| RAUSCH-STROOMANN, JG | 1 |
| DAVID CHAUSSE, J | 1 |
| DAVID CHAUSSE, F | 1 |
| PICOT, C | 1 |
| GOTH, E | 2 |
| GOERGENYI, G | 1 |
| FOEVENYI, J | 1 |
| SZANTO, E | 2 |
| UDDIN, J | 1 |
| MATHIES, H | 10 |
| HEINSIUS, M | 1 |
| RASPE, J | 1 |
| HINGORANI, K | 1 |
| ZINOVIEFF, A | 1 |
| KIRSCH, K | 1 |
| HOLZKNECHT, F | 1 |
| PALLIS, CA | 1 |
| SCOTT, JT | 4 |
| NUGENT, CA | 1 |
| WARD, J | 1 |
| MACDIARMID, WD | 1 |
| MCCALL, JC | 1 |
| BAUKOL, J | 1 |
| TYLER, FH | 1 |
| DENMAN, AM | 1 |
| HUBER, H | 1 |
| WOOD, PH | 1 |
| COOMES, EN | 5 |
| FORGACS, P | 1 |
| KATONA, A | 1 |
| FRIGYER, E | 1 |
| IUEL, J | 1 |
| KRYGER, J | 1 |
| BAECKDAHL, M | 1 |
| STRANDBERG, O | 1 |
| BYWATERS, EG | 1 |
| BOLLET, AJ | 1 |
| BUNIM, JJ | 1 |
| KALLIOMAKI, JL | 1 |
| HAKKINEN, IP | 1 |
| JAUREGUI, RA | 1 |
| TREVINO DE LA PENA, E | 1 |
| KELLY, M | 1 |
| SANS SOLA, L | 1 |
| SERRA PERALBA, A | 1 |
| Kwak, JJ | 1 |
| Chang, JE | 1 |
| Lee, J | 1 |
| Cho, YJ | 1 |
| Sung, SH | 1 |
| Mazurov, VI | 2 |
| Lila, AM | 2 |
| Raĭmuev, KV | 1 |
| Yamagishi, F | 2 |
| Sambrook, PN | 5 |
| Hughes, DR | 1 |
| Nelson, AE | 1 |
| Robinson, BG | 1 |
| Mason, RS | 1 |
| Nakamura, T | 3 |
| Yamamura, Y | 1 |
| Tomoda, K | 1 |
| Tsukano, M | 1 |
| Shono, M | 1 |
| Baba, S | 1 |
| Hoekstra, M | 1 |
| van de Laar, MA | 3 |
| Bernelot Moens, HJ | 1 |
| Kruijsen, MW | 1 |
| Haagsma, CJ | 1 |
| Finesilver, AG | 1 |
| Vuori, K | 3 |
| Hepburn, AL | 1 |
| Mason, JC | 1 |
| Davies, KA | 1 |
| Kondo, H | 1 |
| Hashimoto, H | 1 |
| Uchida, S | 1 |
| Irimajiri, S | 1 |
| Hara, M | 4 |
| Sugawara, S | 1 |
| Onda, K | 1 |
| Rimbara, E | 1 |
| Oka, K | 2 |
| Abe, H | 3 |
| Takanashi, H | 2 |
| Tsuboi, N | 2 |
| Niitsuma, T | 1 |
| Gono, T | 1 |
| Tokuda, T | 1 |
| Shikama, N | 1 |
| Tagami, T | 1 |
| Katori, H | 1 |
| Sohen, S | 2 |
| Tsuzake, K | 1 |
| Kameda, H | 3 |
| Lamb, SR | 1 |
| Stables, GI | 1 |
| Merchant, W | 1 |
| Chekalin, AF | 2 |
| Rossokhin, VF | 2 |
| Shishkanov, SF | 2 |
| Kazakova, MA | 1 |
| Kirwan, JR | 11 |
| Hällgren, R | 11 |
| Mielants, H | 4 |
| Wollheim, F | 1 |
| Bjorck, E | 2 |
| Persson, T | 2 |
| Book, C | 1 |
| Bowman, S | 1 |
| Byron, M | 3 |
| Cox, N | 1 |
| Field, M | 2 |
| Kanerud, L | 1 |
| Malaise, M | 1 |
| Mohammad, A | 1 |
| Palmer, R | 1 |
| Ringertz, B | 1 |
| Sheldon, P | 1 |
| Simonsson, M | 1 |
| Snowden, N | 1 |
| Van den Bosch, F | 1 |
| te Koppele, J | 1 |
| Ulubaş, B | 1 |
| Sahin, G | 1 |
| Ozer, C | 1 |
| Aydin, O | 1 |
| Ozgür, E | 1 |
| Apaydin, D | 1 |
| Capell, HA | 1 |
| Madhok, R | 1 |
| Hunter, JA | 1 |
| Morrison, E | 2 |
| Larkin, J | 1 |
| Thomson, EA | 1 |
| Hampson, R | 1 |
| Poon, FW | 1 |
| Noorwali, AA | 1 |
| Forrest, CM | 1 |
| Kennedy, A | 1 |
| Stone, TW | 1 |
| Stoy, N | 1 |
| Darlington, LG | 1 |
| Takabayashi, K | 1 |
| Hanaoka, H | 1 |
| Nishimura, S | 1 |
| Kimura, H | 1 |
| Oki, M | 1 |
| Nojima, M | 1 |
| Taga, M | 1 |
| Matsumoto, S | 1 |
| Takahashi, H | 3 |
| Imai, K | 2 |
| Korthals-de Bos, I | 1 |
| Van Tulder, M | 1 |
| Verhoeven, AC | 9 |
| Adèr, HJ | 1 |
| Bibo, J | 1 |
| Ota, K | 1 |
| Kumon, Y | 1 |
| Ishibashi, A | 1 |
| Takao, T | 1 |
| Hashimoto, K | 1 |
| Patten, C | 1 |
| Bush, K | 1 |
| Rioja, I | 1 |
| Morgan, R | 1 |
| Wooley, P | 1 |
| Trill, J | 1 |
| Life, P | 1 |
| Kirwan, J | 3 |
| Niang, A | 1 |
| Diallo, S | 1 |
| Ka, MM | 1 |
| Pouye, A | 1 |
| Diop, S | 1 |
| Ndongo, S | 1 |
| Diop, TM | 1 |
| Tschampa, HJ | 1 |
| Sommer, T | 1 |
| Tasci, S | 1 |
| Haringman, JJ | 2 |
| Smeets, TJ | 2 |
| Zwinderman, AH | 2 |
| Laud, PJ | 1 |
| Morgan, S | 1 |
| Nash, AF | 1 |
| Järvinen, P | 2 |
| Ahonen, J | 2 |
| Forsberg, S | 2 |
| Panthakalam, S | 1 |
| Bhatnagar, D | 1 |
| Klimiuk, P | 1 |
| Kanemoto, M | 1 |
| Ota, Y | 1 |
| Karahashi, T | 1 |
| Nozue, N | 1 |
| Mayer, DF | 1 |
| Matteson, EL | 1 |
| O'Daunt, S | 1 |
| Sugita, K | 1 |
| Hirokawa, H | 1 |
| Izu, K | 1 |
| Tokura, Y | 1 |
| Ochi, T | 2 |
| Kawai, S | 3 |
| Raza, K | 1 |
| Banks, M | 1 |
| Fath, R | 1 |
| Takeishi, M | 1 |
| Akiba, H | 1 |
| Adachi, D | 1 |
| Hirano, M | 1 |
| Härle, P | 2 |
| Wiest, R | 1 |
| Mayer, A | 1 |
| Atzeni, F | 2 |
| Carrabba, M | 2 |
| Sarzi-Puttini, P | 2 |
| Kobayashi, S | 1 |
| Kida, I | 1 |
| Strand, A | 1 |
| Vinkenoog, M | 1 |
| Zimmer, C | 1 |
| Beiderlinden, M | 1 |
| Peters, J | 1 |
| Parodi, M | 1 |
| Garlaschi, G | 1 |
| Silvestri, E | 1 |
| Cimmino, MA | 1 |
| Albertsson, K | 2 |
| Keller, C | 1 |
| Steinfeld, P | 1 |
| Zeidler, H | 4 |
| Harris, ED | 2 |
| Kapetanovic, MC | 1 |
| Sjöholm, A | 1 |
| Truedsson, L | 1 |
| Jönsson, G | 1 |
| Kawakami, K | 1 |
| Ito, R | 1 |
| Watanabe, Y | 2 |
| Goto, T | 1 |
| Wernicke, D | 1 |
| Seipelt, E | 1 |
| Schmidt, WA | 1 |
| Gromnica-Ihle, E | 2 |
| Skoumal, M | 1 |
| Haberhauer, G | 1 |
| Feyertag, J | 1 |
| Kittl, EM | 1 |
| Bauer, K | 1 |
| Dunky, A | 2 |
| Kuuliala, K | 1 |
| Orpana, A | 1 |
| Hurme, M | 1 |
| Repo, H | 1 |
| Toyosaki-Maeda, T | 1 |
| Yonenobu, K | 1 |
| Villeneuve, E | 1 |
| St-Pierre, A | 1 |
| Haraoui, B | 1 |
| Hickey, SH | 1 |
| Wollheim, FA | 1 |
| Ferraccioli, G | 1 |
| Zoli, A | 1 |
| Alivernini, S | 1 |
| De Santis, M | 1 |
| Verrillo, A | 1 |
| Loperfido, F | 1 |
| Yamana, S | 2 |
| Matsuda, T | 1 |
| Takasugi, K | 2 |
| Kishimoto, T | 1 |
| Nishimoto, N | 1 |
| Wong, SY | 1 |
| Chan, TM | 1 |
| Tang, WM | 1 |
| Lau, CS | 1 |
| Asada, Y | 1 |
| Isomoto, H | 1 |
| Shikuwa, S | 1 |
| Wen, CY | 1 |
| Fukuda, E | 1 |
| Miyazato, M | 1 |
| Okamoto, K | 1 |
| Nishiyama, H | 1 |
| Mizuta, Y | 1 |
| Kohno, S | 1 |
| Dreher, R | 1 |
| Demary, W | 1 |
| Görtz, B | 1 |
| Hein, G | 1 |
| Kern, P | 1 |
| Schulz, A | 1 |
| Boyle, DL | 1 |
| Rosengren, S | 1 |
| Nash, T | 1 |
| Firestein, GS | 1 |
| Yasuko, A | 1 |
| Takahashi, A | 1 |
| Nakahara, T | 1 |
| Odajima, H | 1 |
| Nagano, A | 2 |
| Ichikawa, T | 1 |
| Iwatani, M | 1 |
| Nakajima, A | 2 |
| Tomatsu, T | 3 |
| Kamatani, N | 5 |
| Sekiguchi, N | 1 |
| Nagasawa, H | 1 |
| Takei, H | 1 |
| Nishi, E | 1 |
| Ogawa, H | 1 |
| Urata, Y | 2 |
| Wakai, Y | 1 |
| Kowatari, K | 1 |
| Nitobe, T | 1 |
| Mizushima, Y | 7 |
| Harigai, T | 1 |
| Hagiwara, H | 1 |
| Ishizuka, T | 1 |
| Kaneda, S | 1 |
| Kimura, J | 1 |
| Schueller-Weidekamm, C | 1 |
| Krestan, C | 1 |
| Schueller, G | 1 |
| Kapral, T | 2 |
| Aletaha, D | 2 |
| Kainberger, F | 1 |
| Grisar, J | 1 |
| Steiner, CW | 1 |
| Steiner, S | 1 |
| Säemann, M | 1 |
| Schwarzinger, I | 1 |
| Buranyi, B | 1 |
| Steiner, G | 1 |
| Pincus, T | 1 |
| Yazici, Y | 1 |
| Podas, T | 1 |
| Nightingale, JM | 1 |
| Oldham, R | 1 |
| Roy, S | 1 |
| Sheehan, NJ | 1 |
| Mayberry, JF | 1 |
| Yokoo, H | 1 |
| Nakazato, Y | 1 |
| Harigaya, Y | 1 |
| Sasaki, N | 1 |
| Igeta, Y | 1 |
| Itoh, H | 1 |
| Ramsay, DB | 1 |
| Long, SE | 1 |
| Ali, MA | 1 |
| Entwisle, C | 1 |
| Orenstein, JM | 1 |
| Rossi, C | 1 |
| Borum, ML | 1 |
| Häupl, T | 1 |
| Yahyawi, M | 1 |
| Lübke, C | 1 |
| Ringe, J | 1 |
| Rohrlach, T | 1 |
| Burmester, GR | 1 |
| Sittinger, M | 1 |
| Kaps, C | 1 |
| Terai, C | 1 |
| Hagiwara, K | 1 |
| Sato, T | 1 |
| Takagi-Kobayashi, S | 1 |
| Hasegawa, S | 2 |
| Shigihara, N | 1 |
| Akiyama, O | 1 |
| Simsek, I | 1 |
| Erdem, H | 1 |
| Pay, S | 1 |
| Sobaci, G | 1 |
| Dinc, A | 1 |
| Augustsson, J | 1 |
| Eksborg, S | 1 |
| Gullström, E | 1 |
| Shigehara, K | 1 |
| Yamamoto, M | 1 |
| Suzuki, C | 1 |
| Naishiro, Y | 1 |
| Hirohashi, Y | 1 |
| Satoh, N | 1 |
| Shijubo, N | 1 |
| Shinomura, Y | 1 |
| Ito, E | 1 |
| Mochizuki, A | 1 |
| Ohara, K | 1 |
| Kato, M | 1 |
| Terashima, Y | 1 |
| Takagi, K | 1 |
| Uchiyama, S | 1 |
| Iwata, M | 2 |
| Tsuchiya, Y | 1 |
| Tokunaga, D | 1 |
| Yamaguchi, S | 1 |
| Saito, H | 1 |
| Ubukata, M | 1 |
| Kurashima, K | 1 |
| Coyne, P | 1 |
| Hamilton, J | 1 |
| Heycock, C | 1 |
| Saravanan, V | 1 |
| Coulson, E | 1 |
| Kelly, CA | 1 |
| Strunk, J | 1 |
| Strube, K | 1 |
| Rumbaur, C | 1 |
| Lange, U | 2 |
| Müller-Ladner, U | 3 |
| Rohani, M | 1 |
| Deneberg, S | 1 |
| Wörnert, M | 1 |
| Jogestrand, T | 1 |
| Frostegård, J | 1 |
| Song, YW | 1 |
| Lee, EY | 1 |
| Koh, EM | 1 |
| Cha, HS | 1 |
| Baek, HJ | 1 |
| Suh, Y | 1 |
| Kang, SW | 1 |
| Lee, YJ | 1 |
| Jung, HG | 1 |
| Nozaki, Y | 1 |
| Nagare, Y | 1 |
| Kinoshita, K | 1 |
| Urase, F | 1 |
| Funauchi, M | 2 |
| Smith, CM | 1 |
| Farewell, V | 1 |
| Walker, D | 1 |
| Hassell, A | 1 |
| Chau, L | 1 |
| Kvalvik, AG | 1 |
| Lefsaker, L | 1 |
| Dyvik, S | 1 |
| Hämäläinen, H | 1 |
| Kaarela, K | 1 |
| Kröger, H | 1 |
| Kotaniemi, A | 1 |
| Edwards, CJ | 1 |
| Cooper, C | 2 |
| Fisher, D | 1 |
| van Staa, TP | 1 |
| Arden, NK | 1 |
| Verschueren, P | 1 |
| Esselens, G | 1 |
| Panoulas, VF | 1 |
| Douglas, KM | 1 |
| Stavropoulos-Kalinoglou, A | 1 |
| Metsios, GS | 1 |
| Nightingale, P | 1 |
| Kita, MD | 1 |
| Elisaf, MS | 1 |
| Sote, Y | 1 |
| Green, S | 1 |
| Maddison, P | 1 |
| Dinser, R | 1 |
| Fousse, M | 1 |
| Sester, U | 1 |
| Singh, M | 1 |
| Köhler, H | 1 |
| Sester, M | 1 |
| Ho, S | 1 |
| Srinivasan, U | 1 |
| Bevan, M | 1 |
| López, FJ | 1 |
| Ardecky, RJ | 1 |
| Bebo, B | 1 |
| De Grandpre, L | 1 |
| Liu, S | 1 |
| Leibowitz, MD | 1 |
| Rungta, D | 1 |
| Viveros, HO | 1 |
| Yen, WC | 1 |
| Morishita, M | 1 |
| Wauke, K | 1 |
| Takenouchi, K | 1 |
| Katayama, K | 1 |
| Matsuno, T | 1 |
| Noguchi, T | 1 |
| Nohara, J | 1 |
| Sakaguchi, Y | 1 |
| Kono, T | 1 |
| Terada, Y | 1 |
| Tambo, Y | 1 |
| Fujimura, M | 1 |
| Yasui, M | 1 |
| Kasahara, K | 1 |
| Nakatsumi, Y | 1 |
| Nakao, S | 1 |
| Iikuni, N | 1 |
| Komatsuda, A | 2 |
| Wakui, H | 1 |
| Nimura, T | 1 |
| Sawada, K | 2 |
| Malysheva, OA | 1 |
| Wagner, U | 1 |
| Pierer, M | 1 |
| Arnold, S | 2 |
| Häntzschel, H | 7 |
| Baerwald, CG | 1 |
| Renner, R | 1 |
| Sticherling, M | 1 |
| Thumb, N | 1 |
| Beilhack, H | 1 |
| Gangl, A | 1 |
| Nakamura, R | 2 |
| Kudo, H | 1 |
| Baum, J | 3 |
| Ziff, M | 3 |
| Asai, H | 1 |
| Sonozaki, H | 1 |
| Nagano, M | 1 |
| Nakahara, M | 1 |
| Tokita, T | 1 |
| Whittingham, S | 1 |
| Balazs, ND | 1 |
| Mackay, IR | 1 |
| Funada, H | 1 |
| Ishizaki, T | 1 |
| Hattori, K | 1 |
| Nakamura, S | 1 |
| Brandslund, I | 2 |
| Peters, ND | 2 |
| Ejstrup, L | 2 |
| Teisner, B | 1 |
| Rasmussen, GG | 1 |
| Million, R | 1 |
| Kellgren, JH | 1 |
| Poole, P | 1 |
| Jayson, MI | 2 |
| Butler, RC | 1 |
| Goddard, DH | 1 |
| Masi, AT | 2 |
| Verbruggen, G | 3 |
| Veys, EM | 3 |
| Hermanns, P | 2 |
| Delanghe, J | 1 |
| Vansteenkiste, M | 1 |
| McConkey, B | 2 |
| Trautwein, G | 1 |
| Shiokawa, Y | 1 |
| Horiuchi, Y | 1 |
| Kageyama, T | 1 |
| Ofuji, T | 1 |
| Honma, M | 2 |
| Yoshizawa, H | 2 |
| Abe, C | 1 |
| Nishimura, T | 1 |
| De Silva, M | 2 |
| Binder, A | 1 |
| Hazleman, BL | 3 |
| Malaviya, AN | 1 |
| Khan, KM | 1 |
| Tiwari, SC | 1 |
| Swannell, AJ | 4 |
| Chakraborty, J | 2 |
| English, J | 2 |
| Marks, V | 2 |
| Baruah, DR | 1 |
| Tellkamp, F | 1 |
| Kunath, B | 1 |
| Omdal, R | 2 |
| Husby, G | 2 |
| Bröll, H | 2 |
| Révész, T | 1 |
| Kardos, G | 1 |
| Kajtár, P | 1 |
| Vargha, M | 1 |
| Kabos, S | 1 |
| Schuler, D | 1 |
| Nishikai, M | 1 |
| Mukohda, Y | 1 |
| Sato, A | 2 |
| Pullar, T | 2 |
| Sturrock, RD | 2 |
| Hajiroussou, VJ | 1 |
| Webley, M | 1 |
| Thomas, TP | 1 |
| Shettar, SP | 1 |
| Chattopadhyay, C | 1 |
| Wolstenholme, RJ | 1 |
| Swinson, DR | 1 |
| Kowanko, IC | 1 |
| Pownall, R | 1 |
| Knapp, MS | 1 |
| Mahoney, PG | 1 |
| Otto, J | 1 |
| Otto, W | 4 |
| Reid, DM | 3 |
| Kennedy, NS | 1 |
| Smith, MA | 2 |
| Tothill, P | 2 |
| Nuki, G | 7 |
| Wolff, E | 4 |
| Pybus, PK | 1 |
| Berne, C | 1 |
| MacFarlane, DG | 1 |
| Dieppe, PA | 1 |
| Rudyk, BI | 1 |
| Fujita, T | 1 |
| Kono, I | 1 |
| Kabashima, T | 1 |
| Yamane, K | 1 |
| Tamura, N | 1 |
| Kashiwagi, H | 2 |
| Ohno, I | 1 |
| Negishi, M | 1 |
| Ide, H | 1 |
| Takahashi, T | 1 |
| Fitzcharles, MA | 1 |
| Halsey, J | 1 |
| Currey, HL | 3 |
| Nahon, E | 1 |
| Delfraissy, JF | 1 |
| Kahn, MF | 1 |
| Jeusset, J | 1 |
| Galanaud, P | 1 |
| Lacour, F | 1 |
| Kutsuna, T | 1 |
| Maeda, K | 2 |
| Marwah, RJ | 1 |
| Pickup, ME | 1 |
| Al-Shakarchi, H | 1 |
| Dixon, JS | 3 |
| Lowe, JR | 1 |
| Bird, HA | 3 |
| Lloyd, EL | 1 |
| Keitel, W | 2 |
| Reeback, JS | 1 |
| Payne, CR | 1 |
| Connellan, SJ | 1 |
| Muramatsu, S | 1 |
| Konagaya, M | 1 |
| Sakonjuu, T | 1 |
| Yamashita, T | 1 |
| Harasawa, S | 1 |
| Miwa, T | 1 |
| Fries, JF | 1 |
| Singh, G | 1 |
| Deodhar, AA | 1 |
| Woolf, AD | 1 |
| Tsurko, VV | 1 |
| Ivanova, MM | 1 |
| Tokmachev, IuK | 1 |
| Stichtenoth, DO | 1 |
| Fauler, J | 1 |
| Frölich, JC | 1 |
| Vreugdenhil, G | 1 |
| Schattenberg, A | 1 |
| Dompeling, EC | 1 |
| Swaak, AJ | 1 |
| De Witte, T | 1 |
| Kuroki, S | 1 |
| Ohta, A | 1 |
| Katoh, O | 1 |
| Sueko, N | 1 |
| Yamada, H | 3 |
| Yamaguchi, M | 1 |
| Hirakata, M | 1 |
| Akizuki, M | 1 |
| Schmidt, Z | 1 |
| Szilágyi, M | 1 |
| Megyeri, A | 1 |
| Merétey, K | 1 |
| Menard, O | 1 |
| Petit, N | 1 |
| Gillet, P | 1 |
| Gaucher, A | 1 |
| Martinet, Y | 1 |
| Breedveld, FC | 1 |
| Hakoda, M | 1 |
| Akahoshi, T | 1 |
| Kashiwazaki, S | 2 |
| Onishi, R | 1 |
| Namiuchi, S | 1 |
| Moore, S | 1 |
| Ruska, K | 1 |
| Peters, L | 1 |
| Olsen, NJ | 2 |
| Puchner, R | 1 |
| Steglegger-Friede, B | 1 |
| Roithinger, FX | 1 |
| Knoflach, P | 1 |
| Maezawa, A | 1 |
| Mitsuhashi, H | 2 |
| Tsukada, Y | 2 |
| Kanai, H | 1 |
| Yano, S | 2 |
| Naruse, T | 2 |
| Mitsuhashi, M | 1 |
| Arvidson, NG | 5 |
| Elfman, L | 1 |
| Rydén, AC | 1 |
| Tötterman, TH | 1 |
| Førre, O | 1 |
| Aritomi, H | 1 |
| Miyazawa, H | 1 |
| Sasaki, Y | 1 |
| Sugito, K | 1 |
| Ihara, S | 1 |
| Wakayama, H | 1 |
| Itoh, Y | 1 |
| Noguchi, M | 1 |
| Kawaguchi, H | 1 |
| Ohshika, H | 1 |
| Totani, Y | 1 |
| Torii, Y | 1 |
| Senda, Y | 1 |
| Mukohyama, N | 1 |
| Bolla, G | 1 |
| Disdier, P | 1 |
| Harle, JR | 1 |
| Verrot, D | 1 |
| Weiller, PJ | 1 |
| Laroche, M | 1 |
| Arlet, J | 1 |
| Aida, S | 1 |
| Okawa-Takatsuji, M | 1 |
| Aotsuka, S | 1 |
| Shimoji, K | 1 |
| Yokohari, R | 1 |
| Hall, GM | 2 |
| Spector, TD | 2 |
| Griffin, AJ | 1 |
| Jawad, AS | 1 |
| Hall, ML | 1 |
| Doyle, DV | 1 |
| Zen-nyoji, A | 1 |
| Oshimoto, K | 1 |
| Kobayashi, Y | 1 |
| Mori, M | 1 |
| Azais, I | 1 |
| Lambert de Cursay, G | 1 |
| Deblais, F | 1 |
| Deschamps, O | 1 |
| Gandon, P | 1 |
| Alcalay, M | 1 |
| Bontoux, D | 1 |
| Yamanishi, Y | 1 |
| Taooka, Y | 1 |
| Mukuzono, H | 1 |
| Aoi, K | 1 |
| Ishibe, Y | 1 |
| Pettersson, T | 1 |
| Tarkka, M | 1 |
| Mattila, T | 1 |
| Airaksinen, J | 1 |
| Sutinen, S | 2 |
| Yasuda, M | 1 |
| Yasuda, D | 1 |
| Tomooka, K | 1 |
| Nobunaga, M | 1 |
| Miyagawa, Y | 1 |
| Nagata, N | 1 |
| Nakanishi, Y | 1 |
| Aizawa, H | 1 |
| Satake, M | 1 |
| Hayashi, S | 1 |
| Yagawa, Y | 1 |
| Jones, PB | 1 |
| Economou, G | 1 |
| Adams, JE | 1 |
| Bernstein, RM | 1 |
| Garton, MJ | 1 |
| Kendall, R | 1 |
| Wasti, A | 1 |
| Harvey, A | 1 |
| Hill, J | 1 |
| Chapman, C | 1 |
| Norfolk, DR | 1 |
| Lafforgue, P | 1 |
| Monjanel-Mouterde, S | 1 |
| Durand, A | 1 |
| Catalin, J | 1 |
| Acquaviva, PC | 1 |
| Perry, LA | 1 |
| Umeki, S | 1 |
| Sumi, M | 1 |
| Soejima, R | 1 |
| Noguchi, A | 1 |
| Capell, H | 1 |
| Maillefert, JF | 1 |
| Maynadie, M | 1 |
| Tebib, JG | 1 |
| Aho, S | 1 |
| Walker, P | 1 |
| Chatard, C | 1 |
| Dulieu, V | 1 |
| Bouvier, M | 1 |
| Carli, PM | 1 |
| Tavernier, C | 1 |
| Moro, H | 2 |
| Okazaki, H | 1 |
| Eguchi, S | 2 |
| Yazawa, M | 1 |
| Togashi, K | 1 |
| Sato, Y | 1 |
| Inoue, F | 1 |
| Ohno, T | 1 |
| Lim, KK | 1 |
| Chrousos, GP | 1 |
| Skogseid, B | 1 |
| Oberg, K | 1 |
| Wide, L | 1 |
| Lane, SJ | 1 |
| Lee, TH | 1 |
| Walsh, LJ | 1 |
| Wong, CA | 1 |
| Pringle, M | 1 |
| Tattersfield, AE | 1 |
| Doita, M | 1 |
| Terukina, M | 1 |
| Mizuno, K | 1 |
| Touno, M | 1 |
| Senda, M | 1 |
| Nakago, K | 1 |
| Inoue, H | 1 |
| Leitch, R | 1 |
| Walker, SE | 1 |
| Hillard, AE | 1 |
| Bekkelund, SI | 1 |
| Torbergsen, T | 1 |
| Mellgren, SI | 1 |
| Chappel, R | 1 |
| Willems, J | 1 |
| Morita, S | 1 |
| Chida, K | 1 |
| Sato, J | 1 |
| Todate, A | 1 |
| Tsukamoto, K | 1 |
| Toyoshima, M | 1 |
| Imokawa, S | 1 |
| Takayama, K | 1 |
| Kimotsuki, K | 1 |
| Hidaka, K | 1 |
| Miyazaki, H | 1 |
| Kuwano, K | 1 |
| Hara, N | 1 |
| Rodríguez-García, MI | 1 |
| Fernández, JA | 1 |
| Rodríguez, A | 1 |
| Fernández, MP | 1 |
| Gutierrez, C | 1 |
| Torre-Alonso, JC | 1 |
| Larsson, A | 1 |
| Harper, L | 1 |
| Cockwell, P | 1 |
| Howie, AJ | 1 |
| Michael, J | 1 |
| Richards, NT | 1 |
| Savage, CO | 1 |
| Wheeler, DC | 1 |
| Bacon, PA | 8 |
| Adu, D | 1 |
| Gürsel, T | 1 |
| Firat, S | 1 |
| Ercan, ZS | 1 |
| Sugawara, M | 1 |
| Namura, O | 1 |
| Takahashi, M | 3 |
| Yagi, N | 1 |
| Tsuji, K | 1 |
| Takagaki, M | 1 |
| Hori, K | 1 |
| Nakai, M | 1 |
| Kino, K | 1 |
| Sano, S | 1 |
| Novik, AA | 1 |
| Cohen, MD | 1 |
| Conn, DL | 2 |
| Sugiyama, T | 1 |
| Sueishi, M | 1 |
| Matsumura, R | 1 |
| Tomioka, H | 1 |
| Akikusa, B | 1 |
| Hirano, K | 1 |
| Saitoh, T | 1 |
| Kadono, K | 1 |
| Oose, H | 1 |
| Watanabe, S | 1 |
| Cuchacovich, M | 1 |
| Tchernitchin, NN | 1 |
| Wurgaft, R | 1 |
| Contreras, L | 1 |
| Tchernitchin, AN | 1 |
| Kagamu, H | 1 |
| Hasegawa, T | 1 |
| Kurashige, K | 1 |
| Saitoh, Y | 1 |
| Terada, M | 1 |
| Satoh, M | 1 |
| Abe, Y | 3 |
| Nakano, M | 1 |
| Suzuki, E | 1 |
| Arakawa, M | 1 |
| Emery, P | 1 |
| Markusse, HM | 3 |
| van Zeben, D | 1 |
| van den Brink, HR | 1 |
| Schouten, HJ | 1 |
| van der Heijde, DM | 2 |
| Glennås, A | 1 |
| Andrup, O | 1 |
| Clarke-Jenssen, O | 1 |
| Karstensen, B | 1 |
| Brodin, U | 1 |
| Göbel, D | 1 |
| Gratz, S | 1 |
| von Rothkirch, T | 1 |
| Becker, W | 1 |
| Willert, HG | 1 |
| Okuda, Y | 1 |
| Oyama, T | 1 |
| Oyama, H | 1 |
| Nanba, S | 1 |
| Miyamoto, T | 1 |
| Somerville, MF | 1 |
| Scott, DG | 1 |
| Isshiki, K | 1 |
| Nagato, Y | 1 |
| Tsujie, M | 1 |
| Nakayama, Y | 2 |
| Kakihara, M | 1 |
| Yamada, Y | 1 |
| Kamata, T | 1 |
| Ishii, O | 1 |
| Ohya, S | 1 |
| Moriuchi, E | 1 |
| Kase, C | 1 |
| Yamasaki, K | 1 |
| Pommepuy, I | 1 |
| Farny, M | 1 |
| Billey, T | 1 |
| Olivier, P | 1 |
| Lassoued, S | 1 |
| Dennison, EM | 1 |
| Gøtzsche, PC | 2 |
| Shinozawa, T | 1 |
| Hama, N | 1 |
| Ohosone, Y | 1 |
| Sharif, M | 1 |
| Salisbury, C | 1 |
| Taylor, DJ | 1 |
| Miyamoto, S | 2 |
| Hoshino, H | 1 |
| Kushida, K | 2 |
| Miura, M | 1 |
| Matsuo, T | 2 |
| Fukuchi, M | 1 |
| Hori, T | 1 |
| Kobayashi, M | 1 |
| Hickling, P | 1 |
| Jacoby, RK | 1 |
| O'Neill, EA | 1 |
| Bibo, JC | 1 |
| Engel, GL | 1 |
| Yamanouchi, J | 1 |
| Yamauchi, Y | 1 |
| Yokota, E | 1 |
| Chen, JR | 1 |
| Weller, R | 1 |
| White, MI | 1 |
| Kimura, K | 1 |
| Toyama, K | 1 |
| Yoshida, M | 1 |
| Hojyo, T | 1 |
| Ryo, H | 1 |
| Nakata, M | 1 |
| Sim, J | 1 |
| Czerwony, G | 1 |
| Alten, R | 1 |
| Hagemann, D | 1 |
| Reuter, U | 1 |
| Sörensen, H | 1 |
| Müller, B | 1 |
| Kuper, IH | 1 |
| van Leeuwen, MA | 1 |
| van Riel, PL | 2 |
| Sluiter, WJ | 1 |
| Houtman, NM | 1 |
| Cats, HA | 1 |
| van Rijswijk, MH | 1 |
| Morita, K | 1 |
| Ohtani, H | 1 |
| Yamaguchi, A | 1 |
| Miura, AB | 1 |
| Asanuma, Y | 1 |
| Aoshima, H | 1 |
| Kaburaki, J | 1 |
| Edmonds, J | 1 |
| Saudan, A | 1 |
| Torsteinsdóttir, I | 3 |
| Håkansson, L | 3 |
| Ostergaard, M | 2 |
| Hansen, M | 3 |
| Stoltenberg, M | 3 |
| Gideon, P | 2 |
| Klarlund, M | 2 |
| Jensen, KE | 2 |
| Lorenzen, I | 3 |
| Nissilä, M | 4 |
| Yli-Kerttula, U | 1 |
| Piirainen, H | 2 |
| Pälvimäki, I | 1 |
| Koota, K | 1 |
| Friman, C | 1 |
| Laan, RF | 2 |
| Jansen, TL | 1 |
| Caccavo, D | 1 |
| Sebastiani, GD | 1 |
| Di Monaco, C | 1 |
| Guido, F | 1 |
| Galeazzi, M | 1 |
| Ferri, GM | 1 |
| Bonomo, L | 1 |
| Afeltra, A | 1 |
| Clement, F | 1 |
| Young, PJ | 1 |
| Weeden, S | 1 |
| Boss, B | 2 |
| Engelhardt, B | 1 |
| Riedel, W | 1 |
| Harada, S | 1 |
| Mitsunobu, F | 1 |
| Kodama, F | 1 |
| Hosaki, Y | 1 |
| Mifune, T | 1 |
| Tsugeno, H | 1 |
| Yamamura, M | 1 |
| Tanizaki, Y | 1 |
| Ikeda, M | 1 |
| Johansen, JS | 1 |
| Florescu, A | 2 |
| Price, PA | 1 |
| Kötter, I | 1 |
| Müller, CA | 1 |
| Einsele, H | 1 |
| Mohren, M | 1 |
| Kanz, L | 1 |
| McGeoch, P | 1 |
| Butler, R | 1 |
| Podenphant, J | 1 |
| Borch, A | 1 |
| Kluger, E | 1 |
| Sørensen, SF | 1 |
| Hansen, TM | 1 |
| Burova, K | 1 |
| Bansal, D | 1 |
| Venge, P | 2 |
| Xuereb Anastasi, A | 1 |
| Buhagiar, A | 1 |
| Camilleri, F | 1 |
| Cauchi, M | 1 |
| Mallia, C | 1 |
| O'Dell, JR | 1 |
| Jeppsson, C | 1 |
| Säveland, H | 1 |
| Rydholm, U | 1 |
| Aspenberg, P | 1 |
| Rautenstrauch, J | 1 |
| Nagahama, T | 1 |
| Matsumura, M | 1 |
| Matake, H | 1 |
| Tsuda, S | 1 |
| Yao, T | 1 |
| Schlemper, R | 1 |
| Hahtola, PA | 1 |
| Järvenpää, RE | 1 |
| Lounatmaa, K | 1 |
| Mattila, JJ | 1 |
| Rantala, I | 1 |
| Uitti, JA | 1 |
| Osiri, M | 1 |
| Akkasilpa, S | 1 |
| Deesomchok, U | 1 |
| Eastell, R | 1 |
| Devogelaer, JP | 1 |
| Peel, NF | 1 |
| Chines, AA | 1 |
| Bax, DE | 1 |
| Sacco-Gibson, N | 1 |
| Nagant de Deuxchaisnes, C | 1 |
| Russell, RG | 1 |
| Ozaki, D | 1 |
| Shirai, Y | 1 |
| Uesaka, S | 1 |
| Lee, YH | 1 |
| Choi, SJ | 1 |
| Ji, JD | 1 |
| Seo, HS | 1 |
| Song, GG | 1 |
| Hansen, MS | 1 |
| Stoltenberg, MB | 1 |
| Homma, M | 2 |
| Takekoshi, T | 1 |
| Yoshida, K | 2 |
| Kurosaka, D | 1 |
| Yokoyama, T | 1 |
| Tajima, N | 1 |
| Asano, G | 1 |
| Yoshino, S | 1 |
| Kullmann, F | 1 |
| Judex, M | 1 |
| Ballhorn, W | 1 |
| Jüsten, HP | 1 |
| Wessinghage, D | 1 |
| Welsh, J | 1 |
| Yen, TJ | 1 |
| Lang, B | 1 |
| Hittle, JC | 1 |
| McClelland, M | 1 |
| Gay, S | 1 |
| Higuchi, M | 1 |
| Sakai, Y | 1 |
| Koyanagi, M | 1 |
| Tsuda, Y | 1 |
| Motomura, S | 1 |
| Teichmann, J | 1 |
| Stracke, H | 1 |
| Knobel, B | 1 |
| Rosman, P | 1 |
| Polnau, U | 1 |
| Braun, MG | 1 |
| van den Boom, H | 1 |
| Becker-Capeller, D | 1 |
| Tani, K | 1 |
| Sone, S | 1 |
| Iizuka, H | 1 |
| Yilmaz, L | 1 |
| Ozoran, K | 1 |
| Gündüz, OH | 1 |
| Uçan, H | 1 |
| Yücel, M | 1 |
| Watt, I | 1 |
| Yücel, AE | 1 |
| Kart, H | 1 |
| Aydin, P | 1 |
| Ağildere, AM | 1 |
| Benli, S | 1 |
| Altinörs, N | 1 |
| Demirhan, B | 1 |
| Hall, RL | 1 |
| Leahy, MF | 1 |
| Gok, U | 1 |
| Sahin, S | 1 |
| Kaygusuz, I | 1 |
| Ardicoglu, O | 1 |
| Yalcin, S | 1 |
| Egsmose, C | 1 |
| Wakata, N | 1 |
| Nakazato, A | 1 |
| Sugimoto, H | 1 |
| Iguchi, H | 1 |
| Saito, R | 1 |
| Helenius, LM | 1 |
| Hietanen, JH | 1 |
| Helenius, I | 1 |
| Lappalainen, M | 1 |
| Suuronen, R | 1 |
| Lindqvist, C | 1 |
| Niki, Y | 1 |
| Matsushima, T | 1 |
| Lukina, GV | 1 |
| Skurkovich, SV | 1 |
| Skurkovich, BS | 1 |
| Bando, Y | 1 |
| Ushiogi, Y | 1 |
| Toya, D | 1 |
| Fujisawa, M | 1 |
| Louthrenoo, W | 1 |
| Kongtawelert, P | 1 |
| Sivasomboon, C | 1 |
| Sukitawut, W | 1 |
| te Koppele, JM | 1 |
| van der Laan, WH | 1 |
| de Nijs, RN | 1 |
| Houben, HH | 1 |
| ter Borg, EJ | 1 |
| Huisman, AM | 1 |
| Bruyn, GA | 1 |
| van Oijen, PL | 1 |
| Westgeest, AA | 1 |
| Algra, A | 1 |
| Hofman, DM | 1 |
| Machein, U | 1 |
| Buss, B | 1 |
| Spiller, I | 1 |
| Rudwaleit, M | 1 |
| Faerber, L | 1 |
| Sieper, J | 1 |
| Ribbens, C | 1 |
| Martin y Porras, M | 1 |
| Franchimont, N | 1 |
| Kaiser, MJ | 1 |
| Jaspar, JM | 1 |
| Damas, P | 1 |
| Houssiau, FA | 1 |
| Malaise, MG | 1 |
| Komuro, M | 1 |
| Kakuo, H | 1 |
| Kawaguchi, Y | 1 |
| Narushima, M | 1 |
| Suzuki, H | 1 |
| Kasai, T | 1 |
| Tsuzura, Y | 1 |
| Tomita, S | 1 |
| Endoh, S | 1 |
| Yamada, M | 1 |
| Ohtsuka, H | 1 |
| Sekine, S | 1 |
| Yumura, W | 1 |
| Suganuma, S | 1 |
| Onuki, T | 1 |
| Uchida, K | 1 |
| Kawashima, A | 1 |
| Nitta, K | 1 |
| Nihei, H | 1 |
| Chaudhuri, K | 1 |
| Dubey, S | 1 |
| Zaphiropoulos, G | 1 |
| Böcher, W | 1 |
| Galle, PR | 1 |
| Märker-Hermann, E | 1 |
| Ilonen, J | 1 |
| Franzen, P | 1 |
| Helve, T | 1 |
| Gripenberg-Gahmberg, M | 1 |
| Myllykangas-Luosujärvi, R | 1 |
| Chang, HK | 1 |
| Park, W | 1 |
| Ryu, DS | 1 |
| Nesterov, SL | 1 |
| Witbreuk, M | 1 |
| Ball, C | 1 |
| Nanchahal, J | 1 |
| Tsuduki, E | 1 |
| Kawada, H | 1 |
| Toyoda, E | 1 |
| Kobayashi, N | 1 |
| Kudo, K | 1 |
| Osuka, K | 1 |
| Kuroki, H | 1 |
| Morita, T | 1 |
| Inada, S | 1 |
| Morita, H | 2 |
| Rezai, KA | 1 |
| Patel, SC | 1 |
| Eliott, D | 1 |
| Becker, MA | 1 |
| Wauben, MH | 1 |
| Pang, M | 1 |
| Setoyama, Y | 1 |
| Tsuzaka, K | 1 |
| Yoshimoto, K | 1 |
| Capstick, RB | 1 |
| Lewis, DA | 2 |
| Best, R | 1 |
| Geller, LI | 1 |
| Glinskaia, TP | 1 |
| Ozherel'eva, NIa | 1 |
| Kazimirchik, AP | 1 |
| Bitensky, L | 1 |
| Cashman, B | 1 |
| Johnstone, JJ | 1 |
| Chayen, J | 1 |
| Brandt, L | 2 |
| Richardson, AT | 1 |
| Toguchi, T | 1 |
| Kawagoe, M | 1 |
| Saito, E | 3 |
| Stewart, IM | 1 |
| Marks, JS | 1 |
| Arikawa, K | 1 |
| Kennedy, AC | 1 |
| Boddy, K | 1 |
| Williams, ED | 1 |
| Elliott, AT | 1 |
| Harvey, I | 1 |
| Holloway, I | 1 |
| Haywood, JK | 1 |
| Tala, E | 1 |
| Jalava, S | 1 |
| Nurmela, T | 1 |
| Bul'diak, IuS | 1 |
| Ring, EF | 4 |
| Raptis, S | 1 |
| von Berger, L | 1 |
| Dollinger, HC | 1 |
| Fazekas, AA | 1 |
| Pfeiffer, EF | 1 |
| Vater, CA | 1 |
| Mainardi, CL | 1 |
| Werb, Z | 1 |
| Menkes, CJ | 1 |
| Gô, AL | 1 |
| Verrier, P | 1 |
| Aignan, M | 1 |
| Delbarre, F | 2 |
| Reinicke, C | 1 |
| Faust-Tinnefeldt, GF | 1 |
| Geissler, HE | 1 |
| Menkes, C | 1 |
| Le Go, A | 1 |
| Gonsalves, HJ | 1 |
| Peklina, GP | 1 |
| Hoffmann, H | 1 |
| Weber, G | 1 |
| Wenz, W | 1 |
| Bartuschka, B | 1 |
| Altus, R | 1 |
| Tanner, E | 1 |
| Wesser, M | 1 |
| Zielke, A | 1 |
| Lindau, P | 1 |
| Rössner, B | 1 |
| Wessel, G | 1 |
| In der Au, A | 1 |
| Jäckel, R | 1 |
| Römhild, N | 2 |
| de Ceulaer, K | 1 |
| Papazoglou, SN | 1 |
| Kimbel, KH | 1 |
| Matsuo, H | 1 |
| Mattingly, PC | 1 |
| Bentley, G | 1 |
| Cohen, ML | 2 |
| Mowat, AG | 4 |
| Esselinckx, W | 1 |
| Crooke, D | 1 |
| Collins, AJ | 3 |
| Demottaz, D | 1 |
| Matveĭkov, GP | 1 |
| Zhivutskiĭ, II | 1 |
| Jäger, M | 1 |
| Baumann, D | 1 |
| Murthy, MH | 1 |
| Rhymer, AR | 1 |
| An, HK | 1 |
| Chamberlain, MA | 1 |
| Keenan, J | 1 |
| Downie, WW | 3 |
| Smiley, JD | 1 |
| Warnatz, H | 1 |
| Scheiffarth, F | 1 |
| Gutmann, W | 1 |
| Wiermann, H | 1 |
| Hackenberg, K | 1 |
| Reinwein, D | 1 |
| Matsui, N | 1 |
| Inoue, S | 1 |
| Suguro, T | 1 |
| Balch, HW | 1 |
| Gibson, JM | 1 |
| El-Ghobarey, AF | 1 |
| Bain, LS | 1 |
| Lynch, MP | 1 |
| Habib, MA | 1 |
| Belov, VA | 1 |
| Brooks, PM | 2 |
| Buchanan, WW | 10 |
| Grove, M | 1 |
| Stuhlsatz, HW | 1 |
| Eberhard, A | 1 |
| Kristin, H | 1 |
| Vojtisek, O | 1 |
| Greiling, H | 2 |
| Pedersen, NC | 1 |
| Castles, JJ | 1 |
| Weisner, K | 1 |
| Astapenko, MG | 1 |
| Tautenhahn, B | 1 |
| Trofimowa, TM | 1 |
| Fischer, H | 2 |
| Muirden, KD | 1 |
| Barraclough, DR | 1 |
| Kuzuna, S | 1 |
| Kawai, K | 2 |
| Vidal Ferrandis, J | 1 |
| Menchón Galiana, M | 1 |
| López Dasí, JL | 1 |
| López Prats, JL | 1 |
| Tausch, G | 3 |
| Reinelt, D | 1 |
| Balla, L | 1 |
| Sziklai, P | 1 |
| Oláh, M | 1 |
| Kiss, G | 1 |
| Li, P | 1 |
| Starrok, RD | 1 |
| Grennan, DM | 1 |
| Deodger, ShD | 1 |
| Dik, VS | 1 |
| Lugossy, G | 1 |
| Myles, AB | 5 |
| Schiller, LF | 1 |
| Glass, D | 1 |
| Daly, JR | 4 |
| Buskila, D | 1 |
| Thomson, GT | 1 |
| Klein, M | 1 |
| Keystone, EC | 1 |
| Mitsui, T | 1 |
| Kira, J | 1 |
| Miyata, K | 1 |
| Hosokawa, S | 1 |
| Goto, I | 1 |
| Vyse, T | 1 |
| So, AK | 1 |
| Brooks, H | 1 |
| Taylor, HG | 1 |
| Nichol, FE | 1 |
| Ohashi, H | 1 |
| Itoh, M | 1 |
| Sudo, Y | 1 |
| Endo, S | 1 |
| Okugawa, T | 1 |
| Mineta, H | 1 |
| Nozue, M | 1 |
| van der Veen, MJ | 1 |
| Denissov, LN | 1 |
| Sharafetdinov, Kh | 1 |
| Samsonov, MA | 1 |
| Dohi, K | 1 |
| Nakamoto, Y | 1 |
| Tabuchi, Y | 1 |
| Saeki, S | 1 |
| Mikami, H | 1 |
| Ogihara, T | 1 |
| Hirose, S | 1 |
| Sugishima, H | 1 |
| Minoda, M | 1 |
| Horiuchi, A | 1 |
| Chernokhvostova, EV | 1 |
| German, GP | 1 |
| Varlamova, EIu | 1 |
| Andreeva, NE | 1 |
| Kotova, TS | 1 |
| Teal, GP | 1 |
| Brooks, RH | 1 |
| Seidel, W | 2 |
| Clerc, D | 1 |
| Brousse, C | 1 |
| Mariette, X | 1 |
| Bennet, P | 1 |
| Bisson, M | 1 |
| Nambu, Y | 1 |
| Oida, K | 1 |
| Kohri, Y | 1 |
| Taguchi, Y | 1 |
| Tomii, K | 1 |
| Mino, M | 1 |
| Yunoki, Y | 1 |
| Ichijima, K | 1 |
| Tishler, M | 1 |
| Kahn, Y | 1 |
| Yaron, M | 1 |
| Gibson, JN | 1 |
| Poyser, NL | 1 |
| Morrison, WL | 1 |
| Scrimgeour, CM | 1 |
| Rennie, MJ | 1 |
| van Thiel, RJ | 1 |
| van der Burg, S | 1 |
| Groote, AD | 1 |
| Nossent, GD | 1 |
| Wills, SH | 1 |
| Prónai, L | 1 |
| Nakazawa, H | 1 |
| Arimori, S | 1 |
| Niwa, Y | 1 |
| Iio, A | 1 |
| Niwa, G | 1 |
| Sakane, T | 1 |
| Tsunematsu, T | 1 |
| Kanoh, T | 1 |
| Uno-Komase, Y | 1 |
| Azuma, T | 1 |
| Seppälä, E | 2 |
| Isomäki, H | 2 |
| Wuorela, H | 1 |
| Vapaatalo, H | 2 |
| Ernst, E | 2 |
| Espersen, GT | 2 |
| Andersen, MV | 1 |
| Weinstabl, R | 1 |
| Hertz, H | 1 |
| Sattar, MA | 2 |
| Wilske, KR | 1 |
| Healey, LA | 1 |
| Nakabayashi, K | 1 |
| Arimura, Y | 1 |
| Crellin, AM | 1 |
| Shareef, DS | 1 |
| Maher, EJ | 1 |
| Levesque, H | 1 |
| Delpech, B | 1 |
| Le Loet, X | 1 |
| Deshayes, P | 1 |
| Nakao, H | 1 |
| Otsubo, T | 1 |
| Shimomura, C | 1 |
| Tezuka, H | 1 |
| Matsunaga, M | 1 |
| Goulding, NJ | 1 |
| Podgorski, MR | 1 |
| Hall, ND | 1 |
| Flower, RJ | 1 |
| Browning, JL | 1 |
| Pepinsky, RB | 1 |
| Maddison, PJ | 1 |
| Hempel, M | 1 |
| Wietschel, F | 1 |
| Malberg, K | 1 |
| Kästner, P | 1 |
| Sumida, S | 1 |
| Nagata, A | 1 |
| Kuboshiro, M | 1 |
| Shiraishi, T | 1 |
| Katsuki, M | 1 |
| Tokunaga, N | 1 |
| Kaji, M | 1 |
| Herrmann, F | 1 |
| Hambsch, K | 1 |
| Sorger, D | 1 |
| Müller, P | 1 |
| Nagel, I | 1 |
| Kumagai, I | 1 |
| Sasaki, T | 1 |
| Takatori, K | 1 |
| Shikata, K | 1 |
| Takaoka, M | 1 |
| Ota, Z | 1 |
| Knopf, HL | 1 |
| Bach, LA | 1 |
| Buchanan, RR | 1 |
| Scarlett, JD | 1 |
| Fraser, KJ | 1 |
| Yoshioka, H | 1 |
| Amano, Y | 1 |
| Tatumi, I | 1 |
| Takeda, Z | 1 |
| Hashimoto, Y | 1 |
| Takishita, Y | 1 |
| Bando, H | 1 |
| Atagi, S | 1 |
| Tezuka, U | 1 |
| Berezhnitskiĭ, MN | 1 |
| Ornat, SIa | 1 |
| Aleksandruk, DP | 1 |
| Aroso Dias, A | 1 |
| Lopes Vaz, A | 1 |
| Hargreaves, M | 1 |
| Afonso, C | 1 |
| Araújø, D | 1 |
| Bravo, T | 1 |
| Hirohata, K | 1 |
| Eisman, JA | 4 |
| Pocock, NA | 4 |
| Champion, GD | 4 |
| Yeates, MG | 3 |
| Bai, HY | 1 |
| Vestergaard, M | 1 |
| Pedersen, JO | 1 |
| Grunnet, N | 1 |
| Farah, DA | 1 |
| Mills, PR | 1 |
| Lee, FD | 1 |
| McLay, A | 1 |
| Russell, RI | 1 |
| Forster, PJ | 1 |
| Laurikainen, J | 1 |
| Appelboom, T | 1 |
| Mandelbaum, I | 1 |
| Vertongen, F | 1 |
| Ekenstam, EA | 1 |
| Ljunghall, S | 1 |
| Bell, AL | 1 |
| Hurst, NP | 1 |
| Kaye, O | 1 |
| D'Orio, V | 1 |
| Maertens de Noordhout, B | 1 |
| Franchimont, P | 2 |
| Krüger, W | 1 |
| Winiecki, P | 1 |
| Astbury, G | 1 |
| Blowers, LE | 1 |
| Jasani, MK | 6 |
| Haar, D | 1 |
| Montecucco, C | 1 |
| Baldi, F | 1 |
| Fortina, A | 1 |
| Tomassini, G | 1 |
| Caporali, R | 1 |
| Cherie-Ligniere, EL | 1 |
| Fratino, P | 1 |
| Ahern, MJ | 1 |
| Roberts-Thomson, PJ | 1 |
| Needs, CJ | 1 |
| Smith, M | 1 |
| Boutagy, J | 1 |
| Donovan, S | 1 |
| Cosh, D | 1 |
| McCredie, M | 1 |
| Al-Sughyer, AA | 1 |
| Siboo, R | 1 |
| Taniguchi, H | 1 |
| Nakajima, Y | 1 |
| Ogawa, K | 1 |
| Majima, K | 1 |
| Yokoyama, S | 1 |
| Kishimoto, H | 1 |
| Cherevatov, BG | 1 |
| Shelest, AN | 1 |
| Volnenko, NB | 1 |
| Cherevatova, SKh | 1 |
| Herman, L | 1 |
| Ackerman, C | 1 |
| Byron, MA | 1 |
| Trofimova, TM | 1 |
| Alekberova, ZS | 1 |
| Pokryshkin, VI | 1 |
| Kobaladze, SG | 1 |
| Taletene, IP | 1 |
| Kriukov, AP | 1 |
| Bagirova, VV | 1 |
| Iaglinskiĭ, VA | 1 |
| Konishi, T | 1 |
| Yamamuro, M | 1 |
| Isaka, N | 1 |
| Wei, M | 1 |
| Takezawa, H | 1 |
| Eberl, S | 2 |
| Koni, I | 1 |
| Tsugawa, Y | 1 |
| Hamada, M | 1 |
| Nakashima, A | 1 |
| Konoshita, T | 1 |
| Andou, A | 1 |
| Miyazaki, R | 1 |
| Toufuku, Y | 1 |
| Takeda, R | 1 |
| Matsushima, Y | 1 |
| Amemiya, R | 1 |
| Taira, O | 1 |
| Osada, K | 1 |
| Hayata, Y | 1 |
| Amemiya, T | 1 |
| Furuse, K | 1 |
| Taggart, AJ | 1 |
| Astbury, C | 1 |
| Yanase, T | 1 |
| Nawata, H | 1 |
| Kato, K | 1 |
| Ibayashi, H | 1 |
| Nuotio, P | 1 |
| Nykänen, E | 1 |
| Laitinen, O | 1 |
| Zaremba, EF | 1 |
| Perret, G | 1 |
| Brinckerhoff, CE | 1 |
| Guyre, PM | 1 |
| Nicoll, JJ | 1 |
| Brown, N | 1 |
| Feltelius, N | 1 |
| Svenson, K | 1 |
| Myles, A | 1 |
| Piette-Brion, B | 1 |
| de Bast, C | 1 |
| Chamoun, E | 1 |
| de Dobbeleer, G | 1 |
| André, J | 1 |
| Huybrechts, A | 1 |
| Ledoux, M | 1 |
| Achten, G | 1 |
| Dormidontov, EN | 2 |
| Korshunov, NI | 1 |
| Baranova, EIa | 1 |
| Zheltkevich, SN | 1 |
| Razumova, EB | 1 |
| Aikawa, T | 1 |
| Francis, MJ | 1 |
| Smith, R | 1 |
| Aylward, M | 1 |
| Maddock, J | 1 |
| Phlippen, R | 1 |
| Beardwell, CG | 2 |
| Bailey, E | 2 |
| Hedberg, H | 1 |
| Danielezyk, W | 1 |
| Hurd, ER | 2 |
| Snyder, WB | 1 |
| Huss, V | 1 |
| Bürgisser, J | 1 |
| Dettmer, N | 1 |
| Josenhans, G | 1 |
| Kaiser, G | 1 |
| Tönnis, D | 1 |
| Hördegen, K | 1 |
| Bär, HW | 1 |
| Samuels, BM | 1 |
| Görgényi, G | 1 |
| Fövényi, J | 1 |
| Owen, ET | 1 |
| Lawson, AA | 1 |
| Besser, GM | 1 |
| Butler, PW | 1 |
| Plumpton, FS | 1 |
| Williams, KA | 1 |
| Pevchikh, VV | 1 |
| Reinikainen, M | 1 |
| Grönroos, P | 1 |
| Inkovaara, J | 1 |
| Egorova, LI | 1 |
| Jakobson, T | 1 |
| Sundberg, M | 1 |
| Kotovirta, ML | 1 |
| Strandström, L | 1 |
| Sako, Y | 1 |
| Grahame, R | 1 |
| Lloyd, K | 1 |
| Agarwal, A | 1 |
| Carter, ME | 3 |
| James, VH | 3 |
| Vasilenko, VKh | 1 |
| Tsodikov, GV | 1 |
| Minushkin, ON | 1 |
| Weimann, G | 1 |
| Burkhardt, H | 1 |
| Rommel, K | 1 |
| Wepler, R | 1 |
| Gifford, RH | 1 |
| Wittenborg, A | 1 |
| Gesthovel, W | 1 |
| Cosh, JA | 3 |
| Ballabio, BC | 1 |
| Colombo, B | 1 |
| Watson, PG | 2 |
| Lobascher, D | 1 |
| Haslock, DI | 1 |
| Harriman, DG | 1 |
| McArthur, JN | 2 |
| Dawkins, PD | 2 |
| Smith, MJ | 2 |
| Abou Zeina, A | 1 |
| el-Sawy, M | 1 |
| Tewfik, S | 1 |
| Badawi, HS | 1 |
| Siegmeth, W | 1 |
| Herkner, W | 1 |
| Martel, RR | 1 |
| Klicius, J | 1 |
| Herr, F | 1 |
| Akatsuka, N | 1 |
| Sariols, M | 1 |
| Klein, G | 2 |
| Eberl, R | 2 |
| Altmann, H | 2 |
| Tuschl, P | 1 |
| Marmont, AM | 1 |
| Rossi, FA | 1 |
| Sell, G | 1 |
| Beck, W | 1 |
| Gallagher, JC | 1 |
| Aaron, J | 1 |
| Horsman, A | 1 |
| Wilkinson, R | 1 |
| Nordin, BE | 1 |
| Smyth, CJ | 1 |
| Skinner, MD | 1 |
| Schwartz, RS | 1 |
| Jessop, JD | 3 |
| Vernon-Roberts, B | 2 |
| Harris, J | 3 |
| Moiseev, VS | 1 |
| Lee, P | 2 |
| Dick, WC | 8 |
| Kornreich, H | 1 |
| Koster, K | 1 |
| Hanson, V | 1 |
| Deodhar, SD | 1 |
| Hodgkinson, R | 1 |
| Brunt, MF | 1 |
| James, DG | 1 |
| Stastny, P | 1 |
| Baxter, A | 1 |
| Webb, J | 1 |
| Rekonen, A | 2 |
| Kuikka, J | 2 |
| Berry, H | 1 |
| Huskisson, EC | 1 |
| Chapman, AH | 1 |
| Gietka, J | 1 |
| Luciak, M | 1 |
| Collan, Y | 2 |
| Lörincz, G | 1 |
| Laine, V | 1 |
| Gandzha, IM | 1 |
| Shub, NI | 1 |
| Tiunina, EA | 1 |
| Gacs, G | 1 |
| Kun, E | 1 |
| Czirbesz, Z | 1 |
| Burry, HC | 2 |
| Wenger, ME | 1 |
| Bole, GG | 1 |
| Stern, LZ | 1 |
| Gruener, R | 1 |
| Amundsen, P | 1 |
| Desai, SN | 1 |
| Meinel, H | 1 |
| Ruotsi, A | 1 |
| Gullberg, R | 1 |
| Elman, A | 1 |
| Williamson, J | 2 |
| Gibson, AA | 1 |
| Wilson, T | 1 |
| Forrester, JV | 1 |
| Whaley, K | 4 |
| Pérez Gil, L | 1 |
| Hall, DA | 1 |
| Reed, FB | 1 |
| Vince, JD | 1 |
| Baloch, N | 1 |
| Ratnesar, P | 1 |
| Klugmann, HJ | 1 |
| Geiler, G | 1 |
| Ritchie, DM | 1 |
| Boyle, JA | 3 |
| McInnes, JM | 2 |
| Dalakos, TG | 2 |
| Grieveson, P | 2 |
| Mason, M | 1 |
| Barnes, CG | 2 |
| Dunne, JF | 2 |
| Strickland, ID | 2 |
| Schoger, GA | 1 |
| Ritchie, DA | 1 |
| Hazleman, B | 1 |
| Mason, RM | 1 |
| Vaughan, J | 1 |
| Walton, J | 1 |
| Watson, BS | 1 |
| Ney, RL | 1 |
| Bluestone, R | 1 |
| Cochrane, G | 1 |
| Kitridou, RC | 1 |
| Solomon, SD | 1 |
| Deicher, H | 3 |
| Fricke, R | 2 |
| Krull, P | 2 |
| Jones, CE | 1 |
| Goldie, I | 2 |
| Seidel, A | 1 |
| Day, EH | 1 |
| Harris, MC | 1 |
| Servo, C | 1 |
| Winblad, I | 1 |
| Chaput de Saintonge, DM | 1 |
| Matveev, MP | 1 |
| Gamburg, RL | 1 |
| Solomatina, OG | 1 |
| Ignatova, MS | 1 |
| Gavriushova, LP | 1 |
| Menarini, C | 1 |
| Lanzarini, AM | 1 |
| Maruyama, S | 1 |
| Seidel, K | 2 |
| Schneider, H | 1 |
| da Gama, GG | 1 |
| Lucca, F | 1 |
| Souto, MG | 1 |
| Silva, JR | 1 |
| Stacher, A | 1 |
| Böhnel, J | 1 |
| Schindler, H | 1 |
| Seifert, E | 1 |
| de Châtel, A | 1 |
| Wille, T | 1 |
| Doury, P | 1 |
| Kersley, GD | 1 |
| Olhagen, B | 1 |
| Reizenstein, P | 1 |
| Sjöberg, HE | 1 |
| Goerz, G | 1 |
| Brass, H | 1 |
| Lapp, H | 1 |
| Brånemark, PI | 1 |
| Ekholm, R | 1 |
| Lundskog, J | 1 |
| Nesterov, AI | 1 |
| Chlud, K | 1 |
| Neufeld, RR | 1 |
| Prentice, AG | 1 |
| Woodburn, A | 1 |
| Hayreh, SS | 1 |
| Montgomery, PR | 1 |
| Komissarova, IA | 1 |
| Sura, VV | 1 |
| Martynova, MA | 1 |
| Albrecht, HJ | 1 |
| Szegedi, G | 1 |
| Nagy, G | 1 |
| Deodhar, S | 2 |
| Durance, RA | 1 |
| Hamilton, EB | 2 |
| Collins, KE | 1 |
| Husmann, F | 1 |
| Dobos, L | 1 |
| Koppány, G | 1 |
| Böhm, C | 1 |
| Schwenk, D | 1 |
| Ivkov, VG | 1 |
| Chaĭkhova, GG | 1 |
| Pfaffenberg, R | 1 |
| Sage, RE | 1 |
| Forbes, IJ | 1 |
| Gerdes, H | 1 |
| Schmitz-Moormann, P | 1 |
| Frank, O | 1 |
| Klemmayer, K | 1 |
| Zubov, AP | 1 |
| Kodama, T | 1 |
| McBride, WW | 1 |
| Dodson, WH | 1 |
| Bennett, JC | 1 |
| Baker, DM | 1 |
| Burland, WL | 1 |
| Paterson, RW | 1 |
| McGavin, DD | 1 |
| Doig, WM | 1 |
| Lewis-Faning, E | 1 |
| Tregubenko, RA | 1 |
| Kviatkovskaia, AN | 1 |
| Kaĭnova, AS | 1 |
| Mikhaĭlova, IN | 1 |
| Tancer, ML | 1 |
| Zahiruddin, S | 1 |
| Pitkeathly, DA | 1 |
| Miller, WT | 1 |
| Restifo, RA | 1 |
| Greaves, MS | 1 |
| Murphy, D | 1 |
| Siró, B | 1 |
| Ferguson, GC | 1 |
| Gaspardy, G | 1 |
| Balint, G | 1 |
| Sakamoto, T | 1 |
| Garbsch, H | 1 |
| Pietschmann, H | 1 |
| Sans-Solá, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 3 Study of ASP015K - A Randomized, Double-blind, Placebo-controlled Confirmatory Study of the Efficacy and Safety of ASP015K in Patients With Rheumatoid Arthritis Who Had an Inadequate Response to MTX[NCT02305849] | Phase 3 | 519 participants (Actual) | Interventional | 2014-07-25 | Completed | ||
| The Glucocorticoid Low-dose Outcome in RheumatoId Arthritis Study Comparing the Cost-effectiveness and Safety of Additional Low-dose Glucocorticoid in Treatment Strategies for Elderly Patients With Rheumatoid Arthritis[NCT02585258] | Phase 4 | 451 participants (Actual) | Interventional | 2016-06-30 | Completed | ||
| An Impaired Functional Reserve of Adrenal Cortex May Associate With difficult-to Treat RA: Can a Disturbed Cortisol Circadian Rhythm Serve as a Predictor of Difficult-to-treat RA?[NCT05671627] | 50 participants (Anticipated) | Observational | 2022-02-02 | Recruiting | |||
| Trivalent Chromium as a Treatment for Rheumatoid Arthritis Patients[NCT05545020] | Phase 2/Phase 3 | 60 participants (Anticipated) | Interventional | 2022-12-25 | Active, not recruiting | ||
| Hematological Indices in Rheumatoid Arthritis and Its Association With Disease Activity and Severity[NCT04416997] | 40 participants (Anticipated) | Observational | 2020-03-01 | Recruiting | |||
| A Multicenter, Randomized, Open-label, Blinded-assessor, Phase 4 Study in Patients With Early Rheumatoid Arthritis to Compare Active Conventional Therapy Versus Three Biologic Treatments, and Two De-escalation Strategies in Patients Who Respond to Treatme[NCT01491815] | Phase 4 | 812 participants (Actual) | Interventional | 2012-12-14 | Active, not recruiting | ||
| Phase II/III Study of Oral Prednisolone Test in Patients With Rheumatoid Arthritis[NCT01395251] | Phase 2/Phase 3 | 130 participants (Actual) | Interventional | 2012-02-29 | Completed | ||
| An Experimental Medicine Study to Assess the Pharmacodynamics Following Administration of Multiple Doses of Prednisolone to Healthy Male Subjects[NCT03196557] | Phase 1 | 24 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| A Phase IIB, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept vs Placebo on a Background of Oral Glucocorticosteroids in the Treatment of Subjects With Systemic Lupus Erythematosus and the P[NCT00119678] | Phase 2 | 183 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
| Placebo-Controlled, Double-Blind, Ascending Single and Multiple Oral Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-791826 and to Assess Its Marker Specific Pharmacodynamics in Relation to Prednisolone in Healthy Males[NCT03198013] | Phase 1 | 120 participants (Actual) | Interventional | 2008-11-11 | Completed | ||
| Use of TNF-blocking Therapy in Combination With DMARDs in Patients With Early Rheumatoid Arthritis[NCT00908089] | Phase 4 | 100 participants (Actual) | Interventional | 2003-03-31 | Active, not recruiting | ||
| "Screening Protein Predictive of Response to Tumor Necrosis Factor-α Inhibitors Treatment in Chinese Rheumatoid Arthritis From Real World and Investigating Its Mechanism Through Signal Pathway"[NCT02878161] | Phase 4 | 240 participants (Anticipated) | Interventional | 2016-01-31 | Enrolling by invitation | ||
| The Effect of Prednisone on Atherogenesis as Studied in the Macrophage Foam Cell Formation Model System.[NCT03367663] | Early Phase 1 | 10 participants (Actual) | Interventional | 2018-01-17 | Completed | ||
| Comparison of the Efficacy and Safety of Two Different Starting Dosages of Prednisolone in Early Active Rheumatoid Arthritis: a Randomized, Placebo Controlled Trial[NCT02000336] | Phase 3 | 395 participants (Actual) | Interventional | 2014-01-31 | Completed | ||
| Telehealth Follow-up in Patients With Rheumatoid Arthritis. A Noninferiority Randomized Control Trial[NCT04536844] | 220 participants (Actual) | Interventional | 2020-06-15 | Active, not recruiting | |||
| A Prospective Randomized, Open, Multi-Center Trial Comparing TNF-Blockade + MTX to MTX+SSZ+HCQ in Patients With Early RA With an Inadequate Response to MTX[NCT00764725] | Phase 4 | 487 participants (Actual) | Interventional | 2002-12-31 | Completed | ||
| Multicenter, Randomized, Controlled Clinical Trial Research Evaluating the Use of Combination Therapy of Glucocorticoids and Metformin to Decrease Glucocorticoids Side Effects in Patients With Autoimmune Uveitis[NCT03525028] | 138 participants (Anticipated) | Interventional | 2018-11-01 | Recruiting | |||
| Hydroxychloroquine Exposure in Systemic Lupus Erythematosus (SLE)[NCT03802188] | 3,700 participants (Anticipated) | Observational | 2018-05-09 | Recruiting | |||
| Phase 2, Rand, Placebo-Controlled, Double-Blind, Dose Ranging Study to Evaluating Safety/Efficacy of Gerilimzumab in Patients With Moderately to Severely Active Rheumatoid Arthritis Inadequately Treated With Methotrexate or TNFα Antagonist[NCT02795299] | Phase 2 | 0 participants (Actual) | Interventional | 2018-01-31 | Withdrawn (stopped due to Study not started due to Sponsor decision to not move forward with compound.) | ||
| Phase 3: Randomised Controlled Trial of Rituximab in Active Ulcerative Colitis[NCT00261118] | Phase 2/Phase 3 | 24 participants (Actual) | Interventional | 2004-04-30 | Completed | ||
| Rituximab in the Treatment of Patients With Bullous Pemphigoid[NCT00286325] | Phase 1/Phase 2 | 8 participants (Actual) | Interventional | 2005-03-31 | Completed | ||
| Combined Pneumococcal Conjugate and Polysaccharide Vaccination in Inflammatory Rheumatic Disease. Impact of Antirheumatic Treatment on Antibody Response.[NCT03762824] | Phase 4 | 300 participants (Actual) | Interventional | 2016-06-14 | Completed | ||
| Comparison of the Tuberculin Skin Test (TST) and QuantiFERON ®-TB Gold Test (QFT-G) In Patients With Rheumatoid Arthritis Being Considered for Anti-TNF-Alpha Therapy[NCT00925249] | 90 participants (Anticipated) | Observational | 2009-05-31 | Recruiting | |||
| A 2 Year Prospective Multicentre Randomised Controlled Trial Comparing Effectiveness in Daily Practice of Different Treatment Strategies for Early Rheumatoid Arthritis.[NCT01172639] | Phase 4 | 400 participants (Actual) | Interventional | 2009-02-28 | Completed | ||
| Monoarticular Corticosteroid Injection Versus Systemic Administration in the Treatment of Rheumatoid Arthritis Patients: A Randomized Double-Blind Controlled Study[NCT00506896] | Phase 2 | 60 participants (Actual) | Interventional | 2004-07-31 | Completed | ||
| Teriparatide for Joint Erosions in Rheumatoid Arthritis: The TERA Trial[NCT01400516] | Phase 4 | 26 participants (Actual) | Interventional | 2011-08-31 | Completed | ||
| Comparative Analysis of the Th17 Cellular Response in Active and Inactive Pemphigus Vulgaris Patients[NCT04096222] | 42 participants (Anticipated) | Observational | 2021-06-29 | Recruiting | |||
| Effectiveness of a Combination of Methotrexate and a Step Down Glucocorticoid Regimen (COBRA-Slim) for Remission Induction in Patients With Early Rheumatoid Arthritis (RA), With or Without Fast Access to 24 Weeks of Tumor Necrosis Factor (TNF) Blockade in[NCT03649061] | Phase 4 | 284 participants (Actual) | Interventional | 2018-06-08 | Completed | ||
| Treat-to-target in RA: Collaboration To Improve adOption and adhereNce (TRACTION)[NCT02260778] | 11 participants (Actual) | Interventional | 2014-09-30 | Active, not recruiting | |||
| Cell Phone Based Automated Monitoring of Patients With Early Rheumatoid Arthritis[NCT02424877] | 165 participants (Actual) | Interventional | 2013-08-01 | Completed | |||
| Effects of Intra-articular Versus Subacromial Steroid Injections on Clinical Outcomes in Adhesive Capsulitis[NCT00742846] | 0 participants (Actual) | Interventional | 2008-08-31 | Withdrawn (stopped due to No enrollment) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Higher CRP indicates greater disease activity. (NCT02305849)
Timeframe: Baseline and week 12/ET
| Intervention | mg/dL (Mean) |
|---|---|
| Placebo | -0.001 |
| Peficitinib 100 mg | -1.499 |
| Peficitinib 150 mg | -1.421 |
DAS28-ESR response consisted of following parameters: TJC (28 joints), SJC (28 joints), ESR, SGA , and calculated according to description: DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.70 ln ESR + 0.014 × SGA. DAS28-ESR scores range from 0 to approximately 10. Higher DAS28 score indicated greater disease activity. (NCT02305849)
Timeframe: Baseline and week 12/ET
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | -0.51 |
| Peficitinib 100 mg | -1.66 |
| Peficitinib 150 mg | -2.12 |
DAS28-CRP response consisted of following parameters: TJC (28 joints), SJC (28 joints), CRP, SGA, and calculated according to description: DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.36 ln (CRP + 1) + 0.014 × SGA + 0.96. DAS28-CRP scores range from 0.96 to approximately 10. Higher DAS28 score indicated greater disease activity. (NCT02305849)
Timeframe: Baseline and week 12/ET
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | -0.51 |
| Peficitinib 100 mg | -1.70 |
| Peficitinib 150 mg | -2.09 |
Higher ESR indicates greater disease activity. (NCT02305849)
Timeframe: Baseline and week 12/ET
| Intervention | mm/h (Mean) |
|---|---|
| Placebo | -2.42 |
| Peficitinib 100 mg | -18.90 |
| Peficitinib 150 mg | -22.17 |
Participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item was scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty. (NCT02305849)
Timeframe: Baseline and week 12/ET
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | 0.01 |
| Peficitinib 100 mg | -0.22 |
| Peficitinib 150 mg | -0.37 |
mTSS was defined as the sum of joint erosion scores graded by assessing erosion severity in 44 joints (16 per hand and 6 per feet) and JSN scores graded by assessing narrowing of joint spaces in 42 joints (15 per hand and 6 per feet). Erosion score was scored from 0 (no erosion) to 5 (complete collapse of bone) and the score for erosion ranges from 0 to 160 in the hands and from 0 to 120 in the feet (the maximum erosion score for a joint in the foot is 10). JSN including subluxation, was scored from 0 (normal) to 4 (complete loss of joint space, bony ankylosis, or luxation), with a maximum JSN score of 168. mTSS scores ranged from 0 (normal) to 448 (worst possible total score). Change from baseline was calculated as score at week 28 (ET) minus score at baseline. An increase in mTSS from baseline represented disease progression and/or joint worsening, no change represented halting of disease progression, and a decrease represented improvement. (NCT02305849)
Timeframe: Baseline and week 28/ET
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | 3.37 |
| Peficitinib 100 mg | 1.62 |
| Peficitinib 150 mg | 1.03 |
mTSS was defined as the sum of joint erosion scores graded by assessing erosion severity in 44 joints (16 per hand and 6 per feet) and JSN scores graded by assessing narrowing of joint spaces in 42 joints (15 per hand and 6 per feet). Erosion score was scored from 0 (no erosion) to 5 (complete collapse of bone) and the score for erosion ranges from 0 to 160 in the hands and from 0 to 120 in the feet (the maximum erosion score for a joint in the foot is 10). JSN including subluxation, was scored from 0 (normal) to 4 (complete loss of joint space, bony ankylosis, or luxation), with a maximum JSN score of 168. mTSS scores ranged from 0 (normal) to 448 (worst possible total score). Change from baseline was calculated as score at week 52 (ET) minus score at baseline. An increase in mTSS from baseline represented disease progression and/or joint worsening, no change represented halting of disease progression, and a decrease represented improvement. (NCT02305849)
Timeframe: Baseline and week 52/ET
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | 6.27 |
| Peficitinib 100 mg | 2.12 |
| Peficitinib 150 mg | 1.54 |
WPAI consisted of 6 questions (Q1=Employment status; Q2=Hours absent from work due to the rheumatoid arthritis; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the rheumatoid arthritis on productivity while working; Q6=Impact of the rheumatoid arthritis on productivity while doing regular daily activities other than work). Higher WPAI scores indicated greater activity impairment. The scores were multiplied by 100 to express in percentages. Percent overall work impairment due to problem was calculated as Q2/(Q2+Q4)+[(1-(Q2/(Q2+Q4))x(Q5/10)]. Negative values indicate improvement from baseline. (NCT02305849)
Timeframe: Baseline and week 12/ET
| Intervention | percent overall work impairment (Mean) |
|---|---|
| Placebo | -2.75 |
| Peficitinib 100 mg | -11.58 |
| Peficitinib 150 mg | -16.91 |
The investigator assessed the participants' disease activity on a VAS of 0-100 mm on the physician assessment table. Higher PGA (100 mm VAS) scores indicate greater activity impairment. (NCT02305849)
Timeframe: Baseline and week 12/ET
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | -11.88 |
| Peficitinib 100 mg | -28.83 |
| Peficitinib 150 mg | -35.96 |
SDAI score consisted of following parameters: TJC (28 joints), SJC (28 joints), SGA, PGA, CRP (mg/dL), and calculated according to description: SDAI = TJC + SJC + SGA + PGA + CRP. The SDAI score ranges from 0 to approximately 86. Higher SDAI indicates greater disease activity. (NCT02305849)
Timeframe: Baseline and week 12/ET
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | -4.90 |
| Peficitinib 100 mg | -15.66 |
| Peficitinib 150 mg | -19.57 |
The SF-36v2 was scored for the 8 subscales (each range: 0-100 scale): 1. physical functioning, 2. role physical, 3. bodily pain, 4. general health, 5. vitality, 6. social functioning, 7. role-emotional, and 8. mental health. Physical Component Summary Score, Mental Component Summary Score and Roll/Social Component Summary Score were calculated based on the 2007 General Japanese Population Means and Standard Deviations and coefficient. Component summary measures had means of 50 in 2007 General Japanese Population and deviation was expressed by the scale of 10. Higher score indicated better health state. (NCT02305849)
Timeframe: Baseline and week 12/ET
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | 1.07 |
| Peficitinib 100 mg | 3.28 |
| Peficitinib 150 mg | 2.50 |
The SF-36v2 was scored for the 8 subscales (each range: 0-100 scale): 1. physical functioning, 2. role physical, 3. bodily pain, 4. general health, 5. vitality, 6. social functioning, 7. role-emotional, and 8. mental health. Physical Component Summary Score, Mental Component Summary Score and Roll/Social Component Summary Score were calculated based on the 2007 General Japanese Population Means and Standard Deviations and coefficient. Component summary measures had means of 50 in 2007 General Japanese Population and deviation was expressed by the scale of 10. Higher score indicated better health state. (NCT02305849)
Timeframe: Baseline and week 12/ET
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | -0.09 |
| Peficitinib 100 mg | 2.30 |
| Peficitinib 150 mg | 3.90 |
The participant assessed his/her own disease activity on a VAS of 0-100 mm on the questionnaire form. Higher SGA (100 mm VAS) scores indicate greater activity impairment. (NCT02305849)
Timeframe: Baseline and week 12/ET
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | -7.11 |
| Peficitinib 100 mg | -21.09 |
| Peficitinib 150 mg | -26.57 |
The participant assessed his/her own pain severity on a visual analog scale (VAS) of 0-100 mm on the questionnaire form. Higher SGA of pain (100 mm VAS) scores indicated greater activity pain. (NCT02305849)
Timeframe: Baseline and week 12/ET
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | -6.64 |
| Peficitinib 100 mg | -21.09 |
| Peficitinib 150 mg | -26.87 |
The SF-36v2 was scored for the 8 subscales (each range: 0-100 scale): 1. physical functioning, 2. role physical, 3. bodily pain, 4. general health, 5. vitality, 6. social functioning, 7. role-emotional, and 8. mental health. Physical Component Summary Score, Mental Component Summary Score and Roll/Social Component Summary Score were calculated based on the 2007 General Japanese Population Means and Standard Deviations and coefficient. Component summary measures had means of 50 in 2007 General Japanese Population and deviation was expressed by the scale of 10. Higher score indicated better health state. (NCT02305849)
Timeframe: Baseline and week 12/ET
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | 0.57 |
| Peficitinib 100 mg | 6.60 |
| Peficitinib 150 mg | 9.02 |
The participants were examined for the swollen joints and the location was confirmed by the investigator who assessed the following 66 joints which included temporomandibular joints (2), sternoclavicular joints (2), acromioclavicular joints (2), shoulder joints (2), elbow joints (2), wrist joints (2), distal interphalangeal joints (8), proximal interphalangeal joints of both hands (10), metacarpophalangeal joints (10), knee joints (2), ankle joints (2), tarsal bones (2), metatarsophalangeal joints (10), interphalangeal joint joints of toes (2), proximal interphalangeal joints of both feet (8). Higher SJC indicated greater disease activity. (NCT02305849)
Timeframe: Baseline and week 12/ET
| Intervention | swollen joint count (Mean) |
|---|---|
| Placebo | -2.2 |
| Peficitinib 100 mg | -5.9 |
| Peficitinib 150 mg | -7.6 |
The participants were examined for the tender joints and the location was confirmed by the investigator who assessed the following 68 joints which included temporomandibular joints (2), sternoclavicular joints (2), acromioclavicular joints (2), shoulder joints (2), elbow joints (2), wrist joints (2), distal interphalangeal joints (8), proximal interphalangeal joints of both hands (10), metacarpophalangeal joints (10), knee joints (2), ankle joints (2), tarsal bones (2), metatarsophalangeal joints (10), interphalangeal joint joints of toes (2), proximal interphalangeal joints of both feet (8). Higher TJC indicated greater disease activity. (NCT02305849)
Timeframe: Baseline and week 12/ET
| Intervention | tender joint count (Mean) |
|---|---|
| Placebo | -2.1 |
| Peficitinib 100 mg | -6.9 |
| Peficitinib 150 mg | -9.1 |
WPAI consisted of 6 questions (Q1=Employment status; Q2=Hours absent from work due to the rheumatoid arthritis; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the rheumatoid arthritis on productivity while working; Q6=Impact of the rheumatoid arthritis on productivity while doing regular daily activities other than work). Higher WPAI scores indicated greater activity impairment. The scores were multiplied by 100 to express in percentages. Percent work time missed due to problem was calculated as Q2/(Q2+Q4). Negative values indicate improvement from baseline. (NCT02305849)
Timeframe: Baseline and week 12/ET
| Intervention | percent work time missed (Mean) |
|---|---|
| Placebo | -0.82 |
| Peficitinib 100 mg | 0.36 |
| Peficitinib 150 mg | -1.46 |
WPAI consisted of 6 questions (Q1=Employment status; Q2=Hours absent from work due to the rheumatoid arthritis; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the rheumatoid arthritis on productivity while working; Q6=Impact of the rheumatoid arthritis on productivity while doing regular daily activities other than work) and a 1-week recall period. Higher WPAI scores indicated greater activity impairment. The scores were multiplied by 100 to express in percentages. Percent activity impairment due to problem was calculated as Q6/10. Negative values indicate improvement from baseline. (NCT02305849)
Timeframe: Baseline and week 12/ET
| Intervention | percent activity impairment (Mean) |
|---|---|
| Placebo | -2.50 |
| Peficitinib 100 mg | -13.98 |
| Peficitinib 150 mg | -19.35 |
WPAI consisted of 6 questions (Q1=Employment status; Q2=Hours absent from work due to the rheumatoid arthritis; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the rheumatoid arthritis on productivity while working; Q6=Impact of the rheumatoid arthritis on productivity while doing regular daily activities other than work). Higher WPAI scores indicated greater activity impairment. The scores were multiplied by 100 to express in percentages. Percent impairment while working due to problem was calculated as Q5/10. Negative values indicate improvement from baseline. (NCT02305849)
Timeframe: Baseline and week 12/ET
| Intervention | percent work impairment (Mean) |
|---|---|
| Placebo | -2.42 |
| Peficitinib 100 mg | -11.71 |
| Peficitinib 150 mg | -15.96 |
Participants who discontinued due to lack of efficacy have been reported. (NCT02305849)
Timeframe: Up to week 52
| Intervention | Participants (Count of Participants) |
|---|---|
| Peficitinib 100 mg | 10 |
| Peficitinib 150 mg | 6 |
| Placebo / Peficitinib 100 mg | 3 |
| Placebo / Peficitinib 150 mg | 9 |
ACR/EULAR Remission was defined as TJC (68 joints) ≤ 1, SJC (66 joints) ≤1, CRP ≤1 mg/dL, and participant's global assessment of arthritis ≤ 1 cm (on a visual analog scale (VAS) of 0 - 100 mm). (NCT02305849)
Timeframe: Week 12/ET
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 0.6 |
| Peficitinib 100 mg | 5.8 |
| Peficitinib 150 mg | 9.9 |
DAS28-CRP response consisted of following parameters: TJC (28 joints), SJC (28 joints), CRP, SGA, and calculated according to description: DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.36 ln (CRP + 1) + 0.014 × SGA + 0.96. DAS28-CRP scores range from 0.96 to approximately 10. If the DAS28 score was less than 2.6, the participant was considered to be in DAS28 remission. (NCT02305849)
Timeframe: Week 12/ET
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 7.7 |
| Peficitinib 100 mg | 31.4 |
| Peficitinib 150 mg | 35.1 |
DAS28-CRP response consisted of following parameters: TJC (28 joints), SJC (28 joints), CRP, SGA, and calculated according to description: DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.36 ln (CRP + 1) + 0.014 × SGA + 0.96. DAS28-CRP scores range from 0.96 to approximately 10. DAS28 score of less than or equal to 3.2 was considered to be low disease activity. (NCT02305849)
Timeframe: Week 12/ET
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 12.4 |
| Peficitinib 100 mg | 47.1 |
| Peficitinib 150 mg | 57.9 |
DAS28-ESR response consisted of following parameters: TJC (28 joints), SJC (28 joints), ESR, SGA , and calculated according to description: DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.70 ln ESR + 0.014 × SGA. DAS28-ESR scores range from 0 to approximately 10. If the DAS28 score was less than 2.6, the participant was considered to be in DAS28 remission. (NCT02305849)
Timeframe: Week 12/ET
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 2.4 |
| Peficitinib 100 mg | 12.8 |
| Peficitinib 150 mg | 19.3 |
DAS28-ESR response consisted of following parameters: TJC (28 joints), SJC (28 joints), ESR, SGA , and calculated according to description: DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.70 ln ESR + 0.014 × SGA. DAS28-ESR scores range from 0 to approximately 10. DAS28 score of less than or equal to 3.2 was considered to be low disease activity. (NCT02305849)
Timeframe: Week 12/ET
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 4.7 |
| Peficitinib 100 mg | 25.0 |
| Peficitinib 150 mg | 36.3 |
SDAI score consisted of following parameters: TJC (28 joints), SJC (28 joints), SGA, PGA, CRP (mg/dL), and calculated according to description. SDAI = TJC + SJC + SGA + PGA + CRP. SDAI Remission was defined as SDAI score ≤ 3.3. (NCT02305849)
Timeframe: Week 12/ET
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 0.6 |
| Peficitinib 100 mg | 7.0 |
| Peficitinib 150 mg | 14.0 |
The Disease Activity Score Based on 28-joints Count based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders: change from baseline >1.2 with DAS28 =< 3.2; moderate responders: change from baseline >1.2 with DAS28 >3.2 to =<5.1 or change from baseline >0.6 to =<1.2 with DAS28 =<5.1; non-responders: change from baseline =< 0.6 or change from baseline >0.6 and =<1.2 with DAS28 >5.1. Percentage of participants with good or moderate response have been reported in this outcome measure. (NCT02305849)
Timeframe: Week 12/ET
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 32.0 |
| Peficitinib 100 mg | 74.4 |
| Peficitinib 150 mg | 78.9 |
The Disease Activity Score Based on 28-joints Count based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders: change from baseline >1.2 with DAS28 =< 3.2; moderate responders: change from baseline >1.2 with DAS28 >3.2 to =<5.1 or change from baseline >0.6 to =<1.2 with DAS28 =<5.1; non-responders: change from baseline =< 0.6 or change from baseline >0.6 and =<1.2 with DAS28 >5.1. Percentage of participants with good response have been reported in the outcome measure. (NCT02305849)
Timeframe: Week 12/ET
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 4.1 |
| Peficitinib 100 mg | 23.8 |
| Peficitinib 150 mg | 34.5 |
The Disease Activity Score Based on 28-joints Count based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders: change from baseline >1.2 with DAS28 =< 3.2; moderate responders: change from baseline >1.2 with DAS28 >3.2 to =<5.1 or change from baseline >0.6 to =<1.2 with DAS28 =<5.1; non-responders: change from baseline =< 0.6 or change from baseline >0.6 and =<1.2 with DAS28 >5.1. Percentage of participants with good response have been reported in this outcome measure. (NCT02305849)
Timeframe: Week 12/ET
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 10.1 |
| Peficitinib 100 mg | 43.0 |
| Peficitinib 150 mg | 55.6 |
The Disease Activity Score Based on 28-joints Count based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders: change from baseline >1.2 with DAS28 =< 3.2; moderate responders: change from baseline >1.2 with DAS28 >3.2 to =<5.1 or change from baseline >0.6 to =<1.2 with DAS28 =<5.1; non-responders: change from baseline =< 0.6 or change from baseline >0.6 and =<1.2 with DAS28 >5.1. Percentage of participants with good or moderate response have been reported in this outcome measure. (NCT02305849)
Timeframe: Week 12/ET
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 35.5 |
| Peficitinib 100 mg | 77.9 |
| Peficitinib 150 mg | 84.8 |
ACR50 response: ≥50% improvement in tender and swollen joint counts and 50% improvement in 3 of the following 5 criteria compared with baseline: 1) physician's global assessment of disease activity, 2) participant's assessment of disease activity, 3) participant's assessment of pain, 4) participant's assessment of functional ability via a health assessment questionnaire-Disability Index, and 5) C-reactive protein at each visit. (NCT02305849)
Timeframe: Baseline and week 12/ET
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 7.6 |
| Peficitinib 100 mg | 29.9 |
| Peficitinib 150 mg | 46.0 |
ACR70 response: ≥ 70% improvement in tender and swollen joint counts and 70% improvement in 3 of the following 5 criteria compared with baseline: 1) physician's global assessment of disease activity, 2) participant's assessment of disease activity, 3) participant's assessment of pain, 4) participant's assessment of functional ability via a health assessment questionnaire-Disability Index, and 5) C-reactive protein at each visit. (NCT02305849)
Timeframe: Baseline and week 12/ET
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 2.4 |
| Peficitinib 100 mg | 12.1 |
| Peficitinib 150 mg | 23.6 |
ACR20 response: greater than and equal to (≥) 20 percent (%) improvement in tender and swollen joint count; and ≥ 20% improvement in at least 3 of the following 5 criteria compared with baseline: 1) physician's global assessment of disease activity, 2) participant's assessment of disease activity, 3) participant's assessment of pain, 4) participant's assessment of functional disability via a health assessment questionnaire, and 5) C-reactive protein at each visit. (NCT02305849)
Timeframe: Baseline and week 12/Early termination (ET)
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 21.8 |
| Peficitinib 100 mg | 58.6 |
| Peficitinib 150 mg | 64.4 |
Higher CRP indicates greater disease activity. (NCT02305849)
Timeframe: Baseline, weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and EOT
| Intervention | mg/dL (Mean) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 4 | Week 8 | Week 12 | Week 16 | Week 20 | Week 24 | Week 28 | Week 32 | Week 36 | Week 40 | Week 44 | Week 48 | Week 52 | EOT | |
| Peficitinib 100 mg | -1.055 | -1.207 | -1.532 | -1.666 | -1.660 | -1.774 | -1.803 | -1.844 | -1.832 | -1.833 | -1.815 | -1.771 | -1.841 | -1.545 |
| Peficitinib 150 mg | -1.411 | -1.569 | -1.458 | -1.513 | -1.660 | -1.721 | -1.721 | -1.640 | -1.696 | -1.716 | -1.725 | -1.751 | -1.912 | -1.629 |
DAS28-CRP response consisted of following parameters: TJC (28 joints), SJC (28 joints), CRP, SGA, and calculated according to description: DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.36 ln (CRP + 1) + 0.014 × SGA + 0.96. DAS28-CRP scores range from 0.96 to approximately 10. Higher DAS28 score indicated greater disease activity. (NCT02305849)
Timeframe: Baseline, weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and EOT
| Intervention | units on a scale (Mean) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 4 | Week 8 | Week 12 | Week 16 | Week 20 | Week 24 | Week 28 | Week 32 | Week 36 | Week 40 | Week 44 | Week 48 | Week 52 | EOT | |
| Peficitinib 100 mg | -1.11 | -1.48 | -1.72 | -2.01 | -2.21 | -2.40 | -2.42 | -2.50 | -2.55 | -2.66 | -2.65 | -2.62 | -2.67 | -2.43 |
| Peficitinib 150 mg | -1.39 | -1.87 | -2.15 | -2.40 | -2.53 | -2.71 | -2.70 | -2.77 | -2.83 | -2.86 | -2.88 | -2.92 | -2.96 | -2.76 |
| Placebo / Peficitinib 100 mg at Week 12 | -0.28 | -0.21 | 0.24 | -1.11 | -1.69 | -2.01 | -2.24 | -2.49 | -2.49 | -2.66 | -2.68 | -2.86 | -2.80 | -2.61 |
| Placebo / Peficitinib 100 mg at Week 28 | -0.82 | -0.94 | -1.34 | -1.37 | -1.38 | -1.41 | -1.53 | -2.18 | -2.22 | -2.62 | -2.63 | -2.66 | -2.70 | -2.72 |
| Placebo / Peficitinib 150 mg at Week 12 | -0.30 | -0.10 | 0.27 | -1.37 | -1.76 | -2.26 | -2.51 | -2.72 | -2.70 | -2.72 | -2.72 | -2.90 | -2.74 | -2.52 |
| Placebo / Peficitinib 150 mg at Week 28 | -0.74 | -0.90 | -1.20 | -1.31 | -1.48 | -1.64 | -1.71 | -2.47 | -2.57 | -2.73 | -2.87 | -2.96 | -2.89 | -2.87 |
DAS28-ESR response consisted of following parameters: TJC (28 joints), SJC (28 joints), ESR, SGA , and calculated according to description: DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.70 ln ESR + 0.014 × SGA. DAS28-ESR scores range from 0 to approximately 10. Higher DAS28 score indicated greater disease activity. (NCT02305849)
Timeframe: Baseline, weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and EOT
| Intervention | units on a scale (Mean) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 4 | Week 8 | Week 12 | Week 16 | Week 20 | Week 24 | Week 28 | Week 32 | Week 36 | Week 40 | Week 44 | Week 48 | Week 52 | EOT | |
| Peficitinib 100 mg | -1.07 | -1.47 | -1.68 | -1.98 | -2.23 | -2.43 | -2.47 | -2.56 | -2.59 | -2.70 | -2.71 | -2.64 | -2.70 | -2.47 |
| Peficitinib 150 mg | -1.37 | -1.88 | -2.18 | -2.46 | -2.60 | -2.78 | -2.79 | -2.87 | -2.91 | -2.96 | -3.00 | -3.01 | -3.07 | -2.86 |
| Placebo / Peficitinib 100 mg at Week 12 | -0.26 | -0.24 | 0.24 | -1.01 | -1.61 | -1.94 | -2.11 | -2.39 | -2.45 | -2.60 | -2.63 | -2.80 | -2.77 | -2.60 |
| Placebo / Peficitinib 100 mg at Week 28 | -0.87 | -1.00 | -1.40 | -1.47 | -1.45 | -1.47 | -1.63 | -2.27 | -2.38 | -2.71 | -2.74 | -2.72 | -2.79 | -2.80 |
| Placebo / Peficitinib 150 mg at Week 12 | -0.26 | -0.12 | 0.25 | -1.38 | -1.78 | -2.24 | -2.48 | -2.68 | -2.71 | -2.78 | -2.76 | -2.88 | -2.78 | -2.56 |
| Placebo / Peficitinib 150 mg at Week 28 | -0.67 | -0.85 | -1.10 | -1.21 | -1.37 | -1.56 | -1.62 | -2.37 | -2.54 | -2.68 | -2.78 | -2.93 | -2.85 | -2.82 |
The joint erosion score was a summary of erosion severity in 32 joints of the hands and 12 joints of the feet. Each joint in the hand is scored from 0-5 and each joint in the foot is scored from 0-10. The score for erosion ranges from 0 to 160 in the hands and from 0 to 120 in the feet. By summing these score, the range of total erosion score is 0-280. Higher erosion score indicates greater disease activity. (NCT02305849)
Timeframe: Baseline and weeks 28/ET and 52/ET
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Week 28/ET | Week 52/ET | |
| Peficitinib 100 mg | 0.63 | 0.82 |
| Peficitinib 150 mg | 0.18 | 0.32 |
| Placebo | 1.35 | 2.52 |
Higher ESR indicates greater disease activity. (NCT02305849)
Timeframe: Baseline, weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and EOT
| Intervention | mm/h (Mean) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 4 | Week 8 | Week 12 | Week 16 | Week 20 | Week 24 | Week 28 | Week 32 | Week 36 | Week 40 | Week 44 | Week 48 | Week 52 | EOT | |
| Peficitinib 100 mg | -11.09 | -14.96 | -19.14 | -21.42 | -23.22 | -25.35 | -26.03 | -26.92 | -25.95 | -25.86 | -27.13 | -25.63 | -26.86 | -24.00 |
| Peficitinib 150 mg | -16.59 | -21.10 | -22.92 | -24.29 | -26.20 | -27.36 | -27.88 | -27.21 | -27.25 | -27.74 | -27.99 | -27.83 | -29.12 | -26.11 |
Participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item was scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty. (NCT02305849)
Timeframe: Baseline, weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and EOT
| Intervention | units on a scale (Mean) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 4 | Week 8 | Week 12 | Week 16 | Week 20 | Week 24 | Week 28 | Week 32 | Week 36 | Week 40 | Week 44 | Week 48 | Week 52 | EOT | |
| Peficitinib 100 mg | -0.08 | -0.18 | -0.23 | -0.30 | -0.33 | -0.36 | -0.36 | -0.37 | -0.39 | -0.42 | -0.45 | -0.44 | -0.43 | -0.36 |
| Peficitinib 150 mg | -0.21 | -0.32 | -0.38 | -0.41 | -0.47 | -0.48 | -0.51 | -0.53 | -0.53 | -0.56 | -0.54 | -0.56 | -0.56 | -0.51 |
JSN was defined as narrowing in joint space width over the course of the study. The JSN score summarizes the severity of JSN in 30 joints of the hands and 12 joints of the feet. JSN, including subluxation, was scored from 0 (normal) to 4 (complete loss of joint space, bony ankylosis, or luxation), with a maximum JSN score of 168. Higher scores indicate greater disease activity. (NCT02305849)
Timeframe: Baseline and weeks 28/ET and 52/ET
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Week 28/ET | Week 52/ET | |
| Peficitinib 100 mg | 0.99 | 1.30 |
| Peficitinib 150 mg | 0.82 | 1.19 |
| Placebo | 1.90 | 3.55 |
The investigator assessed the participants disease activity on a VAS of 0-100 mm on the physician assessment table. Higher PGA (100 mm VAS) scores indicate greater activity impairment. (NCT02305849)
Timeframe: Baseline, weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and EOT
| Intervention | units on a scale (Mean) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 4 | Week 8 | Week 12 | Week 16 | Week 20 | Week 24 | Week 28 | Week 32 | Week 36 | Week 40 | Week 44 | Week 48 | Week 52 | EOT | |
| Peficitinib 100 mg | -18.36 | -25.79 | -29.07 | -33.60 | -36.18 | -37.13 | -38.72 | -40.04 | -39.35 | -41.04 | -41.47 | -41.55 | -41.49 | -38.41 |
| Peficitinib 150 mg | -22.94 | -31.54 | -36.55 | -38.86 | -41.44 | -43.67 | -42.43 | -43.96 | -44.37 | -44.32 | -46.00 | -45.84 | -45.46 | -43.33 |
SDAI score consisted of following parameters: TJC (28 joints), SJC (28 joints), SGA, PGA, CRP (mg/dL), and calculated according to description: SDAI = TJC + SJC + SGA + PGA + CRP. The SDAI score ranges from 0 to approximately 86. Higher SDAI indicates greater disease activity. (NCT02305849)
Timeframe: Baseline, weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and EOT
| Intervention | units on a scale (Mean) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 4 | Week 8 | Week 12 | Week 16 | Week 20 | Week 24 | Week 28 | Week 32 | Week 36 | Week 40 | Week 44 | Week 48 | Week 52 | EOT | |
| Peficitinib 100 mg | -11.02 | -14.60 | -15.94 | -18.75 | -20.24 | -21.62 | -21.89 | -22.61 | -22.89 | -23.55 | -23.55 | -23.23 | -23.67 | -21.48 |
| Peficitinib 150 mg | -13.79 | -18.36 | -20.08 | -22.21 | -23.03 | -24.68 | -24.57 | -25.38 | -25.55 | -26.14 | -26.44 | -26.50 | -26.63 | -24.72 |
The SF-36v2 was scored for the 8 subscales (each range: 0-100 scale): 1. physical functioning, 2. role physical, 3. bodily pain, 4. general health, 5. vitality, 6. social functioning, 7. role-emotional, and 8. mental health. Physical Component Summary Score, Mental Component Summary Score and Roll/Social Component Summary Score were calculated based on the 2007 General Japanese Population Means and Standard Deviations and coefficient. Component summary measures had means of 50 in 2007 General Japanese Population and deviation was expressed by the scale of 10. Higher score indicated better health state. (NCT02305849)
Timeframe: Baseline, weeks 4, 8, 12, 28, 52 and EOT
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Week 4 | Week 8 | Week 12 | Week 28 | Week 52 | EOT | |
| Peficitinib 100 mg | 1.45 | 2.72 | 3.44 | 3.06 | 2.62 | 2.21 |
| Peficitinib 150 mg | 1.33 | 2.44 | 2.67 | 3.12 | 1.85 | 1.67 |
The SF-36v2 was scored for the 8 subscales (each range: 0-100 scale): 1. physical functioning, 2. role physical, 3. bodily pain, 4. general health, 5. vitality, 6. social functioning, 7. role-emotional, and 8. mental health. Physical Component Summary Score, Mental Component Summary Score and Roll/Social Component Summary Score were calculated based on the 2007 General Japanese Population Means and Standard Deviations and coefficient. Component summary measures had means of 50 in 2007 General Japanese Population and deviation was expressed by the scale of 10. Higher score indicated better health state. (NCT02305849)
Timeframe: Baseline, weeks 4, 8, 12, 28, 52 and EOT
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Week 4 | Week 8 | Week 12 | Week 28 | Week 52 | EOT | |
| Peficitinib 100 mg | 3.84 | 4.92 | 6.68 | 9.89 | 11.27 | 9.92 |
| Peficitinib 150 mg | 5.77 | 7.91 | 9.32 | 12.44 | 12.45 | 11.51 |
The SF-36v2 was scored for the 8 subscales (each range: 0-100 scale): 1. physical functioning, 2. role physical, 3. bodily pain, 4. general health, 5. vitality, 6. social functioning, 7. role-emotional, and 8. mental health. Physical Component Summary Score, Mental Component Summary Score and Roll/Social Component Summary Score were calculated based on the 2007 General Japanese Population Means and Standard Deviations and coefficient. Component summary measures had means of 50 in 2007 General Japanese Population and deviation was expressed by the scale of 10. Higher score indicated better health state. (NCT02305849)
Timeframe: Baseline, weeks 4, 8, 12, 28, 52 and EOT
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Week 4 | Week 8 | Week 12 | Week 28 | Week 52 | EOT | |
| Peficitinib 100 mg | 1.41 | 2.50 | 2.32 | 4.06 | 4.30 | 3.49 |
| Peficitinib 150 mg | 1.70 | 3.30 | 3.92 | 4.81 | 7.17 | 5.88 |
The participant assessed his/her own disease activity on a VAS of 0-100 mm on the questionnaire form. Higher SGA (100 mm VAS) scores indicate greater activity impairment. (NCT02305849)
Timeframe: Baseline, weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and EOT
| Intervention | units on a scale (Mean) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 4 | Week 8 | Week 12 | Week 16 | Week 20 | Week 24 | Week 28 | Week 32 | Week 36 | Week 40 | Week 44 | Week 48 | Week 52 | EOT | |
| Peficitinib 100 mg | -13.80 | -19.11 | -21.59 | -25.20 | -26.94 | -29.00 | -30.04 | -31.92 | -32.38 | -32.80 | -33.49 | -33.69 | -33.18 | -29.34 |
| Peficitinib 150 mg | -17.59 | -24.97 | -27.40 | -30.14 | -31.20 | -32.79 | -34.25 | -33.46 | -34.01 | -34.24 | -35.31 | -35.33 | -36.16 | -34.05 |
The participant assessed his/her own pain severity on a visual analog scale (VAS) of 0-100 mm on the questionnaire form. Higher SGA of pain (100 mm VAS) scores indicated greater activity pain. (NCT02305849)
Timeframe: Baseline, weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and EOT
| Intervention | units on a scale (Mean) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 4 | Week 8 | Week 12 | Week 16 | Week 20 | Week 24 | Week 28 | Week 32 | Week 36 | Week 40 | Week 44 | Week 48 | Week 52 | EOT | |
| Peficitinib 100 mg | -12.94 | -19.10 | -21.27 | -24.03 | -25.57 | -27.34 | -28.54 | -31.32 | -31.95 | -32.17 | -32.73 | -33.60 | -33.34 | -28.94 |
| Peficitinib 150 mg | -16.18 | -24.98 | -27.81 | -28.42 | -30.63 | -32.72 | -34.18 | -33.74 | -32.66 | -34.07 | -34.88 | -35.07 | -35.00 | -32.68 |
The participants were examined for the swollen joints and the location was confirmed by the investigator who assessed the following 66 joints which included temporomandibular joints (2), sternoclavicular joints (2), acromioclavicular joints (2), shoulder joints (2), elbow joints (2), wrist joints (2), distal interphalangeal joints (8), proximal interphalangeal joints of both hands (10), metacarpophalangeal joints (10), knee joints (2), ankle joints (2), tarsal bones (2), metatarsophalangeal joints (10), interphalangeal joint joints of toes (2), proximal interphalangeal joints of both feet (8). Higher SJC indicated greater disease activity. (NCT02305849)
Timeframe: Baseline, weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and EOT
| Intervention | swollen joint count (Mean) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 4 | Week 8 | Week 12 | Week 16 | Week 20 | Week 24 | Week 28 | Week 32 | Week 36 | Week 40 | Week 44 | Week 48 | Week 52 | EOT | |
| Peficitinib 100 mg | -4.3 | -5.6 | -6.0 | -7.5 | -8.1 | -8.8 | -8.8 | -9.0 | -9.0 | -9.4 | -9.4 | -9.2 | -9.6 | -8.8 |
| Peficitinib 150 mg | -5.3 | -7.1 | -7.8 | -8.9 | -9.2 | -9.9 | -9.8 | -10.3 | -10.5 | -10.7 | -10.8 | -11.0 | -11.0 | -10.3 |
The participants were examined for the tender joints and the location was confirmed by the investigator who assessed the following 68 joints which included temporomandibular joints (2), sternoclavicular joints (2), acromioclavicular joints (2), shoulder joints (2), elbow joints (2), wrist joints (2), distal interphalangeal joints (8), proximal interphalangeal joints of both hands (10), metacarpophalangeal joints (10), knee joints (2), ankle joints (2), tarsal bones (2), metatarsophalangeal joints (10), interphalangeal joint joints of toes (2), proximal interphalangeal joints of both feet (8). Higher TJC indicated greater disease activity. (NCT02305849)
Timeframe: Baseline, weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and EOT
| Intervention | tender joint count (Mean) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 4 | Week 8 | Week 12 | Week 16 | Week 20 | Week 24 | Week 28 | Week 32 | Week 36 | Week 40 | Week 44 | Week 48 | Week 52 | EOT | |
| Peficitinib 100 mg | -5.1 | -6.8 | -7.1 | -8.1 | -9.1 | -9.9 | -9.6 | -9.7 | -10.4 | -10.8 | -10.6 | -10.5 | -10.8 | -9.8 |
| Peficitinib 150 mg | -6.3 | -8.3 | -9.3 | -10.5 | -10.8 | -11.3 | -11.4 | -12.1 | -11.8 | -11.9 | -12.1 | -12.1 | -11.9 | -11.2 |
WPAI consisted of 6 questions (Q1=Employment status; Q2=Hours absent from work due to the rheumatoid arthritis; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the rheumatoid arthritis on productivity while working; Q6=Impact of the rheumatoid arthritis on productivity while doing regular daily activities other than work) and a 1-week recall period. Higher WPAI scores indicated greater activity impairment. The scores were multiplied by 100 to express in percentages. Percent activity impairment due to problem was calculated as Q6/10. Negative values indicate improvement from baseline. (NCT02305849)
Timeframe: Baseline, weeks 4, 8, 12, 28, 52 and EOT
| Intervention | percent activity impairment (Mean) | |||||
|---|---|---|---|---|---|---|
| Week 4 | Week 8 | Week 12 | Week 28 | Week 52 | EOT | |
| Peficitinib 100 mg | -9.23 | -13.07 | -13.71 | -22.17 | -24.10 | -21.58 |
| Peficitinib 150 mg | -10.65 | -17.44 | -19.88 | -26.99 | -26.71 | -23.47 |
WPAI consisted of 6 questions (Q1=Employment status; Q2=Hours absent from work due to the rheumatoid arthritis; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the rheumatoid arthritis on productivity while working; Q6=Impact of the rheumatoid arthritis on productivity while doing regular daily activities other than work). Higher WPAI scores indicated greater activity impairment. The scores were multiplied by 100 to express in percentages. Percent impairment while working due to problem was calculates as Q5/10. Negative values indicate improvement from baseline. (NCT02305849)
Timeframe: Baseline, weeks 4, 8, 12, 28, 52 and EOT
| Intervention | percent work impairment (Mean) | |||||
|---|---|---|---|---|---|---|
| Week 4 | Week 8 | Week 12 | Week 28 | Week 52 | EOT | |
| Peficitinib 100 mg | -10.00 | -12.50 | -11.97 | -20.00 | -22.97 | -17.35 |
| Peficitinib 150 mg | -6.56 | -13.98 | -16.29 | -21.40 | -22.41 | -20.43 |
WPAI consisted of 6 questions (Q1=Employment status; Q2=Hours absent from work due to the rheumatoid arthritis; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the rheumatoid arthritis on productivity while working; Q6=Impact of the rheumatoid arthritis on productivity while doing regular daily activities other than work). Higher WPAI scores indicated greater activity impairment. The scores were multiplied by 100 to express in percentages. Percent overall work impairment due to problem was calculated as Q2/(Q2+Q4)+[(1-(Q2/(Q2+Q4))x(Q5/10)]. Negative values indicate improvement from baseline. (NCT02305849)
Timeframe: Baseline, weeks 4, 8, 12, 28, 52 and EOT
| Intervention | percent overall work impairment (Mean) | |||||
|---|---|---|---|---|---|---|
| Week 4 | Week 8 | Week 12 | Week 28 | Week 52 | EOT | |
| Peficitinib 100 mg | -10.61 | -13.13 | -12.15 | -20.76 | -22.48 | -17.43 |
| Peficitinib 150 mg | -7.51 | -14.67 | -17.15 | -22.49 | -23.40 | -21.59 |
WPAI consisted of 6 questions (Q1=Employment status; Q2=Hours absent from work due to the rheumatoid arthritis; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the rheumatoid arthritis on productivity while working; Q6=Impact of the rheumatoid arthritis on productivity while doing regular daily activities other than work). Higher WPAI scores indicated greater activity impairment. The scores were multiplied by 100 to express in percentages. Percent work time missed due to problem was calculated as Q2/(Q2+Q4). Negative values indicate improvement from baseline. (NCT02305849)
Timeframe: Baseline, weeks 4, 8, 12, 28, 52 and EOT
| Intervention | percent work time missed (Mean) | |||||
|---|---|---|---|---|---|---|
| Week 4 | Week 8 | Week 12 | Week 28 | Week 52 | EOT | |
| Peficitinib 100 mg | -0.90 | -1.48 | -0.70 | -0.58 | -1.93 | -1.76 |
| Peficitinib 150 mg | 0.02 | -1.73 | -1.97 | -3.49 | -1.66 | -1.66 |
TEAEs were defined as any AE that started or worsened in severity after initial dose of study drug or reference drug through week 52 or withdrawal. TEAEs were summarized using MedDRA (Version 11.1) by SOC and PT. Participants reporting more than 1 AE for a given MedDRA PT were counted only once for that term. Participants reporting more than 1 AE within a SOC were counted only once for the SOC total. Based on NCI-CTCAE, AEs were graded as grade 1=mild; grade 2=moderate: grade 3 = severe or medically significant, grade 4 = life threatening, grade 5 = death related to AE (NCT02305849)
Timeframe: Week 12 to week 28
| Intervention | Participants (Count of Participants) | |||||||
|---|---|---|---|---|---|---|---|---|
| TEAEs | Drug-related TEAEs | TEAEs leading to death | Serious TEAEs | Drug-related serious TEAEs | ≥ Grade 3 TEAEs | TEAEs leading to permanent discontinuation | Drug-Related TEAE leading to permanent dicont. | |
| Peficitinib 100 mg | 95 | 63 | 0 | 5 | 3 | 7 | 4 | 3 |
| Peficitinib 150 mg | 104 | 72 | 0 | 3 | 1 | 6 | 1 | 1 |
| Placebo | 50 | 27 | 0 | 2 | 2 | 5 | 4 | 3 |
| Placebo / Peficitinib 100 mg at Week 12 | 21 | 16 | 0 | 0 | 0 | 1 | 0 | 0 |
| Placebo / Peficitinib 150 mg at Week 12 | 25 | 11 | 0 | 0 | 0 | 1 | 0 | 0 |
TEAEs were defined as any AE that started or worsened in severity after initial dose of study drug or reference drug through week 52 or withdrawal. TEAEs were summarized using MedDRA (Version 11.1) by SOC and PT. Participants reporting more than 1 AE for a given MedDRA PT were counted only once for that term. Participants reporting more than 1 AE within a SOC were counted only once for the SOC total. Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), AEs were graded as grade 1=mild; grade 2=moderate: grade 3 = severe or medically significant, grade 4 = life threatening, grade 5 = death related to AE. (NCT02305849)
Timeframe: Week 28 to week 52, plus 28 days after the week 52 visit for participants who did not enroll in the extension study
| Intervention | Participants (Count of Participants) | ||||||
|---|---|---|---|---|---|---|---|
| TEAEs | Drug-related TEAEs | TEAEs leading to death | Serious TEAEs | Drug-related serious TEAEs | ≥ Grade 3 TEAEs | TEAEs leading to permanent discontinuation | |
| Peficitinib 100 mg | 114 | 72 | 0 | 10 | 4 | 15 | 4 |
| Peficitinib 150 mg | 112 | 74 | 0 | 8 | 5 | 15 | 6 |
| Placebo / Peficitinib 100 mg at Week 12 | 22 | 14 | 0 | 2 | 2 | 2 | 3 |
| Placebo / Peficitinib 100 mg at Week 28 | 25 | 17 | 1 | 1 | 0 | 2 | 2 |
| Placebo / Peficitinib 150 mg at Week 12 | 27 | 18 | 0 | 1 | 1 | 2 | 2 |
| Placebo / Peficitinib 150 mg at Week 28 | 26 | 17 | 0 | 1 | 1 | 2 | 0 |
TEAEs were defined as any AE that started or worsened in severity after initial dose of study drug or reference drug through week 52 or withdrawal. TEAEs were summarized using MedDRA (Version 11.1) by System Organ Class (SOC) and Preferred Term (PT). Participants reporting more than 1 AE for a given MedDRA PT were counted only once for that term. Participants reporting more than 1 AE within a SOC were counted only once for the SOC total. Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), AEs were graded as grade 1=mild; grade 2=moderate: grade 3 = severe or medically significant, grade 4 = life threatening, grade 5 = death related to AE. (NCT02305849)
Timeframe: Week 0 to week 12
| Intervention | Participants (Count of Participants) | |||||||
|---|---|---|---|---|---|---|---|---|
| TEAEs | Drug-related TEAEs | TEAEs leading to death | Serious TEAEs | Drug-related serious TEAEs | ≥ Grade 3 TEAEs | TEAEs leading to permanent discontinuation | Drug-Related AE leading to permanent discont. | |
| Peficitinib 100 mg | 89 | 57 | 0 | 5 | 3 | 9 | 5 | 3 |
| Peficitinib 150 mg | 104 | 80 | 0 | 3 | 3 | 16 | 5 | 5 |
| Placebo | 84 | 47 | 0 | 4 | 2 | 8 | 7 | 6 |
ACR/EULAR Remission was defined as TJC (68 joints) ≤ 1, SJC (66 joints) ≤1, CRP ≤1 mg/dL, and participant's global assessment of arthritis ≤ 1 cm (on a visual analog scale (VAS) of 0 - 100 mm). (NCT02305849)
Timeframe: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and EOT
| Intervention | percentage of participants (Number) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 4 | Week 8 | Week 12 | Week 16 | Week 20 | Week 24 | Week 28 | Week 32 | Week 36 | Week 40 | Week 44 | Week 48 | Week 52 | EOT | |
| Peficitinib 100 mg | 1.2 | 1.2 | 6.0 | 9.0 | 11.0 | 11.8 | 14.6 | 17.2 | 17.0 | 19.1 | 16.1 | 17.6 | 21.4 | 19.2 |
| Peficitinib 150 mg | 1.2 | 3.6 | 10.2 | 12.1 | 14.1 | 18.1 | 20.1 | 25.8 | 27.7 | 20.9 | 20.3 | 21.2 | 26.5 | 23.4 |
mTSS was defined as the sum of joint erosion scores graded by assessing erosion severity in 44 joints (16 per hand and 6 per feet) and JSN scores graded by assessing narrowing of joint spaces in 42 joints (15 per hand and 6 per feet). Erosion score was scored from 0 (no erosion) to 5 (complete collapse of bone) and the score for erosion ranges from 0 to 160 in the hands and from 0 to 120 in the feet (the maximum erosion score for a joint in the foot is 10). JSN including subluxation, was scored from 0 (normal) to 4 (complete loss of joint space, bony ankylosis, or luxation), with a maximum JSN score of 168. mTSS scores ranged from 0 (normal) to 448 (worst possible total score). An increase in mTSS from baseline represented disease progression and/or joint worsening, no change represented halting of disease progression, and a decrease represented improvement. (NCT02305849)
Timeframe: Baseline and week 28/ET and 52/ET
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Week 28/ET | Week 52/ET | |
| Peficitinib 100 mg | 67.1 | 64.0 |
| Peficitinib 150 mg | 72.6 | 68.9 |
| Placebo | 45.8 | 42.5 |
DAS28-CRP response consisted of following parameters: TJC (28 joints), SJC (28 joints), CRP, SGA, and calculated according to description: DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.36 ln (CRP + 1) + 0.014 × SGA + 0.96. DAS28-CRP scores range from 0.96 to approximately 10. If the DAS28 score was less than 2.6, the participant was considered to be in DAS28 remission. (NCT02305849)
Timeframe: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and EOT
| Intervention | percentage of participants (Number) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 4 | Week 8 | Week 12 | Week 16 | Week 20 | Week 24 | Week 28 | Week 32 | Week 36 | Week 40 | Week 44 | Week 48 | Week 52 | EOT | |
| Peficitinib 100 mg | 11.2 | 19.0 | 31.0 | 39.2 | 45.7 | 51.6 | 51.9 | 54.1 | 53.6 | 59.9 | 57.0 | 56.1 | 60.0 | 56.4 |
| Peficitinib 150 mg | 14.7 | 21.7 | 36.1 | 43.0 | 52.1 | 56.9 | 52.8 | 52.9 | 53.5 | 58.8 | 55.6 | 60.3 | 62.6 | 57.9 |
| Placebo / Peficitinib 100 mg at Week 12 | 0.0 | 0.0 | 0.0 | 8.1 | 21.6 | 27.8 | 30.6 | 44.4 | 50.0 | 42.9 | 50.0 | 54.5 | 54.5 | 54.1 |
| Placebo / Peficitinib 100 mg at Week 28 | 15.4 | 10.3 | 20.5 | 20.5 | 17.9 | 20.5 | 25.6 | 30.8 | 35.1 | 61.1 | 55.6 | 62.9 | 55.9 | 56.4 |
| Placebo / Peficitinib 150 mg at Week 12 | 0.0 | 0.0 | 0.0 | 13.5 | 16.2 | 33.3 | 38.9 | 50.0 | 48.6 | 50.0 | 42.4 | 54.5 | 39.4 | 34.2 |
| Placebo / Peficitinib 150 mg at Week 28 | 5.9 | 11.8 | 11.8 | 8.8 | 29.4 | 32.4 | 26.5 | 44.1 | 54.5 | 54.5 | 57.6 | 66.7 | 63.6 | 64.7 |
DAS28-CRP response consisted of following parameters: TJC (28 joints), SJC (28 joints), CRP, SGA, and calculated according to description: DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.36 ln (CRP + 1) + 0.014 × SGA + 0.96. DAS28-CRP scores range from 0.96 to approximately 10. DAS28 score of less than or equal to 3.2 was considered to be low disease activity. (NCT02305849)
Timeframe: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and EOT
| Intervention | percentage of participants (Number) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 4 | Week 8 | Week 12 | Week 16 | Week 20 | Week 24 | Week 28 | Week 32 | Week 36 | Week 40 | Week 44 | Week 48 | Week 52 | EOT | |
| Peficitinib 100 mg | 22.4 | 36.3 | 47.0 | 55.4 | 62.2 | 67.1 | 67.7 | 65.6 | 69.3 | 76.3 | 70.5 | 73.6 | 71.7 | 66.9 |
| Peficitinib 150 mg | 24.1 | 44.0 | 59.6 | 63.6 | 69.9 | 71.9 | 76.7 | 70.3 | 73.5 | 80.4 | 82.4 | 78.8 | 77.6 | 71.3 |
DAS28-ESR response consisted of following parameters: TJC (28 joints), SJC (28 joints), ESR, SGA , and calculated according to description: DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.70 ln ESR + 0.014 × SGA. DAS28-ESR scores range from 0 to approximately 10. If the DAS28 score was less than 2.6, the participant was considered to be in DAS28 remission. (NCT02305849)
Timeframe: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and EOT
| Intervention | percentage of participants (Number) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 4 | Week 8 | Week 12 | Week 16 | Week 20 | Week 24 | Week 28 | Week 32 | Week 36 | Week 40 | Week 44 | Week 48 | Week 52 | EOT | |
| Peficitinib 100 mg | 4.1 | 8.9 | 13.1 | 18.1 | 22.6 | 28.0 | 30.4 | 33.8 | 32.7 | 37.1 | 34.0 | 33.3 | 38.6 | 34.9 |
| Peficitinib 150 mg | 5.9 | 12.7 | 19.9 | 24.2 | 33.1 | 31.3 | 32.1 | 41.3 | 40.0 | 36.2 | 37.3 | 40.4 | 42.9 | 38.6 |
| Placebo / Peficitinib 100 mg at Week 12 | 0.0 | 0.0 | 0.0 | 0.0 | 5.4 | 5.6 | 11.1 | 22.2 | 13.9 | 20.0 | 17.6 | 21.2 | 27.3 | 24.3 |
| Placebo / Peficitinib 100 mg at Week 28 | 2.6 | 2.6 | 5.1 | 10.3 | 7.7 | 12.8 | 12.8 | 15.4 | 13.5 | 22.2 | 25.0 | 34.3 | 26.5 | 25.6 |
| Placebo / Peficitinib 150 mg at Week 12 | 0.0 | 0.0 | 0.0 | 10.8 | 10.8 | 27.8 | 22.2 | 30.6 | 37.1 | 35.3 | 24.2 | 39.4 | 36.4 | 31.6 |
| Placebo / Peficitinib 150 mg at Week 28 | 0.0 | 2.9 | 5.9 | 2.9 | 5.9 | 5.9 | 8.8 | 26.5 | 24.2 | 30.3 | 30.3 | 36.4 | 39.4 | 41.2 |
DAS28-ESR response consisted of following parameters: TJC (28 joints), SJC (28 joints), ESR, SGA , and calculated according to description: DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.70 ln ESR + 0.014 × SGA. DAS28-ESR scores range from 0 to approximately 10. DAS28 score of less than or equal to 3.2 was considered to be low disease activity. (NCT02305849)
Timeframe: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and EOT
| Intervention | percentage of participants (Number) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 4 | Week 8 | Week 12 | Week 16 | Week 20 | Week 24 | Week 28 | Week 32 | Week 36 | Week 40 | Week 44 | Week 48 | Week 52 | EOT | |
| Peficitinib 100 mg | 10.6 | 17.9 | 25.6 | 34.9 | 44.5 | 52.2 | 49.4 | 52.2 | 53.6 | 58.3 | 53.7 | 55.8 | 55.2 | 50.6 |
| Peficitinib 150 mg | 12.9 | 29.5 | 37.3 | 44.2 | 48.5 | 57.5 | 56.0 | 56.1 | 56.8 | 60.5 | 60.8 | 62.9 | 60.5 | 57.3 |
SDAI score consisted of following parameters: TJC (28 joints), SJC (28 joints), SGA, PGA, CRP (mg/dL), and calculated according to description. SDAI = TJC + SJC + SGA + PGA + CRP. SDAI Remission was defined as SDAI score ≤ 3.3. (NCT02305849)
Timeframe: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and EOT
| Intervention | percentage of participants (Number) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 4 | Week 8 | Week 12 | Week 16 | Week 20 | Week 24 | Week 28 | Week 32 | Week 36 | Week 40 | Week 44 | Week 48 | Week 52 | EOT | |
| Peficitinib 100 mg | 1.2 | 3.0 | 7.1 | 14.5 | 18.3 | 20.5 | 22.2 | 25.5 | 24.2 | 31.6 | 27.5 | 25.7 | 30.3 | 28.5 |
| Peficitinib 150 mg | 2.4 | 8.4 | 14.5 | 18.2 | 20.9 | 22.5 | 23.3 | 28.4 | 32.9 | 28.8 | 30.1 | 32.5 | 39.5 | 35.1 |
The Disease Activity Score Based on 28-joints Count based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders: change from baseline >1.2 with DAS28 =< 3.2; moderate responders: change from baseline >1.2 with DAS28 >3.2 to =<5.1 or change from baseline >0.6 to =<1.2 with DAS28 =<5.1; non-responders: change from baseline =< 0.6 or change from baseline >0.6 and =<1.2 with DAS28 >5.1. Percentage of participants with good or moderate response have been reported in this outcome measure. (NCT02305849)
Timeframe: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and EOT
| Intervention | percentage of participants (Number) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 4 | Week 8 | Week 12 | Week 16 | Week 20 | Week 24 | Week 28 | Week 32 | Week 36 | Week 40 | Week 44 | Week 48 | Week 52 | EOT | |
| Peficitinib 100 mg | 55.9 | 72.0 | 75.0 | 80.7 | 82.3 | 87.6 | 88.0 | 90.4 | 94.1 | 92.7 | 96.6 | 94.6 | 93.8 | 86.0 |
| Peficitinib 150 mg | 68.2 | 76.5 | 80.1 | 87.9 | 92.0 | 91.9 | 91.2 | 92.9 | 94.8 | 94.1 | 94.1 | 95.4 | 94.6 | 90.6 |
The Disease Activity Score Based on 28-joints Count based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders: change from baseline >1.2 with DAS28 =< 3.2; moderate responders: change from baseline >1.2 with DAS28 >3.2 to =<5.1 or change from baseline >0.6 to =<1.2 with DAS28 =<5.1; non-responders: change from baseline =< 0.6 or change from baseline >0.6 and =<1.2 with DAS28 >5.1. Percentage of participants with good response have been reported in this outcome measure. (NCT02305849)
Timeframe: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and EOT
| Intervention | percentage of participants (Number) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 4 | Week 8 | Week 12 | Week 16 | Week 20 | Week 24 | Week 28 | Week 32 | Week 36 | Week 40 | Week 44 | Week 48 | Week 52 | EOT | |
| Peficitinib 100 mg | 19.4 | 30.4 | 42.9 | 51.8 | 59.1 | 65.2 | 63.3 | 63.1 | 67.3 | 73.7 | 65.8 | 71.6 | 69.0 | 64.5 |
| Peficitinib 150 mg | 21.8 | 41.0 | 57.2 | 60.0 | 68.1 | 70.0 | 74.2 | 69.0 | 72.9 | 79.1 | 81.0 | 78.1 | 76.9 | 70.8 |
The Disease Activity Score Based on 28-joints Count based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders: change from baseline >1.2 with DAS28 =< 3.2; moderate responders: change from baseline >1.2 with DAS28 >3.2 to =<5.1 or change from baseline >0.6 to =<1.2 with DAS28 =<5.1; non-responders: change from baseline =< 0.6 or change from baseline >0.6 and =<1.2 with DAS28 >5.1. Percentage of participants with good response have been reported in this outcome measure. (NCT02305849)
Timeframe: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and EOT
| Intervention | percentage of participants (Number) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 4 | Week 8 | Week 12 | Week 16 | Week 20 | Week 24 | Week 28 | Week 32 | Week 36 | Week 40 | Week 44 | Week 48 | Week 52 | EOT | |
| Peficitinib 100 mg | 7.6 | 16.1 | 24.4 | 34.3 | 43.3 | 51.6 | 48.1 | 51.0 | 53.6 | 57.6 | 52.4 | 53.7 | 53.8 | 49.4 |
| Peficitinib 150 mg | 12.4 | 28.3 | 35.5 | 43.6 | 46.0 | 55.6 | 54.1 | 54.8 | 54.8 | 58.6 | 59.5 | 60.9 | 59.2 | 56.1 |
The Disease Activity Score Based on 28-joints Count based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders: change from baseline >1.2 with DAS28 =< 3.2; moderate responders: change from baseline >1.2 with DAS28 >3.2 to =<5.1 or change from baseline >0.6 to =<1.2 with DAS28 =<5.1; non-responders: change from baseline =< 0.6 or change from baseline >0.6 and =<1.2 with DAS28 >5.1. Percentage of participants with good or moderate response have been reported in this outcome measure. (NCT02305849)
Timeframe: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and EOT
| Intervention | percentage of participants (Number) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 4 | Week 8 | Week 12 | Week 16 | Week 20 | Week 24 | Week 28 | Week 32 | Week 36 | Week 40 | Week 44 | Week 48 | Week 52 | EOT | |
| Peficitinib 100 mg | 67.1 | 73.8 | 78.6 | 84.3 | 86.6 | 89.4 | 91.1 | 93.0 | 94.8 | 92.8 | 95.3 | 95.3 | 95.2 | 88.4 |
| Peficitinib 150 mg | 77.1 | 80.1 | 85.5 | 89.1 | 91.4 | 95.6 | 93.7 | 94.2 | 95.5 | 96.1 | 94.1 | 97.4 | 94.6 | 92.4 |
ACR20 response:≥ 20% improvement in tender and swollen joint count; and ≥ 20% improvement in at least 3 of the following 5 criteria compared with baseline: 1) physician's global assessment of disease activity, 2) participant's assessment of disease activity, 3) participant's assessment of pain, 4) participant's assessment of functional disability via a health assessment questionnaire, and 5) C-reactive protein at each visit. EOT was defined as end of treatment i.e, either early termination or week 52. (NCT02305849)
Timeframe: Baseline, weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and EOT
| Intervention | percentage of participants (Number) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 4 | Week 8 | Week 12 | Week 16 | Week 20 | Week 24 | Week 28 | Week 32 | Week 36 | Week 40 | Week 44 | Week 48 | Week 52 | EOT | |
| Peficitinib 100 mg | 38.2 | 51.2 | 59.5 | 70.5 | 74.4 | 74.5 | 79.1 | 79.6 | 78.4 | 80.9 | 79.9 | 83.8 | 84.8 | 76.4 |
| Peficitinib 150 mg | 48.2 | 62.0 | 66.3 | 77.0 | 79.8 | 85.0 | 83.0 | 85.2 | 86.5 | 86.9 | 86.9 | 89.4 | 87.1 | 81.0 |
| Placebo / Peficitinib 100 mg at Week 12 | 8.1 | 10.8 | 0.0 | 43.2 | 59.5 | 63.9 | 72.2 | 77.8 | 80.6 | 80.0 | 76.5 | 81.8 | 75.8 | 73.0 |
| Placebo / Peficitinib 100 mg at Week 28 | 38.5 | 33.3 | 51.3 | 64.1 | 61.5 | 59.0 | 64.1 | 84.6 | 78.4 | 88.9 | 88.9 | 85.7 | 91.2 | 92.3 |
| Placebo / Peficitinib 150 mg at Week 12 | 2.7 | 0.0 | 0.0 | 51.4 | 67.6 | 80.6 | 83.3 | 86.1 | 85.7 | 88.2 | 90.9 | 90.9 | 90.9 | 78.9 |
| Placebo / Peficitinib 150 mg at Week 28 | 14.7 | 29.4 | 38.2 | 58.8 | 61.8 | 52.9 | 64.7 | 76.5 | 75.8 | 78.8 | 87.9 | 90.9 | 90.9 | 91.2 |
ACR50 response: ≥50% improvement in tender and swollen joint counts and 50% improvement in 3 of the following 5 criteria compared with baseline: 1) physician's global assessment of disease activity, 2) participant's assessment of disease activity, 3) participant's assessment of pain, 4) participant's assessment of functional ability via a health assessment questionnaire-Disability Index, and 5) C-reactive protein at each visit. (NCT02305849)
Timeframe: Baseline, weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and EOT
| Intervention | percentage of participants (Number) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 4 | Week 8 | Week 12 | Week 16 | Week 20 | Week 24 | Week 28 | Week 32 | Week 36 | Week 40 | Week 44 | Week 48 | Week 52 | EOT | |
| Peficitinib 100 mg | 10.0 | 19.6 | 29.8 | 46.4 | 51.2 | 56.5 | 53.8 | 59.2 | 55.6 | 61.8 | 57.7 | 60.8 | 66.9 | 60.3 |
| Peficitinib 150 mg | 15.9 | 33.1 | 48.2 | 53.9 | 54.6 | 60.6 | 63.5 | 65.8 | 67.7 | 68.0 | 71.2 | 64.9 | 68.0 | 62.6 |
| Placebo / Peficitinib 100 mg at Week 12 | 2.7 | 2.7 | 0.0 | 13.5 | 35.1 | 47.2 | 50.0 | 52.8 | 58.3 | 48.6 | 52.9 | 60.6 | 63.6 | 62.2 |
| Placebo / Peficitinib 100 mg at Week 28 | 10.3 | 12.8 | 23.1 | 38.5 | 35.9 | 33.3 | 28.2 | 56.4 | 64.9 | 66.7 | 72.2 | 71.4 | 67.6 | 69.2 |
| Placebo / Peficitinib 150 mg at Week 12 | 0.0 | 0.0 | 0.0 | 21.6 | 37.8 | 52.8 | 69.4 | 61.1 | 71.4 | 67.6 | 72.7 | 69.7 | 63.6 | 55.3 |
| Placebo / Peficitinib 150 mg at Week 28 | 0.0 | 2.9 | 5.9 | 8.8 | 29.4 | 29.4 | 23.5 | 52.9 | 60.6 | 66.7 | 63.6 | 66.7 | 69.7 | 70.6 |
ACR70 response: ≥ 70% improvement in tender and swollen joint counts and 70% improvement in 3 of the following 5 criteria compared with baseline: 1) physician's global assessment of disease activity, 2) participant's assessment of disease activity, 3) participant's assessment of pain, 4) participant's assessment of functional ability via a health assessment questionnaire-Disability Index, and 5) C-reactive protein at each visit. (NCT02305849)
Timeframe: Baseline, weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and EOT
| Intervention | percentage of participants (Number) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 4 | Week 8 | Week 12 | Week 16 | Week 20 | Week 24 | Week 28 | Week 32 | Week 36 | Week 40 | Week 44 | Week 48 | Week 52 | EOT | |
| Peficitinib 100 mg | 1.2 | 7.7 | 12.5 | 24.1 | 26.2 | 31.7 | 29.1 | 36.3 | 34.0 | 34.9 | 38.3 | 33.8 | 39.3 | 35.1 |
| Peficitinib 150 mg | 4.1 | 13.9 | 24.7 | 32.1 | 35.0 | 36.0 | 42.8 | 43.9 | 47.1 | 41.8 | 48.4 | 49.0 | 52.4 | 48.3 |
| Placebo / Peficitinib 100 mg at Week 12 | 0.0 | 0.0 | 0.0 | 5.4 | 8.1 | 22.2 | 33.3 | 33.3 | 33.3 | 31.4 | 41.2 | 45.5 | 42.4 | 40.5 |
| Placebo / Peficitinib 100 mg at Week 28 | 2.6 | 2.6 | 7.7 | 12.8 | 12.8 | 17.9 | 17.9 | 20.5 | 13.5 | 36.1 | 38.9 | 45.7 | 44.1 | 43.6 |
| Placebo / Peficitinib 150 mg at Week 12 | 0.0 | 0.0 | 0.0 | 2.7 | 2.7 | 16.7 | 38.9 | 44.4 | 42.9 | 38.2 | 36.4 | 42.4 | 48.5 | 42.1 |
| Placebo / Peficitinib 150 mg at Week 28 | 0.0 | 0.0 | 2.9 | 2.9 | 2.9 | 2.9 | 8.8 | 20.6 | 33.3 | 33.3 | 39.4 | 39.4 | 48.5 | 50.0 |
"2-year change in total Sharp/van der Heijde damage score of hands and forefeet radiographs. Range of damage score: 0-448.~score at 24 months minus score at baseline: positive result means increasing/worsening of damage." (NCT02585258)
Timeframe: 0, 24 months
| Intervention | score on a scale (Mean) |
|---|---|
| Prednisolone | 0.3 |
| Placebo | 1.9 |
AESI: (a serious adverse event [SAE], or an AE on a prespecified list of clinically relevant AEs commonly associated with the disease and glucocorticoid use (NCT02585258)
Timeframe: 24 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Prednisolone | 134 |
| Placebo | 111 |
mean of the DAS28 (disease activity score-28 joints) post baseline. Range 0-8, higher scores mean more disease activity. See link in reference list. (NCT02585258)
Timeframe: 0,3,6,12,18,24 months
| Intervention | score on a scale (Mean) | ||||
|---|---|---|---|---|---|
| 3 months | 6 months | 12 months | 18 months | 24 months | |
| Placebo | 3.62 | 3.42 | 3.25 | 3.89 | 3.33 |
| Prednisolone | 3.26 | 3.06 | 2.89 | 3.02 | 2.97 |
Elapsed days between start of corticosteroid taper & first day of flare.Scored using BILAG:A:presence of =>1 serious;B:more moderate;C:mild symptomatic;D:prior activity,no current symptoms;E:organ that has never been involved.Calculated based on change during previous 4 weeks (1=improving,2=staying same,3=worsening,4=new).New SLE flare:first BILAG 'A' or 'B' event adjudicated to be flare following resolution of entry flare and/or start of corticosteroid taper.Inception treatment failure included (entry flare did not subside by Day 57/participant discontinued double-blind period before Day 29). (NCT00119678)
Timeframe: From start of corticosteroid taper to confirmation of disease flare or the end of double-blind period
| Intervention | Days (Median) |
|---|---|
| Abatacept | 107.0 |
| Placebo | 92.0 |
SLE flares scored using BILAG:A:presence of =>1 serious;B:more moderate;C:mild symptomatic;D:prior activity,no current symptoms;E:organ that has never been involved.Calculated based on change during previous 4 weeks (1=improving,2=staying same,3=worsening,4=new).New SLE flare:first BILAG 'A' or 'B' event adjudicated to be flare following resolution of entry flare and/or start of prednisone/prednisone-equivalent taper.Inception treatment failure included (entry flare did not subside by Day 57/participant discontinued double-blind period before Day 29). (NCT00119678)
Timeframe: From start of corticosteroid taper to 6 months.
| Intervention | Participants (Number) |
|---|---|
| Abatacept | 75 |
| Placebo | 36 |
Electrochemiluminescence (ECL) immunoassay based on Meso Scale Discovery (MSD) technology was used to detect antibodies specific for CTLA4-T and for abatacept. (NCT00119678)
Timeframe: From Day 1 to Day 365
| Intervention | participants (Number) |
|---|---|
| Abatacept | 2 |
SLE flares scored using BILAG:A:presence of =>1 serious;B:more moderate;C:mild symptomatic;D:prior activity,no current symptoms;E:organ that has never been involved. Calculated based on change during previous 4 weeks (1=improving,2=staying same,3=worsening,4=new).New SLE flare:first BILAG 'A' or 'B' event adjudicated to be flare following resolution of entry flare and start of prednisone/prednisone-equivalent taper.Inception treatment failure included (entry flare did not subside by Day 57/participant discontinued double-blind period before Day 29). (NCT00119678)
Timeframe: From start of corticosteroid taper to Day 365
| Intervention | Participants (Number) |
|---|---|
| Abatacept | 94 |
| Placebo | 47 |
MSD technology was used to detect antibodies specific for CTLA4-T and for abatacept. (NCT00119678)
Timeframe: After the first dose of open-label period
| Intervention | participants (Number) |
|---|---|
| Abatacept | 30 |
AEs: any new untoward medical occurrences/worsening of pre-existing medical condition, whether or not related to study drug. SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was an overdose. Drug-related AEs: events with a certain; probable; possible; or missing relationship to the study therapy. Participants who discontinued the study due to an AE were recorded. (NCT00119678)
Timeframe: Events recorded at each participant encounter, from start of study drug therapy up to Day 337, including up to 56 days after the last dose or up to the first dose of open-label, whichever occurred earlier
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Deaths | AEs | SAEs | All AEs Leading to Discontinuation | Drug related AEs | |
| Abatacept | 0 | 110 | 24 | 10 | 59 |
| Placebo | 0 | 54 | 4 | 3 | 28 |
SLICC/ACR score or damage index is a measure of cumulative damage due to Systemic Lupus Erythematosus (SLE). Damage is defined as non-reversible change (not related to active inflammation) occurring since onset of lupus, ascertained by clinical assessment and present for at least 6 months. A score of 0=no damage, early damage is defined as ≥1. The total maximum score is 48, and increasing score indicates increasing disease severity. (NCT00119678)
Timeframe: From start of study drug treatment to Day 365
| Intervention | participants (Number) | ||
|---|---|---|---|
| No change | Increased 1 | Increased >1 | |
| Abatacept | 101 | 3 | 3 |
| Placebo | 44 | 2 | 1 |
MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following hematology MA definitions specify the criteria for the data presented. Hemoglobin: >3 g/dL decrease from pre-treatment (pre-Rx) value; hematocrit: <0.75* pre-Rx value; erythrocyte count: <0.75* pre-Rx value; platelet count: <0.67* LLN or >1.5* ULN (or, if pre-Rx value
Timeframe: Events recorded at each participant encounter, from start of study drug therapy up to Day 337, including up to 56 days after the last dose or up to the first dose of open-label, whichever occurred earlier
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Hemoglobin (n = 120, 58) | Hematocrit (n=120, 58) | Erythrocytes (n=120, 58) | Platelet count (n= 118, 58) | |
| Abatacept | 1 | 1 | 1 | 3 |
| Placebo | 1 | 1 | 1 | 0 |
MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following hematology MA definitions specify the criteria for the data presented. Leukocytes: <0.75* LLN or >1.25* ULN (or, if pre-Rx value
Timeframe: Events recorded at each participant encounter, from start of study drug therapy up to Day 337, including up to 56 days after the last dose or up to the first dose of open-label, whichever occurred earlier
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| Leukocytes (n = 120, 58) | Neutrophils+bands (absolute) (n = 120, 59) | Lymphocytes (absolute) (n = 120, 59) | Monocytes (absolute) (n = 120, 59) | Basophils (absolute) (n = 120, 59) | Eosinophils (absolute) (n = 120, 59) | |
| Abatacept | 26 | 8 | 46 | 1 | 0 | 6 |
| Placebo | 11 | 2 | 30 | 0 | 0 | 2 |
MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following serum chemistry MA definitions specify MA criteria, Glucose: <65 mg/dl or >220 mg/dl; Glucose (fasting serum): <0.8* LLN or >1.5 ULN (if pre-Rx
Timeframe: Events recorded at each participant encounter, from start of study drug therapy up to Day 337, including up to 56 days after the last dose or up to the first dose of open-label, whichever occurred earlier
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| Glucose (serum) (n = 120, 59) | Glucose, fasting (n = 77, 37) | Albumin (n = 120, 59) | Cholesterol (total) (n = 118, 58) | Triglycerides (n = 75, 36) | Triglycerides (fasting) (n = 64, 34) | |
| Abatacept | 27 | 5 | 4 | 0 | 0 | 0 |
| Placebo | 10 | 1 | 1 | 0 | 0 | 0 |
MAs are laboratory measurements marked as abnormal as per pre-defined study criteria, at any study time point. The following serum chemistry MA definitions specify MA criteria, Sodium (serum): <0.95* LLN or >1.05* ULN (if pre-Rx
Timeframe: Events recorded at each participant encounter, from start of study drug therapy up to Day 337, including up to 56 days after the last dose or up to the first dose of open-label, whichever occurred earlier
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Sodium (serum) (n = 120, 59) | Potassium (serum) (n = 120, 59) | Chloride (serum) (n = 120, 59) | Calcium (total) (n= 120, 59) | Protein (total) (n = 120, 59) | |
| Abatacept | 1 | 1 | 0 | 0 | 1 |
| Placebo | 0 | 1 | 0 | 0 | 0 |
MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following definitions specify the criteria for MAs in urinalysis, Protein, glucose, blood, Leukocyte esterase, RBC, WBC: >=2+ (or, if value >=4, or if pre-Rx value = 0 or 0.5, then >= 2* pre-Rx, or if pre-Rx value =1, then >=3, or if pre-Rx = 2 or 3, then >=4); protein (24 hour urine): >1000 mg/24 hrs and >=2* pre-Rx; GFR: <=60 mL/min/1.73m^2 or > 15% change from baseline; Protein/creatinine ratio: > 100 mg/mmol. (NCT00119678)
Timeframe: Events recorded at each participant encounter, from start of study drug therapy up to Day 337, including up to 56 days after the last dose or up to the first dose of open-label, whichever occurred earlier
| Intervention | participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Protein (n = 120, 58) | Glucose (n = 120, 58) | Blood (n = 120, 58) | Leukocyte esterase (n = 107, 51) | RBC (n = 107, 55) | WBC (n = 115, 54) | Protein, 24 hours (n = 89, 40) | GFR (n = 120, 59) | Protein/creatinine ratio (n = 119, 58) | |
| Abatacept | 15 | 1 | 39 | 23 | 38 | 61 | 4 | 7 | 11 |
| Placebo | 9 | 2 | 18 | 8 | 16 | 26 | 1 | 4 | 4 |
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition (even if not caused by the study drug). For this study, AEs of special interest were associated with the use of immunomodulatory agents. Number of participants with infections, malignant neoplasms, pre-specified autoimmune disorders, acute infusional AEs and peri-infusional AEs were recorded. (NCT00119678)
Timeframe: Events recorded at each participant encounter, from start of study drug therapy up to Day 337, including up to 56 days after the last dose or up to the first dose of open-label, whichever occurred earlier
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Infections | Malignant neoplasms | Pre-specified autoimmune disorders | Acute-infusional AEs | Peri-infusional AEs | |
| Abatacept | 71 | 1 | 4 | 5 | 27 |
| Placebo | 38 | 0 | 2 | 5 | 13 |
SLE flares scored using BILAG:A:presence of =>1 serious;B:more moderate;C:mild symptomatic;D:prior activity,no current symptoms;E:organ that has never been involved.Calculated based on change during previous 4 weeks (1=improving,2=staying same,3=worsening,4=new).New SLE flare:BILAG 'A' or 'B' event adjudicated to be flare following resolution of entry flare and/or start of prednisone/prednisone-equivalent taper.Inception treatment failure included (entry flare did not subside by Day 57/participant discontinued double-blind period before Day 29). (NCT00119678)
Timeframe: From start of corticosteroid taper to Day 365
| Intervention | Participants (Number) | ||||
|---|---|---|---|---|---|
| None | 1 | 2 | >=3 | Inception treatment failure | |
| Abatacept | 24 | 47 | 21 | 17 | 9 |
| Placebo | 10 | 21 | 10 | 11 | 5 |
MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following serum chemistry MA definitions specify MA criteria. ALP, GGT: >2* ULN (if pre-Rx >ULN, then >3* pre-Rx); AST, ALT: >3* ULN (if pre-Rx >ULN, then >4* pre-Rx). Bilirubin (total): >2* ULN (if pre-Rx >ULN, then >4* pre-Rx), BUN:>2* pre-Rx; Creatinine:>1.5* pre-Rx. (NCT00119678)
Timeframe: Events recorded at each participant encounter, from start of study drug therapy up to Day 337, including up to 56 days after the last dose or up to the first dose of open-label, whichever occurred earlier
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| ALP (n = 120, 59) | AST (n = 120, 59) | ALT (n = 120, 59) | GGT (n = 120, 59) | Bilirubin (total) (n = 120, 59) | BUN (n = 120, 59) | Creatinine (n = 120, 59) | |
| Abatacept | 2 | 3 | 2 | 3 | 0 | 4 | 6 |
| Placebo | 0 | 0 | 0 | 3 | 0 | 3 | 4 |
MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following hematology MA definitions specify the criteria for the data presented. Hemoglobin: >3 g/dL decrease from pre-treatment (pre-Rx) value; hematocrit: <0.75* pre-Rx value; erythrocyte count: <0.75* pre-Rx value; platelet count: <0.67* lower limit of normal (LLN) or >1.5* upper limit of normal (ULN) (or, if pre-Rx value
Timeframe: From start of study drug therapy in open-label period (Day 365) up to 56 days after the last dose of open-label period
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Hemoglobin (n = 110) | Hematocrit (n = 110) | Erythrocytes (n = 110) | Platelet count (n = 108) | |
| Abatacept | 2 | 3 | 2 | 3 |
MMAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following hematology MA definitions specify the criteria for the data presented. Leukocytes: <0.75* LLN or >1.25* ULN (or, if pre-Rx value
Timeframe: From start of study drug therapy in open-label period (Day 365) up to 56 days after the last dose of open-label period
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| Leukocytes | Neutrophils+bands (absolute) | Lymphocytes (absolute) | Monocytes (absolute) | Basophils (absolute) | Eosinophils (absolute) | |
| Abatacept | 18 | 6 | 32 | 0 | 0 | 3 |
MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following serum chemistry MA definitions specify MA criteria. ALP, GGT: >2* ULN (if pre-Rx >ULN, then >3* pre-Rx); AST, ALT: >3* ULN (if pre-Rx >ULN, then >4* pre-Rx). Bilirubin (total): >2* ULN (if pre-Rx >ULN, then >4* pre-Rx), BUN:>2* pre-Rx; Creatinine:>1.5* pre-Rx. (NCT00119678)
Timeframe: From start of study drug therapy in open-label period (Day 365) up to 56 days after the last dose of open-label period
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| ALP | AST | ALT | GGT | Bilirubin (total) | BUN | Creatinine | |
| Abatacept | 0 | 3 | 4 | 6 | 0 | 3 | 7 |
MAs are laboratory measurements marked as abnormal, as per pre-defined study criteria, at any study time point. The following serum chemistry MA definitions specify MA criteria, Glucose: <65 mg/dL or >220 mg/dL; Glucose (fasting serum): <0.8* LLN or >1.5 ULN (if pre-Rx
Timeframe: From start of study drug therapy in open-label period (Day 365) up to 56 days after the last dose of open-label period
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| Glucose (serum) (n = 110) | Glucose (fasting serum) (n = 55) | Albumin (n = 110) | Cholesterol (total) (n = 15) | Triglycerides (n = 10) | Triglycerides (fasting) (n = 9) | |
| Abatacept | 21 | 6 | 6 | 0 | 0 | 0 |
MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following serum chemistry MA definitions specify MA criteria, Sodium (serum): <0.95x LLN or >1.05x ULN (if pre-Rx
Timeframe: From start of study drug therapy in open-label period (Day 365) up to 56 days after the last dose of open-label period
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Sodium (serum) | Potassium (serum) | Chloride (serum) | Calcium (total) | Protein (total) | |
| Abatacept | 0 | 7 | 0 | 1 | 4 |
MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following definitions specify the criteria for MAs in urinalysis, Protein, glucose, blood, Leukocyte esterase, red blood cells (RBC), white blood cells (WBC): >=2+ (or, if value >=4, or if pre-Rx value = 0 or 0.5, then >= 2* or if pre-Rx value =1, then >=3, or if pre-Rx = 2 or 3, then >=4); protein (24 hour urine): >1000 mg/24 hrs and >=2* pre-Rx; Glomerular filtration rate (GFR): <=60 mL/min/1.73m^2 or > 15% change from baseline; Protein/creatinine ratio: > 100 mg/mmol. (NCT00119678)
Timeframe: From start of study drug therapy in open-label period (Day 365) up to 56 days after the last dose of open-label period
| Intervention | participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Protein (n = 110) | Glucose (n= 110) | Blood (n = 110) | Leukocyte esterase (n = 104) | WBC (n = 105) | RBC (n = 101) | GFR (n = 110) | Protein/creatinine ratio (n = 109) | |
| Abatacept | 12 | 0 | 41 | 28 | 57 | 35 | 9 | 10 |
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition (even if not caused by the study drug). For this study, it was decided that AEs of particular importance were associated with the use of immunomodulatory agents. Number of participants with infections, malignant Neoplasms, pre-specified autoimmune disorders, acute-infusional AEs and peri-infusional AEs were recorded. (NCT00119678)
Timeframe: From start of study drug therapy in open-label period (Day 365) up to 56 days after the last dose of open-label period
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Infections | Malignant neoplasms | Pre-specified autoimmune disorders | Acute-infusional AEs | Peri-infusional AEs | |
| Abatacept | 82 | 1 | 4 | 3 | 15 |
AEs: any new untoward medical occurrences/worsening of pre-existing medical condition, whether or not related to study drug. SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was an overdose. Participants who discontinued the study due to an AE were recorded. Drug-related AEs or SAEs: events with a relationship to the study therapy of certain; probable; possible; or missing. (NCT00119678)
Timeframe: From start of study drug therapy in open-label period (Day 365) up to 56 days after the last dose of open-label period
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| Deaths | AEs | SAEs | All AEs Leading to Discontinuation | Drug related AEs | Drug related SAEs | |
| Abatacept | 1 | 97 | 21 | 3 | 49 | 11 |
Peripheral blood B cell number at week 24 compared to B cell number at week 0 (NCT00286325)
Timeframe: Week 0 and at 24 weeks
| Intervention | B cells per microliter (Median) |
|---|---|
| Treated | 3.99 |
IgG antibodies against BP 180 measured in units (by ELISA) for each participant at week 0 compared to value at week 24, (NCT00286325)
Timeframe: Week 0 and at 24 weeks
| Intervention | Elisa Units (Median) |
|---|---|
| Treated | 40.5 |
The first study visit in which patient reported and was confirmed to have no new blister or lesion formation . (NCT00286325)
Timeframe: 1 year
| Intervention | Days (Median) |
|---|---|
| Treated | 57 |
Subject systemic corticosteroid dosage at week 24 was 25% of starting dose or 10 mg/day of prednisone or less (NCT00286325)
Timeframe: 24 weeks
| Intervention | participants (Number) |
|---|---|
| Treated | 7 |
The primary safety endpoint is the occurrence of treatment emergent adverse events including infections, infusion reactions and disease progression. These were determined by clinical evaluation and laboratory questions. Disease progression is defined as development of new blisters despite therapy. These are reported as the number of participants with a study related SAE. (NCT00286325)
Timeframe: 1 year
| Intervention | participants (Number) | ||
|---|---|---|---|
| Treatment emergent adverse events | Infusion reactions | Disease Progression | |
| Treated | 0 | 0 | 1 |
"Number of patients with a change of > 0.22 in the Health Assessment Questionnaire (HAQ) score over the period between baseline and week 104.~A change of > 0.22 in this score is considered as clinical relevant for rheumatoid arthritis patients." (NCT01172639)
Timeframe: Baseline-week104
| Intervention | Participants (Count of Participants) |
|---|---|
| CoBRA Classic High Risk Group | 71 |
| CoBRA Slim High Risk Group | 62 |
| CoBRA Avant-garde High Risk Group | 64 |
| CoBRA Slim Low Risk Group | 25 |
| Tight Step Up Low Risk Group | 26 |
"Number of patients in remission according to DAS28-CRP (Disease Activity Score based on 28 joint count and C-reactive Protein) at week 104. (co-primary endpoints)~DAS28-CRP is calculated with the following formula : 0.56*SQRT TJC28+0.28*SQRT SJC28+0.36*ln (CRP+1)+0.014*GH+0.96 in which TJC is the tender joint count, SJC the Swollen Joint Count and GH the general health estimated by the patient on a Visual Analogue Scale (VAS).~A value below 2.6 is indicating remission, below or equal to 3.2 low disease activity, between 3.2 and 5.1 moderate disease activity and above 5.1 high disease activity." (NCT01172639)
Timeframe: week 104
| Intervention | Participants (Count of Participants) |
|---|---|
| CoBRA Classic High Risk Group | 64 |
| CoBRA Slim High Risk Group | 71 |
| CoBRA Avant-garde High Risk Group | 69 |
| CoBRA Slim Low Risk Group | 29 |
| Tight Step Up Low Risk Group | 34 |
"Number of patients in remission according to DAS28-CRP (Disease Activity Score based on 28 joint count and C-reactive Protein) at week 16.~DAS28-CRP is calculated with the following formula : 0.56*SQRT TJC28+0.28*SQRT SJC28+0.36*ln (CRP+1)+0.014*GH+0.96 in which TJC is the tender joint count, SJC the Swollen Joint Count and GH the general health estimated by the patient on a Visual Analogue Scale (VAS).~A value below 2.6 is indicating remission, below or equal to 3.2 low disease activity, between 3.2 and 5.1 moderate disease activity and above 5.1 high disease activity." (NCT01172639)
Timeframe: week 16
| Intervention | Participants (Count of Participants) |
|---|---|
| CoBRA Classic High Risk Group | 69 |
| CoBRA Slim High Risk Group | 72 |
| CoBRA Avant-garde High Risk Group | 61 |
| CoBRA Slim Low Risk Group | 25 |
| Tight Step Up Low Risk Group | 23 |
"Number of patients in remission according to DAS28-CRP (Disease Activity Score based on 28 joint count and C-reactive Protein) at week 52. (co-primary end point)~DAS28-CRP is calculated with the following formula : 0.56*SQRT TJC28+0.28*SQRT SJC28+0.36*ln (CRP+1)+0.014*GH+0.96 in which TJC is the tender joint count, SJC the Swollen Joint Count and GH the general health estimated by the patient on a Visual Analogue Scale (VAS).~A value below 2.6 is indicating remission, below or equal to 3.2 low disease activity, between 3.2 and 5.1 moderate disease activity and above 5.1 high disease activity." (NCT01172639)
Timeframe: week 52
| Intervention | Participants (Count of Participants) |
|---|---|
| CoBRA Classic High Risk Group | 63 |
| CoBRA Slim High Risk Group | 57 |
| CoBRA Avant-garde High Risk Group | 57 |
| CoBRA Slim Low Risk Group | 29 |
| Tight Step Up Low Risk Group | 29 |
"Number of patients in remission according to SDAI (Simplified Disease Activity Index) at week 16.~SDAI is calculated with the following formula : TJC28+SJC28+GH+GA ph in which TJC is the number of tender joints, SJC the number of Swollen Joint and GH the general health assessed by the patient on a Visual Analogue Scale (VAS) and GA ph the general assessment of the physician on a VAS.~A value below 3.3 is indicating remission, between 3.4 and 11.0 low disease activity, between 11.1 and 26.0 moderate disease activity and above 26.0 high disease activity." (NCT01172639)
Timeframe: week 16
| Intervention | Participants (Count of Participants) |
|---|---|
| CoBRA Classic High Risk Group | 42 |
| CoBRA Slim High Risk Group | 33 |
| CoBRA Avant-garde High Risk Group | 44 |
| CoBRA Slim Low Risk Group | 12 |
| Tight Step Up Low Risk Group | 12 |
"Number of patients in remission according to SDAI (Simplified Disease Activity Index) at week 104.~SDAI is calculated with the following formula : TJC28+SJC28+GH+GA ph in which TJC is the number of tender joints, SJC the number of Swollen Joint and GH the general health assessed by the patient on a Visual Analogue Scale (VAS) and GA ph the general assessment of the physician on a VAS.~A value below 3.3 is indicating remission, between 3.4 and 11.0 low disease activity, between 11.1 and 26.0 moderate disease activity and above 26.0 high disease activity." (NCT01172639)
Timeframe: week 104
| Intervention | Participants (Count of Participants) |
|---|---|
| CoBRA Classic High Risk Group | 31 |
| CoBRA Slim High Risk Group | 28 |
| CoBRA Avant-garde High Risk Group | 41 |
| CoBRA Slim Low Risk Group | 20 |
| Tight Step Up Low Risk Group | 13 |
"Number of patients in remission according to SDAI (Simplified Disease Activity Index) at week 52.~SDAI is calculated with the following formula : TJC28+SJC28+GH+GA ph in which TJC is the number of tender joints, SJC the number of Swollen Joint and GH the general health assessed by the patient on a Visual Analogue Scale (VAS) and GA ph the general assessment of the physician on a VAS.~A value below 3.3 is indicating remission, between 3.4 and 11.0 low disease activity, between 11.1 and 26.0 moderate disease activity and above 26.0 high disease activity." (NCT01172639)
Timeframe: week 52
| Intervention | Participants (Count of Participants) |
|---|---|
| CoBRA Classic High Risk Group | 36 |
| CoBRA Slim High Risk Group | 27 |
| CoBRA Avant-garde High Risk Group | 39 |
| CoBRA Slim Low Risk Group | 20 |
| Tight Step Up Low Risk Group | 15 |
BMD was measured at the lumbosacral spine antero-posterior and at the femoral neck using a densitometer. A positive change from Baseline (increased bone density) indicates improvement. (NCT01400516)
Timeframe: Baseline and Month 12
| Intervention | grams/centimeters squared (g/cm^2) (Mean) | |||
|---|---|---|---|---|
| Spine, Baseline | Spine, Change from Baseline at Month12 | Femoral neck, Baseline | Femoral neck, Change from Baseline at Month 12 | |
| Control Arm | 0.93 | -0.002 | 0.73 | -0.03 |
| Teriparatide | 0.91 | 0.06 | 0.68 | 0.03 |
The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) [28 joints], swollen joint count (SJC) [28 joints], patient's global assessment of disease activity [visual analog scale: 0=no disease activity to 100=maximum disease activity] and C-Reactive Protein (CRP) for a total possible score of 2 to 10. Higher values indicate higher disease activity. A negative change from baseline indicates improvement. (NCT01400516)
Timeframe: Baseline and Month 12
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Baseline | Change from Baseline at Month 12 | |
| Control Arm | 2.73 | -0.50 |
| Teriparatide | 2.66 | 0.42 |
Both hands were scanned using a CT scanner. A semi-automated software tool was used to segment the erosion margins in 3D. A board certified radiologist identified the individual erosions in six sub-regions: radius, ulna, proximal carpals, distal carpals, metacarpophalangeal (MCP) joints and proximal interphalangeal (PIP) joints. The average total in a single hand/wrist was calculated. A negative change from Baseline(less joint erosions) indicates improvement. (NCT01400516)
Timeframe: Baseline and Month 12
| Intervention | cubic millimeter (mm^3) (Median) | |
|---|---|---|
| Baseline | Change from Baseline at Month 12 | |
| Control Arm | 571.4 | 9.1 |
| Teriparatide | 369.8 | -0.4 |
89 reviews available for prednisolone and Rheumatoid Arthritis
| Article | Year |
|---|---|
A pooled analysis of serious infections and herpes zoster-related disease in Asian patients with rheumatoid arthritis treated with peficitinib (ASP015K) over a median of 3 years.
Topics: Adamantane; Antirheumatic Agents; Arthritis, Rheumatoid; Herpes Zoster; Humans; Niacinamide; Prednis | 2022 |
The safety of glucocorticoids in the treatment of inflammatory rheumatic disease: new evidence.
Topics: Arthritis, Rheumatoid; Glucocorticoids; Humans; Prednisolone | 2022 |
Anti-cyclic citrullinated peptide antibody in the cerebrospinal fluid in patients with rheumatoid arthritis who have central nervous system involvement.
Topics: Administration, Oral; Anti-Citrullinated Protein Antibodies; Arthritis, Rheumatoid; Biomarkers; Brai | 2020 |
[Safety aspects of the treatment with glucocorticoids for rheumatoid arthritis].
Topics: Arthritis, Rheumatoid; Comorbidity; Glucocorticoids; Humans; Osteoporosis; Prednisolone | 2021 |
C reactive protein may not be reliable as a marker of severe bacterial infection in patients receiving tocilizumab.
Topics: Aged; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Inf | 2013 |
Safety of low- to medium-dose glucocorticoid treatment in rheumatoid arthritis: myths and reality over the years.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Bone Density; Glucocorticoids; Humans; Observational St | 2014 |
Glucocorticoid treatment in rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Therapy, Combination; Glucoco | 2014 |
[Diagnosis and treatment of rheumatoid arthritis].
Topics: Adalimumab; Adult; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; B | 2014 |
Ascites and other incidental findings revealing undiagnosed systemic rheumatoid arthritis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Ascites | 2015 |
Allergic bronchopulmonary aspergillosis in a patient with rheumatoid arthritis under adalimumab therapy: a case report.
Topics: Adalimumab; Aged; Antifungal Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Aspergillosis, All | 2016 |
[Prevention of surgical site infection for orthopaedic surgery in rheumatoid arthritis].
Topics: Abatacept; Antibiotic Prophylaxis; Antibodies, Monoclonal, Humanized; Arthritis, Rheumatoid; Arthrop | 2016 |
[Pregnancy and lactation in rheumatoid arthritis].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Pro | 2016 |
The BeSt story: on strategy trials in rheumatoid arthritis.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Clinical T | 2009 |
Safety of medium- to long-term glucocorticoid therapy in rheumatoid arthritis: a meta-analysis.
Topics: Arthritis, Rheumatoid; Glucocorticoids; Humans; Odds Ratio; Prednisolone; Randomized Controlled Tria | 2009 |
[Rheumatoid arthritis].
Topics: Adult; Antirheumatic Agents; Arthralgia; Arthritis, Rheumatoid; C-Reactive Protein; Diagnosis, Diffe | 2009 |
Leg ulceration in rheumatoid arthritis--an underreported multicausal complication with considerable morbidity: analysis of thirty-six patients and review of the literature.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Arthritis, Rheumatoid; Etoricoxib; Female; Gram-Posi | 2010 |
New-onset psoriasis associated with etanercept therapy.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Etanercept; Humans; Immunoglobulin G; Isoxazoles | 2010 |
Posterior interosseous nerve palsy: an unusual complication of rheumatoid arthritis: case report and review of the literature.
Topics: Arthritis, Rheumatoid; Databases, Bibliographic; Elbow Joint; Glucocorticoids; Humans; Magnetic Reso | 2011 |
Infections and biologic therapy in rheumatoid arthritis: our changing understanding of risk and prevention.
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Biological Therapy; Humans; Opportunistic Infection | 2012 |
Meta-analysis suggests that intensive non-biological combination therapy with step-down prednisolone (COBRA strategy) may also 'disconnect' disease activity and damage in rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Therapy, Combination; Humans; | 2013 |
Involvement of the glucocorticoid receptor in the pathogenesis of rheumatoid arthritis.
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Autoimmune Diseases; Down-Regulation; Gene Expressi | 2002 |
Short-term low-dose corticosteroids vs placebo and nonsteroidal antiinflammatory drugs in rheumatoid arthritis.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Humans; In | 2003 |
[Current concepts of pharmacotherapy in rheumatoid arthritis].
Topics: Adult; Aged; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents | 2003 |
[TREATMENT OF KIDNEY DISEASES, CARDIAC AND VASCULAR DISORDERS AS WELL AS COLLAGENOSES WITH CORTISONES].
Topics: Adams-Stokes Syndrome; Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Arthritis, Rheumatoid; | 1964 |
[Measures for tuberculosis in compromised hosts--mainly on chemoprophylaxis].
Topics: Antibiotic Prophylaxis; Antitubercular Agents; Arthritis, Rheumatoid; Collagen Diseases; Crohn Disea | 2003 |
Newer approaches to the treatment of rheumatoid arthritis.
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthrit | 2003 |
[Glucocorticoid-induced osteoporosis in patients with rheumatoid arthritis and collagen diseases].
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Bone Resorption; Collagen Disea | 2004 |
[Collagen diseases and rheumatic diseases].
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Autoimmunity; Drug Therapy, Com | 2004 |
Short-term low-dose corticosteroids vs placebo and nonsteroidal antiinflammatory drugs in rheumatoid arthritis.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Humans; In | 2004 |
[Collagen diseases with opportunistic infections].
Topics: Adult; Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheu | 2004 |
[A case of rheumatoid arthritis/Sjogren's syndrome with acute renal failure due to hyperuricemia associated with mizoribine therapy].
Topics: Acute Kidney Injury; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Drug Therapy, C | 2004 |
[SIADH caused by elevated IL-6 in an elderly patient with rheumatoid arthritis].
Topics: Aged; Anti-Bacterial Agents; Arthritis, Rheumatoid; Consciousness Disorders; Female; Humans; Hyponat | 2004 |
[Secondary amyloidosis associated with rheumatoid arthritis (RA)].
Topics: Amyloidosis; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Diet, Protein-Rest | 2005 |
[Guidelines for RA therapies].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rh | 2005 |
[Corticosteroids for treatment of rheumatoid arthritis].
Topics: Arthritis, Rheumatoid; Drug Resistance; Femur Head Necrosis; Glucocorticoids; Humans; Methylpredniso | 2005 |
[Combination drug therapy in rheumatoid arthritis].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rh | 2005 |
[Adverse effects of corticosteroids in treatment of rheumatoid arthritis].
Topics: Adrenal Cortex Hormones; Adrenal Insufficiency; Arthritis, Rheumatoid; Communicable Diseases; Fractu | 2005 |
[Malignant rheumatoid arthritis].
Topics: Arthritis, Rheumatoid; Azathioprine; Cyclophosphamide; HLA-DR Antigens; HLA-DRB1 Chains; Humans; Imm | 2005 |
Necrotizing fasciitis in rheumatic diseases.
Topics: Adult; Aeromonas; Animals; Anti-Bacterial Agents; Arthritis, Infectious; Arthritis, Rheumatoid; Arth | 2006 |
Optic neuritis occurring with anti-tumour necrosis factor alpha therapy.
Topics: Adalimumab; Adolescent; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheuma | 2007 |
[Rheumatoid arthritis in the dog].
Topics: Animals; Arthritis, Rheumatoid; Aspirin; Azathioprine; Cyclophosphamide; Dog Diseases; Dogs; Drug Th | 1983 |
[Development of new steroid preparations and their clinical applications].
Topics: Administration, Topical; Aerosols; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Asthma; Beclomet | 1984 |
[Osteoporosis in collagen diseases].
Topics: Arthritis, Rheumatoid; Bone and Bones; Fractures, Stress; Humans; Osteoporosis; Prednisolone | 1994 |
[Should long-term corticosteroid treatment be given in rheumatoid arthritis?].
Topics: Arthritis, Rheumatoid; Glucocorticoids; Humans; Long-Term Care; Prednisolone; Prednisone | 1993 |
[Emergency therapy of collagen diseases and their complications].
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Collagen Diseases; Drug Administration Schedule; Em | 1995 |
[A case of rheumatoid arthritis associated with multiple myeloma].
Topics: Aged; Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Arthritis, Rheumatoid; Female; Hu | 1996 |
Low dose corticosteroids in early rheumatoid arthritis. Can these drugs slow disease progression?
Topics: Arthritis, Rheumatoid; Clinical Trials as Topic; Disease Progression; Glucocorticoids; Humans; Multi | 1996 |
Hypothalamic-pituitary-adrenal-glucocorticoid axis function in rheumatoid arthritis.
Topics: Adrenocorticotropic Hormone; Animals; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Glucocorticoi | 1996 |
Corticosteroid resistance in other disease states and tissues.
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Asthma; Drug Resistance; Glucocorticoids; Graft Rej | 1996 |
[Rheumatoid arthritis and multiple myeloma--the risk of a combination of the 2 diseases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arthritis, Rheumatoid; Cyclophosphamide; Dexam | 1997 |
Benefits of low-dose corticosteroids in rheumatoid arthritis.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; A | 1997 |
[Conversion of chronic necrotizing pulmonary aspergillosis to invasive pulmonary aspergillosis, and successful treatment with fluconazole].
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antifungal Agents; Arthritis, Rheumatoid; Aspergi | 1997 |
Meta-analysis of short-term low dose prednisolone versus placebo and non-steroidal anti-inflammatory drugs in rheumatoid arthritis.
Topics: Administration, Oral; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, | 1998 |
Glucocorticosteroids in the management of rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Ro | 1999 |
[Interferon-alpha-associated polyarthritis. Possible induction of seropositive rheumatoid arthritis by interferon-alpha: two case reports and review of the literature].
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Arthritis, Rheumatoid; Female; Humans; Injections, | 1999 |
Rheumatoid arthritis: new developments in the use of existing therapies.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Hydroxychloroquine; | 1999 |
Short-term low-dose corticosteroids vs placebo and nonsteroidal antiinflammatory drugs in rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Glucocorticoids; Humans; Prednisolon | 2000 |
Effects of long-term glucocorticoid therapy in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Glucocorticoids; Humans; Joints; Long-Term Care; Prednisolone; Randomized Con | 2000 |
[Listeria arthritis in chronic polyarthritis during low dose prednisolone and methotrexate therapy. Case report and review of the literature].
Topics: Aged; Arthritis, Infectious; Arthritis, Rheumatoid; Arthroscopy; Diagnosis, Differential; Dose-Respo | 2001 |
[Immunologic pleuritis].
Topics: Arthritis, Rheumatoid; Autoimmune Diseases; Diagnosis, Differential; Humans; Lupus Erythematosus, Sy | 2000 |
[Malignant rheumatoid arthritis].
Topics: Antigen-Antibody Complex; Arthritis, Rheumatoid; Diagnosis, Differential; Humans; Immunosuppressive | 2000 |
Short-term low-dose corticosteroids vs placebo and nonsteroidal antiinflammatory drugs in rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Glucocorticoids; Humans; Prednisolon | 2001 |
[Use of glucocorticoids in rheumatoid arthritis. Inhibition of disease progression versus risk of steroid osteoporosis].
Topics: Arthritis, Rheumatoid; Clinical Trials as Topic; Disease Progression; Dose-Response Relationship, Dr | 2001 |
Short-term low-dose corticosteroids vs placebo and nonsteroidal antiinflammatory drugs in rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Glucocorticoids; Humans; Prednisolon | 2002 |
[Indications and limits of glucocorticoid therapy in collagen disease (author's transl)].
Topics: Antibodies, Antinuclear; Arthritis, Rheumatoid; Female; gamma-Globulins; Humans; Lupus Erythematosus | 1979 |
Thermography and rheumatic diseases.
Topics: Adrenocorticotropic Hormone; Arthritis; Arthritis, Juvenile; Arthritis, Rheumatoid; Body Temperature | 1975 |
[Cortisonoids in the therapy of rheumatic diseases].
Topics: Adrenal Cortex Hormones; Arthritis, Rheumatoid; Betamethasone; Chemical Phenomena; Chemistry; Dexame | 1977 |
Steroid therapy.
Topics: Adrenal Cortex Hormones; Animals; Arthritis, Rheumatoid; Drug Hypersensitivity; Gastrointestinal Dis | 1976 |
[Current concept of the management of rheumatoid arthritis based on the pathogenesis].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Azathioprine; Cyclophosphamide; Drug | 1992 |
[Glucocorticoids].
Topics: Arthritis, Rheumatoid; Betamethasone; Glucocorticoids; Humans; Methylprednisolone; Prednisolone | 1992 |
[A case of rheumatoid arthritis associated with polyneuritis].
Topics: Arthritis, Rheumatoid; Female; Humans; Immunoglobulin G; Middle Aged; Polyneuropathies; Prednisolone | 1989 |
[A case of rheumatoid arthritis with interstitial pneumonitis followed by polymyositis].
Topics: Arthritis, Rheumatoid; Female; Humans; Middle Aged; Myositis; Prednisolone; Pulmonary Fibrosis | 1989 |
[Rheumatoid pericarditis, an unusual complication of rheumatoid disease: apropos of a clinical case].
Topics: Arthritis, Rheumatoid; Female; Humans; Middle Aged; Pericarditis; Pleural Effusion; Prednisolone | 1988 |
[Drug therapy in rheumatoid arthritis].
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Drug Admin | 1988 |
Treatment of severe rheumatoid arthritis.
Topics: Aged; Arthritis, Rheumatoid; Azathioprine; Chlorambucil; Cyclophosphamide; Drainage; Humans; Immunos | 1986 |
[Use of cortisol and its derivatives in clinic practice].
Topics: Adrenal Cortex Hormones; Adrenal Insufficiency; Adrenocorticotropic Hormone; Arthritis, Rheumatoid; | 1967 |
An attempt at combining corticotrophin with long-term corticosteroid therapy. With a view to preserving hypothalmic-pituitary-adrenal function.
Topics: Adolescent; Adrenal Glands; Adrenocorticotropic Hormone; Adult; Aged; Arthritis, Rheumatoid; Blood G | 1970 |
[Effect of some antirheumatic agents on the gastric mucous membrane].
Topics: Adrenocorticotropic Hormone; Aged; Aminopyrine; Animals; Anti-Inflammatory Agents; Arthritis, Rheuma | 1971 |
Corticosteroid therapy for rheumatoid arthritis.
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Arthritis, Rheumatoid; Atrophy; Betamethasone; | 1973 |
Therapy of rheumatoid arthritis. A pyramidal plan.
Topics: Arthritis, Rheumatoid; Chloroquine; Cyclophosphamide; Glucocorticoids; Gold; Hospitalization; Hot Te | 1972 |
Immunosuppressive therapy. 1.
Topics: Alkylating Agents; Anemia, Hemolytic, Autoimmune; Antibodies; Antimetabolites; Arthritis, Rheumatoid | 1972 |
[Pathologic changes in the cardiovascular system during treatment with glucocorticoid hormones].
Topics: Animals; Arteriosclerosis; Arthritis, Rheumatoid; Asparagine; Biological Transport, Active; Calcium; | 1972 |
The rheumatic diseases in adolescence.
Topics: Adolescent; Adult; Antimalarials; Arthritis, Rheumatoid; Child; Child, Preschool; Dermatomyositis; D | 1973 |
[Corticosteroid therapy in modern medicine (on the 25th anniversary of the first application of cortisone)].
Topics: Adrenal Cortex Hormones; Arthritis, Rheumatoid; Asthma; Collagen Diseases; Cortisone; Glucocorticoid | 1974 |
Advances in the treatment of rheumatic disorders.
Topics: Alkylating Agents; Allopurinol; Analgesics; Anti-Inflammatory Agents; Antimalarials; Antimetabolites | 1968 |
Immunosuppressive drugs in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Azathioprine; Chlorambucil; Cyclophosphamide; Female; Humans; Immunosuppressi | 1969 |
Rheumatoid arthritis. Medical management.
Topics: Arthritis, Rheumatoid; Aspirin; Diet; Gold; Humans; Hydrocortisone; Immunosuppressive Agents; Indome | 1970 |
The patient with rheumatoid arthritis.
Topics: Activities of Daily Living; Arthritis, Rheumatoid; Bursitis; Chloroquine; Diagnosis, Differential; F | 1971 |
Advances in the treatment of rheumatic disorders.
Topics: Acetaminophen; Analgesics; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Chloroquine; Female; Flu | 1971 |
174 trials available for prednisolone and Rheumatoid Arthritis
| Article | Year |
|---|---|
Post hoc analysis of clinical characteristics of patients with radiographic progression in a Japanese phase 3 trial of peficitinib and methotrexate treatment (RAJ4).
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; C-Reactive Protein; Disease Progression; East Asian Peo | 2023 |
Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Drug Therapy, Combination; G | 2022 |
The Efficacy of Short-Term Bridging Strategies With High- and Low-Dose Prednisolone on Radiographic and Clinical Outcomes in Active Early Rheumatoid Arthritis: A Double-Blind, Randomized, Placebo-Controlled Trial.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Delayed-Action Preparations; Double-Blind Method | 2022 |
Development of prediction models to select older RA patients with comorbidities for treatment with chronic low-dose glucocorticoids.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Glucocorticoids; Humans; Prednisolone | 2023 |
Favourable effect of a 'second hit' after 13 weeks in early RA non-responders: the Amsterdam COBRA treat-to-target randomized trial.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Methotrexate; Predni | 2023 |
Cost-effectiveness and cost-utility of add-on, low-dose prednisolone in patients with rheumatoid arthritis aged 65+: The pragmatic, multicenter, placebo-controlled GLORIA trial.
Topics: Arthritis, Rheumatoid; Cost-Benefit Analysis; Ethnicity; Humans; Prednisolone; Quality-Adjusted Life | 2022 |
Changes in body weight and body composition in patients with active rheumatoid arthritis aged 65+ treated with 2-year low-dose add-on prednisolone in the randomised double-blind placebo-controlled GLORIA trial.
Topics: Arthritis, Rheumatoid; Body Composition; Body Weight; Glucocorticoids; Humans; Prednisolone | 2023 |
Three-month tapering and discontinuation of long- term, low-dose glucocorticoids in senior patients with rheumatoid arthritis is feasible and safe: placebo-controlled double blind tapering after the GLORIA trial.
Topics: Adrenal Insufficiency; Antirheumatic Agents; Arthritis, Rheumatoid; Glucocorticoids; Humans; Prednis | 2023 |
Observation of the clinical effect of the combined therapy of zushima tablet and western medicine in the treatment of rheumatoid arthritis and MRI test results.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Drugs, Chinese Herbal; Female; Humans; Magnetic | 2019 |
Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial.
Topics: Abatacept; Adult; Aged; Anti-Citrullinated Protein Antibodies; Antibodies, Monoclonal, Humanized; An | 2020 |
Predictors for clinical effectiveness of baricitinib in rheumatoid arthritis patients in routine clinical practice: data from a Japanese multicenter registry.
Topics: Aged; Arthritis, Rheumatoid; Azetidines; Female; Follow-Up Studies; Humans; Japan; Male; Methotrexat | 2020 |
Long-term effects on bone mineral density after four years of treatment with two intensive combination strategies, including initially high-dose prednisolone, in early rheumatoid arthritis patients: the COBRA-light trial.
Topics: Absorptiometry, Photon; Antirheumatic Agents; Arthritis, Rheumatoid; Bone Density; Drug Therapy, Com | 2021 |
Medication adherence in older people with rheumatoid arthritis is lower according to electronic monitoring than according to pill count.
Topics: Aged; Aged, 80 and over; Arthritis, Rheumatoid; Drug Packaging; Female; Glucocorticoids; Humans; Mal | 2021 |
Diagnostic value of a 3-day course of prednisolone in patients with possible rheumatoid arthritis - the TryCort study.
Topics: Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Diagnosis, Differential; Female; Finger Joint | 2017 |
Synbiotic supplementation and the effects on clinical and metabolic responses in patients with rheumatoid arthritis: a randomised, double-blind, placebo-controlled trial.
Topics: Adult; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Bifidobacterium bifidu | 2017 |
Similar efficacy and safety of initial COBRA-light and COBRA therapy in rheumatoid arthritis: 4-year results from the COBRA-light trial.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Comorbidity; Disease Progression; Drug Adm | 2017 |
Adrenal insufficiency is seen in more than one-third of patients during ongoing low-dose prednisolone treatment for rheumatoid arthritis.
Topics: Adrenal Insufficiency; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Arthritis, Rheumato | 2017 |
Harm, benefit and costs associated with low-dose glucocorticoids added to the treatment strategies for rheumatoid arthritis in elderly patients (GLORIA trial): study protocol for a randomised controlled trial.
Topics: Age Factors; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials, Phase IV as Topic; | 2018 |
Early Targeted Combination Treatment With Conventional Synthetic Disease-Modifying Antirheumatic Drugs and Long-Term Outcomes in Rheumatoid Arthritis: Ten-Year Follow-Up Results of a Randomized Clinical Trial.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Double-Blind Method; Drug T | 2019 |
Normal mortality of the COBRA early rheumatoid arthritis trial cohort after 23 years of follow-up.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Therapy, Combina | 2019 |
Early local swelling and tenderness are associated with large-joint damage after 8 years of treatment to target in patients with recent-onset rheumatoid arthritis.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Disability Evaluation; Drug The | 2013 |
A non-inferiority trial of an attenuated combination strategy ('COBRA-light') compared to the original COBRA strategy: clinical results after 26 weeks.
Topics: Adult; Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Drug | 2014 |
Targeted treatment with a combination of traditional DMARDs produces excellent clinical and radiographic long-term outcomes in early rheumatoid arthritis regardless of initial infliximab. The 5-year follow-up results of a randomised clinical trial, the NE
Topics: Adult; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Dou | 2014 |
Physicians' adherence to tight control treatment strategy and combination DMARD therapy are additively important for reaching remission and maintaining working ability in early rheumatoid arthritis: a subanalysis of the FIN-RACo trial.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Monitoring; Drug Therapy, Combination; Glucocortic | 2014 |
Vertebral fractures affect functional status in postmenopausal rheumatoid arthritis patients.
Topics: Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Bone Density; Bone Density Conservation Agent | 2014 |
ACPA-positive and ACPA-negative rheumatoid arthritis differ in their requirements for combination DMARDs and corticosteroids: secondary analysis of a randomized controlled trial.
Topics: Adrenal Cortex Hormones; Antirheumatic Agents; Arthritis, Rheumatoid; Autoantibodies; Autoantigens; | 2014 |
Low-dose prednisolone treatment of early rheumatoid arthritis and late cardiovascular outcome and survival: 10-year follow-up of a 2-year randomised trial.
Topics: Age Factors; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Cardiovascular Diseases; Coronary Dise | 2014 |
Intensive combination treatment regimens, including prednisolone, are effective in treating patients with early rheumatoid arthritis regardless of additional etanercept: 1-year results of the COBRA-light open-label, randomised, non-inferiority trial.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Co | 2015 |
Rheumatoid factor and anti-CCP do not predict progressive joint damage in patients with early rheumatoid arthritis treated with prednisolone: a randomised study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoi | 2014 |
Comparison of the efficacy and safety of two starting dosages of prednisolone in early active rheumatoid arthritis (CORRA): study protocol for a randomized controlled trial.
Topics: Arthritis, Rheumatoid; Clinical Protocols; Double-Blind Method; Drug Administration Schedule; Humans | 2014 |
Initial high-dose prednisolone combination therapy using COBRA and COBRA-light in early rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Drug Therapy, Combina | 2015 |
Failure in longterm treatment is rare in actively treated patients with rheumatoid arthritis, but may be predicted by high health assessment score at baseline and by residual disease activity at 3 and 6 months: the 5-year followup results of the randomize
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Arthrography; Biological Products; Disease Progr | 2014 |
Predictors for low disease activity and remission in rheumatoid arthritis patients treated with biological DMARDs.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Factors; Cohort Studies; Dose-Response | 2014 |
Reducing glucocorticoid dosage improves serum osteocalcin in patients with rheumatoid arthritis-results from the TOMORROW study.
Topics: Adult; Aged; Arthritis, Rheumatoid; Biomarkers; Bone and Bones; Bone Resorption; Case-Control Studie | 2016 |
Impact of physicians' adherence to treat-to-target strategy on outcomes in early rheumatoid arthritis in the NEO-RACo trial.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Double-Blind M | 2015 |
Effect of acute and chronic glucocorticoid therapy on insulin sensitivity and postprandial vascular function.
Topics: Aged; Arthritis, Rheumatoid; Blood Glucose; Cross-Sectional Studies; Drug Administration Schedule; F | 2016 |
Calprotectin (S100A8/A9) and S100A12 are associated with measures of disease activity in a longitudinal study of patients with rheumatoid arthritis treated with infliximab.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; Blood Sedimentation; C-Reactiv | 2016 |
The short-term effects of two high-dose, step-down prednisolone regimens on body composition in early rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Body Composition; Body Mass Index; Dose-Response Relati | 2016 |
Tight control and intensified COBRA combination treatment in early rheumatoid arthritis: 90% remission in a pilot trial.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; Collagen Type II; Drug Adminis | 2008 |
Impact of low-dose prednisolone on bone synthesis and resorption in early rheumatoid arthritis: experiences from a two-year randomized study.
Topics: Arthritis, Rheumatoid; Biomarkers; Bone Density; Bone Resorption; Female; Humans; Male; Middle Aged; | 2008 |
Rheumatoid atlantoaxial subluxation can be prevented by intensive use of traditional disease modifying antirheumatic drugs.
Topics: Adult; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Arthrography; Atlanto- | 2009 |
Relapse-remission and remission-relapse switches in rheumatoid arthritis patients were modeled by random effects.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Methotrexate; Models | 2009 |
A comparative study of the effects of bucillamine and salazosulfapyridine in the treatment of rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; C-Reactive Protein; Cysteine; Drug Therapy, Combination | 2009 |
The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Drug | 2009 |
Survival, comorbidities and joint damage 11 years after the COBRA combination therapy trial in early rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Therapy, Combina | 2010 |
Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy trial.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Therapy, Combination; Finland | 2010 |
Efficacy and safety of mizoribine by one single dose administration for patients with rheumatoid arthritis.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; C-Reactive Protein; Dru | 2010 |
Treatment with low-dose prednisolone is associated with altered body composition but no difference in bone mineral density in rheumatoid arthritis patients: a controlled cross-sectional study.
Topics: Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Body Composition; Bone Density; Cross-Section | 2011 |
Predictors of response to methotrexate in early DMARD naive rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial.
Topics: Adult; Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheuma | 2011 |
Association of soluble apoptotic markers with impaired left ventricular deformation in patients with rheumatoid arthritis. Effects of inhibition of interleukin-1 activity by anakinra.
Topics: Adrenal Cortex Hormones; Adult; Aged; Analysis of Variance; Antirheumatic Agents; Apoptosis; Arthrit | 2011 |
Metabolic effects of high-dose prednisolone treatment in early rheumatoid arthritis: balance between diabetogenic effects and inflammation reduction.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Glucose; | 2012 |
A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate.
Topics: Analgesics; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Aspirin; | 2012 |
Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study).
Topics: Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid | 2013 |
Low-dose prednisolone in early rheumatoid arthritis inhibits collagen type I degradation by matrix metalloproteinases as assessed by serum 1CTP--a possible mechanism for specific inhibition of radiological destruction.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Bone Resorption; Collagen Type I; | 2013 |
Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging study.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Dose-Response | 2002 |
Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anti | 2002 |
Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anti | 2002 |
Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anti | 2002 |
Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anti | 2002 |
Association of baseline levels of markers of bone and cartilage degradation with long-term progression of joint damage in patients with early rheumatoid arthritis: the COBRA study.
Topics: Arthritis, Rheumatoid; Biomarkers; Blood Sedimentation; Collagen Type I; Collagen Type II; Disease P | 2002 |
Effectiveness of a measurement feedback system on outcome in rheumatoid arthritis: a controlled clinical trial.
Topics: Acute Disease; Aged; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Hu | 2003 |
Osteocyte viability with glucocorticoid treatment: relation to histomorphometry.
Topics: Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Biopsy; Cell Survival; Female; Glucocorticoid | 2003 |
Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: a five-year randomized followup trial.
Topics: Adult; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Disability Evaluation; | 2004 |
Efficacy and safety of tacrolimus (FK506) in treatment of rheumatoid arthritis: a randomized, double blind, placebo controlled dose-finding study.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Double-Blind Method; Drug The | 2004 |
[High performance liquid chromatography in cortisol kinetics and its kinetic parameters in patients treated with exogenous glucocorticoids].
Topics: Adult; Arthritis, Rheumatoid; Chromatography, High Pressure Liquid; Female; Glucocorticoids; Humans; | 2004 |
A randomised placebo controlled 12 week trial of budesonide and prednisolone in rheumatoid arthritis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoi | 2004 |
Markers for type II collagen breakdown predict the effect of disease-modifying treatment on long-term radiographic progression in patients with rheumatoid arthritis.
Topics: Adult; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; Collagen; | 2004 |
Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Arthrography; Double-Blind Method; Drug Ad | 2004 |
Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FIN-RACo study.
Topics: Adult; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Arthrography; Disease | 2004 |
Indirect and total costs of early rheumatoid arthritis: a randomized comparison of combined step-down prednisolone, methotrexate, and sulfasalazine with sulfasalazine alone.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Cost-Benefit Ana | 2004 |
Effects of oral prednisolone on biomarkers in synovial tissue and clinical improvement in rheumatoid arthritis.
Topics: Administration, Oral; Adult; Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Biomarkers; Cell | 2004 |
Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial.
Topics: Adult; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Disability Evaluation; | 2005 |
Reduced loss of hand bone density with prednisolone in early rheumatoid arthritis: results from a randomized placebo-controlled trial.
Topics: Adult; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Bone Demineralization, | 2005 |
Anti-TNF antibody treatment improves glucocorticoid induced insulin-like growth factor 1 (IGF1) resistance without influencing myoglobin and IGF1 binding proteins 1 and 3.
Topics: Adalimumab; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; A | 2006 |
Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial.
Topics: Absorptiometry, Photon; Antirheumatic Agents; Arthritis, Rheumatoid; Arthrography; Bone Density; Dis | 2005 |
Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Arthrography; Disease Progress | 2005 |
Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Arthrography; Disease Progress | 2005 |
Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Arthrography; Disease Progress | 2005 |
Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Arthrography; Disease Progress | 2005 |
Polymorphism at position +896 of the toll-like receptor 4 gene interferes with rapid response to treatment in rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Female; Genotype; Glucocorti | 2006 |
The effect of therapeutic glucocorticoids on the adrenal response in a randomized controlled trial in patients with rheumatoid arthritis.
Topics: Adrenal Glands; Adrenocorticotropic Hormone; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Budeso | 2006 |
Anti-interleukin-6 receptor antibody therapy favors adrenal androgen secretion in patients with rheumatoid arthritis: a randomized, double-blind, placebo-controlled study.
Topics: 17-alpha-Hydroxyprogesterone; Adrenal Glands; Adrenocorticotropic Hormone; Adult; Aged; Androgens; A | 2006 |
Early rheumatoid arthritis: combination therapy with disease-modifying antirheumatic drugs and low-dose glucocorticoids?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Dose-Respon | 2006 |
Real-time quantitative PCR to detect changes in synovial gene expression in rheumatoid arthritis after corticosteroid treatment.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; Cytokines; Female; Gene Expres | 2007 |
Anti-tumor necrosis factor-alpha antibody treatment reduces serum CXCL16 levels in patients with rheumatoid arthritis.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal; Arthritis, Rheumatoid; Chemokine CX3CL1; Chemokine | 2007 |
Efficacy profile of bucillamine in rheumatoid arthritis patients in a large observational cohort study, IORRA.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cohort Studies; Cysteine; Drug Thera | 2006 |
Power Doppler sonography and pulse-inversion harmonic imaging in evaluation of rheumatoid arthritis synovitis.
Topics: Adult; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Contrast Media; Female; Finger Joint; Humans | 2007 |
Is rheumatoid arthritis a disease that starts in the intestine? A pilot study comparing an elemental diet with oral prednisolone.
Topics: Administration, Oral; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Female; Food, Formulated; Hum | 2007 |
Influence of methotrexate dose on its efficacy and safety in rheumatoid arthritis patients: evidence based on the variety of prescribing approaches among practicing Japanese rheumatologists in a single institute-based large observational cohort (IORRA).
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cohort Studies; Cross-Sectional Studies; Female; Humans | 2007 |
Effects of low-dose prednisolone on endothelial function, atherosclerosis, and traditional risk factors for atherosclerosis in patients with rheumatoid arthritis--a randomized study.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Atherosclerosis; Caroti | 2007 |
Assessment of comparative pain relief and tolerability of SKI306X compared with celecoxib in patients with rheumatoid arthritis: a 6-week, multicenter, randomized, double-blind, double-dummy, phase III, noninferiority clinical trial.
Topics: Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Celecoxib; Clematis; Cyclooxy | 2007 |
Factorial randomised controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Cyclosporine; Double-Bl | 2008 |
Anti-tumor necrosis factor-alpha therapy in the ordinary clinical setting: Three-year effectiveness in patients with rheumatoid arthritis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antirheumatic Agents; | 2007 |
Daily practice effectiveness of a step-down treatment in comparison with a tight step-up for early rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Drug Administration S | 2008 |
Osteoclast inhibitory effects of vitamin K2 alone or in combination with etidronate or risedronate in patients with rheumatoid arthritis: 2-year results.
Topics: Aged; Alkaline Phosphatase; Arthritis, Rheumatoid; Bone Density; Bone Density Conservation Agents; C | 2008 |
Effects of bisphosphonates on fracture incidence and bone metabolism in rheumatoid arthritis patients in general practice taking long-term corticosteroid therapy: a retrospective study.
Topics: Aged; Alendronate; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Bone and Bones; Bone Density Con | 2008 |
Long-term study of management of rheumatoid arthritis.
Topics: Acute Disease; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Bed Rest; Clinical Trials as Topic; | 1984 |
A multicenter double-blind controlled study of lobenzarit, a novel immunomodulator, in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Blood Sedimentation; Clinical Trials as Topic; Double-Blind Method; Drug Ther | 1984 |
The timing of prednisolone dosage and its effect on morning stiffness in rheumatoid arthritis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Clinical Trials as Topic; Double-Blind Method; Drug Administrati | 1984 |
Time of day of prednisolone administration in rheumatoid arthritis.
Topics: 11-Hydroxycorticosteroids; Aged; Arthritis, Rheumatoid; Circadian Rhythm; Clinical Trials as Topic; | 1982 |
[Prednisolone-saving effect of tiaprofenic acid. Clinical trial].
Topics: Adult; Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Dose-Respons | 1982 |
A pharmacological and clinical comparison of prednisolone and betamethasone in rheumatoid arthritis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Betamethasone; Diarrhea; Dizziness; Drug Evaluation; Humans; Iso | 1982 |
[Low-dose methotrexate therapy of rheumatoid arthritis in the elderly].
Topics: Age Factors; Aged; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Female; Gold; Humans; Ma | 1995 |
The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group.
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Disease Progression; Double-Blind Method; Drug Thera | 1995 |
The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group.
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Disease Progression; Double-Blind Method; Drug Thera | 1995 |
The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group.
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Disease Progression; Double-Blind Method; Drug Thera | 1995 |
The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group.
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Disease Progression; Double-Blind Method; Drug Thera | 1995 |
The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group.
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Disease Progression; Double-Blind Method; Drug Thera | 1995 |
The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group.
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Disease Progression; Double-Blind Method; Drug Thera | 1995 |
The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group.
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Disease Progression; Double-Blind Method; Drug Thera | 1995 |
The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group.
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Disease Progression; Double-Blind Method; Drug Thera | 1995 |
The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group.
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Disease Progression; Double-Blind Method; Drug Thera | 1995 |
Intermittent treatment with D-penicillamine is effective in lower doses and with fewer adverse effects in patients with rheumatoid arthritis.
Topics: Adult; Arthritis, Rheumatoid; Data Interpretation, Statistical; Drug Administration Schedule; Drug T | 1994 |
Radiologic evidence of disease modification in rheumatoid arthritis patients treated with cyclosporine. Results of a 48-week multicenter study comparing low-dose cyclosporine with placebo. Norwegian Arthritis Study Group.
Topics: Administration, Oral; Adult; Aged; Arthritis, Rheumatoid; Cyclosporine; Double-Blind Method; Drug Ad | 1994 |
Is there an interaction between low doses of corticosteroids and methotrexate in patients with rheumatoid arthritis? A pharmacokinetic study in 33 patients.
Topics: Adrenal Cortex Hormones; Adult; Aged; Arthritis, Rheumatoid; Drug Administration Schedule; Drug Inte | 1993 |
Nerve conduction studies in rheumatoid arthritis.
Topics: Adolescent; Adult; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Female; Humans; Middle Aged; Mot | 1996 |
The timing of glucocorticoid administration in rheumatoid arthritis.
Topics: Aged; Aged, 80 and over; Arthritis, Rheumatoid; C-Reactive Protein; Circadian Rhythm; Drug Administr | 1997 |
The relationship between synovitis and erosions in rheumatoid arthritis.
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Hand; Humans; Joint Diseases; Metacarpophalangeal Jo | 1997 |
[Patients with rheumatoid arthritis: study of the correlation between density of glucocorticoid receptors in synovial cells and clinical response to steroidal treatment].
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Female; Humans; Male; Midd | 1996 |
Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis.
Topics: Adult; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Administration Sc | 1997 |
Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis.
Topics: Adult; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Administration Sc | 1997 |
Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis.
Topics: Adult; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Administration Sc | 1997 |
Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis.
Topics: Adult; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Administration Sc | 1997 |
Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis.
Topics: Adult; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Administration Sc | 1997 |
Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis.
Topics: Adult; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Administration Sc | 1997 |
Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis.
Topics: Adult; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Administration Sc | 1997 |
Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis.
Topics: Adult; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Administration Sc | 1997 |
Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis.
Topics: Adult; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Administration Sc | 1997 |
Auranofin is safe and superior to placebo in elderly-onset rheumatoid arthritis.
Topics: Age of Onset; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Auranofin; D | 1997 |
Radiosynoviorthesis with rhenium-186 in rheumatoid arthritis: a prospective study of three treatment regimens.
Topics: Adolescent; Adult; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Child; Child, Preschool; Combine | 1997 |
Neoral--new cyclosporin for old?
Topics: Adolescent; Adult; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Juvenile; Arthritis, P | 1997 |
[Combination therapy in early rheumatoid arthritis: the COBRA study].
Topics: Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Cost of Illness; Double-Blind | 1997 |
Changes in biochemical markers of joint tissue metabolism in a randomized controlled trial of glucocorticoid in early rheumatoid arthritis.
Topics: Adult; Arthritis, Rheumatoid; Biomarkers; Collagenases; Cytidine Deaminase; Enzyme Precursors; Femal | 1998 |
Joint destruction after glucocorticoids are withdrawn in early rheumatoid arthritis. Arthritis and Rheumatism Council Low Dose Glucocorticoid Study Group.
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Disease Progression; Double-Blind Method; Finger Joi | 1998 |
Cost-effectiveness and cost-utility of combination therapy in early rheumatoid arthritis: randomized comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone. COBRA Trial Group. Combinatietherapie Bij Reumat
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Cost-Benefit Analysis; Disease Progression; Doub | 1998 |
Smallest detectable difference in radiological progression.
Topics: Adolescent; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Double-Bl | 1999 |
Magnetic resonance imaging-determined synovial membrane volume as a marker of disease activity and a predictor of progressive joint destruction in the wrists of patients with rheumatoid arthritis.
Topics: Administration, Oral; Adult; Aged; Arthritis, Rheumatoid; Humans; Hypertrophy; Longitudinal Studies; | 1999 |
Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Co | 1999 |
Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Co | 1999 |
Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Co | 1999 |
Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Co | 1999 |
Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Co | 1999 |
Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Co | 1999 |
Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Co | 1999 |
Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Co | 1999 |
Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Co | 1999 |
The analysis of a bivariate multi-state Markov transition model for rheumatoid arthritis with an incomplete disease history.
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Female; Glucocorticoids; Humans; Male; Markov Chains | 1999 |
A randomised trial of differentiated prednisolone treatment in active rheumatoid arthritis. Clinical benefits and skeletal side effects.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Bone Density; Drug | 1999 |
Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients.
Topics: Administration, Oral; Aged; Arthritis, Rheumatoid; Bone Density; Calcium Channel Blockers; Double-Bl | 2000 |
[Magnetic resonance imaging as a marker of inflammation, destruction and prognosis in rheumatoid arthritis wrists].
Topics: Adult; Aged; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Follow-Up Studie | 2000 |
Low dose prednisolone therapy (LDPT) retards radiographically detectable destruction in early rheumatoid arthritis--preliminary results of a multicenter, randomized, parallel, double blind study.
Topics: Adult; Aged; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Double-Blind Method; Female; H | 2000 |
Alendronate in rheumatoid arthritis patients treated with methotrexate and glucocorticoids.
Topics: Absorptiometry, Photon; Aged; Alendronate; Arthritis, Rheumatoid; Bone and Bones; Bone Density; Calc | 2001 |
The relationship between soft tissue swelling, joint space narrowing and erosive damage in hand X-rays of patients with rheumatoid arthritis.
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Cartilage, Articular; Disease Progression; Finger Jo | 2001 |
American College of Rheumatology criteria for improvement in rheumatoid arthritis should only be calculated from scores that decrease on improvement.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, | 2001 |
[Low dose steroid therapy in rheumatoid arthritis: a model for therapy of inflammatory diseases?--Results of the LDPT Study].
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Disease Progression; Dose- | 2001 |
[Double-blind trial of the effectiveness of antibodies to interferon-gamma and tumor necrosis factor-alpha in rheumatoid arthritis (preliminary results)].
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, | 2001 |
Inflammation and damage in an individual joint predict further damage in that joint in patients with early rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Drug Therapy, Combina | 2001 |
Bone turnover, joint damage and bone mineral density in early rheumatoid arthritis treated with combination therapy including high-dose prednisolone.
Topics: Adult; Aged; Amino Acids; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antirhe | 2001 |
Prevalence of vertebral deformities and symptomatic vertebral fractures in corticosteroid treated patients with rheumatoid arthritis.
Topics: Aged; Arthritis, Rheumatoid; Cross-Sectional Studies; Female; Glucocorticoids; Humans; Male; Middle | 2001 |
COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention.
Topics: Adult; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; D | 2002 |
Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis.
Topics: Adult; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combinat | 2002 |
Ernest Fletcher Lecture. The painful shoulder.
Topics: Adult; Aged; Arthritis; Arthritis, Rheumatoid; Arthropathy, Neurogenic; Bursitis; Clinical Trials as | 1975 |
Double-blind study of erbium 169 injection (synoviorthesis) in rheumatoid digital joints.
Topics: Arthritis, Rheumatoid; Clinical Trials as Topic; Erbium; Finger Joint; Humans; Injections, Intra-Art | 1977 |
[Azapropazone and rheumatic combination therapy considering drug interactions: azapropazone aurothioglucose and azapropazone prednisolone].
Topics: Adult; Aged; Apazone; Arthritis, Rheumatoid; Aurothioglucose; Clinical Trials as Topic; Drug Interac | 1978 |
Clinical studies with ketoprofen in rheumatoid arthritis.
Topics: Administration, Oral; Arthritis, Rheumatoid; Clinical Trials as Topic; Humans; Ketoprofen; Phenylpro | 1979 |
[Proof, by a double-blind study, of the efficacy of synoviorthesis by erbium-169 in rheumatoid arthritis of the fingers].
Topics: Arthritis, Rheumatoid; Clinical Trials as Topic; Erbium; Finger Joint; Humans; Prednisolone; Radiois | 1977 |
A thermographic assessment of three intra-articular prednisolone analogues given in rheumatoid synovitis.
Topics: Arthritis, Rheumatoid; Blood Viscosity; Body Temperature; Humans; Prednisolone; Synovitis; Thermogra | 1978 |
Indomethacin or prednisolone at night in rheumatoid arthritis?
Topics: Adult; Aged; Analgesics; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; | 1978 |
The effect of low doses of prednisolone compared with placebo on function and on the hypothalamic pituitary adrenal axis in patients with rheumatoid arthritis.
Topics: Adrenal Glands; Adult; Aged; Arthritis, Rheumatoid; Clinical Trials as Topic; Dose-Response Relation | 1976 |
[Long term treatment of rheumatoid arthritis. Experiences with D-penicillamine in comparison with gold and immunosuppressive drugs (author's transl)].
Topics: Adolescent; Adult; Arthritis, Rheumatoid; Blood Sedimentation; Clinical Trials as Topic; Female; Gol | 1975 |
[Results of different long term treatments of patients in the early stages of rheumatoid arthritis].
Topics: Adrenal Cortex Hormones; Arthritis, Rheumatoid; Chloroquine; Cyclophosphamide; Drug Therapy, Combina | 1976 |
[Practical experiences in the intra-articular treatment of chronic rheumatic diseases].
Topics: Arthritis, Rheumatoid; Cyclophosphamide; Humans; Injections, Intra-Articular; Prednisolone; Spondyli | 1975 |
Effects of different regimes of corticosteroid treatment on calcium and bone metabolism in rheumatoid arthritis.
Topics: Administration, Oral; Adrenal Cortex Hormones; Adult; Aged; Arthritis, Rheumatoid; Bone and Bones; C | 1992 |
On the medicinal efficacy of dietetic therapy in patients with rheumatoid arthritis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Combined Modality Therapy; Diclofenac; Female; Humans; Ibuprofen | 1992 |
IgM-rheumatoid factor and responses to second-line drugs in rheumatoid arthritis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Auranofin; Double-Blind Method; Drug Therapy, Combination; Femal | 1991 |
[Determination of lymphocyte subpopulations and their activation status in patients with rheumatoid arthritis treated with plasma exchange and pulse therapy].
Topics: Arthritis, Rheumatoid; Combined Modality Therapy; Cyclophosphamide; Drug Administration Schedule; Hu | 1991 |
Effects of non-steroidal anti-inflammatory drugs and prednisolone on synovial fluid white cells, prostaglandin E2, leukotriene B4 and cyclic AMP in patients with rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cyclic AMP; Dinoprostone; Female; Hu | 1990 |
Pulse steroid therapy in rheumatoid arthritis: can equivalent doses of oral prednisolone give similar clinical results to intravenous methylprednisolone?
Topics: Administration, Oral; Adult; Aged; Arthritis, Rheumatoid; Clinical Trials as Topic; Double-Blind Met | 1988 |
Corticosteroids in rheumatoid arthritis: is a trial of their 'disease modifying' potential feasible?
Topics: Adrenal Cortex Hormones; Age Factors; Arthritis, Rheumatoid; Clinical Trials as Topic; Follow-Up Stu | 1986 |
[Study of pirprofen (rengasil) combined with maintenance doses of corticosteroids in rheumatoid arthritis in a double-blind multicenter trial].
Topics: Adult; Aged; Arthritis, Rheumatoid; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Com | 1986 |
[Experimental substantiation of the treatment of patients with rheumatoid arthritis with prednisolone and its combination with retabolil (clinico-experimental study)].
Topics: Adult; Animals; Arthritis, Rheumatoid; Clinical Trials as Topic; Drug Therapy, Combination; Female; | 1986 |
[Ulcerogenic potential of corticoids in man: a reality or methodologic artifact?].
Topics: Adrenal Cortex Hormones; Animals; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Clinical Trials a | 1985 |
Corticosteroid withdrawal in rheumatoid arthritis.
Topics: Adrenal Glands; Adrenocorticotropic Hormone; Adult; Aged; Arthritis, Rheumatoid; Female; Follow-Up S | 1966 |
Ibuprofen in rheumatoid arthritis. Clinical study of analgesic and anti-inflammatory activity.
Topics: Adult; Aged; Alanine Transaminase; Arthritis, Rheumatoid; Aspartate Aminotransferases; Aspirin; Doub | 1968 |
Adrenocorticotrophic action of long-acting tetracosactrin compared with corticotrophin-gel.
Topics: Adrenal Glands; Adrenocorticotropic Hormone; Arthritis, Rheumatoid; Asthma; Delayed-Action Preparati | 1967 |
Mefenamic acid in rheumatoid arthritis.
Topics: Adrenocorticotropic Hormone; Adult; Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspirin; | 1967 |
[Clinical picture of rheumatic diseases. Experiences with interval corticoid therapy].
Topics: Adrenocorticotropic Hormone; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Clinical Trials as Top | 1974 |
The diagnosis and management of episcleritis and scleritis.
Topics: Arteritis; Arthritis, Rheumatoid; Behcet Syndrome; Clinical Trials as Topic; Deafness; Eczema; Epine | 1965 |
[Experiences with a new combination drug (Realin) in the treatment of acute rheumatic conditions].
Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Drug Combinations; Drug | 1974 |
Immunosuppressive therapy. 1.
Topics: Alkylating Agents; Anemia, Hemolytic, Autoimmune; Antibodies; Antimetabolites; Arthritis, Rheumatoid | 1972 |
Evaluation of a functional index in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Arthroplasty; Aspirin; Clinical Trials as Topic; Disability Evaluation; Drug | 1973 |
Measurement of clinical response to anti-inflammatory drug therapy in rheumatoid arthritis.
Topics: Administration, Oral; Adult; Analgesics; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Clinical T | 1973 |
[Reports on long-term treatments with sintisone (prednisolon-stearoylglycolate)].
Topics: Arthritis, Rheumatoid; Asthma; Behcet Syndrome; Clinical Trials as Topic; Drug Evaluation; Eosinophi | 1974 |
An assessment of grip strength measurement in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Biomechanical Phenomena; Circadian Rhythm; Clinical Trials as Topic; Function | 1974 |
Measurement of joint inflammation. Local 99mTc indices of knees, hands, elbows and feet.
Topics: Arthritis, Rheumatoid; Clinical Trials as Topic; Elbow Joint; Finger Joint; Humans; Knee Joint; orth | 1974 |
Isotopic indices as a measure of inflammation in rheumatoid arthritis.
Topics: Acetaminophen; Adult; Aged; Arthritis, Rheumatoid; Clinical Trials as Topic; Female; Humans; Indium; | 1974 |
Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Aspirin; Clinical Trials as Topic; Humans; Joints; Methods; Movement; Pain; P | 1968 |
Azathioprine in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Azathioprine; Clinical Trials as Topic; Drug Synergism; Female; Humans; Male; | 1969 |
[On the evaluation of the effect of a combination of salicylates and prednisolone in rheumatic diseases].
Topics: Acute Disease; Arthritis, Rheumatoid; Bone Diseases; Clinical Trials as Topic; Drug Synergism; Human | 1968 |
Evaluation of a simple articular index for joint tenderness in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Aspirin; Clinical Trials as Topic; Humans; Joints; Methods; Pain; Placebos; P | 1969 |
Azathioprine: a controlled, double-blind trial in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Azathioprine; Clinical Trials as Topic; Humans; Middle Aged; Placebos; Predni | 1969 |
Alternate-day vs shorter-interval steroid administration.
Topics: Adult; Arthritis, Rheumatoid; Blood Glucose; Calcium; Clinical Trials as Topic; Creatinine; Cushing | 1970 |
Comparison of oral prednisolone and intramuscular methylprednisolone in classical rheumatoid arthritis in out-patients.
Topics: Administration, Oral; Arthritis, Rheumatoid; Clinical Trials as Topic; Humans; Injections, Intramusc | 1971 |
[On long term drug therapy of primary chronic polyarthritis].
Topics: Adult; Arthritis, Rheumatoid; Chronic Disease; Female; Gold; Humans; Indomethacin; Male; Middle Aged | 1967 |
889 other studies available for prednisolone and Rheumatoid Arthritis
| Article | Year |
|---|---|
Antiinflammatory glucocorticoid receptor ligand with reduced side effects exhibits an altered protein-protein interaction profile.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Arthritis, Rheumatoid; Benzopyrans; Benz | 2007 |
Blood chemokine levels are markers of disease activity but not predictors of remission in early rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; Humans; Methotrexate; Prednisolone; Remissi | 2022 |
Risk of adrenal insufficiency in patients with polymyalgia rheumatica versus patients with rheumatoid arthritis: A cross-sectional study.
Topics: Adrenal Insufficiency; Adrenocorticotropic Hormone; Arthritis, Rheumatoid; Cross-Sectional Studies; | 2022 |
Quantitative in vivo micro-computed tomography for monitoring disease activity and treatment response in a collagen-induced arthritis mouse model.
Topics: Animals; Arthritis, Rheumatoid; Bone and Bones; Collagen; Connective Tissue; Disease Models, Animal; | 2022 |
Risk of severe COVID-19 in patients with inflammatory rheumatic diseases treated with immunosuppressive therapy in Scotland.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Case-Control Studies; COVID-19; Humans; Immunosuppressi | 2023 |
Rheumatoid arthritis patients initiating rituximab with low number of previous bDMARDs failures may effectively reduce rituximab dose and experience fewer serious adverse events than patients on full dose: a 5-year cohort study.
Topics: Arthritis, Rheumatoid; Cohort Studies; Female; Humans; Middle Aged; Prednisolone; Prospective Studie | 2022 |
Efficacy of leflunomide in the treatment of palindromic rheumatism.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Leflunomide; Methotr | 2022 |
Impaired adrenal cortex reserve in patients with rheumatic and musculoskeletal diseases who relapse upon tapering of low glucocorticoid dose.
Topics: Adrenal Cortex; Adrenal Cortex Hormones; Adrenal Insufficiency; Antirheumatic Agents; Arthritis, Rhe | 2022 |
Risks of femoral localized periosteal thickening in patients with autoimmune inflammatory rheumatic diseases.
Topics: Arthritis, Rheumatoid; Bone Density Conservation Agents; Diphosphonates; Female; Femoral Fractures; | 2023 |
Trivalent chromium supplementation ameliorates adjuvant induced rheumatoid arthritis through up-regulation of FOXP3 and decrease in synovial Cathepsin G expression.
Topics: Adjuvants, Immunologic; Animals; Arthritis, Experimental; Arthritis, Rheumatoid; Cathepsin G; Chromi | 2022 |
Outcomes of coronavirus disease 19 patients with a history of rheumatoid arthritis: A retrospective registry-based study in Iran.
Topics: Adrenal Cortex Hormones; Arthritis, Rheumatoid; COVID-19; Female; Humans; Iran; Middle Aged; Prednis | 2022 |
Analysis of risk factors of mortality in rheumatoid arthritis patients with interstitial lung disease: a nationwide, population-based cohort study in Taiwan.
Topics: Arthritis, Rheumatoid; Cohort Studies; Humans; Lung Diseases, Interstitial; Prednisolone; Pulmonary | 2022 |
Takotsubo Syndrome in a Rheumatoid Arthritis Patient Under Tofacitinib: A Case Report.
Topics: Arthritis, Rheumatoid; Female; Humans; Middle Aged; Piperidines; Prednisolone; Pyrimidines; Takotsub | 2022 |
Differences in trajectory of disease activity according to biologic and targeted synthetic disease-modifying anti-rheumatic drug treatment in patients with rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Humans; Prednisolone; Remission In | 2022 |
Prevalence and risk factors of herpes zoster infection in patients with rheumatic diseases not receiving biologic or targeted therapies.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Female; Herpes Zoster; Herp | 2023 |
Prevalence and risk factors of herpes zoster infection in patients with rheumatic diseases not receiving biologic or targeted therapies.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Female; Herpes Zoster; Herp | 2023 |
Prevalence and risk factors of herpes zoster infection in patients with rheumatic diseases not receiving biologic or targeted therapies.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Female; Herpes Zoster; Herp | 2023 |
Prevalence and risk factors of herpes zoster infection in patients with rheumatic diseases not receiving biologic or targeted therapies.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Female; Herpes Zoster; Herp | 2023 |
Prevalence and risk factors of herpes zoster infection in patients with rheumatic diseases not receiving biologic or targeted therapies.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Female; Herpes Zoster; Herp | 2023 |
Prevalence and risk factors of herpes zoster infection in patients with rheumatic diseases not receiving biologic or targeted therapies.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Female; Herpes Zoster; Herp | 2023 |
Prevalence and risk factors of herpes zoster infection in patients with rheumatic diseases not receiving biologic or targeted therapies.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Female; Herpes Zoster; Herp | 2023 |
Prevalence and risk factors of herpes zoster infection in patients with rheumatic diseases not receiving biologic or targeted therapies.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Female; Herpes Zoster; Herp | 2023 |
Prevalence and risk factors of herpes zoster infection in patients with rheumatic diseases not receiving biologic or targeted therapies.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Female; Herpes Zoster; Herp | 2023 |
Post-mRNA vaccine flares in autoimmune inflammatory rheumatic diseases: Results from the COronavirus National Vaccine registry for ImmuNe diseases SINGapore (CONVIN-SING).
Topics: Arthritis, Rheumatoid; Autoimmune Diseases; Child; Coronavirus; COVID-19; COVID-19 Vaccines; Female; | 2023 |
Post-mRNA vaccine flares in autoimmune inflammatory rheumatic diseases: Results from the COronavirus National Vaccine registry for ImmuNe diseases SINGapore (CONVIN-SING).
Topics: Arthritis, Rheumatoid; Autoimmune Diseases; Child; Coronavirus; COVID-19; COVID-19 Vaccines; Female; | 2023 |
Post-mRNA vaccine flares in autoimmune inflammatory rheumatic diseases: Results from the COronavirus National Vaccine registry for ImmuNe diseases SINGapore (CONVIN-SING).
Topics: Arthritis, Rheumatoid; Autoimmune Diseases; Child; Coronavirus; COVID-19; COVID-19 Vaccines; Female; | 2023 |
Post-mRNA vaccine flares in autoimmune inflammatory rheumatic diseases: Results from the COronavirus National Vaccine registry for ImmuNe diseases SINGapore (CONVIN-SING).
Topics: Arthritis, Rheumatoid; Autoimmune Diseases; Child; Coronavirus; COVID-19; COVID-19 Vaccines; Female; | 2023 |
ALK-positive lung adenocarcinoma in a patient with rheumatoid arthritis with long-term treatment for organizing pneumonia: A case report.
Topics: Adenocarcinoma of Lung; Aged, 80 and over; Arthritis, Rheumatoid; Dyspnea; Female; Humans; Inflammat | 2022 |
[Low dosed prednisolone in older patients with rheumatoid arthritis].
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Glucocorticoids; Humans; Prednisolone; Treatment | 2022 |
Herpes Zoster Risk in Patients with Rheumatoid Arthritis and Its Association with Medications Used.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Herpes Zoster; Humans; Incidence; Prednisolone; Retrosp | 2023 |
Effect of prednisolone and saireito co-administration on T-cells of rheumatoid arthritis patients.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Interleukin-6; Leukocytes, Mononuclear; | 2023 |
A case of chronic eosinophilic pneumonia associated with rheumatoid arthritis in glucocorticoid-free remission with JAK inhibitor: A case report.
Topics: Adult; Arthritis, Rheumatoid; Asthma; Female; Glucocorticoids; Humans; Janus Kinase Inhibitors; Meth | 2023 |
Prognostic Factors Affecting Death in Patients with Rheumatoid Arthritis Complicated by
Topics: Aged; Arthritis, Rheumatoid; Cohort Studies; Female; Humans; Male; Pneumocystis carinii; Pneumonia, | 2023 |
Prediction of flare following glucocorticoids withdrawal in rheumatoid arthritis patients with continuation of csDMARDs: a real-life study.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Glucocorticoids; Humans; Methotrexate; Prednisolone; Tr | 2023 |
Trajectories of self-reported pain-related health outcomes and longitudinal effects on medication use in rheumatoid arthritis: a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD).
Topics: Analgesics, Opioid; Antirheumatic Agents; Arthritis, Rheumatoid; Australia; Cohort Studies; Female; | 2023 |
Immunomodulatory Effects of Combined Nicotinic Acid and Prednisolone in Adjuvant-induced Arthritis.
Topics: Animals; Arthritis, Experimental; Arthritis, Rheumatoid; Male; Niacin; Prednisolone; Rats; Rats, Wis | 2023 |
In RA, use of systemic glucocorticoids ≥5 mg/d (prednisolone-equivalent) was linked to MACE at 8.7 y.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Glucocorticoids; Humans; Prednisolone | 2023 |
Successful Treatment of a Patient with Drug-Refractory Rheumatoid Arthritis-Associated Interstitial Lung Disease with Upadacitinib: A Case Report.
Topics: Aged; Arthritis, Rheumatoid; Dyspnea; Humans; Lung Diseases, Interstitial; Male; Methotrexate; Predn | 2023 |
Rheumatoid meningitis can present MRI findings that mimic chronic subdural haematoma.
Topics: Aged; Aphasia; Arthritis, Rheumatoid; Diagnosis, Differential; Female; Hematoma, Subdural, Chronic; | 2019 |
Associations between WNT1-inducible signaling pathway protein-1 (WISP-1) genetic polymorphisms and clinical aspects of rheumatoid arthritis among Chinese Han subjects.
Topics: Aged; Alleles; Antirheumatic Agents; Arthritis, Rheumatoid; Asian People; Biomarkers; Case-Control S | 2019 |
Oral steroid decreases the progression of joint destruction of large joints in the lower extremities in rheumatoid arthritis.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Ankle Joint; Arthritis, Rheumatoid; Disease Pr | 2019 |
Co-Delivery of Prednisolone and Curcumin in Human Serum Albumin Nanoparticles for Effective Treatment of Rheumatoid Arthritis.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Biological Availability; Curcumin; Cytokin | 2019 |
[Neurological symptoms in a patient on anti-TNF therapy, methotrexate and prednisolone for rheumatoid arthritis].
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Brain; Diagnosis, Differential; Drug Therapy, Com | 2020 |
Development of hypocomplementemic urticarial vasculitis during certolizumab pegol treatment for rheumatoid arthritis: A case report.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Certolizumab Pegol; Female; Hereditary Complement Defic | 2020 |
A case of IgG4-related disease presented with Kimura disease-like skin eruption, rheumatoid arthritis-like abnormality and interstitial pneumonia.
Topics: Administration, Oral; Aged; Arthritis, Rheumatoid; Eosinophils; Erythema; Fatal Outcome; Female; Glu | 2020 |
Tocilizumab-induced immunocomplex glomerulonephritis: a report of two cases.
Topics: Administration, Oral; Aged; Anti-Inflammatory Agents; Antibodies, Antinuclear; Antibodies, Monoclona | 2020 |
Prognosis of pneumonia in patients with rheumatoid arthritis: the role of medication and disease activity prior to admission a population-based cohort study.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; C-Reactive Protein; Cas | 2020 |
Subcutaneous Tocilizumab Is Effective for Treatment of Elderly-Onset Rheumatoid Arthritis.
Topics: Adult; Age of Onset; Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antirheumati | 2020 |
[Probable rheumatoid meningitis complicated by cryptococcal meningitis: A case report].
Topics: Antibodies; Arthritis, Rheumatoid; Biomarkers; Brain; Female; Humans; Magnetic Resonance Imaging; Me | 2020 |
Two-year Outcomes of Infliximab Discontinuation in Patients with Rheumatoid Arthritis: A Retrospective Analysis from a Single Center.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Blood Sedimentation; | 2020 |
A methotrexate-associated lymphoproliferative disorder expressing CD10 and BCL6 with the IGH/CCND1 translocation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arthritis, Rheumatoid; Chromosomes, Human, Pai | 2020 |
Simplified disease activity index and clinical disease activity index before and during pregnancy correlate with those at postpartum in patients with rheumatoid arthritis.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Factors; C-Reactive Protein; Female; | 2021 |
Tuberculosis osteomyelitis in an old fused hip; activated by prednisolone, salazosulfapyridine, and low-dose methotrexate therapy in a patient with rheumatoid arthritis.
Topics: Aged; Antirheumatic Agents; Antitubercular Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; | 2020 |
Oral ulcers with amyloidosis secondary to rheumatoid arthritis.
Topics: Aged; Amyloidosis; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Hu | 2021 |
COVID-19 pandemic and biological therapy in rheumatologic disorders: how to deal with?
Topics: Adalimumab; Adult; Antirheumatic Agents; Antiviral Agents; Arthritis, Rheumatoid; Azathioprine; Beta | 2020 |
Tapering and discontinuation of oral glucocorticoids without deterioration of disease status in patients with rheumatoid arthritis under a stable treatment.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Female; Glucocorticoid | 2021 |
Cricoarytenoid arthritis in rheumatoid arthritis.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Arytenoid Cart | 2021 |
Network theoretic analysis of JAK/STAT pathway and extrapolation to drugs and viruses including COVID-19.
Topics: Antibodies, Monoclonal, Humanized; Arthritis, Rheumatoid; Azetidines; Gene Regulatory Networks; Huma | 2021 |
Pneumothorax Due to a Nontraumatic Thoracic Wall Rupture Due to Steroid-Induced Muscle Wasting.
Topics: Arthritis, Rheumatoid; Glucocorticoids; Humans; Male; Middle Aged; Muscular Diseases; Pneumothorax; | 2021 |
Should we use glucocorticoids in early rheumatoid arthritis? Results at 5 years from the early RA UCLouvain Brussels cohort.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Belgium; Decision Making; Female; Follow-Up Studies; Gl | 2021 |
Reactive arthritis after COVID-19.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Arthralgia; Arthritis; Arthritis, | 2021 |
Dynamical trajectory of glucocorticoids tapering and discontinuation in patients with rheumatoid arthritis commencing glucocorticoids with csDMARDs: a real-world data from 2009 to 2020.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Glucocorticoids; Humans; Kaplan-Meier Estimate; Prednis | 2021 |
Elderly patients with comorbidities in the definition of difficult-to-treat rheumatoid arthritis.
Topics: Abatacept; Age Factors; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Biolog | 2021 |
Multiple calcifications of fingers in patients with rheumatoid arthritis after intra-articular triamcinolone acetonide injections.
Topics: Aged; Arthritis, Rheumatoid; Calcinosis; Female; Finger Joint; Glucocorticoids; Hand Joints; Humans; | 2021 |
The aggressive clinical courses of Hodgkin lymphoma primarily diagnosed as methotrexate-induced non-specific lymphoproliferative disorder in patients with rheumatoid arthritis.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Arthritis, Rheumatoid; Female; Hodgkin Disea | 2017 |
Vitamin D and Calcium Are Required during Denosumab Treatment in Osteoporosis with Rheumatoid Arthritis.
Topics: Aged; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Calcium Carbonate; Deno | 2017 |
Contribution of subjective Disease Activity Score 28 (DAS28) components to the response to treatment of rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Glucocorticoids; Humans; Male; Met | 2017 |
Factorial Analysis of Hepatitis B Virus Reactivation-Induced Hepatitis B Using JADER.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Antineoplastic | 2017 |
Steroid therapy and renal dysfunction are independently associated with serum levels of matrix metalloproteinase-3 in patients with rheumatoid arthritis.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; C-Reactive Protein; Female; Glomerul | 2018 |
Opposing effects of rheumatoid arthritis and low dose prednisolone on arginine metabolomics.
Topics: Administration, Oral; Aged; Arginine; Arthritis, Rheumatoid; Biomarkers; Case-Control Studies; Chrom | 2017 |
Course of hepatitis E infection in a patient with rheumatoid arthritis and autoimmune hepatitis: A case report.
Topics: Arthritis, Rheumatoid; Hepatitis E; Hepatitis, Autoimmune; Humans; Immunosuppressive Agents; Liver; | 2017 |
Development of a Molecular Signature to Monitor Pharmacodynamic Responses Mediated by In Vivo Administration of Glucocorticoids.
Topics: Administration, Oral; Arthritis, Rheumatoid; Biomarkers; Dose-Response Relationship, Drug; Down-Regu | 2018 |
Development of a Molecular Signature to Monitor Pharmacodynamic Responses Mediated by In Vivo Administration of Glucocorticoids.
Topics: Administration, Oral; Arthritis, Rheumatoid; Biomarkers; Dose-Response Relationship, Drug; Down-Regu | 2018 |
Development of a Molecular Signature to Monitor Pharmacodynamic Responses Mediated by In Vivo Administration of Glucocorticoids.
Topics: Administration, Oral; Arthritis, Rheumatoid; Biomarkers; Dose-Response Relationship, Drug; Down-Regu | 2018 |
Development of a Molecular Signature to Monitor Pharmacodynamic Responses Mediated by In Vivo Administration of Glucocorticoids.
Topics: Administration, Oral; Arthritis, Rheumatoid; Biomarkers; Dose-Response Relationship, Drug; Down-Regu | 2018 |
Development of a Molecular Signature to Monitor Pharmacodynamic Responses Mediated by In Vivo Administration of Glucocorticoids.
Topics: Administration, Oral; Arthritis, Rheumatoid; Biomarkers; Dose-Response Relationship, Drug; Down-Regu | 2018 |
Development of a Molecular Signature to Monitor Pharmacodynamic Responses Mediated by In Vivo Administration of Glucocorticoids.
Topics: Administration, Oral; Arthritis, Rheumatoid; Biomarkers; Dose-Response Relationship, Drug; Down-Regu | 2018 |
Development of a Molecular Signature to Monitor Pharmacodynamic Responses Mediated by In Vivo Administration of Glucocorticoids.
Topics: Administration, Oral; Arthritis, Rheumatoid; Biomarkers; Dose-Response Relationship, Drug; Down-Regu | 2018 |
Development of a Molecular Signature to Monitor Pharmacodynamic Responses Mediated by In Vivo Administration of Glucocorticoids.
Topics: Administration, Oral; Arthritis, Rheumatoid; Biomarkers; Dose-Response Relationship, Drug; Down-Regu | 2018 |
Development of a Molecular Signature to Monitor Pharmacodynamic Responses Mediated by In Vivo Administration of Glucocorticoids.
Topics: Administration, Oral; Arthritis, Rheumatoid; Biomarkers; Dose-Response Relationship, Drug; Down-Regu | 2018 |
Safety and efficacy of alternate-day corticosteroid treatment as adjunctive therapy for rheumatoid arthritis: a comparative study.
Topics: Administration, Oral; Adrenal Cortex Hormones; Antirheumatic Agents; Arthritis, Rheumatoid; C-Reacti | 2018 |
Rheumatoid meningitis developed in patient with stable rheumatoid arthritis and myasthenia gravis-detailed analysis of intracranial inflammation using flow cytometry.
Topics: Adult; Anti-Inflammatory Agents; Antigens, CD; Arthritis, Rheumatoid; Female; Flow Cytometry; Humans | 2018 |
[The treatment of patients with elderly-onset rheumatoid arthritis at Niigata Rheumatic Center].
Topics: Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Middle Aged; Prednisol | 2018 |
Hyaluronic acid-conjugated pH-sensitive liposomes for targeted delivery of prednisolone on rheumatoid arthritis therapy.
Topics: Animals; Arthritis, Rheumatoid; Cell Line; Endocytosis; Fibroblasts; Hyaluronic Acid; Hydrogen-Ion C | 2018 |
The three-year efficacy of iguratimod in clinical daily practice in patients with rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Chromones; Drug Thera | 2019 |
Subgingival microbiome of rheumatoid arthritis patients in relation to their disease status and periodontal health.
Topics: Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Cross-Sectional Studies; DNA, Bacterial; Fema | 2018 |
Organizing pneumonia in a patient with rheumatoid arthritis with progression to usual interstitial pneumonia.
Topics: Arthritis, Rheumatoid; Cryptogenic Organizing Pneumonia; Disease Progression; Humans; Lung; Male; Mi | 2019 |
Rheumatoid Arthritis Complicated with Anti-melanoma Differentiation-associated Gene 5 Antibody-positive Interstitial Pneumonia.
Topics: Aged; Arthritis, Rheumatoid; Autoantibodies; Drug Therapy, Combination; Female; Glucocorticoids; Hum | 2019 |
Increased expression of the proprotein convertase enzyme FURIN in rheumatoid arthritis.
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Correlation of Data; Female; Finland; Furin; Humans | 2019 |
Cardiac involvement of malignant lymphoma presenting intra-ventricular-wall nodules.
Topics: Abdominal Neoplasms; Aged; Antineoplastic Combined Chemotherapy Protocols; Antirheumatic Agents; Art | 2019 |
Relapsing Course of Sulfasalazine-Induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Complicated by Alopecia Universalis and Vitiligo.
Topics: Alopecia; Antirheumatic Agents; Arthritis, Rheumatoid; Biopsy; Cyclosporine; Dermatologic Agents; Dr | 2018 |
Rheumatoid arthritis presenting as rheumatoid meningitis.
Topics: Administration, Intravenous; Administration, Oral; Aftercare; Anti-Citrullinated Protein Antibodies; | 2019 |
The Atypical Presentation of Rheumatoid Arthritis in an Elderly Woman: A Case Report.
Topics: Aged; Anti-Inflammatory Agents; Antibodies, Antineutrophil Cytoplasmic; Antirheumatic Agents; Arthri | 2019 |
Repair of Erosions in Patients with Rheumatoid Arthritis.
Topics: Adult; Age Factors; Aged; Anti-Citrullinated Protein Antibodies; Anti-Inflammatory Agents; Antirheum | 2019 |
Iatrogenic transverse myelitis in a patient with rheumatoid arthritis.
Topics: Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Cervical Cord; Etanercept; Fe | 2019 |
Investigating Dimensions of Stiffness in Rheumatoid and Psoriatic Arthritis: The Australian Rheumatology Association Database Registry and OMERACT Collaboration.
Topics: Aged; Antirheumatic Agents; Arthritis, Psoriatic; Arthritis, Rheumatoid; Australia; Databases, Factu | 2019 |
Membranous nephropathy caused by rheumatoid arthritis.
Topics: Anti-Citrullinated Protein Antibodies; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Female; Glom | 2019 |
Rheumatoid arthritis-like active synovitis with T-cell activation in a case of idiopathic multicentric Castleman disease: A case report.
Topics: Adult; Arthritis; Arthritis, Rheumatoid; Castleman Disease; Chemokine CXCL10; Diagnosis, Differentia | 2019 |
Relationships between concomitant biologic DMARDs and prednisolone administration and blood tacrolimus exposure or serum CYP3A4/5-related markers in rheumatoid arthritis patients.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; Cytochrome P-450 CYP3A; Female; Human | 2019 |
Association between seropositivity and discontinuation of tumor necrosis factor inhibitors due to ineffectiveness in rheumatoid arthritis.
Topics: Adult; Aged; Anti-Citrullinated Protein Antibodies; Antirheumatic Agents; Arthritis, Rheumatoid; Bio | 2019 |
Folate Conjugated Double Liposomes Bearing Prednisolone and Methotrexate for Targeting Rheumatoid Arthritis.
Topics: Animals; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Experimental; Arthritis, Rheumat | 2019 |
Glucocorticoid-sensitive Paroxysmal Atrial Fibrillation, Sick Sinus Syndrome, and Mitral Regurgitation in a Patient with Malignant Rheumatoid Vasculitis.
Topics: Aged, 80 and over; Arthritis, Rheumatoid; Atrial Fibrillation; Echocardiography; Electrocardiography | 2019 |
A case of ulcerative colitis complicating anti-tumor necrosis factor treatment for rheumatoid arthritis: successful treatment with leukocytapheresis.
Topics: Antibodies, Monoclonal; Arthritis, Rheumatoid; Colitis, Ulcerative; Drug Resistance, Multiple; Drug | 2013 |
Does modern treatment of early rheumatoid arthritis reduce the need for intra-articular glucocorticoids?
Topics: Administration, Oral; Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Female; Glucocorticoids | 2013 |
Effective treatment of a steroid-induced femoral neck fracture nonunion with a once-weekly administration of teriparatide in a rheumatoid patient: a case report.
Topics: Aged, 80 and over; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Bone Density Conservation Agents | 2013 |
[Interdisciplinary cooperation essential. Hand in hand against rheumatic disease].
Topics: Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Cooperat | 2013 |
[Perception of pain in rheumatoid arthritis: relation to inflammation, psychic disorders, functional status, and quality of life].
Topics: Arthritis, Rheumatoid; Depression; Female; Glucocorticoids; Health Status; Humans; Inflammation; Mal | 2013 |
An under-recognized cause of polyarthritis: leprosy.
Topics: Anti-Inflammatory Agents; Arthritis; Arthritis, Rheumatoid; Clofazimine; Dapsone; Delayed Diagnosis; | 2013 |
Is swollen to tender joint count ratio a new and useful clinical marker for biologic drug response in rheumatoid arthritis? Results from a Swedish cohort.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Chi-Square Distribution; Disability Evaluation; Feasibi | 2014 |
Clinical efficacy of abatacept compared to adalimumab and tocilizumab in rheumatoid arthritis patients with high disease activity.
Topics: Abatacept; Adalimumab; Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthrit | 2014 |
Renal cell carcinoma in a patient with rheumatoid arthritis treated with adalimumab.
Topics: Adalimumab; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthr | 2014 |
Risk factors associated with the occurrence of distal radius fractures in Japanese patients with rheumatoid arthritis: a prospective observational cohort study.
Topics: Adult; Age Factors; Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Body Mass Index; Bone Den | 2014 |
Early diagnosis and treatment of steroid-induced diabetes mellitus in patients with rheumatoid arthritis and other connective tissue diseases.
Topics: Acarbose; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Glucose; Connective Tissue | 2014 |
Development of pulmonary and cardiac sarcoidosis during etanercept therapy.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cardiomyopathies; Etanercept; Female; Glucocortic | 2014 |
Parkinsonism as an initial manifestation of rheumatoid meningitis.
Topics: Aged; Arthritis, Rheumatoid; Diffusion Magnetic Resonance Imaging; Humans; Male; Meningitis; Parkins | 2014 |
Anti-citrullinated protein antibody-positive rheumatoid arthritis associated with RS3PE syndrome-like symptoms and an elevated serum vascular endothelial growth factor level in a patient with myasthenia gravis.
Topics: Aged; Arthritis, Rheumatoid; Diagnosis, Differential; Edema; Humans; Male; Myasthenia Gravis; Predni | 2014 |
Cost-effectiveness of treatment strategies using combination disease-modifying anti-rheumatic drugs and glucocorticoids in early rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cost-Benefit Analysis; Cyclosporine; Drug Costs; Drug T | 2014 |
Bone safety of low-dose glucocorticoids in rheumatic diseases.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Bone and Bones; Bone Density; Bone Density Conservation | 2014 |
Deterioration of the immune response induced by sulfamethoxazole-trimethoprim in a rheumatoid arthritis patient with Pneumocystis jirovecii pneumonia.
Topics: Aged; Anti-Infective Agents; Arthritis, Rheumatoid; Chemotherapy, Adjuvant; Female; Glucocorticoids; | 2014 |
Clinical and serological predictors of remission in rheumatoid arthritis are dependent on treatment regimen.
Topics: Adult; Age Factors; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Autoantibodies; Cyclosporine; | 2014 |
Treatment of rheumatoid arthritis with methotrexate alone and in combination with other conventional DMARDs using the T2T strategy. A cohort study.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; Cohort Stu | 2015 |
Quantifying not only bone loss, but also soft tissue swelling, in a murine inflammatory arthritis model using micro-computed tomography.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Arthritis, Rheumatoid; Bone Resorption; | 2015 |
Analysis of clinical factors related to the efficacy of shoulder arthroscopic synovectomy plus capsular release in patients with rheumatoid arthritis.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal; Arthritis, Rheumatoid; C-Reactive Pro | 2015 |
High variability in glucocorticoid starting doses in patients with rheumatoid arthritis: observational data from an early arthritis cohort.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cohort Studies; Drug Therapy, Combination; | 2015 |
Acute postoperative inflammatory polyarthritis associated with a lone IgM cardiolipin antibody.
Topics: Aged; Anti-Inflammatory Agents; Arthritis; Arthritis, Rheumatoid; Arthroscopy; Cardiolipins; Diagnos | 2015 |
Risk factors for established vertebral fractures in Japanese patients with rheumatoid arthritis: Results from a large prospective observational cohort study.
Topics: Adult; Age Factors; Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Female; Humans; Incidence | 2015 |
Improvement of large-joint ultrasonographic synovitis is delayed in patients with newly diagnosed rheumatoid arthritis: results of a 12-month clinical and ultrasonographic follow-up study of a local cohort.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Female; Follow- | 2015 |
Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: A retrospective analysis of real-world data from the St. Gallen cohort.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Drug Therapy, Combina | 2015 |
[(18)]F FDG PET/CT imaging to monitor the therapeutic effect of liposome-encapsulated prednisolone in experimental rheumatoid arthritis.
Topics: Adjuvants, Immunologic; Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Arthritis, Rheum | 2015 |
Rheumatoid lung.
Topics: Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Male; Methotrexate; M | 2015 |
Interplay between patient global assessment, pain, and fatigue and influence of other clinical disease activity measures in patients with active rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Denmark; Fatigue; Female; Humans; Male; Me | 2015 |
Putative IL-10 Low Producer Genotypes Are Associated with a Favourable Etanercept Response in Patients with Rheumatoid Arthritis.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antirheumatic Agents; Arthritis, Rheumatoid; Etanercept; Fe | 2015 |
Is this still just sarcoidosis, or should we a-DRESS a different diagnosis?
Topics: Anticonvulsants; Arthritis, Rheumatoid; Diagnosis, Differential; Drug Hypersensitivity Syndrome; Dys | 2015 |
The role of methotrexate and low-dose prednisolone on adiponectine levels and insulin resistance in patients with rheumatoid arthritis naïve to disease-modifying antirheumatic drugs.
Topics: Adiponectin; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; Blood Glucose; Dr | 2016 |
[18F]fluorodeoxyglucose uptake as a predictor of large joint destruction in patients with rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Female; Fluorodeoxygl | 2016 |
Ten years of change in clinical disease status and treatment in rheumatoid arthritis: results based on standardized monitoring of patients in an ordinary outpatient clinic in southern Norway.
Topics: Aged; Aged, 80 and over; Ambulatory Care Facilities; Antirheumatic Agents; Arthritis, Rheumatoid; Di | 2015 |
MRI evidence of persistent joint inflammation and progressive joint damage despite clinical remission during treatment of early rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progressio | 2016 |
Risk factors associated with the occurrence of proximal humerus fractures in patients with rheumatoid arthritis: a custom strategy for preventing proximal humerus fractures.
Topics: Adult; Age Factors; Aged; Arthritis, Rheumatoid; Biomarkers; Bone Density Conservation Agents; C-Rea | 2016 |
Risk of Incident Diabetes Mellitus Associated With the Dosage and Duration of Oral Glucocorticoid Therapy in Patients With Rheumatoid Arthritis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Cohort Studies; Diabetes Mellitus, Type 2; Female; Glucocorticoi | 2016 |
Rare Cause of Nuchal Pain: Calcification of the Alar Ligament.
Topics: Adult; Arthritis, Rheumatoid; Atlanto-Axial Joint; Calcinosis; Female; Follow-Up Studies; Humans; Li | 2016 |
Postcardiac Injury Syndrome: A Rare Complication of Elective Coronary Angioplasty.
Topics: Angioplasty, Balloon, Coronary; Anti-Inflammatory Agents; Arteries; Arthritis, Rheumatoid; C-Reactiv | 2016 |
Systemic effects of surgical intervention on disease activity, daily function, and medication in patients with rheumatoid arthritis.
Topics: Activities of Daily Living; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Arthrodesis; Arthropl | 2016 |
Tocilizumab and pregnancy: Four cases of pregnancy in young women with rheumatoid arthritis refractory to anti-TNF biologics with exposure to tocilizumab.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Human | 2016 |
Intractable leg ulcers in Blau syndrome.
Topics: Arthritis; Arthritis, Rheumatoid; Behcet Syndrome; Biopsy; Erythema Nodosum; Female; Glucocorticoids | 2016 |
Anti-signal recognition particle antibody-positive polymyositis in a patient with Sjögren's syndrome showing various types of annular erythema: Positive correlation between the activities of annular erythema and myositis.
Topics: Arthritis, Rheumatoid; Autoantibodies; Erythema; Humans; Male; Middle Aged; Polymyositis; Prednisolo | 2016 |
Acquired reactive perforating collagenosis associated with systemic lupus erythematosus.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Back; Collagen Diseases; Epidermis; Etanercept; | 2016 |
Recurrent Stenosis of the Ileum Caused by Rheumatoid Vasculitis.
Topics: Aged; Arthritis, Rheumatoid; Constriction, Pathologic; Endoscopy, Gastrointestinal; Humans; Ileum; I | 2016 |
Drug-induced bullous Sweet's syndrome by celecoxib.
Topics: Antirheumatic Agents; Arthralgia; Arthritis, Rheumatoid; Biopsy; Blister; Blood Sedimentation; C-Rea | 2016 |
Postoperative Surgical Infection After Spinal Surgery in Rheumatoid Arthritis.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheum | 2016 |
Oral glucocorticoid therapy and all-cause and cause-specific mortality in patients with rheumatoid arthritis: a retrospective cohort study.
Topics: Administration, Oral; Arthritis, Rheumatoid; Female; Glucocorticoids; Humans; Male; Middle Aged; Pre | 2016 |
Effects of prednisolone on energy and fat metabolism in patients with rheumatoid arthritis: tissue-specific insulin resistance with commonly used prednisolone doses.
Topics: Adipocytes; Aged; Arthritis, Rheumatoid; Calorimetry, Indirect; Energy Metabolism; Fatty Acids, None | 2016 |
Neutrophil/Lymphocyte Ratio in Patients with Rheumatoid Arthritis Treated with Biological Agents.
Topics: Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Biological Factors; Biomarkers; Blood Sedimen | 2016 |
Active Rheumatoid Arthritis in Central Africa: A Comparative Study Between Sudan and Sweden.
Topics: Adolescent; Adult; Age of Onset; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoi | 2016 |
Rheumatoid arthritis heralded by the hypereosinophilic syndrome.
Topics: Arthritis, Rheumatoid; Eosinophils; Humans; Hypereosinophilic Syndrome; Male; Middle Aged; Prednisol | 2016 |
[Not Available].
Topics: Aged; Arthritis, Rheumatoid; Azathioprine; Diagnosis, Differential; Drug Hypersensitivity; Drug Ther | 2016 |
Predictive factors associated with the progression of large-joint destruction in patients with rheumatoid arthritis after biologic therapy: A post-hoc analysis using FDG-PET/CT and the ARASHI (assessment of rheumatoid arthritis by scoring of large-joint d
Topics: Adult; Arthritis, Rheumatoid; Biological Therapy; Disease Progression; Female; Fluorodeoxyglucose F1 | 2017 |
Nivolumab-Induced Recurrence of Rheumatoid Arthritis in a Patient With Advanced Non-Small Cell Lung Cancer: A Case Report.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Agents; Arthritis, Rheumatoid; Carcinoma, Non-Small-Cel | 2016 |
Long-term use of biologic agents does not increase the risk of serious infections in elderly patients with rheumatoid arthritis.
Topics: Age Factors; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Factors; Case-Control Stu | 2017 |
Biopsy-proven case of Epstein-Barr virus (EBV)-associated vasculitis of the central nervous system.
Topics: Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Brain; Central Nervous System; Epstein-Barr V | 2017 |
pH-sensitive polymeric micelles for targeted delivery to inflamed joints.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Delayed-Action Preparations; Drug Delivery | 2017 |
Efficacy of golimumab for preventing large joint destruction in patients with rheumatoid arthritis as determined by the ARASHI score.
Topics: Aged; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination | 2017 |
Polymorphisms in the multidrug-resistance 1 gene related to glucocorticoid response in rheumatoid arthritis treatment.
Topics: Adult; Aged; Alleles; Arthritis, Rheumatoid; ATP Binding Cassette Transporter, Subfamily B, Member 1 | 2017 |
Glucocorticoids improve endothelial function in rheumatoid arthritis: a study in rats with adjuvant-induced arthritis.
Topics: Acetylcholine; Animals; Aorta; Arginase; Arthritis; Arthritis, Experimental; Arthritis, Rheumatoid; | 2017 |
Atherosclerosis is not accelerated in rheumatoid arthritis of low activity or remission, regardless of antirheumatic treatment modalities.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Atherosclerosis; Biological Factors; Carotid Artery Dis | 2017 |
Low dose prednisolone and insulin sensitivity differentially affect arterial stiffness and endothelial function: An open interventional and cross-sectional study.
Topics: Administration, Oral; Aged; Arthritis, Rheumatoid; Blood Glucose; Cross-Sectional Studies; Drug Admi | 2017 |
Co-occurrence of subchondral insufficiency fracture of the femoral head and contralateral femoral neck fracture in a rheumatic patient receiving steroid treatment.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Diagnosis, Differential; Drug | 2008 |
A sudden onset of diabetic ketoacidosis and acute pancreatitis after introduction of mizoribine therapy in a patient with rheumatoid arthritis.
Topics: Acute Disease; Aged; Arthritis, Rheumatoid; Benzamidines; Diabetic Ketoacidosis; Drug Therapy, Combi | 2008 |
An asymptomatic case of pulmonary cryptococcosis with endobronchial polypoid lesions and bilateral infiltrative shadow.
Topics: Arthritis, Rheumatoid; Bronchoscopy; Cryptococcosis; Female; Glucocorticoids; Humans; Immunocompromi | 2008 |
Discordant perspectives of rheumatologists and patients on COBRA combination therapy in rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Attitude of Health Personnel; Attitude to Health; Drug | 2008 |
Leflunomide-induced toxic epidermal necrolysis in a patient with rheumatoid arthritis.
Topics: Adjuvants, Immunologic; Adult; Arthritis, Rheumatoid; Cholestyramine Resin; Female; Glucocorticoids; | 2008 |
Etanercept improved primary biliary cirrhosis associated with rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Cysteine; Drug | 2009 |
Unilateral supratentorial lesion due to rheumatoid meningitis on MRI.
Topics: Aged, 80 and over; Arthritis, Rheumatoid; Cerebrum; Diagnosis, Differential; Female; Humans; Magneti | 2008 |
Generalized pustulosis induced by adalimumab in a patient with rheumatoid arthritis - a therapeutic challenge.
Topics: Adalimumab; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant | 2008 |
A case of Poncet's disease (tuberculous rheumatism).
Topics: Adult; Antitubercular Agents; Arthritis, Reactive; Arthritis, Rheumatoid; Asian People; Cyclosporine | 2009 |
Dendriform filamentary keratopathy.
Topics: Acute Disease; Arthritis, Rheumatoid; Cornea; Corneal Diseases; Cyclosporine; Diagnosis, Differentia | 2009 |
Case report: a case of pyoderma gangrenosum with intractable leg ulcers treated by allogeneic cultured dermal substitutes.
Topics: Aged; Arthritis, Rheumatoid; Cells, Cultured; Combined Modality Therapy; Debridement; Female; Fibrob | 2008 |
[Megaloblastic anemia associated with salazosulfapyridine treatment for rheumatoid arthritis].
Topics: Aged; Anemia, Megaloblastic; Antirheumatic Agents; Arthritis, Rheumatoid; Folic Acid; Folic Acid Def | 2008 |
Innovative combination strategy to enhance effect and diminish adverse effects of glucocorticoids: another promise?
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Dipyridamole; Drug Therapy, Combination; Gluco | 2009 |
A new low-field extremity magnetic resonance imaging and proposed compact MRI score: evaluation of anti-tumor necrosis factor biologics on rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Comb | 2009 |
Empyema in a rheumatoid patient.
Topics: Adenosine Deaminase; Aged; Arthritis, Rheumatoid; Empyema, Pleural; Female; Glucocorticoids; Humans; | 2009 |
Facilitating the use of COBRA combination therapy in early rheumatoid arthritis: a pilot implementation study.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Drug The | 2009 |
Diffuse chronic leptomeningitis with seropositive rheumatoid arthritis: report of a case successfully treated as rheumatoid leptomeningitis.
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Brain; Chronic Disease; Cytokines; Disease Progress | 2009 |
Leflunomide-induced polymyositis in a patient with rheumatoid arthritis.
Topics: Adjuvants, Immunologic; Alanine Transaminase; Anti-Inflammatory Agents; Antirheumatic Agents; Arthri | 2009 |
Macrophagic myofascitis associated with rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Biopsy; Fascia; Female; Gait Disorders, Neurologic; Humans; Immunosuppressive | 2010 |
Successful resolution of pneumonia developed in a patient affected by Crohn's disease, rheumatoid arthritis, myasthenia gravis and recurrent uveitis during concomitant treatment with tumour necrosis factor alpha inhibitors and conventional immunosuppressi
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, R | 2010 |
Rituximab therapy in patients with rheumatoid arthritis refractory or with contraindication to anti-tumour necrosis factor drugs: real-life experience in Finnish patients.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monocl | 2009 |
Gingival crevicular fluid MMP-8 and -13 and TIMP-1 levels in patients with rheumatoid arthritis and inflammatory periodontal disease.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Sedimentation; C-Reactive Protein; D | 2009 |
Iliopectineal bursitis associated with rapid destruction of a rheumatoid hip joint.
Topics: Aged; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Arthroplasty, Replacement | 2009 |
Infliximab treatment reduces the serum levels of interleukin-23 in patients with rheumatoid arthritis.
Topics: Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; | 2009 |
Uveitis associated with sarcoidosis exacerbated by etanercept therapy.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Etanercept; Female; Glucocorticoids; Humans; Immunoglob | 2009 |
Prediction of DAS28-CRP remission in patients with rheumatoid arthritis treated with tacrolimus at 6 months by baseline variables.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; C-Reactive Prote | 2009 |
Development of rheumatoid arthritis during the course of gefitinib therapy.
Topics: Adenocarcinoma; Antineoplastic Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Interaction | 2009 |
A case with rheumatoid arthritis and systemic reactive AA amyloidosis showing rapid regression of amyloid deposition on gastroduodenal mucosa after a combined therapy of corticosteroid and etanercept.
Topics: Aged; Amyloidosis; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Etanercep | 2011 |
Infected abdominal aortic aneurysm caused by nontyphoid Salmonella in an immunocompromised patient with rheumatoid arthritis.
Topics: Aged; Anti-Inflammatory Agents; Aortic Aneurysm, Abdominal; Arthritis, Rheumatoid; Bacteremia; Human | 2009 |
The clinical course of polymyalgia rheumatica in Chinese.
Topics: Age of Onset; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Asian People | 2010 |
[Case of goodpasture syndrome associated with minimal change nephrotic syndrome (MCNS) in a patient with rheumatoid arthritis (RA)].
Topics: Anti-Glomerular Basement Membrane Disease; Arthritis, Rheumatoid; Female; Humans; Kidney; Methylpred | 2009 |
Unusual central nervous system involvement of rheumatoid arthritis: successful treatment with steroid and azathioprine.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Azathioprine; Central Nervous System Diseases; Dr | 2011 |
Rheumatoid arthritis among Nigerians: the first 200 patients from a rheumatology clinic.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; | 2010 |
Coexistence of bullous rheumatoid neutrophilic dermatosis and palmoplantar pustulosis in a patient with rheumatoid arthritis.
Topics: Adrenal Cortex Hormones; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid | 2010 |
A case of adalimumab-associated interstitial pneumonia with rheumatoid arthritis.
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthrit | 2010 |
A 78-joints ultrasonographic assessment is associated with clinical assessments and is highly responsive to improvement in a longitudinal study of patients with rheumatoid arthritis starting adalimumab treatment.
Topics: Adalimumab; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Ag | 2010 |
Efficacy and safety of tacrolimus in 101 consecutive patients with rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Drug Resistance; Drug Therapy, Combination; Drug-Related Side Effects and Adv | 2010 |
Comparison between adalimumab, etanercept, and infliximab in rheumatoid arthritis: comment on the article by Hetland et al.
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthrit | 2010 |
Are there patients with inflammatory disease who do not respond to prednisone?
Topics: Adult; Aged; Arthritis, Rheumatoid; Drug Administration Routes; Female; Glucocorticoids; Humans; Mal | 2010 |
Development of myeloperoxidase-antineutrophil cytoplasmic antibody-associated renal vasculitis in a patient receiving treatment with anti-tumor necrosis factor-α.
Topics: Administration, Oral; Adult; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal; Antirhe | 2010 |
[Arthritis of the atlanto-axial joint with inflammatory neck pain as a primary manifestation of seronegative rheumatoid arthritis].
Topics: Aged; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Atlanto-Axial Joint; Di | 2010 |
Rheumatoid leptomeningitis: radiological alteration of cerebral hypoperfusion and subarachnoid lesions.
Topics: Affective Symptoms; Anticonvulsants; Arthritis, Rheumatoid; Cerebrovascular Circulation; Diffusion M | 2010 |
[Unilateral odynophagia in rheumatoid arthritis].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cooperative Behavior; Deglutition Disorders; Diagnosis, | 2011 |
Unilateral RS3PE with young-onset rheumatoid arthritis.
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Edema; Humans; Male; Middle Aged; Prednisolone; Tre | 2011 |
Minimal-change nephrotic syndrome associated with isoniazid in anti-tuberculosis chemoprophylaxis for a patient with rheumatoid arthritis.
Topics: Aged; Antirheumatic Agents; Antitubercular Agents; Arthritis, Rheumatoid; Chemoprevention; Comorbidi | 2011 |
Prednisolone treatment affects the performance of the QuantiFERON gold in-tube test and the tuberculin skin test in patients with autoimmune disorders screened for latent tuberculosis infection.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Autoimmune Diseases; Cohor | 2011 |
A change in treatment from etanercept to infliximab was effective to control scleritis in a patient with rheumatoid arthritis.
Topics: Aged; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Substitution; Drug T | 2012 |
Comparison of QuantiFERON-TB Gold and the tuberculin skin test for detecting previous tuberculosis infection evaluated by chest CT findings in Japanese rheumatoid arthritis patients.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Bacteriological Techniques; BCG Vaccine; E | 2011 |
Effects of methotrexate on the expression of the translational isoforms of glucocorticoid receptors α and β: correlation with methotrexate efficacy in rheumatoid arthritis patients.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Blottin | 2011 |
Investigation of the association between metabolic syndrome and disease activity in rheumatoid arthritis.
Topics: Adult; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Body Mass Index; Femal | 2011 |
Pyoderma gangrenosum requiring inpatient management: a report of 26 cases with follow up.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Colitis, Ulcerative | 2011 |
Raman spectroscopy detects deterioration in biomechanical properties of bone in a glucocorticoid-treated mouse model of rheumatoid arthritis.
Topics: Analysis of Variance; Animals; Arthritis, Rheumatoid; Biomechanical Phenomena; Disease Models, Anima | 2011 |
[Autoimmune pancreatitis associated with rheumatoid arthritis: successful combination therapy with steroids and methotrexate].
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Autoimmune Diseases; Biops | 2011 |
[Pneumocystis pneumonia developed in two patients with rheumatoid arthritis during treatment of adalimumab].
Topics: Adalimumab; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; be | 2011 |
Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case-control analysis.
Topics: Administration, Oral; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Canada; Case-Control Studie | 2012 |
Long-term outcome of Japanese patients with type 1 autoimmune hepatitis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Asian People; Cerebral Hemorrhage | 2012 |
Rituximab effectively reduces macrophage migration inhibitory factor in patients with active rheumatoid arthritis.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antirheumatic Agents; Arthritis, Rheumatoid; C-Reacti | 2012 |
Treatment-specific changes in circulating adipocytokines: a comparison between tumour necrosis factor blockade and glucocorticoid treatment for rheumatoid arthritis.
Topics: Adalimumab; Adipokines; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumato | 2012 |
Tocilizumab treatment in a patient suffering from rheumatoid arthritis and concomitant chronic hepatitis C infection.
Topics: Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combin | 2012 |
A dynamic real time in vivo and static ex vivo analysis of granulomonocytic cell migration in the collagen-induced arthritis model.
Topics: Animals; Arthritis, Experimental; Arthritis, Rheumatoid; Cell Movement; Female; Granulocytes; Kineti | 2012 |
Kirenol exerts a potent anti-arthritic effect in collagen-induced arthritis by modifying the T cells balance.
Topics: Animals; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Experimental; Arthritis, Rheumat | 2012 |
Mechanisms of bone fragility in a mouse model of glucocorticoid-treated rheumatoid arthritis: implications for insufficiency fracture risk.
Topics: Animals; Arthritis, Rheumatoid; Biomechanical Phenomena; Bone Remodeling; Disease Models, Animal; Fr | 2012 |
Hyperglycemia and methylprednisolone: comment on the article by den Uyl et al.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Diabetes Mellitus, Type 2; Female; Glucocorticoids; Hum | 2012 |
A case of disseminated sporotrichosis treated with prednisolone, immunosuppressants, and tocilizumab under the diagnosis of rheumatoid arthritis.
Topics: Aged; Antibodies, Monoclonal, Humanized; Arthritis, Infectious; Arthritis, Rheumatoid; Diagnosis, Di | 2012 |
Therapeutic efficacy of tocilizumab in patients with rheumatoid arthritis refractory to anti-tumor-necrosis-factor inhibitors: 1 year follow-up with low-field extremity MRI.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arth | 2013 |
Clinical outcome in patients with rheumatoid arthritis switched to tocilizumab after etanercept or infliximab failure.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthri | 2013 |
Clinical characteristics and risk factors for Pneumocystis jirovecii pneumonia in patients with rheumatoid arthritis receiving adalimumab: a retrospective review and case-control study of 17 patients.
Topics: Adalimumab; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Ca | 2013 |
Interstitial keratitis and sensorineural hearing loss as a manifestation of rheumatoid arthritis: clinical lessons from a rare complication.
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Cogan Syndrome; Diagnostic Errors; Female; Humans; | 2012 |
A predictive model for remission and low disease activity in patients with established rheumatoid arthritis receiving TNF blockers.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; C-Reactive Protein; Female; Humans; Isoxazoles; L | 2013 |
Atherosclerosis in rheumatoid arthritis: morphologic evidence obtained by carotid ultrasound.
Topics: Antirheumatic Agents; Arteriosclerosis; Arthritis, Rheumatoid; Carotid Artery, Common; Female; Human | 2002 |
[Depressive tendency in patients with RA].
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Depression; Female; | 2002 |
Gastric perforation induced by combination chemotherapy in a patient with long-term use of corticosteroids.
Topics: Adenocarcinoma; Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Arthritis, | 2002 |
Soluble HLA-DR levels in serum are associated with therapy and genetic factors in rheumatoid arthritis.
Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Ar | 2002 |
Elderly onset rheumatoid arthritis complicated by polymyalgia rheumatica.
Topics: Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Humans; Male; Polymyalgia Rheumatica; Prednis | 2002 |
Active-dimeric form of lipoprotein lipase increases in the adipose tissue of patients with rheumatoid arthritis treated with prednisolone.
Topics: Adipose Tissue; Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Chromatography; Dimerization; | 2002 |
Prednisolone induces interleukin-18 expression in mononuclear blood and myeloid progenitor cells.
Topics: Adult; Aged; Arthritis, Rheumatoid; Cells, Cultured; Female; Glucocorticoids; Humans; Interleukin-18 | 2002 |
Expression analysis of the glucocorticoid receptor and the nuclear factor-kB subunit p50 in lymphocytes from patients with rheumatoid arthritis.
Topics: Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Female; Humans; Immunoblotting; Leukocytes, M | 2002 |
[The patient suffers from rheumatism for many years. It also makes the bones brittle].
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Diphosphonates; Female; Glucocorticoids; Humans; Ma | 2002 |
Cost-effectiveness of low dose corticosteroids versus non-steroidal anti-inflammatory drugs and COX-2 specific inhibitors in the long-term treatment of rheumatoid arthritis.
Topics: Adult; Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis, Rheumatoi | 2003 |
[Evidence-based treatment of methotrexate-resistant rheumatoid arthritis. Combinations of conventional disease-modifying antirheumatic agents].
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, | 2003 |
[Reconsideration of glucocorticoid therapy for rheumatoid arthritis].
Topics: Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Hu | 2002 |
Relationship between glucocorticoid-induced osteoporosis and vitamin D receptor genotypes.
Topics: Adolescent; Adult; Arthritis, Rheumatoid; Bone Density; Female; Genotype; Humans; Lupus Erythematosu | 2002 |
Management of a patient with active rheumatoid arthritis and suspected tuberculosis causing effusive-constrictive pericarditis.
Topics: Antitubercular Agents; Arthritis, Rheumatoid; Female; Humans; Middle Aged; Pericardial Effusion; Per | 2003 |
The prevalence of patients with rheumatoid arthritis in the West Midlands fulfilling the BSR criteria for anti-tumour necrosis factor therapy: an out-patient study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; | 2003 |
Spontaneous pneumoperitoneum: an unusual complication of systemic reactive AA amyloidosis secondary to rheumatoid arthritis.
Topics: Aged; Amyloidosis; Arthritis, Rheumatoid; Gastric Mucosa; Glucocorticoids; Humans; Intestinal Pseudo | 2003 |
Long-term anti-tumor necrosis factor antibody therapy in rheumatoid arthritis patients sensitizes the pituitary gland and favors adrenal androgen secretion.
Topics: 17-alpha-Hydroxyprogesterone; Adrenocorticotropic Hormone; Adult; Androstenedione; Antibodies, Monoc | 2003 |
[A case of sarcoidosis overlapping with rheumatoid arthritis].
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Humans; Hypercalcemia; Middle Aged; Nephritis, Inte | 2003 |
Circadian rhythms in RA.
Topics: Arthritis, Rheumatoid; Circadian Rhythm; Cytokines; Finger Joint; Glucocorticoids; Humans; Hydrocort | 2003 |
Anti-arthritic agents--SMi conference: trapping cytokines. 28-29 April 2003, London, UK.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, | 2003 |
Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monocl | 2003 |
Prednisone and prednisolone as therapeutic agents; progress report on their integration into general medical practice.
Topics: Arthritis; Arthritis, Rheumatoid; Prednisolone; Prednisone; Research Report; Steroids | 1955 |
Prednisone and prednisolone in the treatment of rheumatoid arthritis.
Topics: Arthritis; Arthritis, Rheumatoid; Prednisolone; Prednisone; Steroids | 1955 |
Prednisone and prednisolone therapy in rheumatoid arthritis; clinical evaluation based on continuous observations for periods of six to nine months.
Topics: Adrenal Cortex; Adrenal Cortex Hormones; Arthritis; Arthritis, Rheumatoid; Prednisolone; Prednisone; | 1956 |
Prednisone and prednisolone as suppressive agents for rheumatoid arthritis.
Topics: Arthritis; Arthritis, Rheumatoid; Prednisolone; Prednisone; Steroids | 1956 |
Clinical and metabolic effects of prednisone and prednisolone in rheumatoid arthritis.
Topics: Arthritis; Arthritis, Rheumatoid; Prednisolone; Prednisone; Steroids | 1956 |
Metabolic effects of metacortandracin (prednisone) and metacortandralone (prednisone): comparison with ACTH, cortisone, hydrocortisone and 9-alphafluorohydrocortisone.
Topics: Adrenal Cortex; Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Arthritis; Arthritis, Rheumato | 1956 |
Hydrocortisone versus prednisolone in rheumatoid arthritis.
Topics: Adrenal Cortex; Adrenal Cortex Hormones; Arthritis; Arthritis, Rheumatoid; Hydrocortisone; Prednisol | 1956 |
[Deltacortril (prednisolone) in therapy of rheumatoid arthritis; preliminary report].
Topics: Arthritis; Arthritis, Rheumatoid; Prednisolone; Steroids | 1956 |
Perforated duodenal ulcer complicating prednisolone therapy.
Topics: Arthritis; Arthritis, Rheumatoid; Duodenal Ulcer; Humans; Peptic Ulcer Perforation; Prednisolone | 1957 |
Perforated duodenal ulcer complicating prednisolone therapy.
Topics: Arthritis; Arthritis, Rheumatoid; Duodenal Ulcer; Humans; Peptic Ulcer Perforation; Prednisolone | 1957 |
Perforated duodenal ulcer complicating prednisolone therapy.
Topics: Arthritis; Arthritis, Rheumatoid; Duodenal Ulcer; Humans; Peptic Ulcer Perforation; Prednisolone | 1957 |
Perforated duodenal ulcer complicating prednisolone therapy.
Topics: Arthritis; Arthritis, Rheumatoid; Duodenal Ulcer; Humans; Peptic Ulcer Perforation; Prednisolone | 1957 |
Prednisolone-hydroxyzine combination in rheumatoid arthritis.
Topics: Arthritis; Arthritis, Rheumatoid; Humans; Hydroxyzine; Prednisolone; Tranquilizing Agents | 1957 |
Prednisolone-hydroxyzine combination in rheumatoid arthritis.
Topics: Arthritis; Arthritis, Rheumatoid; Humans; Hydroxyzine; Prednisolone; Tranquilizing Agents | 1957 |
Prednisolone-hydroxyzine combination in rheumatoid arthritis.
Topics: Arthritis; Arthritis, Rheumatoid; Humans; Hydroxyzine; Prednisolone; Tranquilizing Agents | 1957 |
Prednisolone-hydroxyzine combination in rheumatoid arthritis.
Topics: Arthritis; Arthritis, Rheumatoid; Humans; Hydroxyzine; Prednisolone; Tranquilizing Agents | 1957 |
Local injection of prednisolone TBA in the treatment of rheumatic diseases.
Topics: Arthritis; Arthritis, Rheumatoid; Injections; Prednisolone; Rheumatic Diseases | 1957 |
Local injection of prednisolone TBA in the treatment of rheumatic diseases.
Topics: Arthritis; Arthritis, Rheumatoid; Injections; Prednisolone; Rheumatic Diseases | 1957 |
Local injection of prednisolone TBA in the treatment of rheumatic diseases.
Topics: Arthritis; Arthritis, Rheumatoid; Injections; Prednisolone; Rheumatic Diseases | 1957 |
Local injection of prednisolone TBA in the treatment of rheumatic diseases.
Topics: Arthritis; Arthritis, Rheumatoid; Injections; Prednisolone; Rheumatic Diseases | 1957 |
[Rheumatoid arthritis treatment with prednisolone].
Topics: Arthritis; Arthritis, Rheumatoid; Prednisolone | 1956 |
[Rheumatoid arthritis treatment with prednisolone].
Topics: Arthritis; Arthritis, Rheumatoid; Prednisolone | 1956 |
[Rheumatoid arthritis treatment with prednisolone].
Topics: Arthritis; Arthritis, Rheumatoid; Prednisolone | 1956 |
[Rheumatoid arthritis treatment with prednisolone].
Topics: Arthritis; Arthritis, Rheumatoid; Prednisolone | 1956 |
[Changes in prognosis of rheumatic disease in children after introduction of new hormones in therapy (hydrocortisone, prednisone, prednisolone); clinical and biological study of 25 treated cases].
Topics: Arthritis; Arthritis, Rheumatoid; Child; Humans; Hydrocortisone; Infant; Prednisolone; Prednisone; P | 1956 |
Prednisone and prednisolone in rheumatoid arthritis; an evaluation of their therapeutic efficiency.
Topics: Arthritis; Arthritis, Rheumatoid; Humans; Prednisolone; Prednisone | 1957 |
The use of sigmagen in the treatment of rheumatoid diseases.
Topics: Arthritis, Rheumatoid; Ascorbic Acid; Aspirin; Humans; Prednisolone; Rheumatic Diseases; Vitamins | 1957 |
[Treatment of rheumatoid arthritis with prednisolone].
Topics: Arthritis; Arthritis, Rheumatoid; Prednisolone | 1956 |
Treatment of rheumatoid arthritis with prednisolone and hydroxyzine.
Topics: Arthritis; Arthritis, Rheumatoid; Humans; Hydroxyzine; Prednisolone; Tranquilizing Agents | 1957 |
[Treatment of inflammatory rheumatisms with a combination of delta-hydrocortisone & aspirin].
Topics: Arthritis; Arthritis, Rheumatoid; Aspirin; Humans; Hydrocortisone; Prednisolone; Rheumatic Fever | 1957 |
Prednisone and prednisolone in the management of rheumatoid arthritis; observations during the past 16 months.
Topics: Arthritis; Arthritis, Rheumatoid; Disease Management; Humans; Prednisolone; Prednisone | 1957 |
[Prednisolone in the treatment of rheumatic & rheumatoid arthritis; technic of increasing doses].
Topics: Arthritis; Arthritis, Rheumatoid; Prednisolone | 1957 |
[Combined butazolidin-prednisolone treatment].
Topics: Arthritis; Arthritis, Rheumatoid; Disease; Hip; Humans; Osteoarthritis; Phenylbutazone; Prednisolone | 1957 |
[Local & intraarticular treatment of periosteal & tendinous irritations as well as arthrosis deformans with prednisone & prednisolone].
Topics: Arthritis; Arthritis, Rheumatoid; Periarthritis; Prednisolone; Prednisone; Tenosynovitis | 1957 |
Prednisone and prednisolone therapy in rheumatoid arthritis; clinical evaluation, with emphasis on gastrointestinal manifestations in one hundred fifty-six patients observed for periods of four to fourteen months.
Topics: Arthritis; Arthritis, Rheumatoid; Gastrointestinal Diseases; Peptic Ulcer; Prednisolone; Prednisone | 1957 |
[Local and intravenous prednisolone (decortin H) therapy].
Topics: Arthritis; Arthritis, Rheumatoid; Asthma; Dermatitis; Dermatitis, Contact; Humans; Hypersensitivity; | 1957 |
Metabolic and antirheumatic activities of 6-methylprednisolone (medrol).
Topics: Antirheumatic Agents; Arthritis; Arthritis, Rheumatoid; Methylprednisolone; Prednisolone | 1957 |
Salicylates, glucocorticoids and salicylate-glucocorticoid combinations in the treatment of rheumatoid arthritis.
Topics: Arthritis; Arthritis, Rheumatoid; Glucocorticoids; Humans; Prednisolone; Prednisone; Salicylates | 1957 |
[Prednisolone & butazolidine in prolonged combined therapy of active rheumatoid arthritis & Still's disease in children].
Topics: Arthritis; Arthritis, Juvenile; Arthritis, Rheumatoid; Child; Humans; Infant; Phenylbutazone; Predni | 1957 |
Prednisolone in the management of rheumatoid arthritis.
Topics: Arthritis; Arthritis, Rheumatoid; Disease Management; Prednisolone | 1958 |
[Intra-articular hydrocortisone & prednisolone injections in the treatment of rheumatisms].
Topics: Arthritis; Arthritis, Rheumatoid; Hydrocortisone; Injections, Intra-Articular; Prednisolone; Rheumat | 1957 |
Prednisone and prednisolone in the treatment of rheumatoid arthritis.
Topics: Arthritis; Arthritis, Rheumatoid; Humans; Prednisolone; Prednisone | 1957 |
16a-Methyl corticosteroids; a new series of anti-inflammatory compounds; clinical appraisal of their antirheumatic potencies.
Topics: Animals; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Cardiovascular Agent | 1958 |
Hydrocortisone and prednisolone in rheumatoid arthritis.
Topics: Arthritis; Arthritis, Rheumatoid; Humans; Hydrocortisone; Prednisolone | 1958 |
A new antirheumatic steroid; preliminary report.
Topics: Arthritis; Arthritis, Rheumatoid; Minnesota; Prednisolone | 1958 |
On the development of peptic ulcers in patients treated with prednisone or prednisolone.
Topics: Arthritis; Arthritis, Rheumatoid; Humans; Peptic Ulcer; Prednisolone; Prednisone | 1958 |
Intra-articular prednisolone.
Topics: Arthritis; Arthritis, Rheumatoid; Humans; Prednisolone | 1958 |
Rheumatoid arthritis: therapeutic experiences with 6 alpha-methylprednisolone (medrol).
Topics: Arthritis; Arthritis, Rheumatoid; Methylprednisolone; Prednisolone | 1958 |
Effects of methylprednisolone (medrol) in rheumatoid arthritis: a preliminary study.
Topics: Arthritis; Arthritis, Rheumatoid; Eye Diseases; Methylprednisolone; Prednisolone | 1958 |
Use of methylprednisolone in management of rheumatoid arthritis.
Topics: Arthritis; Arthritis, Rheumatoid; Methylprednisolone; Prednisolone | 1958 |
Use of the intramuscular route for prednisolone acetate therapy.
Topics: Arthritis; Arthritis, Rheumatoid; Injections, Intramuscular; Prednisolone | 1958 |
Effectiveness of antacids in reducing digestive disturbances in patients treated with prednisone and prednisolone.
Topics: Aluminum Hydroxide; Antacids; Arthritis, Rheumatoid; Gastrointestinal Diseases; Humans; Prednisolone | 1958 |
Intra-articular injections of hydrocortisone prednisolone, and their tertiary-butylacetate derivatives in patients with rheumatoid arthritis and osteoarthritis.
Topics: Acetates; Arthritis; Arthritis, Rheumatoid; Hydrocortisone; Injections, Intra-Articular; Osteoarthri | 1958 |
[Thioctic acid in therapy of arhtrosis].
Topics: Arthritis; Arthritis, Rheumatoid; Prednisolone; Thioctic Acid; Vitamins | 1958 |
Peptic ulcer during treatment of rheumatoid arthritis with cortisone derivatives.
Topics: Arthritis; Arthritis, Rheumatoid; Cortisone; Humans; Peptic Ulcer; Prednisolone; Prednisone | 1958 |
[Clinical experience with a new hormone combination in tonic therapy].
Topics: Androgens; Arthritis; Arthritis, Rheumatoid; Chronic Disease; Infections; Inositol; Prednisolone | 1958 |
[Efficacy of steroids in rheumatoid arthritis; prednisone, prednisolone-cortisone & hydrocortisone].
Topics: Adrenal Cortex Hormones; Arthritis; Arthritis, Rheumatoid; Cortisone; Hydrocortisone; Prednisolone; | 1958 |
6-Methyl prednisolone in the treatment of rheumatoid arthritis.
Topics: Arthritis; Arthritis, Rheumatoid; Humans; Methylprednisolone; Prednisolone | 1958 |
Long-term use of prednisone and prednisolone in juvenile rheumatoid arthritis; a report of fifteen cases.
Topics: Arthritis; Arthritis, Juvenile; Arthritis, Rheumatoid; Humans; Prednisolone; Prednisone | 1959 |
[Elevation of blood corticoids after intra-articular injection of cortisone derivatives (delta-hydrocortisone)].
Topics: Adrenal Cortex Hormones; Arthritis; Arthritis, Rheumatoid; Cortisone; Hydrocortisone; Injections, In | 1958 |
[Elevation of blood corticoids following intraarticular injection of cortisone derivatives (deltahydrocortisone)].
Topics: Adrenal Cortex Hormones; Arthritis; Arthritis, Rheumatoid; Cortisone; Injections, Intra-Articular; P | 1959 |
[Comparative studies on the effects of hexadecadrol & prednisone in the treatment of chronic rheumatism].
Topics: Arthritis; Arthritis, Rheumatoid; Dexamethasone; Prednisolone; Prednisone; Rheumatic Diseases | 1959 |
Prednisolone trimethylacetate in intra-articular therapy.
Topics: Arthritis; Arthritis, Rheumatoid; Hydrarthrosis; Osteoarthritis; Prednisolone | 1959 |
Synovial fluid changes in intra-articular therapy; effect of prednisolone trimethylacetate.
Topics: Arthritis; Arthritis, Rheumatoid; Humans; Hydrarthrosis; Osteoarthritis; Prednisolone; Synovial Flui | 1959 |
Corticosteroid therapy in rheumatoid arthritis; comparative study of effects of prednisone and prednisolone, methylprednisolone, triamcinolone, and dexamethasone.
Topics: Adrenal Cortex Hormones; Arthritis; Arthritis, Rheumatoid; Dexamethasone; Humans; Methylprednisolone | 1959 |
Treatment of disseminated lupus erythematosus and rheumatoid arthritis with methylprednisolone.
Topics: Arthritis; Arthritis, Rheumatoid; Humans; Lupus Erythematosus, Systemic; Methylprednisolone; Prednis | 1959 |
Treatment of rheumatoid arthritis with dexamethasone. Two hundred fifty-one patients treated for short and long periods.
Topics: Arthritis; Arthritis, Rheumatoid; Dexamethasone; Language; Prednisolone | 1960 |
A preliminary trial of betamethasone.
Topics: Arthritis; Arthritis, Rheumatoid; Betamethasone; Prednisolone | 1961 |
[Injectable dexamethasone acetate. Its use in rheumatology].
Topics: Arthritis; Arthritis, Rheumatoid; Dexamethasone; Prednisolone; Rheumatology | 1961 |
[Dexamethasone in rheumatoid arthritis. Experience in 60 cases].
Topics: Arthritis; Arthritis, Rheumatoid; Dexamethasone; Prednisolone | 1960 |
[On the treatment of rheumatic diseases in childhood with triamcinolone and dexamethasone].
Topics: Arthritis; Arthritis, Rheumatoid; Child; Dexamethasone; Infant; Prednisolone; Rheumatic Diseases; Rh | 1961 |
[Comparative study of the clinical and metabolic effects of prednosteroids and corticofluorates in rheumatoid arthritis].
Topics: Arthritis; Arthritis, Rheumatoid; Prednisolone; Prednisone; Triamcinolone | 1961 |
Prednisolone in rheumatoid arthritis.
Topics: Arthritis; Arthritis, Rheumatoid; Prednisolone | 1961 |
Clinical experiences with dexamethasone.
Topics: Arthritis; Arthritis, Rheumatoid; Dexamethasone; Prednisolone | 1961 |
[Methylprednisolone in the treatment of inflammatory rheumatism].
Topics: Arthritis; Arthritis, Rheumatoid; Methylprednisolone; Prednisolone; Rheumatic Fever | 1961 |
Effectiveness of methylprednisolone and prednisolone tertiary-butylacetate intra-articularly in rheumatoid arthritis: a comparative study.
Topics: Arthritis; Arthritis, Rheumatoid; Methylprednisolone; Prednisolone | 1960 |
[Complex balneological therapy of chronic evolutive polyarthritis].
Topics: Arthritis; Arthritis, Rheumatoid; Balneology; Humans; Prednisolone | 1960 |
The use of Na22 to study the sodium-retaining properties of steroid therapy in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Cortisone; Hypernatremia; Ions; Prednisolone; Sodium; Sodium, Dietary | 1960 |
Intra-articular steroid therapy. Comparative efficiency of 6-methylprednisolone acetate in cases of rheumatoid arthritis.
Topics: Acetates; Arthritis, Rheumatoid; Humans; Methylprednisolone; Methylprednisolone Acetate; Prednisolon | 1959 |
The injection of concentrated prednisolone trimethylacetate intra-articularly in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Injections; Prednisolone | 1959 |
6-alpha-Methyl prednisolone in the treatment of rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Methylprednisolone; Prednisolone | 1959 |
Prednisolone-hydroxyzine treatment of rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Hydroxyzine; Prednisolone | 1960 |
Dexamethasone therapy with gastric function studies in patients with rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Dexamethasone; Food; Gastric Juice; Humans; Prednisolone; Research | 1960 |
A COMPARISON of prednisolone with aspirin on other analgesics in the treatment of rheumatold rthritis.
Topics: Analgesics; Arthritis; Arthritis, Rheumatoid; Aspirin; Prednisolone | 1959 |
[The use of a new combination with steroids in the treatment of rheumatic diseases].
Topics: Arthritis; Arthritis, Rheumatoid; Dexamethasone; Humans; Prednisolone; Rheumatic Diseases; Spondylit | 1961 |
Clinical comparison of the newer anti-inflammatory corticosteroids.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Arthritis; Arthritis, Rheumatoid; Glucocorticoids | 1962 |
Intra-articular steroid therapy in rheumatoid arthritis.
Topics: Arthritis; Arthritis, Rheumatoid; Dextrans; Prednisolone; Triamcinolone | 1962 |
Intra-articular dexamethasone. A double-blind comparison with prednisolone.
Topics: Arthritis; Arthritis, Rheumatoid; Dexamethasone; Disease; Double-Blind Method; Humans; Knee; Prednis | 1962 |
Hazards of steroid treatment.
Topics: Arthritis; Arthritis, Rheumatoid; Prednisolone | 1962 |
[Studies on the extent of action of 16-methyleneprednisolone (Decortilen) in primary chronic polyarthritis].
Topics: Arthritis; Arthritis, Rheumatoid; Prednisolone | 1962 |
Systemic effects of large doses of hydrocortisone acetate and prednisolone acetate administered intra-articularly to patients with rheumatoid arthritis.
Topics: Arthritis; Arthritis, Rheumatoid; Humans; Hydrocortisone; Prednisolone | 1962 |
Intra-muscular prednisolone trimethyl acetate therapy experience in its use and complications.
Topics: Acetates; Arthritis; Arthritis, Rheumatoid; Humans; Prednisolone | 1962 |
[Observations on the use of 16-methyleneprednisolone in pediatrics].
Topics: Adrenal Cortex Hormones; Arthritis; Arthritis, Rheumatoid; Asthma; Leukemia; Nephrosis; Pediatrics; | 1963 |
Carisoprodol-prednisolone in the management of arthritis.
Topics: Arthritis; Arthritis, Rheumatoid; Carisoprodol; Disease Management; Humans; Osteoarthritis; Predniso | 1963 |
Long-term intramuscular prednisolone therapy.
Topics: Arthritis; Arthritis, Rheumatoid; Humans; Prednisolone; Spondylitis; Spondylitis, Ankylosing | 1962 |
The nature of the corticosteroid effect in rheumatoid arthritis.
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Arthritis; Arthritis, Rheumatoid; Hydrocortiso | 1962 |
[Combined cases of Bechterew's disease].
Topics: Arthritis; Arthritis, Rheumatoid; Chloroquine; Humans; Prednisolone; Rheumatic Fever; Spondylitis; S | 1962 |
[CLINICAL TRIALS OF A NEW ANTIRHEUMATIC COMBINATION PREPARATION].
Topics: Acetaminophen; Analgesics; Analgesics, Non-Narcotic; Antipyretics; Arthritis; Arthritis, Rheumatoid; | 1963 |
NIALAMIDE AS A "STEROID SPARING" AGENT IN THE TREATMENT OF RHEUMATOID ARTHRITIS.
Topics: Arthritis; Arthritis, Rheumatoid; Depression; Humans; Methylprednisolone; Nialamide; Placebos; Predn | 1963 |
CHEMOTHERAPY OF ARTHRITIS INDUCED IN RATS BY MYCOBACTERIAL ADJUVANT.
Topics: Adjuvants, Immunologic; Adjuvants, Pharmaceutic; Adrenal Cortex Hormones; Anti-Inflammatory Agents; | 1963 |
TREATMENT OF OSTEOPOROSIS WITH AN ANABOLIC COMPOUND AND L-LYSINE.
Topics: Amino Acids; Anabolic Agents; Appetite; Arthritis; Arthritis, Rheumatoid; Dietary Proteins; Emotions | 1963 |
[TREATMENT OF COLLAGEN DISEASES].
Topics: Arthritis; Arthritis, Rheumatoid; Autoimmune Diseases; Chloroquine; Collagen Diseases; Dermatomyosit | 1963 |
[CHANGES IN THE CARDIOVASCULAR INDICES OF PATIENTS WITH INFECTIOUS NONSPECIFIC POLYARTHRITIS TREATED WITH ACTH AND CORTICOSTEROIDS].
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Arthritis; Arthritis, Rheumatoid; Blood Circul | 1963 |
[TRIAMCINOLONE IN ARTICULAR RHEUMATISM].
Topics: Arthritis; Arthritis, Rheumatoid; Bursitis; Dexamethasone; Dupuytren Contracture; Fibromyalgia; Gout | 1963 |
[THE CUFF METHOD FOR THE ANTALGIC EVALUATION OF DIFFERENT DRUGS].
Topics: Aminopyrine; Arthritis; Arthritis, Rheumatoid; Aspirin; Caffeine; Gout; Osteoarthritis; Phenobarbita | 1963 |
FINGERPRINTING THE HYALURONIC ACID COMPONENT OF NORMAL AND PATHOLOGICAL SYNOVIAL FLUIDS.
Topics: Adolescent; Arthritis; Arthritis, Rheumatoid; Blood Sedimentation; Geriatrics; Humans; Hyaluronic Ac | 1963 |
[ON THE TREATMENT OF RHEUMATIC DISEASES WITH PREDNIFLEX. COMBINED THERAPY WITH ANTIRHEUMATIC AND MYOTONOLYTIC AGENTS].
Topics: Acetaminophen; Analgesics; Analgesics, Non-Narcotic; Antipyretics; Antirheumatic Agents; Arthritis; | 1963 |
[TRANSARTICULAR CORTICOTHERAPY AND CHRONIC INFLAMMATORY RHEUMATISM].
Topics: Administration, Topical; Arthritis, Rheumatoid; Betamethasone; Humans; Hydrocortisone; Methylprednis | 1963 |
MEBUTAMATE AND HYDROCHLOROTHIAZIDE IN HYPERTENSION.
Topics: Antihypertensive Agents; Arthritis; Arthritis, Rheumatoid; Blood Pressure Determination; Carbamates; | 1964 |
[CASE OF HERPES ZOSTER OTICUS ACCOMPANIED BY MULTIPLE CRANIAL NERVE PARALYSIS].
Topics: Adenosine Triphosphate; Arthritis; Arthritis, Rheumatoid; Arthroplasty; Cochlear Nerve; Cranial Nerv | 1964 |
MANAGEMENT OF RHEUMATOID DISEASE IN CHILDHOOD.
Topics: Adrenocorticotropic Hormone; Arthritis; Arthritis, Rheumatoid; Calcium; Child; Humans; Hydrocortison | 1964 |
[CALCIUM THERAPY OF OSTEOPOROSIS. DETERMINATION OF BONE DENSITY AS A CRITERION].
Topics: Aging; Anabolic Agents; Arthritis; Arthritis, Rheumatoid; Bone and Bones; Bone Density; Calcium; Ger | 1963 |
ALLERGY TO ACTH OF ANIMAL AND HUMAN ORIGIN.
Topics: Adrenocorticotropic Hormone; Anaphylaxis; Arthritis; Arthritis, Rheumatoid; Asthma; Cyanosis; Dermat | 1963 |
SMALL DOSES OF PREDNISOLONE IN THE MANAGEMENT OF RHEUMATOID ARTHRITIS.
Topics: Abscess; Adrenal Glands; Adrenal Insufficiency; Arteritis; Arthritis, Rheumatoid; Humans; Intestinal | 1964 |
NONSPECIFIC ANTI-INFLAMMATORY AGENTS. SOME NOTES ON THEIR PRACTICAL APPLICATION, ESPECIALLY IN RHEUMATIC DISORDERS.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Arthritis; Arthritis, Rheumatoid; Betamethasone; | 1964 |
INTRA-ARTICULAR STEROID THERAPY. A SURVEY AND CLINICAL REPORT.
Topics: Arm Injuries; Arthritis; Arthritis, Rheumatoid; Bursitis; Contracture; Humans; Hydrarthrosis; Hydroc | 1964 |
SIDE-EFFECTS OF LONG-TERM TREATMENT WITH CORTICOSTEROIDS AND CORTICOTROPHIN.
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Arthritis; Arthritis, Rheumatoid; Contusions; | 1964 |
PITUITARY-ADRENOCORTICAL RESERVE DURING CORTICOSTEROID THERAPY: A REPORT ON THE METHOPYRAPONE TEST IN TEN PATIENTS TAKING LONG-CONTINUED SMALL DOSES.
Topics: 17-Ketosteroids; Adrenal Cortex Hormones; Arthritis; Arthritis, Rheumatoid; Biomedical Research; Met | 1964 |
GLAUCOMA AND POSTERIOR SUBCAPSULAR CATARACT FOLLOWING TOPICAL PREDNISOLONE (ULTRACORTENOL) THERAPY.
Topics: Administration, Topical; Adolescent; Arthritis; Arthritis, Rheumatoid; Cataract; Glaucoma; Humans; K | 1964 |
[THE PLACE OF 16-METHYLENEPREDNISOLONE IN THE CORTICOTHERAPY OF RHEUMATIC DISEASES].
Topics: Arthritis; Arthritis, Rheumatoid; Methylprednisolone; Prednisolone; Rheumatic Diseases; Rheumatic Fe | 1964 |
[ACUTE ADRENOCORTICAL INSUFFICIENCY RELATED TO THE PROLONGED USE OF CORTICOSTEROIDS].
Topics: Adrenal Cortex Hormones; Adrenal Insufficiency; Adrenocorticotropic Hormone; Arthritis; Arthritis, R | 1963 |
[MODERN VIEWS ON RHEUMATOID ARTHRITIS IN CHILDHOOD (WITH A DESCRIPTION OF A MONO-ARTICULAR CASE)].
Topics: Adolescent; Arthritis; Arthritis, Juvenile; Arthritis, Rheumatoid; Diagnosis; Humans; Infant; Joints | 1964 |
HEMATOLOGICAL COMPLICATIONS OF PHENYLBUTAZONE THERAPY: REVIEW OF THE LITERATURE AND REPORT OF TWO CASES.
Topics: Adrenocorticotropic Hormone; Agranulocytosis; Anemia, Aplastic; Anemia, Macrocytic; Arthritis; Arthr | 1964 |
[COLLAGEN DISEASES AND HEMOPATHIES].
Topics: Arthritis; Arthritis, Rheumatoid; Bone Marrow Examination; C-Reactive Protein; Collagen Diseases; Dr | 1964 |
[REMOTE RESULTS OF HORMONE THERAPY OF RHEUMATIC CHILDREN].
Topics: Adolescent; Aminopyrine; Arthritis; Arthritis, Rheumatoid; Aspirin; Child; Cortisone; Drug Therapy; | 1963 |
[INTRAARTICULAR PUNCTURES, PARAARTICULAR, REGIONAL PERIDURAL AND STELLATE GANGLION INFILTRATIONS IN THE TREATMENT OF RHEUMATIC SYNDROMES].
Topics: Anesthesia; Anesthesia, Conduction; Arthritis; Arthritis, Rheumatoid; Autonomic Nerve Block; Hydroco | 1964 |
CORTISOL TOLERANCE IN RHEUMATIC DISEASES.
Topics: 17-Ketosteroids; Aldosterone; Arthritis; Arthritis, Rheumatoid; Cortisone; Drug Tolerance; Humans; H | 1964 |
DIFFUSE PULMONARY GRANULOMATOSES AND FIBROSES.
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Arthritis; Arthritis, Rheumatoid; Beryllium; C | 1964 |
NEUTROPHILIC AGRANULOCYTOSIS DURING ADMINISTRATION OF PENICILLAMINE.
Topics: Adrenal Cortex Hormones; Agranulocytosis; Arthritis; Arthritis, Rheumatoid; Bone Marrow Examination; | 1964 |
[2 CASES OF TANDERIL SIDE-EFFECTS IN CHILDREN].
Topics: Agranulocytosis; Arthritis; Arthritis, Rheumatoid; Blood Cell Count; Child; Humans; Leukopenia; Oxyp | 1964 |
CATARACT DUE TO ORAL STEROID THERAPY IN A PATIENT WITH RHEUMATOID ARTHRITIS.
Topics: Adrenal Cortex Hormones; Arthritis, Rheumatoid; Blindness; Cataract; Cortisone; Drug Therapy; Glauco | 1964 |
[CHRONIC POLYARTHRITIS].
Topics: Arthritis; Arthritis, Rheumatoid; Diagnosis, Differential; Humans; Pathology; Phenylbutazone; Predni | 1964 |
[CLINICAL ASPECTS AND THERAPY OF STEROID DIABETES].
Topics: Adrenal Cortex Hormones; Adrenal Gland Neoplasms; Adrenocorticotropic Hormone; Arthritis; Arthritis, | 1964 |
[ANTIMALARIALS AND CORTISONE WITHDRAWAL IN 34 CASES OF RHEUMATOID ARTHRITIS].
Topics: Antimalarials; Arthritis; Arthritis, Rheumatoid; Chloroquine; Cortisone; Drug Therapy; Humans; Predn | 1964 |
[ADRENOCORTICAL AND PITUITARY FUNCTION FOLLOWING PROTRACTED PREDNISOLONE TREATMENT].
Topics: 17-Ketosteroids; Adrenocorticotropic Hormone; Arthritis; Arthritis, Rheumatoid; Biomedical Research; | 1964 |
INTRAMUSCULAR ADMINISTRATION OF STEROIDS IN TREATMENT OF RHEUMATOID ARTHRITIS.
Topics: Arthritis; Arthritis, Rheumatoid; Drug Therapy; Humans; Hydrocortisone; Injections, Intramuscular; M | 1964 |
[STUDIES ON THE DOSE-EFFECT RELATIONSHIP OF VARIOUS CORTICOSTEROID DERIVATIVES].
Topics: Adrenal Cortex Hormones; Arthritis; Arthritis, Rheumatoid; Biomedical Research; Dexamethasone; Drug | 1964 |
INTRA-ARTICULAR INJECTIONS OF HYDROCORTISONE ACETATE, PREDNISOLONE TRIMETHYL ACETATE, AND METHYLPREDNISOLONE; A COMPARATIVE STUDY.
Topics: Acetates; Arthritis; Arthritis, Rheumatoid; Drug Therapy; Humans; Hydrocortisone; Injections, Intra- | 1964 |
[ON DRUG THERAPY OF RHEUMATIC DISEASES].
Topics: Anti-Anxiety Agents; Arthritis; Arthritis, Rheumatoid; Carbamates; Drug Therapy; Humans; Phenylbutaz | 1964 |
[A FEMALE PATIENT WITH BEH CET'S DISEASE].
Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Arthritis; Arthritis, Rheumatoid; Behcet Syndrom | 1965 |
PERIPHERAL NEUROPATHY IN RHEUMATOID ARTHRITIS.
Topics: Agglutination; Angiography; Arteritis; Arthritis; Arthritis, Rheumatoid; Brachial Artery; Classifica | 1965 |
GLUCOCORTICOID TOXICITY: SINGLE CONTRASTED WITH DIVIDED DAILY DOSES OF PREDNISOLONE.
Topics: Adrenal Cortex Hormones; Arthritis; Arthritis, Rheumatoid; Drug Therapy; Glucocorticoids; Prednisolo | 1965 |
RETICULOCYTE COUNT IN PATIENTS WITH RHEUMATOID ARTHRITIS, WITH OBSERVATIONS ON THE EFFECT OF GOLD THERAPY ON BONE MARROW FUNCTION.
Topics: Arthritis; Arthritis, Rheumatoid; Bone Marrow; Bone Marrow Examination; Cold Temperature; Drug Thera | 1965 |
THE RATE OF RECOVERY OF REVERSIBLE MYOPATHIES AND THE EFFECTS OF ANABOLIC AGENTS IN STEROID MYOPATHY.
Topics: Adrenal Cortex Hormones; Anabolic Agents; Antithyroid Agents; Arthritis; Arthritis, Rheumatoid; Biom | 1965 |
AN EVALUATION OF PREDNISOLONE TREATMENT FOR RHEUMATOID ARTHRITIS IN HUNGARY.
Topics: Arthritis; Arthritis, Rheumatoid; Drug Therapy; Humans; Hungary; Prednisolone | 1965 |
LOCAL CUTANEOUS ATROPHY FOLLOWING CORTICOSTEROID INJECTION.
Topics: Adolescent; Adrenal Cortex Hormones; Arthritis; Arthritis, Rheumatoid; Atrophy; Biopsy; Drug Therapy | 1965 |
THE TREATMENT OF NODOSE TENDINITIS IN THE RHEUMATOID HAND.
Topics: Arthritis; Arthritis, Rheumatoid; Cortisone; Drug Therapy; Hand; Humans; Prednisolone; Surgical Proc | 1965 |
THE PRESENT STATUS OF STEROID TREATMENT IN RHEUMATOID ARTHRITIS.
Topics: Adolescent; Arthritis; Arthritis, Juvenile; Arthritis, Rheumatoid; Child; Drug Therapy; Humans; Pred | 1965 |
Major undesirable side-effects resulting from prednisolone and prednisone.
Topics: Arthritis; Arthritis, Rheumatoid; Prednisolone; Prednisone; Steroids | 1955 |
On the effects of a new synthetic steroid analogue--6alpha-chloro-prednisolone--in patients with rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Inorganic Chemicals; Organic Chemicals; Prednisolone; Steroids | 1959 |
Experience in Great Britain with steroids (particularly dexamethasone) in rheumatoid arthritis.
Topics: Adrenal Cortex Hormones; Arthritis, Rheumatoid; Dexamethasone; Prednisolone; Steroids; United Kingdo | 1959 |
A comparison of prednisolone with aspirin or other analgesics in the treatment of rheumatoid arthritis. A second report by the joint committee of the Medical Research Council and Nuffield Foundation on clinical trials of cortisone, ACTH, and other therape
Topics: Adrenocorticotropic Hormone; Analgesics; Arthritis; Arthritis, Rheumatoid; Aspirin; Biomedical Resea | 1960 |
[Clinical investigation of paramethasone acetate in patients with rheumatoid arthritis].
Topics: Arthritis, Rheumatoid; Humans; Paramethasone; Prednisolone | 1961 |
The disadvantages of the steroids in the treatment of rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Cortisone; Dexamethasone; Methylphenidate; Prednisolone; Steroids; Triamcinol | 1962 |
Rheumatoid arthritis. Therapeutic experiences with 6-alpha fluoro prednisolone.
Topics: Arthritis; Arthritis, Rheumatoid; Prednisolone | 1962 |
[6-Methylprednisolone and its combinations. Its value as an antirheumatic agent].
Topics: Antirheumatic Agents; Arthritis; Arthritis, Rheumatoid; Methylprednisolone; Prednisolone | 1961 |
Chronic eosinophilic pneumonia associated with an initiation of rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Biopsy, Needle; Blood Chemical Analysis; Chronic Disease; Drug Therapy, Combi | 2003 |
[Innovative technologies in the complex treatment of patients with rheumatoid arthritis].
Topics: Adult; Aged; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Cyclophosphamide | 2003 |
Efficacy of cyclophosphamide combined with prednisolone in patients with AA amyloidosis secondary to rheumatoid arthritis.
Topics: Aged; Amyloidosis; Apolipoproteins; Arthritis, Rheumatoid; Cyclophosphamide; Dose-Response Relations | 2003 |
Longterm observational study of methotrexate use in a Dutch cohort of 1022 patients with rheumatoid arthritis.
Topics: Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Cohort Studies; Drug Therapy, | 2003 |
Expression of Fcgamma and complement receptors on peripheral blood monocytes in systemic lupus erythematosus and rheumatoid arthritis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Female; Glucocorticoids; Humans; Intercellular Adhesion Molecule | 2004 |
Role of mRNA expression of transcription factors in glucocorticoid sensitivity of peripheral blood mononuclear cells and disease state in rheumatoid arthritis.
Topics: Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Drug Resistance; Female; Glucocorticoids; Hum | 2004 |
Malignant lymphoma associated with rheumatoid arthritis, developing shortly after initiation of oral methotrexate.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antirheumatic Agents; Arthritis, Rheumatoid; Cycloph | 2004 |
An abrupt onset of seropositive polyarthritis with prominent distal tenosynovitis concomitant with bronochiolitis obliterans organizing pneumonia (BOOP): consideration of the relationship with RS3PE syndrome.
Topics: Arthritis; Arthritis, Rheumatoid; Cryptogenic Organizing Pneumonia; Edema; Female; Glucocorticoids; | 2004 |
Disseminated cutaneous infection with Mycobacterium chelonae in a patient with steroid-dependent rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Fatal Outcome; Glucocorticoids; Humans; Immunocompromised Host; Male; Middle | 2004 |
Bronchiolitis obliterans organizing pneumonia associated with sulfasalazine in a patient with rheumatoid arthritis.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cryptogenic Organizing Pneumonia; Female; Glucoco | 2004 |
Bone density in rheumatoid arthritis.
Topics: Absorptiometry, Photon; Adult; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Bone Density; Case-C | 2004 |
Kynurenine and neopterin levels in patients with rheumatoid arthritis and osteoporosis during drug treatment.
Topics: Arthritis, Rheumatoid; Case-Control Studies; Etidronic Acid; Female; Humans; Kynurenine; Methotrexat | 2003 |
Characterization of pristane-induced arthritis, a murine model of chronic disease: response to antirheumatic agents, expression of joint cytokines, and immunopathology.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Experimental; Art | 2004 |
Low dose prednisolone for treatment of RA.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Data Interpretation, Statisti | 2004 |
[Hemophagocytic syndrome complicating adult's seropositive rheumatoid arthritis].
Topics: Arthritis, Rheumatoid; Female; Glucocorticoids; Histiocytosis, Non-Langerhans-Cell; Humans; Middle A | 2004 |
[Pneumocystis pneumonia -- atypical manifestation in an immunosuppressed patient with rheumatoid arthritis].
Topics: Aged; Anti-Infective Agents; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; | 2004 |
The prevalence and management of hyperglycaemia in patients with rheumatoid arthritis on corticosteroid therapy.
Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Diabetes Mellitus; F | 2004 |
A case of idiopathic hypertrophic cranial pachymeningitis manifested only by positive rheumatoid factor and abnormal findings of the anterior falx.
Topics: Arthritis, Rheumatoid; Biomarkers; C-Reactive Protein; Cranial Sinuses; Dura Mater; Follow-Up Studie | 2005 |
Testicular involvement in rheumatoid vasculitis.
Topics: Administration, Oral; Arthritis, Rheumatoid; Cyclophosphamide; Drug Therapy, Combination; Glucocorti | 2004 |
Septic arthritis due to Listeria monocytogenes in a patient receiving etanercept.
Topics: Aged; Antirheumatic Agents; Arthritis, Infectious; Arthritis, Rheumatoid; Etanercept; Humans; Immuno | 2005 |
D-penicillamine-induced pemphigus successfully treated with combination therapy of mizoribine and prednisolone.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, | 2004 |
Reversing myocardial microvascular disease in a patient with rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Cardiovascular Diseases; Coronary Angiography; Coronary Circulation; Cyclospo | 2005 |
[When to begin rheumatism treatment? Initial combination therapy helps fastest].
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Cyclo | 2004 |
Leflunomide induced acute interstitial pneumonia.
Topics: Adjuvants, Immunologic; Arthritis, Rheumatoid; Cholestyramine Resin; Drug Therapy, Combination; Fema | 2005 |
Increase of sympathetic outflow measured by neuropeptide Y and decrease of the hypothalamic-pituitary-adrenal axis tone in patients with systemic lupus erythematosus and rheumatoid arthritis: another example of uncoupling of response systems.
Topics: Adalimumab; Adrenocorticotropic Hormone; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Huma | 2006 |
Reliability of computerized image analysis for the evaluation of serial synovial biopsies in randomized controlled trials in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Humans; Image Interpretation, Computer-Assisted; Prednisolone; Randomized Con | 2005 |
Lethal acute respiratory distress syndrome during anti-TNF-alpha therapy for rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Community-Acquired Infections; Drug Therapy, Combination; Etanercept; Fatal O | 2006 |
Magnetic resonance imaging in the differential diagnosis between polymyalgia rheumatica and elderly onset rheumatoid arthritis.
Topics: Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumat | 2006 |
Prednisolone in early rheumatoid arthritis: an antiinvasive effect.
Topics: Arthritis, Rheumatoid; Disease Progression; Early Diagnosis; Enzyme Inhibitors; Glucocorticoids; Hum | 2005 |
Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibo | 2006 |
[Effective treatment for a methotrexate-associated lymphoproliferative disorder with R-CHOP following administration of rituximab].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2005 |
Manifestation of rheumatoid arthritis in a patient with hereditary haemochromatosis.
Topics: Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Azathioprine; Blood Sedimenta | 2006 |
Serum levels of cartilage oligomeric matrix protein (COMP): a rapid decrease in patients with active rheumatoid arthritis undergoing intravenous steroid treatment.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Reactive; Arthritis, Rheumatoid; C-Reactive Protein; C | 2006 |
Adrenocorticotropic hormone and dehydroepiandrosterone sulfate levels of rheumatoid arthritis patients treated with glucocorticoids.
Topics: Adrenal Glands; Adrenocorticotropic Hormone; Adult; Aged; Arthritis, Rheumatoid; Biomarkers; Dehydro | 2006 |
Interstitial pneumonitis associated with infliximab therapy.
Topics: Aged; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination | 2006 |
Lupus anticoagulant and ischemic myocardial microangiopathy in rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Aspirin; Clopidogrel; Echocardiography; Humans; Interle | 2006 |
Development of ulcerative colitis during the course of rheumatoid arthritis: Association with selective IgA deficiency.
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Biopsy; Colitis, Ulcerative; Female; Humans; IgA De | 2006 |
[Insufficiency fractures in rheumatology. Case report and overview].
Topics: Aged; Arthritis, Rheumatoid; Biopsy; Bone and Bones; Chronic Kidney Disease-Mineral and Bone Disorde | 2006 |
[Gastropleural fistula due to perforated gastric ulcer].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Female; Fistula; Gastric Fistu | 2006 |
CD8-positive T cell-induced liver damage was found in a patient with polymyositis.
Topics: Aged; Arthritis, Rheumatoid; CD8-Positive T-Lymphocytes; Female; Glucocorticoids; Humans; Immunoglob | 2006 |
The effect of infliximab on chemokines in patients with rheumatoid arthritis.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; Chemokine CCL3; Che | 2007 |
Development and validation of handy rheumatoid activity score with 38 joints (HRAS38) in rheumatoid arthritis patients receiving infliximab.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Arthrography; Drug Therapy, Com | 2006 |
Polymyositis associated with infliximab treatment for rheumatoid arthritis.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Fema | 2006 |
Prednisolone phosphate-containing TRX-20 liposomes inhibit cytokine and chemokine production in human fibroblast-like synovial cells: a novel approach to rheumatoid arthritis therapy.
Topics: Adult; Arthritis, Rheumatoid; Benzamidines; Cells, Cultured; Fatty Acids; Female; Fibroblasts; Granu | 2007 |
Endothelial progenitor cells in active rheumatoid arthritis: effects of tumour necrosis factor and glucocorticoid therapy.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Cells, Cultured; Colony-Forming | 2007 |
N-of-1 trial of low-dose methotrexate and/or prednisolone in lieu of anti-CCP, MRI, or ultrasound, as first option in suspected rheumatoid arthritis?
Topics: Anti-Inflammatory Agents; Antibodies; Antirheumatic Agents; Arthritis, Rheumatoid; Dose-Response Rel | 2007 |
Massive myelinolytic leukoencephalopathy in a patient medicated with low-dose oral methotrexate for rheumatoid arthritis: an autopsy report.
Topics: Adenocarcinoma; Administration, Oral; Aged; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non- | 2007 |
Isolated gastric cryptosporidiosis in an immunocompetent patient.
Topics: Aged, 80 and over; Animals; Antiparasitic Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Chron | 2007 |
Gene expression profiling of rheumatoid arthritis synovial cells treated with antirheumatic drugs.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cell Death; Cell Line, Transformed; Fibroblasts; Gene E | 2007 |
Why are Dutch rheumatologists reluctant to use the COBRA treatment strategy in early rheumatoid arthritis?
Topics: Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Attitude of Health Personnel; | 2007 |
Acute exacerbation of preexisting interstitial lung disease after administration of etanercept for rheumatoid arthritis.
Topics: Administration, Oral; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Contraindications; Etanerce | 2007 |
Low-dose glucocorticoid therapy decreases risk for treatment-limiting infusion reaction to infliximab in patients with rheumatoid arthritis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anaphylaxis; Antibodies, Monoclonal; Antirheumatic Agent | 2007 |
Interferon gamma assay for detecting latent tuberculosis infection in rheumatoid arthritis patients during infliximab administration.
Topics: Adolescent; Adult; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; | 2007 |
Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome accompanied by Parkinson's disease.
Topics: Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Diagnosis, Differential; Edema; Female; Foot; | 2007 |
[Pulmonary infections in patients with rheumatoid arthritis].
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Immunocompromised Host; Immunosup | 2007 |
Acute lower respiratory tract infections in patients with rheumatoid arthritis.
Topics: Age Factors; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Incidence; Male; Mid | 2007 |
Interobserver agreement in two- and three-dimensional power Doppler sonographic assessment of synovial vascularity during anti-inflammatory treatment in patients with rheumatoid arthritis.
Topics: Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Blood Vessels; Female; Humans; Male; Middle A | 2007 |
Successful treatment using tacrolimus plus corticosteroid in a patient with RA associated with MDS.
Topics: Anemia, Refractory; Arthritis, Rheumatoid; Drug Therapy, Combination; Female; Humans; Immunosuppress | 2008 |
Changes in bone mineral density in premenopausal women with rheumatoid arthritis during a two-year follow-up.
Topics: Adult; Age of Onset; Arthritis, Rheumatoid; Blood Sedimentation; Bone Density; Female; Follow-Up Stu | 2007 |
The importance of the disease process and disease-modifying antirheumatic drug treatment in the development of septic arthritis in patients with rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Infectious; Arthritis, Rheumatoid; Female; Humans; Male; Methotrexa | 2007 |
COBRA combination therapy in daily practice--getting back to the future.
Topics: Abatacept; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antirheumatic Agents; Art | 2008 |
Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis.
Topics: Aged; Arthritis, Rheumatoid; Blood Pressure; Cohort Studies; Comorbidity; Cross-Sectional Studies; D | 2008 |
Complete heart block after infliximab therapy.
Topics: Aged; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Bradycardia; Female; Hear | 2008 |
Evaluation of latent tuberculosis infection in patients with inflammatory arthropathies before treatment with TNF-alpha blocking drugs using a novel flow-cytometric interferon-gamma release assay.
Topics: Aged; Anti-Inflammatory Agents; Arthritis, Psoriatic; Arthritis, Rheumatoid; CD4-Positive T-Lymphocy | 2008 |
Cholesterol crescents and plates in shoulder effusion of a rheumatoid patient.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Biopsy, Fine-Needle; Cholesterol; Disease Progression; | 2008 |
LGD-5552, an antiinflammatory glucocorticoid receptor ligand with reduced side effects, in vivo.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Arthritis, Rheumatoid; Benzopyrans; Benz | 2008 |
[Case of malignant lymphoma associated with rheumatoid arthritis].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2008 |
Eosinophilic pneumonia (EP) associated with rheumatoid arthritis in which drug-induced eosinophilic pneumonia could be ruled out.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Cysteine | 2008 |
Low disease activity state with corticosteroid may not represent 'true' low disease activity state in patients with rheumatoid arthritis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Case-Control Studies; Disability Evaluation; Disease Progression | 2008 |
Reversible infliximab-related lymphoproliferative disorder associated with Epstein-Barr virus in a patient with rheumatoid arthritis.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Biopsy; Drug Therapy, Combinati | 2008 |
Low-dose prednisolone in rheumatoid arthritis: adverse effects of various disease modifying antirheumatic drugs.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoi | 2008 |
Remission achieved after 2 years treatment with low-dose prednisolone in addition to disease-modifying anti-rheumatic drugs in early rheumatoid arthritis is associated with reduced joint destruction still present after 4 years: an open 2-year continuation
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Bone Density; Drug Therapy, Combination; F | 2009 |
[Severe pyoderma associated with rheumatoid arthritis].
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Cyclosporine; Dermatologic Agents; Drug Therapy, Co | 2008 |
[Diagnostic significance of synovial ragocytes].
Topics: Arthritis, Infectious; Arthritis, Rheumatoid; Diagnosis, Differential; Humans; Injections, Intra-Art | 1966 |
Intra-articular nitromin injection in patients with rheumatoid arthritis. (II) Studies on synovial fluid.
Topics: Adult; Arthritis, Rheumatoid; Female; Humans; Injections, Intra-Articular; Knee Joint; Male; Mechlor | 1966 |
Use of the hypospray jet injector for intra-articular injection.
Topics: Administration, Topical; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Humans; Hydrocortisone; In | 1967 |
Phenolsulphonphthalein clearance from the knee joint in normal and pathological states.
Topics: Adult; Arthritis, Infectious; Arthritis, Rheumatoid; Female; Hemarthrosis; Humans; Joint Diseases; K | 1967 |
Capillary permeability effects of synovial fluid, AMCHA, E-ACA, and prednisolone acetate.
Topics: Aminocaproates; Animals; Arthritis, Rheumatoid; Capillary Permeability; Cyclohexanecarboxylic Acids; | 1967 |
The effect of corticosteroid drugs on serum iron levels in systemic lupus erythematosus and rheumatoid arthritis.
Topics: Anemia, Hypochromic; Arthritis, Rheumatoid; Autoanalysis; Chronic Disease; Female; Humans; Hydrocort | 1967 |
Cefotaxime-associated diarrhea and Clostridium difficile.
Topics: Arthritis, Rheumatoid; Cefotaxime; Clostridium Infections; Colitis; Diarrhea; Female; Humans; Middle | 1984 |
Steroids and complement activation in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Complement Activation; Complement C3; Complement C3c; Complement C3d; Humans; | 1983 |
Controversy in the treatment of rheumatoid arthritis.
Topics: Adrenal Cortex Hormones; Arthritis, Rheumatoid; Cost-Benefit Analysis; Gold; Humans; Immunosuppressi | 1984 |
Low dose glucocorticoid therapy in rheumatoid arthritis (RA): transitional or selected add-on therapy?
Topics: Arthritis, Rheumatoid; Drug Eruptions; Glucocorticoids; Humans; Prednisolone | 1983 |
The effect of low doses of prednisolone on the traffic of T helper-inducer cells in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Humans; Kinetics; Leukocyte Count; Prednisolone; Receptors, Fc; T-Lymphocytes | 1982 |
Immunoregulatory changes in autoimmune disease.
Topics: Adult; Aged; Arthritis, Rheumatoid; Autoimmune Diseases; Female; Humans; Immunosuppressive Agents; L | 1983 |
Drugs and rheumatoid arthritis.
Topics: Adrenocorticotropic Hormone; Arthritis, Rheumatoid; Humans; Prednisolone | 1980 |
Experimentally induced streptococcal carditis and arthritis in mice treated with anti-macrophage antiserum and prednisolone.
Topics: Adult; Animals; Arthritis, Rheumatoid; Disease Models, Animal; Humans; Immune Sera; Macrophages; Mal | 1984 |
Pattern of response to systematised drug therapy in rheumatoid arthritis in Indians.
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Cyclophosphamide; Gold Sodium Thiomalate; Humans; I | 1983 |
Biological rhythms and their effect in the assessment of disease activity in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Drug Administration Schedule; Female; Flurbiprofen; Humans; Menstruation; Per | 1984 |
Plasma levels and response to prednisolone therapy in rheumatoid arthritis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Female; Humans; Long-Term Care | 1983 |
Bilateral spontaneous rupture of the Achilles tendons in a patient on long-term systemic steroid therapy.
Topics: Achilles Tendon; Aged; Arthritis, Rheumatoid; Asthma; Female; Humans; Male; Middle Aged; Necrosis; P | 1984 |
[Myasthenic syndrome--complication of D-penicillamine therapy].
Topics: Arthritis, Rheumatoid; Electromyography; Female; Humans; Middle Aged; Muscular Diseases; Penicillami | 1984 |
Coexistence of temporal arteritis/polymyalgia rheumatica and rheumatoid arthritis.
Topics: Aged; Arthritis, Rheumatoid; Blood Sedimentation; Female; Giant Cell Arteritis; Humans; Polymyalgia | 1984 |
[Molecular biology studies of synovial fluid cells of patients with chronic polyarthritis after intra-articular prednisolone medication].
Topics: Amino Acids; Arthritis, Rheumatoid; DNA; DNA Repair; DNA Replication; Dose-Response Relationship, Dr | 1984 |
[Effect of previous prednisolone therapy on the survival of children with acute lymphoid leukemia].
Topics: Agranulocytosis; Anemia, Aplastic; Arthritis, Rheumatoid; Child; Child, Preschool; Female; Humans; L | 1984 |
Serial estimation of anti-RNP antibody titers in systemic lupus erythematosus, mixed connective tissue disease and rheumatoid arthritis.
Topics: Antibodies, Antinuclear; Arthritis, Rheumatoid; Counterimmunoelectrophoresis; Humans; Lupus Erythema | 1984 |
Adrenal response in rheumatoid arthritis treated with long-term steroids.
Topics: Adrenal Glands; Adult; Aged; Arthritis, Rheumatoid; Cosyntropin; Female; Humans; Injections, Intrave | 1983 |
Prolonged low-dose corticosteroid therapy and osteoporosis in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Bone and Bones; Female; Humans; Male; Menopause; Middle Aged; Osteoporosis; P | 1984 |
The complications of systemic corticosteroid therapy in the elderly. A retrospective study.
Topics: Age Factors; Aged; Arthritis, Rheumatoid; Colitis, Ulcerative; Dose-Response Relationship, Drug; Fem | 1984 |
Diffuse alveolitis on a small dose of penicillamine.
Topics: Arthritis, Rheumatoid; Humans; Male; Middle Aged; Penicillamine; Prednisolone; Pulmonary Fibrosis; R | 1984 |
[Functional diagnostics of the adrenal cortex following long term treatment with prednisolone].
Topics: 11-Hydroxycorticosteroids; Adrenal Cortex; Arthritis, Rheumatoid; Ephedrine; Humans; Hydrocortisone; | 1980 |
Total body calcium in rheumatoid arthritis: effects of disease activity and corticosteroid treatment.
Topics: Adult; Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Body Composition; Calcium; Dose-Respon | 1982 |
A constant neurological sign in the arthritic knee.
Topics: Anesthetics, Local; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Delayed-Action Preparations; Dr | 1983 |
Glucose intolerance in patients with chronic inflammatory diseases is normalized by glucocorticoids.
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Blood Glucose; Connective Tissue Diseases; Female; G | 1983 |
Pseudo-rheumatoid deformity in elderly osteoarthritic hands.
Topics: Aged; Arthritis, Rheumatoid; Diagnostic Errors; Female; Hand Deformities, Acquired; Humans; Osteoart | 1983 |
[Drug therapy of rheumatoid arthritis].
Topics: Antineoplastic Agents; Arthritis, Rheumatoid; Bee Venoms; Chloroquine; Chronic Disease; Drug Therapy | 1980 |
[Rheumatic diseases of the joints, problems of diagnosis. Report on 3rd Rheumatism Meeting, June 6, 1980 in Oberammergau].
Topics: Adolescent; Adult; Aged; Antistreptolysin; Arthritis, Rheumatoid; Child; Diagnosis, Differential; Di | 1980 |
Complement-mediated solubilization of immune complexes in systemic lupus erythematosus.
Topics: Adrenal Cortex Hormones; Adult; Antigen-Antibody Complex; Arthritis, Rheumatoid; Complement Activati | 1982 |
[T cell subsets and the helper effect of T cells in rheumatoid arthritis and systemic lupus erythematosus, and the effects of antirheumatic agents (author's transl)].
Topics: Arthritis, Rheumatoid; Cyclophosphamide; Humans; Lupus Erythematosus, Systemic; Prednisolone; T-Lymp | 1982 |
Conversion from daily to alternate daily corticosteroids in rheumatoid arthritis.
Topics: Adrenal Cortex Function Tests; Adult; Aged; Arthritis, Rheumatoid; Cosyntropin; Drug Administration | 1982 |
Anti-poly(G) . poly(C) antibodies in the serum of patients with systemic lupus erythematosus.
Topics: Adult; Aged; Antibodies; Antibody Specificity; Arthritis, Rheumatoid; Binding Sites, Antibody; Chrom | 1982 |
[Prednisolone reduction by benoxaprofen].
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Drug Therapy, Com | 1982 |
[The hip joint in rheumatoid arthritis with special reference to correlating factors].
Topics: Adult; Aged; Arthritis, Rheumatoid; Female; Hip Joint; Humans; Male; Middle Aged; Prednisolone; Radi | 1982 |
[Study of the dose-reducing effect of acemetacin on prednisolon (author's transl)].
Topics: Adult; Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Fema | 1980 |
A rational regimen for perioperative steroid supplements and a clinical assessment of the requirement.
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Female; Humans; Hydrocortisone; Male; Middle Aged; P | 1981 |
[Guiding principles for general practitioners in the diagnosis and therapy in rheumatology].
Topics: Anti-Inflammatory Agents; Arthritis; Arthritis, Rheumatoid; Humans; Immunosuppressive Agents; Joint | 1981 |
Plasma steroid levels after intra-articular injection of prednisolone acetate in patients with rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Female; Humans; Hydrocortisone; Injections, Intra-Articular; Knee Joint; Male | 1980 |
Drugs and rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Cortisone; Humans; Prednisolone | 1980 |
Chronic eosinophilic pneumonia complicating long-standing rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Humans; Male; Prednisolone; Pulmonary Eosinophilia; Radiography | 1980 |
[Secondary gastrointestinal amyloidosis: successful treatment with TPN, prednisolone and colchicine therapy. Report of a case].
Topics: Amyloidosis; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Colchicine; Combined Modality Therapy; | 1995 |
Glucocorticoids and joint destruction in rheumatoid arthritis.
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Glucocorticoids; Humans; Prednisolone | 1995 |
Glucocorticoids and joint destruction in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Data Interpretation, Statistical; Disease Progression; Glucocorticoids; Human | 1995 |
Glucocorticoids and joint destruction in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Bone Density; Glucocorticoids; Humans; Prednisolone; Severity of Illness Inde | 1995 |
[Corticosteroid therapy and aseptic bone necrosis in patients with rheumatoid arthritis].
Topics: Adrenal Cortex Hormones; Adult; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Female; Fem | 1995 |
Urinary nitrate excretion is increased in patients with rheumatoid arthritis and reduced by prednisolone.
Topics: Adult; Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Blood Sedimentation; C-Reactive Protei | 1995 |
Hematopoietic growth factors in rheumatoid arthritis: a critical approach to their use in view of possible adverse effects.
Topics: Adult; Arthritis, Rheumatoid; Bone Marrow Transplantation; Cyclosporine; Female; Graft vs Host Disea | 1993 |
Successful treatment of autoimmune thrombocytopenia and rapidly progressive pneumonitis with recurrent pneumothoraces in a patient with rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Autoimmune Diseases; Cyclophosphamide; gamma-Globulins; Humans; Immunoglobuli | 1993 |
[Three cases with systemic rheumatic diseases who developed pulmonary lesions suggestive of bronchiolitis obliterans organizing pneumonia].
Topics: Adult; Arthritis, Rheumatoid; Cryptogenic Organizing Pneumonia; Female; Humans; Lupus Erythematosus, | 1995 |
Association of histologically proven rheumatoid arthritis with pulmonary sarcoidosis.
Topics: Arthritis, Rheumatoid; Biopsy; Bronchi; Female; Humans; Methotrexate; Middle Aged; Prednisolone; Sar | 1995 |
New perspectives on treating rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Cyclosporine; Disease Progression; Drug Therapy, Combination; Humans; Methotr | 1995 |
Hemophagocytic syndrome in a patient with rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Diagnosis, Differential; Female; Herpesviridae Infections; Herpesvirus 4, Hum | 1994 |
Associations of IgA and IgA-rheumatoid factor with disease features in patients with rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Auranofin; Cells, Cultured; Enzyme-Linked Immunosorbent Assay; Female; Humans | 1994 |
[Early diagnosis and therapy of rheumatoid arthritis. Discussion].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Combined Modality Therapy; Diagnosis, Differential; Fem | 1994 |
[Low dosage methotrexate treatment in chronic polyarthritis].
Topics: Aged; Arthritis, Rheumatoid; Blood Sedimentation; Dose-Response Relationship, Drug; Drug Administrat | 1994 |
Combined treatment with cyclophosphamide and prednisolone can induce remission of nephrotic syndrome in a patient with renal amyloidosis, associated with rheumatoid arthritis.
Topics: Aged; Amyloidosis; Arthritis, Rheumatoid; Cyclophosphamide; Drug Therapy, Combination; Female; Human | 1994 |
Henoch-Schönlein purpura in rheumatoid arthritis.
Topics: Adult; Arthritis, Rheumatoid; Female; Humans; IgA Vasculitis; Prednisolone; Radiography; Wrist Joint | 1994 |
Circadian rhythm of serum interleukin-6 in rheumatoid arthritis.
Topics: Adult; Arthritis; Arthritis, Rheumatoid; Circadian Rhythm; Connective Tissue Diseases; Female; Human | 1994 |
[A case of miliary tuberculosis after adrenocorticosteroid medication for tuberculosis of the wrist].
Topics: Aged; Aged, 80 and over; Arthritis, Rheumatoid; Diagnostic Errors; Fatal Outcome; Humans; Male; Pred | 1994 |
[Successful surgery for pulmonary aspergillosis progressing to subacute process].
Topics: Arthritis, Rheumatoid; Aspergillosis; Female; Humans; Immunocompromised Host; Lung Diseases, Fungal; | 1993 |
Concurrent acute megaloblastic anaemia and pneumonitis: a severe side-effect of low-dose methotrexate therapy during rheumatoid arthritis.
Topics: Acute Disease; Anemia, Megaloblastic; Arthritis, Rheumatoid; Humans; Leucovorin; Lung Diseases, Inte | 1993 |
Calcitonin inhibits production of immunoglobulins, rheumatoid factor and interleukin-1 by mononuclear cells from patients with rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Calcitonin; Cells, Cultured; Dose-Response Relationship, Immunologic; Female; | 1994 |
The effect of rheumatoid arthritis and steroid therapy on bone density in postmenopausal women.
Topics: Absorptiometry, Photon; Aged; Arthritis, Rheumatoid; Body Weight; Bone Density; Female; Femur; Human | 1993 |
Increased RAHA titer and interleukin-6 levels in the synovial fluid in a patient with polymyalgia rheumatica.
Topics: Arthritis, Rheumatoid; Blood Sedimentation; Female; Hemagglutination Tests; Humans; Interleukin-6; M | 1993 |
[Association of rheumatoid arthritis and Kaposi disease. Apropos of a case arising after intraarticular corticotherapy].
Topics: Aged; Arthritis, Rheumatoid; Chlorambucil; Humans; Immunity; Injections, Intra-Articular; Male; Pred | 1993 |
[Two cases of RA-like and SLE-like features similar to remitting seronegative symmetrical synovitis with pitting edema (RS3PE syndrome)].
Topics: Aged; Arthritis, Rheumatoid; Diagnosis, Differential; Edema; Female; Humans; Lupus Erythematosus, Sy | 1993 |
Rheumatoid arthritis as a cause of cardiac compression. Favourable long-term outcome of pericardiectomy.
Topics: Adult; Arthritis, Rheumatoid; Cardiac Tamponade; Follow-Up Studies; Humans; Intraoperative Period; M | 1993 |
Plasma concentration of human atrial natriuretic hormone in patients with connective tissue diseases.
Topics: Adult; Arthritis, Rheumatoid; Atrial Natriuretic Factor; Creatinine; Electrocardiography; Female; He | 1993 |
A case of steroid-responsive organizing pneumonia in a patient with rheumatoid arthritis showing migratory infiltration and normal glucose levels in pleural effusions.
Topics: Arthritis, Rheumatoid; Biopsy; Blood Glucose; Glucose; Humans; Lung; Male; Middle Aged; Pleural Effu | 1993 |
Iliopsoas bursa presenting as deep vein thrombosis in rheumatoid arthritis.
Topics: Aged; Arthritis, Rheumatoid; Bursa, Synovial; Chlorthalidone; Drainage; Female; Femoral Vein; Hepari | 1993 |
Bone mineral density of the hip and of the anteroposterior and lateral dimensions of the spine in men with rheumatoid arthritis. Effects of low-dose corticosteroids.
Topics: Adrenal Cortex Hormones; Aged; Arthritis, Rheumatoid; Bone Density; Dose-Response Relationship, Drug | 1993 |
The relationship of haemoglobin to serum erythropoietin concentrations in the anaemia of rheumatoid arthritis: the effect of oral prednisolone.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anemia; Anemia, Hypochromic; Arthritis, Rheuma | 1993 |
Depressed levels of dehydroepiandrosterone sulphate in postmenopausal women with rheumatoid arthritis but no relation with axial bone density.
Topics: Aged; Arthritis, Rheumatoid; Bone Density; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; E | 1993 |
[A case of rheumatoid arthritis accompanied by repeated pleural effusion associated with rapid tapering of steroid].
Topics: Aged; Arthritis, Rheumatoid; Drug Administration Schedule; Female; Humans; Pleural Effusion; Prednis | 1993 |
Corticosteroids in the management of rheumatoid arthritis.
Topics: Adrenal Cortex Hormones; Arthritis, Rheumatoid; Clinical Trials as Topic; Female; Humans; Prednisolo | 1996 |
Expression of the multidrug resistance glycoprotein 170 in the peripheral blood lymphocytes of rheumatoid arthritis patients. The percentage of lymphocytes expressing glycoprotein 170 is increased in patients treated with prednisolone.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; ATP Bind | 1996 |
[Open heart surgery in patients with systemic diseases requiring steroid treatment].
Topics: Aortic Arch Syndromes; Aortic Valve Insufficiency; Arthritis, Rheumatoid; Cardiac Surgical Procedure | 1996 |
Intact adrenocorticotropic hormone secretion but impaired cortisol response in patients with active rheumatoid arthritis. Effect of glucocorticoids.
Topics: Adolescent; Adrenocorticotropic Hormone; Adult; Aged; Arthritis, Rheumatoid; Blood Sedimentation; Fe | 1996 |
Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study.
Topics: Administration, Oral; Adolescent; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Arthritis | 1996 |
[A case report of systemic calcinosis associated with rheumatoid arthritis].
Topics: Acetazolamide; Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Calcinosis; Carbonic Anhydrase | 1996 |
Muscle fiber changes of the vastus medialis in rheumatoid patients.
Topics: Aged; Aged, 80 and over; Arthritis, Rheumatoid; Humans; Knee; Middle Aged; Muscle Fibers, Skeletal; | 1996 |
The rheumatoid knee before and after arthrocentesis and prednisolone injection: evaluation by Gd-enhanced MRI.
Topics: Adult; Arthritis, Rheumatoid; Drainage; Follow-Up Studies; Gadolinium DTPA; Glucocorticoids; Humans; | 1996 |
D-penicillamine-induced myositis in rheumatoid arthritis.
Topics: Adult; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Biopsy, Needle; Electr | 1996 |
[Follicular bronchiolitis associated with rheumatoid arthritis].
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Bronchi; Bronchiectasis; Bronchiolitis; Bronchiolit | 1996 |
[Interstitial pneumonia treated with intermittent cyclophosphamide pulse therapy].
Topics: Arthritis, Rheumatoid; Cyclophosphamide; Drug Administration Schedule; Female; Humans; Immunosuppres | 1996 |
Annexin V autoantibodies in rheumatoid arthritis.
Topics: Adult; Aged; Annexin A5; Arthritis, Rheumatoid; Autoantibodies; Blood Sedimentation; C-Reactive Prot | 1996 |
Focal segmental necrotizing glomerulonephritis in rheumatoid arthritis.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Azathioprine; Co | 1997 |
Increased serum leukotriene B4 level in the active stage of rheumatoid arthritis in children.
Topics: Adolescent; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid | 1997 |
[Long-term clinical results with a new surgical method for the fragile valvular annulus].
Topics: Adult; Aortic Valve; Aortic Valve Insufficiency; Arthritis, Rheumatoid; Bioprosthesis; Endocarditis, | 1997 |
[Coronary artery bypass grafting using arterial grafts in a patient with rheumatoid arthritis requiring steroid therapy].
Topics: Angina Pectoris; Arthritis, Rheumatoid; Coronary Artery Bypass; Epigastric Arteries; Humans; Male; M | 1997 |
[Focal segmental glomerulosclerosis presenting nephrotic syndrome and acute renal failure in a patient with rheumatoid arthritis].
Topics: Acute Kidney Injury; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antirheumati | 1997 |
[Bronchiolitis obliterans and no radiographic abnormalities in a patient with rheumatoid arthritis].
Topics: Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Bronchiolitis Obliterans; Cyc | 1997 |
Rheumatoid arthritis: not yet curable with early intensive therapy.
Topics: Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Hu | 1997 |
Intractable diarrhoea associated with secondary amyloidosis in rheumatoid arthritis.
Topics: Adult; Aged; Amyloidosis; Arthritis, Rheumatoid; Bacterial Infections; Chronic Disease; Diarrhea; Fe | 1997 |
[Case of remitting seronegative symmetrical synovitis with pitting edema complicated with Sjogren syndrome].
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Edema; Fem | 1997 |
[Remission induction after pentoxifylline treatment in a patient with rheumatoid arthritis].
Topics: Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Hu | 1997 |
Bronchiolitis obliterans organizing pneumonia in a patient with rheumatoid arthritis.
Topics: Aged; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Cryptogenic Organizing | 1998 |
Corticosteroids in rheumatoid arthritis.
Topics: Adrenal Cortex Hormones; Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Humans; Meta-Analysi | 1998 |
[The efficacy of combination therapy with prednisolone (PSL) and methotrexate (MTX) on radiographic progression in patients with rheumatoid arthritis (RA)].
Topics: Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Case-Control Studies; Drug Th | 1998 |
Intermittent low dose prednisolone is safe in rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Humans; Meta-Analysis as Topic; Pred | 1998 |
The effects of menopausal status and disease activity on biochemical markers of bone metabolism in female patients with rheumatoid arthritis.
Topics: Adult; Aged; Alkaline Phosphatase; Amino Acids; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, | 1998 |
Progressive subretinal fibrosis in patients with rheumatoid arthritis and renal dysfunction.
Topics: Aged; Antibodies, Antineutrophil Cytoplasmic; Arthritis, Rheumatoid; Disease Progression; Female; Fi | 1998 |
Cryptococcal pleural effusion in a patient with chronic renal failure receiving long-term corticosteroid therapy for rheumatoid arthritis.
Topics: Amphotericin B; Amyloidosis; Anti-Inflammatory Agents; Antifungal Agents; Arthritis, Rheumatoid; Cry | 1998 |
A new target for aspirin.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, | 1998 |
[Hemophagocytic syndrome in a patient with rheumatoid arthritis].
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Histiocytosis, Non-Langerhans-Cell; Humans; Male; M | 1998 |
Pentosidine in synovial fluid in osteoarthritis and rheumatoid arthritis: relationship with disease activity in rheumatoid arthritis.
Topics: Adult; Aged; Anti-Inflammatory Agents; Arginine; Arthritis, Rheumatoid; Chromatography, High Pressur | 1998 |
Penicillamine in the etiology of bullous pemphigoid.
Topics: Administration, Oral; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Glucocorticoids; Humans; | 1998 |
[Rheumatoid nodule diagnosed by thoracoscopy using flexible fiberoptic bronchoscope].
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Biopsy; Bronchoscopy; Fiber Optic Technology; Human | 1998 |
Differential surface expression of HLA-DRB1 and HLA-DRB4 among peripheral blood cells of DR4 positive individuals.
Topics: Arthritis, Rheumatoid; Disease Susceptibility; Haplotypes; Histocompatibility Testing; HLA-DR Antige | 1999 |
Influence of a ceiling effect on the assessment of radiographic progression in rheumatoid arthritis during the first 6 years of disease.
Topics: Adolescent; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Arthrography; Disease Progress | 1999 |
Remission of the nephrotic syndrome in a patient with renal amyloidosis due to rheumatoid arthritis treated with prednisolone and methotrexate.
Topics: Amyloidosis; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Female; Hum | 1998 |
Serum lipoprotein(a) and apolipoprotein(a) phenotypes in patients with rheumatoid arthritis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Apolipoproteins A; Arteriosclerosis; Arthr | 1999 |
Monocyte activation in rheumatoid arthritis (RA): increased integrin, Fc gamma and complement receptor expression and the effect of glucocorticoids.
Topics: Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; CD18 Antigens; Female; Glucocorticoids; Human | 1999 |
Increased levels of lactoferrin in synovial fluid but not in serum from patients with rheumatoid arthritis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; A | 1999 |
[Stridor caused by laryngeal rheumatoid arthritis].
Topics: Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Humans; Laryngeal Diseases; Male; Prednisolon | 1999 |
Influence of corticosteroids on neutrophils, lymphocytes, their subsets, and T-cell activity markers in patients with active rheumatoid arthritis, compared to healthy controls.
Topics: Adrenal Cortex Hormones; Adult; Arthritis, Rheumatoid; Biomarkers; Female; Glucocorticoids; Humans; | 1999 |
Giant cell arteritis associated with rheumatoid arthritis monitored by magnetic resonance angiography.
Topics: Anti-Inflammatory Agents; Arthritis, Juvenile; Arthritis, Rheumatoid; Female; Giant Cell Arteritis; | 1999 |
Erythema elevatum diutinum complicated by rheumatoid arthritis.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Dapsone; E | 1999 |
Serum YKL-40 concentrations in patients with rheumatoid arthritis: relation to disease activity.
Topics: Adipokines; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antirheumatic Agents; Arthriti | 1999 |
The ARC steroid trial and its effect on clinical practice.
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Drug Prescriptions; Famil | 1999 |
Enhanced expression of integrins and CD66b on peripheral blood neutrophils and eosinophils in patients with rheumatoid arthritis, and the effect of glucocorticoids.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD; Antigens, Neoplasm; Arthritis, Rheumatoid; Cell Adhesi | 1999 |
Skin eruption to generic prednisolone.
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Dextrans; Drug Eruptions; Drugs, Generic; Female; H | 1999 |
Serum lysozyme: a potential marker of monocyte/macrophage activity in rheumatoid arthritis.
Topics: Acute-Phase Proteins; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Arthritis, Rheumatoi | 1999 |
Pyridinium crosslinks excretion in patients with rheumatoid arthritis. Correlation with disease activity and glucocorticoid treatment.
Topics: Adult; Aged; Arthritis, Rheumatoid; Blood Sedimentation; C-Reactive Protein; Disease Progression; Gl | 1999 |
OP-1 for cervical spine fusion: bridging bone in only 1 of 4 rheumatoid patients but prednisolone did not inhibit bone induction in rats.
Topics: Animals; Arthritis, Rheumatoid; Axis, Cervical Vertebra; Bone Morphogenetic Protein 7; Bone Morphoge | 1999 |
[New therapies in rheumatoid arthritis. Stopping joint deterioration].
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Infliximab; Methotrexat | 2000 |
Rheumatoid arthritis accompanied by colonic lesions.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Barium Sulfate; Colitis, Ulcer | 2000 |
Hard metal alveolitis accompanied by rheumatoid arthritis.
Topics: Alloys; Alveolitis, Extrinsic Allergic; Arthritis, Rheumatoid; Biopsy; Cobalt; Female; Granuloma, Re | 2000 |
The ARC steroid trial and its effects on clinical practice.
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Dose-Response Relationshi | 2000 |
Initial disease modifying antirheumatic drugs and prednisolone prescriptions for patients with rheumatoid arthritis: a 15-year study.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Prescriptions; Drug Utilization; Fema | 2000 |
A case report of insufficiency fracture of the Fossa acetabuli in a patient with rheumatoid arthritis.
Topics: Acetabulum; Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Arthroplasty, Replacement, Hip; F | 2000 |
Lipoprotein(a) and lipids in relation to inflammation in rheumatoid arthritis.
Topics: Adult; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Blo | 2000 |
Comparative study of lymphocyte-suppressive potency between prednisolone and methylprednisolone in rheumatoid arthritis.
Topics: Aged; Arthritis, Rheumatoid; Cells, Cultured; Dose-Response Relationship, Immunologic; Female; Human | 2000 |
[A case of rheumatoid arthritis associated with autoimmune hemolytic anemia due to weekly low-dose methotrexate therapy].
Topics: Anemia, Hemolytic, Autoimmune; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Glucocorticoids; | 2000 |
Imbalance in production between vascular endothelial growth factor and endostatin in patients with rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Collagen; Cysteine; Drug Therapy, Co | 2000 |
Kinesin-like protein CENP-E is upregulated in rheumatoid synovial fibroblasts.
Topics: Adult; Aged; Arthritis, Rheumatoid; Cells, Cultured; Chromosomal Proteins, Non-Histone; Cloning, Mol | 1999 |
[Eosinophilic meningoencephalitis in a case of rheumatoid arthritis].
Topics: Antibodies, Antineutrophil Cytoplasmic; Arthritis, Rheumatoid; Autoimmunity; Biomarkers; Eosinophili | 1998 |
Bone mineral density and biochemical markers of bone metabolism in late onset rheumatoid arthritis and polymyalgia rheumatica--a prospective study on the influence of glucocorticoid therapy.
Topics: Aged; Alkaline Phosphatase; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Bone Den | 2000 |
[Cholesterol pericarditis associated with rheumatoid arthritis].
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cholesterol; Female; Humans; Methotrexate; Perica | 2001 |
Pachymeningitis and optic neuritis in rheumatoid arthritis: successful treatment with cyclophosphamide.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; Cyclophosphamide; Drug Therapy, Combinatio | 2001 |
Acquired Factor VIII autoantibody: four cases demonstrating the heterogenous nature of this condition and problems involved in diagnosis and treatment.
Topics: Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Autoantibodies; Autoimmune Diseases; Azathiop | 2001 |
Bilateral cricoarytenoid joint involvement in rheumatoid arthritis: a case report.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Arytenoid Cart | 2001 |
Associations of isokinetic knee extensor and flexor strength with steroid use and walking ability in women with rheumatoid arthritis.
Topics: Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Cross-Sectional Studies; Female; Humans; Kine | 2001 |
A case of myasthenia gravis accompanied by erythema elevatum diutinum and rheumatoid arthritis.
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Erythema; Female; Humans; Middle Aged; Myasthenia G | 2001 |
Focal sialadenitis in patients with ankylosing spondylitis and spondyloarthropathy: a comparison with patients with rheumatoid arthritis or mixed connective tissue disease.
Topics: Adult; Anti-Inflammatory Agents; Antibodies, Antinuclear; Antirheumatic Agents; Arthritis; Arthritis | 2001 |
[Atelectasis of the right lower lobe in association with bronchiolitis obliterans organizing pneumonia].
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Cryptogenic Organizing Pneumonia; Drug Administrati | 2001 |
Painless thyroiditis associated with severe inflammatory reactions in amyloid goiter: a case report.
Topics: Amyloid; Amyloidosis; Arthritis, Rheumatoid; Biopsy; Female; Gallium Radioisotopes; Goiter; Humans; | 2001 |
Correlation between serum hyaluronan and disease activity and severity in Thai patients with rheumatoid arthritis.
Topics: Adult; Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Enzyme-Linked Immunosorbent Assay; Fem | 2001 |
Resolved: Low-dose prednisone is indicated as a standard treatment in patients with rheumatoid arthritis.
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Glucocorticoids; | 2001 |
Resolved: Low-dose glucocorticoids are neither safe nor effective for the long-term treatment of rheumatoid arthritis.
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Glucocorticoids; | 2001 |
Demonstration of response in rheumatoid arthritis patients who are nonresponders according to the American College of Rheumatology 20% criteria: the paradox of beneficial treatment effects in nonresponders in the ATTRACT trial. Anti-Tumor Necrosis Factor
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Drug | 2001 |
Effective treatment of early rheumatoid arthritis with a combination of methotrexate, prednisolone and cyclosporin.
Topics: Adult; Aged; Arthritis, Rheumatoid; Cyclosporine; Dose-Response Relationship, Drug; Drug Administrat | 2002 |
Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment.
Topics: Adult; Aged; Aged, 80 and over; Arthritis, Psoriatic; Arthritis, Rheumatoid; Biomarkers; C-Reactive | 2002 |
Novel transdermal targeting in steroid therapy: evaluation of PK/PD profiles using an animal model of rheumatoid arthritis.
Topics: Administration, Cutaneous; Animals; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Drug Delivery S | 2002 |
Pulmonary nocardiosis in a patient treated with corticosteroid therapy.
Topics: Aged; Arthritis, Rheumatoid; Cilastatin; Cilastatin, Imipenem Drug Combination; Diagnosis, Different | 2002 |
[An elderly case of ANCA-positive membranous nephropathy].
Topics: Aged; Aged, 80 and over; Antibodies, Antineutrophil Cytoplasmic; Arthritis, Rheumatoid; Female; Glom | 2002 |
Idiopathic hypereosinophilic syndrome in a patient with long-standing rheumatoid arthritis: a case report.
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Cyclosporine; Eosinophils; Female; Humans; Hypereos | 2002 |
[Skin nodules and ulcers of the limbs in a patient with rheumatoid arthritis].
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Antirheumatic Agents; Antitubercular Agents; Arthritis | 2002 |
Successful treatment of progressive rheumatoid interstitial lung disease with cyclosporine: a case report.
Topics: Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Cyclophosphamide; Cyclosporin | 2002 |
[Pharmacokinetic of prednisolone in patients with rheumatoid arthritis].
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Female; Glucocorticoid | 2002 |
Influence of steroids and methotrexate on wound complications after elective rheumatoid hand and wrist surgery.
Topics: Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Drug Therapy, Combination; Elective Surgical | 2002 |
[A case of multiple bone and joint tuberculosis which had been misdiagnosed as the rheumatoid arthritis and treated with prednisolone for eleven months].
Topics: Adult; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Diagnostic Errors; Humans; Male; Prednisolon | 2002 |
Secondary amyloidosis in patients with rheumatoid arthritis.
Topics: Amyloidosis; Arthritis, Rheumatoid; Glucocorticoids; Humans; Prednisolone; Serum Amyloid A Protein | 2002 |
Long-term follow-up of systemic reactive AA amyloidosis secondary to rheumatoid arthritis: successful treatment with intermediate-dose corticosteroid.
Topics: Amyloidosis; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Congo Red; Female; Follow-Up Studies; | 2002 |
Rheumatoid hyperviscosity syndrome: reversibility of microvascular abnormalities after treatment.
Topics: Administration, Oral; Arthritis, Rheumatoid; Blood Viscosity; Choroid; Choroid Diseases; Female; Flu | 2002 |
Long-circulating liposomes for i.v. targeted delivery of glucocorticoids in arthritis.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Budesonide; Dexamethasone; Drug Carriers; | 2002 |
Defective expression and tyrosine phosphorylation of the T cell receptor zeta chain in peripheral blood T cells from systemic lupus erythematosus patients.
Topics: Adult; Arthritis, Rheumatoid; Autoimmune Diseases; Autoimmunity; Female; Gene Expression Regulation; | 2002 |
Proceedings: Anti-inflammatory properties of dapsone.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Dapsone; Edema; Male; Prednisolone; Rats; | 1975 |
[Effect of glucocorticoids, beta-adrenergic stimuli and blocking agents on pancreatic secretion].
Topics: Adrenergic beta-Antagonists; Arthritis, Rheumatoid; Gastritis; Glucocorticoids; Hepatitis; Male; Pan | 1977 |
Effect of glucocorticoids on the hexose monophosphate pathway in human rheumatoid synovial lining cells in vitro and in vivo.
Topics: Adult; Arthritis, Rheumatoid; Female; Glucosephosphate Dehydrogenase; Hexosephosphates; Humans; In V | 1977 |
Letter: Effect of penicillamine on peripheral-blood lymphocytes in rheumatoid arthritis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Drug Therapy, Combination; Female; Humans; Immunosuppression The | 1975 |
E.C.G. abnormalities in steroid-treated rheumatoid patients.
Topics: Adult; Aged; Arthritis, Rheumatoid; Electrocardiography; Heart Diseases; Humans; Middle Aged; Predni | 1977 |
E.C.G. abnormalities in steroid-treated rheumatoid patients.
Topics: Arthritis, Rheumatoid; Electrocardiography; Heart Diseases; Humans; Prednisolone | 1977 |
[The prednisolone saving effect of proquazone].
Topics: Arthritis, Rheumatoid; Drug Interactions; Humans; Prednisolone; Quinazolines | 1979 |
Whole body elemental composition during drug treatment of rheumatoid arthritis: a preliminary study.
Topics: Adult; Aged; Arthritis, Rheumatoid; Body Composition; Calcium; Cosyntropin; Female; Humans; Indometh | 1979 |
Pulmonary infiltrates associated with gold therapy. Report of a case.
Topics: Aged; Arthritis, Rheumatoid; Female; Gold Sodium Thiomalate; Humans; Lung; Lung Diseases; Prednisolo | 1979 |
[Dispensarization and results of antirecurrence treatment of patients with infectious nonspecific polyarthritis under rural conditions].
Topics: Adult; Aged; Ambulatory Care; Aminopyrine; Arthritis, Rheumatoid; Female; Follow-Up Studies; Humans; | 1975 |
Hypergastrinemia induced by glucocorticoid and corticotropin treatment in man.
Topics: Adolescent; Adrenocorticotropic Hormone; Adult; Arthritis, Rheumatoid; Gastrins; Glucocorticoids; Hu | 1976 |
Cellular control of collagen breakdown in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Collagen; Enzyme Activation; Female; Humans; Microbial Collagenase; Middle Ag | 1978 |
Spontaneous perforation of gallbladder due to acute non-calculous ulcerative cholecystitis.
Topics: Acute Disease; Aged; Arthritis, Rheumatoid; Cholecystitis; Diagnosis, Differential; Female; Gallblad | 1979 |
[Steroid therapy for collagen diseases and allergic diseases--indications and methods of administration].
Topics: Adult; Arthritis, Rheumatoid; Asthma; Beclomethasone; Collagen Diseases; Female; Humans; Lupus Eryth | 1979 |
[Changes in kidney function in rheumatoid arthritis].
Topics: Adult; Arthritis, Rheumatoid; Female; Gold; Humans; Kidney Diseases; Male; Middle Aged; Prednisolone | 1979 |
[Treatment of rheumatoid arthritis cases before the study].
Topics: Adult; Aged; Arthritis, Rheumatoid; Chloroquine; Exercise Therapy; Female; Gold; Health Resorts; Hos | 1979 |
Drug allergy to prednisolone in rheumatoid arthritis.
Topics: Adolescent; Adult; Arthritis, Rheumatoid; Drug Hypersensitivity; Erythema; Female; Humans; Keratocon | 1979 |
"Herbal" medicines and rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Dexamethasone; Humans; Medicine, Chinese Traditional; Medicine, East Asian Tr | 1979 |
[The compression fracture of the vertebral bodies in patients with rheumatoid arthritis (author's transl)].
Topics: Adult; Arthritis, Rheumatoid; Female; Fractures, Spontaneous; Humans; Lumbar Vertebrae; Male; Middle | 1979 |
Preliminary experience with the geomedic total knee replacement.
Topics: Aged; Arthritis, Rheumatoid; Arthroplasty; Female; Humans; Joint Prosthesis; Knee Joint; Male; Osteo | 1977 |
[Immunosuppressive treatment of rheumatoid arthritis].
Topics: Adult; Aged; Arthritis, Rheumatoid; Azathioprine; Drug Therapy, Combination; Follow-Up Studies; Huma | 1978 |
[Effect of multiple surgical interventions on the activity of chronic progressive polyarthritis].
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Blood Sedimentation; Humans; Knee Joint; Prednisolo | 1978 |
Trigger finger, a report on a series of cases.
Topics: Adult; Aged; Arthritis, Rheumatoid; Female; Fingers; Humans; Injections; Lidocaine; Male; Prednisolo | 1978 |
Rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Aspirin; Aurothioglucose; Cyclophosphamide; Female; Gold Sodium Thiomalate; H | 1975 |
[Induction of growth- and skeleton maturation disorders by long term corticosteroids therapy].
Topics: Adolescent; Adrenal Cortex Hormones; Arthritis, Rheumatoid; Bone Diseases, Developmental; Child; Chi | 1976 |
[Autopsy case of withdrawal syndrome of a patient with malignant rheumatoid arthritis].
Topics: Arteritis; Arthritis, Rheumatoid; Female; Humans; Middle Aged; Phenylbutazone; Prednisolone; Substan | 1977 |
Repeated corticosteroid injections into knee joints.
Topics: Adrenal Cortex Hormones; Arthritis, Rheumatoid; Humans; Hydrocortisone; Injections, Intra-Articular; | 1977 |
Intra-articular steroid injection in acute rheumatoid arthritis of the larynx.
Topics: Acute Disease; Arthritis, Rheumatoid; Female; Humans; Injections, Intra-Articular; Laryngeal Disease | 1977 |
[Uric acid of plasma in patients with rheumatic heart disease, rheumatoid arthritis and systemic lupus erythematosus and its dynamics during treatment].
Topics: Administration, Topical; Adult; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Cardiac Glycosides; | 1976 |
Effects of enzyme induction on metabolism of prednisolone. Clinical and laboratory study.
Topics: 11-Hydroxycorticosteroids; Adult; Aged; Arthritis, Rheumatoid; Cosyntropin; Drug Interactions; Enzym | 1976 |
[Glycosaminoglycans in the synovial fluid of chronic joint diseases (proceedings)].
Topics: Arthritis; Arthritis, Rheumatoid; Chondroitin Sulfates; Female; Fructose-Bisphosphate Aldolase; Huma | 1976 |
Noninfectious canine arthritis: rheumatoid arthritis.
Topics: Animals; Arthritis, Rheumatoid; Azathioprine; Cyclophosphamide; Dog Diseases; Dogs; Female; Male; Pr | 1976 |
Drug interactions in the management of rheumatoid arthritis.
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspirin; Drug Interactions; Drug Therapy, Combinati | 1976 |
Evaluation of analgesic agents in rats with adjuvant arthritis.
Topics: Amphetamine; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Na | 1975 |
[Clinical experience with tandearil-prednisolone].
Topics: Adult; Aged; Arthritis, Rheumatoid; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Male | 1975 |
[Steroid saving effect of naproxen].
Topics: Arthritis, Rheumatoid; Chronic Disease; Drug Therapy, Combination; Humans; Indomethacin; Naphthalene | 1975 |
[Effect of naproxen on DNA synthesis and DNA repair of human lymphocytes in in vivo experiments].
Topics: Arthritis, Rheumatoid; Chronic Disease; Cobalt Radioisotopes; DNA; DNA Repair; Humans; Hydroxyurea; | 1975 |
[Cure of scleromalacia perforans manifesting in the course of rheumatoid arthritis with d-penicillamine and fascia lata-autograft (author's transl)].
Topics: Aged; Arthritis, Rheumatoid; Eye Diseases; Fascia; Fascia Lata; Female; Humans; Penicillamine; Predn | 1975 |
[Evaluation of the effectiveness of antirheumatic preparations].
Topics: Acetaminophen; Adult; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspirin; Drug Evaluation; Fem | 1975 |
[Vogt-Koyanagi-Harada syndrome and cortisone].
Topics: Administration, Topical; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Female; Humans; Hydrocorti | 1976 |
Single daily dose corticosteroid treatment.
Topics: Adrenal Cortex Hormones; Adrenal Glands; Arthritis; Arthritis, Rheumatoid; Growth Hormone; Humans; H | 1976 |
Avascular necrosis of bone mimicking symmetric polyarthritis in a patient with malignant lymphoma treated with high-dose steroids.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arthritis, Rheumatoid; Bleomycin; Cyclophosph | 1992 |
[A case of malignant rheumatoid arthritis with corticosteroid-reactive subacute myelopathy and multiple peripheral neuropathy].
Topics: Acute Disease; Arthritis, Rheumatoid; Humans; Male; Middle Aged; Paralysis; Peripheral Nervous Syste | 1992 |
Sulphasalazine induced autoimmune syndrome.
Topics: Adult; Arthritis, Rheumatoid; Autoimmune Diseases; Chemical and Drug Induced Liver Injury; Drug Erup | 1992 |
The three week sulphasalazine syndrome.
Topics: Arthritis, Rheumatoid; Chemical and Drug Induced Liver Injury; Humans; Male; Middle Aged; Prednisolo | 1992 |
Wegener's granulomatosis in a patient with a rheumatoid arthritis.
Topics: Adult; Antigen-Antibody Complex; Antineoplastic Combined Chemotherapy Protocols; Arthritis, Rheumato | 1992 |
[Progress on diagnosis and therapy of kidney diseases complicated with rheumatoid arthritis and Sjogren's syndrome].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Gold; Humans; Kidney Diseases; Penic | 1992 |
[Cushing's syndrome found during long-term glucocorticoid treatment of rheumatoid arthritis in an elderly woman].
Topics: Aged; Arthritis, Rheumatoid; Cushing Syndrome; Female; Humans; Prednisolone | 1992 |
[Diagnosis and therapy of rheumatoid arthritis].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Autoantibodies; Diagnosis, Different | 1992 |
Serum level of interferon-gamma in autoimmune diseases.
Topics: Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; Antigens, Surface; Arthritis, Rheumatoid; Autoim | 1991 |
[An unusual case of heavy gamma-chain disease with several monoclonal components: IgG kappa, IgM lambda, Bence-Jones proteins kappa and lambda].
Topics: Anemia, Hemolytic, Autoimmune; Antineoplastic Combined Chemotherapy Protocols; Arthritis, Rheumatoid | 1991 |
Cytomegalovirus pneumonia in a patient with rheumatoid arthritis treated with low dose methotrexate and prednisone.
Topics: Arthritis, Rheumatoid; Cytomegalovirus Infections; Humans; Male; Methotrexate; Middle Aged; Opportun | 1991 |
[Cellular interstitial pneumonia and follicular bronchiolitis diagnosed by open lung biopsy in a patient with rheumatoid arthritis].
Topics: Arthritis, Rheumatoid; Biopsy; Bronchiolitis; Cyclophosphamide; Female; Humans; Lung; Middle Aged; P | 1991 |
Pure red cell aplasia caused by D-penicillamine treatment of rheumatoid arthritis.
Topics: Adult; Arthritis, Rheumatoid; Female; Humans; Penicillamine; Prednisolone; Red-Cell Aplasia, Pure | 1991 |
Muscle protein synthesis in patients with rheumatoid arthritis: effect of chronic corticosteroid therapy on prostaglandin F2 alpha availability.
Topics: Aged; Arthritis, Rheumatoid; Dinoprost; Female; Humans; Middle Aged; Muscle Proteins; Muscles; Muscu | 1991 |
Bronchiolitis obliterans organizing pneumonia and rheumatoid arthritis.
Topics: Aged; Arthritis, Rheumatoid; Biopsy; Bronchiolitis Obliterans; Humans; Lung; Male; Pneumonia; Predni | 1991 |
Superoxide scavenging activity of leukocytes in rheumatoid arthritis and Behçet's diseases.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Behcet Syndrome; Colchicine; | 1990 |
Serum albumin metabolism in rheumatic diseases: relationship to corticosteroids and peptic ulcer.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Autoimmune Diseas | 1990 |
[Interstitial lung disease in rheumatoid arthritis].
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Bronchiolitis Obliterans; Bronchoalveolar Lavage | 1990 |
[Osteoporosis in rheumatoid arthritis and related disorders].
Topics: Arthritis, Rheumatoid; Bone and Bones; Bone Resorption; Calcium; Cytokines; Estrogens; Female; Human | 1990 |
[New diagnostic standards in rheumatoid arthritis and recent trends in drug therapy].
Topics: Arthritis, Rheumatoid; Gold Sodium Thiomalate; Humans; Penicillamine; Prednisolone; Prognosis; Refer | 1990 |
Reduction of complement activation in rheumatoid arthritis by steroid treatment.
Topics: Arthritis, Rheumatoid; Complement Activation; Electron Spin Resonance Spectroscopy; Humans; Predniso | 1990 |
[Simultaneous bilateral Achilles tendon rupture following minor trauma on steroid treatment--a case report].
Topics: Achilles Tendon; Aged; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Male; Prednisolone; | 1990 |
Remitting seronegative symmetrical synovitis with pitting oedema in young adults: a subset of rheumatoid arthritis or a distinct syndrome?
Topics: Adult; Arthritis, Rheumatoid; Edema; Female; Foot; Hand; Humans; Male; Prednisolone; Serologic Tests | 1990 |
Challenging the therapeutic pyramid: a new look at treatment strategies for rheumatoid arthritis.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; C | 1990 |
[Fatal infection in patients with systemic lupus erythematosus and incidence, types, predisposing factors, and prevention--comparative study of patients with rheumatoid arthritis and primary nephrotic syndrome].
Topics: Adult; Arthritis, Rheumatoid; Bacterial Infections; Female; Humans; Incidence; Japan; Lupus Erythema | 1990 |
Opportunistic Listeria pericardial effusion.
Topics: Arthritis, Rheumatoid; Carcinoma, Squamous Cell; Female; Humans; Listeriosis; Middle Aged; Opportuni | 1990 |
Serum hyaluronate in rheumatoid arthritis: study by affino-immunoenzymatic assay.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Carrier Proteins; Enzyme-Linked I | 1988 |
Increment of Tal positive cells in peripheral blood from patients with rheumatoid arthritis.
Topics: Aged; Antigens, Surface; Arthritis, Rheumatoid; Blood Cells; Female; Humans; Male; Middle Aged; Oste | 1989 |
Autoantibodies to recombinant lipocortin-1 in rheumatoid arthritis and systemic lupus erythematosus.
Topics: Aged; Annexins; Arthritis, Rheumatoid; Autoantibodies; Calcium-Binding Proteins; Enzyme-Linked Immun | 1989 |
[Clinical relevance of determining lymphocyte subpopulations in peripheral blood of patients with rheumatoid arthritis].
Topics: Adult; Antibodies, Monoclonal; Antigens, Differentiation, B-Lymphocyte; Antigens, Differentiation, T | 1989 |
A case of interstitial pneumonia antedating rheumatoid arthritis.
Topics: Adult; Arthritis, Rheumatoid; Female; Humans; Prednisolone; Pulmonary Fibrosis | 1989 |
[Low T3 syndrome and chronic inflammatory rheumatism].
Topics: Adult; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Eut | 1989 |
[Secondary amyloidosis associated with overlap syndrome of rheumatoid arthritis, progressive systemic sclerosis and polymyositis].
Topics: Amyloidosis; Arthritis, Rheumatoid; Dimethyl Sulfoxide; Female; Humans; Kidney; Middle Aged; Myositi | 1989 |
An unusual case of painful ophthalmoplegia in a patient with rheumatoid arthritis.
Topics: Adult; Arthritis, Rheumatoid; Diplopia; Eye Movements; Female; Humans; Lupus Erythematosus, Systemic | 1989 |
Hyperviscosity syndrome secondary to rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Blood Coagulation Disorders; Blood Viscosity; Female; Humans; Middle Aged; Pl | 1989 |
[The prevention of chrysotherapy complications in patients with rheumatoid arthritis].
Topics: Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Gold; Hu | 1989 |
Biomarks in secondary osteoporosis.
Topics: Arthritis, Rheumatoid; Biomarkers; Calcium; Female; Gonadal Steroid Hormones; Humans; Middle Aged; M | 1989 |
Histopathology of femoral head osteonecrosis in rheumatoid arthritis: the relationship between steroid therapy and lipid degeneration in the osteocyte.
Topics: Aged; Arthritis, Rheumatoid; Female; Femur Head; Femur Head Necrosis; Humans; Male; Middle Aged; Ost | 1989 |
Effects of low dose corticosteroids on bone mass in rheumatoid arthritis: a longitudinal study.
Topics: Arthritis, Rheumatoid; Bone and Bones; Female; Humans; Longitudinal Studies; Middle Aged; Osteoporos | 1989 |
The short-term effect of childhood rheumatoid arthritis treated with combined western & Chinese herbal drugs.
Topics: Adolescent; Arthritis, Rheumatoid; Aspirin; Child; Child, Preschool; Drugs, Chinese Herbal; Female; | 1989 |
Changes in PMN leukocyte migration activity and complement C3d levels in RA patients with high disease activity during steroid treatment.
Topics: Acute Disease; Arthritis, Rheumatoid; Cell Migration Inhibition; Chemotaxis, Leukocyte; Complement A | 1989 |
Collagenous colitis: possible response to sulfasalazine and local steroid therapy.
Topics: Administration, Oral; Arthritis, Rheumatoid; Colitis; Collagen; Enema; Female; Humans; Microscopy, E | 1985 |
The effect of antirheumatic drugs on circulating immune complexes in rheumatoid arthritis.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antigen-Antibody Complex; Arthritis, Rheumatoid; Blood Sedime | 1986 |
[Acute rheumatoid arthritis--unsolved problems in treatment].
Topics: Acute Disease; Aged; Arthritis, Rheumatoid; Humans; Male; Prednisolone; Sulfasalazine | 1988 |
Sex hormone status and osteoporosis in postmenopausal women with rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Bone and Bones; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Femal | 1988 |
Purine enzyme levels in rheumatoid arthritis.
Topics: 5'-Nucleotidase; Adenosine Deaminase; Adult; Aged; Aging; Anti-Inflammatory Agents; Arthritis, Rheum | 1985 |
Serum osteocalcin in rheumatoid arthritis and other inflammatory arthritides: relation between inflammatory activity and the effect of glucocorticoids and remission inducing drugs.
Topics: Adrenocorticotropic Hormone; Adult; Aged; Arthritis; Arthritis, Rheumatoid; Azathioprine; Calcium-Bi | 1986 |
Effect of corticosteroid therapy on blood monocyte superoxide generation in rheumatoid arthritis: studies in vitro and ex vivo.
Topics: Adrenal Cortex Hormones; Adult; Aged; Arthritis, Rheumatoid; Female; Humans; In Vitro Techniques; Le | 1986 |
A comparison of prednisolone with azathioprine and prednisolone with intramuscular gold in rheumatoid arthritis.
Topics: Adult; Arthritis, Rheumatoid; Azathioprine; Drug Therapy, Combination; Gold Sodium Thiomalate; Human | 1988 |
Dexamethasone modulated protein synthesis in polymorphonuclear leukocytes: response in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Cells, Cultured; Dexamethasone; Humans; Methionine; Molecular Weight; Neutrop | 1988 |
Binswanger's disease after prednisolone and azathioprine therapy.
Topics: Aged; Arthritis, Rheumatoid; Azathioprine; Brain Diseases; Female; Humans; Prednisolone; Tomography, | 1988 |
Serum osteocalcin (bone Gla-protein) following corticosteroid therapy in postmenopausal women with rheumatoid arthritis. Comparison of the effect of prednisone and deflazacort.
Topics: Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Calcium-Binding Proteins; Female; Humans; Men | 1988 |
Comparison of methylprednisolone (1 g i.v.) with prednisolone (1 g orally) in rheumatoid arthritis: a pharmacokinetic and clinical study.
Topics: Arthritis, Rheumatoid; Female; Humans; Male; Methylprednisolone; Osmolar Concentration; Prednisolone | 1988 |
Coexistence of rheumatoid arthritis, ankylosing spondylitis and dermatomyositis in a patient with diabetes mellitus and the associated linked HLA antigens.
Topics: Adult; Arthritis, Rheumatoid; Azathioprine; Dermatomyositis; Diabetes Mellitus, Type 1; Hand; HLA An | 1988 |
[A case of bronchiolitis obliterans organizing pneumonia in a patient with rheumatoid arthritis].
Topics: Arthritis, Rheumatoid; Biopsy; Bronchiolitis Obliterans; Humans; Lung; Male; Middle Aged; Prednisolo | 1987 |
[Topical use of Rheumon-Gel in the combined treatment of patients with rheumatoid arthritis].
Topics: Administration, Topical; Adult; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Diclofenac; Drug Ev | 1987 |
The effect of low doses of prednisolone on T-cell subsets in rheumatoid arthritis.
Topics: Administration, Oral; Arthritis, Rheumatoid; Humans; Prednisolone; T-Lymphocytes | 1987 |
Cardiac tamponade in rheumatoid arthritis. Successful treatment with intrapericardial steroid administration.
Topics: Adult; Arthritis, Rheumatoid; Cardiac Tamponade; Combined Modality Therapy; Humans; Male; Pericardiu | 1987 |
Determinants of axial bone loss in rheumatoid arthritis.
Topics: Aged; Arthritis, Rheumatoid; Female; Femur Neck; Humans; Lumbar Vertebrae; Male; Middle Aged; Osteop | 1987 |
[Three cases of rheumatoid arthritis developing glomerulonephritis with crescent formation].
Topics: Arthritis, Rheumatoid; Female; Glomerulonephritis; Humans; Kidney Glomerulus; Male; Middle Aged; Pre | 1987 |
[Recurrent pneumothorax and cystic disease of the lung, in a case receiving steroid therapy for rheumatoid arthritis].
Topics: Arthritis, Rheumatoid; Cysts; Humans; Lung Diseases; Male; Middle Aged; Pneumothorax; Prednisolone; | 1986 |
Prednisolone pharmacokinetics in patients with rheumatoid arthritis, polymyalgia rheumatica and asthma.
Topics: Administration, Oral; Adult; Arthritis, Rheumatoid; Asthma; Female; Humans; Kinetics; Male; Middle A | 1986 |
Osteoporosis in rheumatoid arthritis: safety of low dose corticosteroids.
Topics: Adult; Arthritis, Rheumatoid; Bone and Bones; Female; Humans; Menopause; Middle Aged; Osteoporosis; | 1986 |
In vivo evidence of regulation by pituitary-adrenal axis of urinary epinephrine excretion in men.
Topics: Adrenal Gland Neoplasms; Adrenal Medulla; Adult; Arthritis, Rheumatoid; Dopamine; Epinephrine; Femal | 1986 |
Comparison of the effects of different anti-inflammatory drugs on synovial fluid prostanoid concentrations in patients with rheumatoid arthritis.
Topics: 6-Ketoprostaglandin F1 alpha; Acetaminophen; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspiri | 1985 |
Steroids reduce complement activation in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Complement Activation; Complement C3; Complement C3d; Complement C4; Humans; | 1985 |
[Use of glucocorticoids and insulin in the complex treatment of patients with rheumatoid arthritis].
Topics: Adult; Arthritis, Rheumatoid; Drug Administration Schedule; Drug Therapy, Combination; Female; Human | 1985 |
Increased proliferation of human synovial fibroblasts treated with recombinant immune interferon.
Topics: Arthritis, Rheumatoid; Cell Division; Fibroblasts; Growth Substances; HeLa Cells; Humans; Interferon | 1985 |
Bone mass in corticosteroid treated patients with rheumatoid arthritis, asthma and polymyalgia rheumatica.
Topics: Adrenal Cortex Hormones; Arthritis, Rheumatoid; Asthma; Female; Humans; Male; Osteoporosis; Polymyal | 1985 |
Eosinophil involvement in rheumatoid arthritis as reflected by elevated serum levels of eosinophil cationic protein.
Topics: Anti-Inflammatory Agents; Antigen-Antibody Complex; Arthritis, Rheumatoid; Blood Proteins; Eosinophi | 1985 |
Corticosteroid treatment in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Gold; Humans; Hypothalamo-Hypophyseal System; Methylprednisolone; Pituitary-A | 1985 |
[Superficial pemphigus during the treatment of rheumatoid polyarthritis with D-penicillamine and piroxicam (Feldene)].
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspirin; Azathioprine; Drug Therapy, Combination; H | 1985 |
[Use of high doses of glucocorticoids in patients with rheumatic diseases].
Topics: Acute Disease; Adult; Arthritis, Rheumatoid; Dermatomyositis; Drug Therapy, Combination; Female; Fol | 1985 |
[Rheumatoid vasculitis and malignant rheumatoid arthritis].
Topics: Antigen-Antibody Complex; Arthritis, Rheumatoid; Humans; Immunoglobulin G; Immunosuppressive Agents; | 1985 |
Effects of D(-) penicillamine on polymeric structural collagen of skin.
Topics: Arthritis, Rheumatoid; Collagen; Humans; Penicillamine; Prednisolone; Skin | 1973 |
Total and free-plasma tryptophan concentrations in rheumatoid disease.
Topics: Adult; Arthritis, Rheumatoid; Aspirin; Blood Proteins; Estrogens; Female; Humans; Indomethacin; Male | 1973 |
[Regional enteritis Crohn (author's transl)].
Topics: Adult; Arthritis, Rheumatoid; Azathioprine; Colitis, Ulcerative; Crohn Disease; Diagnosis, Different | 1973 |
Prednisolone metabolism and rheumatoid arthritis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Female; Humans; Male; Middle Aged; Prednisolone | 1967 |
Impaired phagocytosis by peripheral blood granulocytes in systemic lupus erythematosus.
Topics: Adult; Aged; Antibodies, Antinuclear; Arthritis, Rheumatoid; Blood Sedimentation; Complement System | 1969 |
EEG control of a cortisone psychosis.
Topics: Adult; Arthritis, Rheumatoid; Brain; Electroencephalography; Female; Humans; Prednisolone; Psychoses | 1970 |
Choroidal nodules and retinal detachments in rheumatoid arthritis. Improvement with fall in immunoglobulin levels following prednisolone and cyclophosphamide therapy.
Topics: Arthritis, Rheumatoid; Blood Sedimentation; Choroid; Cyclophosphamide; Eye Diseases; gamma-Globulins | 1970 |
[Combined drug therapy in highly acute attacks of pain in the course of rheumatic diseases].
Topics: Acute Disease; Aminopyrine; Arthritis, Rheumatoid; Dexamethasone; Drug Combinations; Female; Humans; | 1974 |
[On Predniflex-plus therapy in general practice].
Topics: Acetaminophen; Analgesics; Arthritis, Rheumatoid; Back Pain; Chlorzoxazone; Family Practice; Humans; | 1966 |
[On the intra-articular use of mucopolysaccharides in joint diseases].
Topics: Arthritis, Rheumatoid; Female; Glycosaminoglycans; Hip Dislocation; Hip Joint; Humans; Injections, I | 1967 |
[Rheumatic and rheumatoid joint inflammations. 1. Disease processes and conservative therapy].
Topics: Aged; Arthritis, Rheumatoid; Female; Glycosaminoglycans; Humans; Immobilization; Male; Middle Aged; | 1969 |
[Irritations of the iliosacral joint, their symptomatics and therapy].
Topics: Acute Disease; Administration, Topical; Adolescent; Adult; Anti-Inflammatory Agents; Arthritis, Rheu | 1970 |
Adrenocortical and pituitary function following long-term prednisolone treatment.
Topics: Adrenal Insufficiency; Adrenocorticotropic Hormone; Adult; Aged; Arthritis, Rheumatoid; Female; Huma | 1966 |
Nature of anaemia in rheumatoid arthritis. VI. Metabolism of endogenous iron.
Topics: Adrenocorticotropic Hormone; Adult; Anemia; Arthritis, Rheumatoid; Blood Transfusion; Female; Humans | 1966 |
Pituitary adrenal function during corticosteroid withdrawal in rheumatoid arthritis.
Topics: Adrenal Glands; Adrenocorticotropic Hormone; Adult; Arthritis, Rheumatoid; Female; Humans; Hydrocort | 1967 |
Method of treatment of rheumatoid arthritis in different countries.
Topics: Adrenocorticotropic Hormone; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspirin; Chloroquine; | 1966 |
[To the problem of the effect of hormone therapy (ACTH, prednisolone) on the protein composition of the blood].
Topics: Adrenocorticotropic Hormone; Arthritis, Rheumatoid; Asthma; Blood Protein Electrophoresis; Humans; P | 1966 |
The correlation of the fasting serum tyrosine level to the clinical status of patients with rheumatoid arthritis.
Topics: Adrenocorticotropic Hormone; Age Factors; Arthritis, Rheumatoid; Fasting; Female; Fluorometry; Human | 1967 |
Pituitary-adrenal function in patients given long-term adrenal steroid therapy.
Topics: 17-Hydroxycorticosteroids; Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Arthritis, Rheumato | 1968 |
[Clinical studies on the stimulation and suppression of the pituitary-adrenocortical system. 3. Studies on the pituitary adrenocortical suppression after long-term glucocorticoid treatment].
Topics: 17-Hydroxycorticosteroids; Adrenal Insufficiency; Adrenocorticotropic Hormone; Adult; Aged; Arthriti | 1968 |
Preliminary results of azathioprine treatment in severe rheumatic disease.
Topics: Adrenocorticotropic Hormone; Adult; Aged; Arthritis; Arthritis, Rheumatoid; Azathioprine; Blood Cell | 1969 |
Elasticity of human skin in vivo. A study of the physical properties of the skin in rheumatoid arthritis and the effect of corticosteroids.
Topics: Adrenocorticotropic Hormone; Arthritis, Rheumatoid; Elasticity; Female; Humans; Male; Middle Aged; P | 1969 |
Tarsal-tunnel syndrome, a presenting feature of rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Female; Foot Diseases; Humans; Middle Aged; Neurologic Examination; Periphera | 1970 |
[Treatment of chronic polyarthritis].
Topics: Adrenocorticotropic Hormone; Arthritis, Rheumatoid; Chloroquine; Gold; Humans; Hydrotherapy; Immunos | 1967 |
The present status of steroid treatment in rheumatoid arthritis.
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Arthritis, Rheumatoid; Child; Child, Preschool | 1970 |
Comparison of effects of corticotrophin and corticosteroids on pituitary-adrenal function.
Topics: 17-Ketosteroids; Adrenal Glands; Adrenocorticotropic Hormone; Adult; Aged; Androstanes; Arthritis; A | 1971 |
Single daily dose corticosteroid treatment. Effect on adrenal function and therapeutic efficacy in various diseases.
Topics: Adrenal Glands; Adrenocorticotropic Hormone; Adult; Aged; Arteritis; Arthritis, Reactive; Arthritis, | 1971 |
The use of steroids in the treatment of rheumatic diseases.
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Adult; Arthritis, Rheumatoid; Female; Humans; | 1972 |
[Corticotherapy in rheumatoid polyarthritis].
Topics: Adrenocorticotropic Hormone; Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Betamethasone; C | 1971 |
Effect of alternate-day, single-dose, corticosteroid therapy on pituitary-adrenal function.
Topics: Adolescent; Adrenocorticotropic Hormone; Adult; Aged; Arthritis, Rheumatoid; Female; Humans; Hydroco | 1972 |
[Collagen metabolism in combined therapy of rheumatoid arthritis].
Topics: Adolescent; Adrenocorticotropic Hormone; Adult; Aged; Arthritis, Rheumatoid; Azathioprine; Baths; Co | 1973 |
Anti-inflammatory drugs in rheumatic diseases.
Topics: Adrenocorticotropic Hormone; Anti-Inflammatory Agents; Antimalarials; Arthritis, Rheumatoid; Aspirin | 1974 |
Clinical evaluation of corticoid administration of rheumatoid arthritis.
Topics: 17-Hydroxycorticosteroids; Adrenocorticotropic Hormone; Arthritis, Rheumatoid; Cortisone; Drug Admin | 1974 |
Neuromuscular disorders in rheumatoid arthritis. A motor-point muscle biopsy study.
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Biopsy; Cachexia; Female; Humans; Male; Middle Aged; | 1970 |
The displacement of L-tryptophan and dipeptides from bovine albumin in vitro and from human plasma in vivo by antirheumatic drugs.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Blood Proteins; Cattle; Chloroquine; Dipep | 1971 |
Effect of prednisolone on platelets coagulation and fibrinolysis in rheumatoid arthritis.
Topics: Adolescent; Adult; Arthritis, Rheumatoid; Blood Cell Count; Blood Platelets; Blood Viscosity; Female | 1974 |
Quantitation of thermography in arthritis using multi-isothermal analysis. II. Effect of nonsteroidal anti-inflammatory therapy on the thermographic index.
Topics: Acetaminophen; Acetanilides; Administration, Oral; Arthritis, Rheumatoid; Aspirin; Foot; Gout; Hand; | 1974 |
Determination of the therapeutic mean effective doses of several anti-inflammatory agents in adjuvant arthritic rats.
Topics: Aminopyrine; Animals; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspirin; Dose-Response Relati | 1974 |
Long-term effect of corticosteroids on cardiac function.
Topics: Adolescent; Adult; Arthritis, Rheumatoid; Collagen Diseases; Cushing Syndrome; Electrocardiography; | 1974 |
[Study of the efficacy and tolerance of oxyphenylbutazone-prednisone combination suppositories in rheumatology].
Topics: Arthritis, Rheumatoid; Drug Combinations; Drug Evaluation; Female; Humans; Male; Oxyphenbutazone; Pr | 1974 |
[Investigation of protein synthesis in cells of the synovial fluid after intra-articular steroid therapy (author's transl)].
Topics: Adrenal Cortex Hormones; Arthritis, Rheumatoid; Cells; Dose-Response Relationship, Drug; Humans; Inj | 1974 |
[In vivo investigation of the effect of antirheumatic drugs on DNA synthesis and DNA repair in patients with chronic rheumatoid arthritis (author's transl)].
Topics: Adult; Aged; Arthritis, Rheumatoid; Chronic Disease; Dimethylamines; DNA; DNA Repair; Female; Flufen | 1974 |
The treatment of connective tissue diseases with a new plurichronocorticoid.
Topics: Arthritis, Rheumatoid; Connective Tissue; Cortisone; Drug Combinations; Drug Evaluation; Female; Hum | 1974 |
Which drugs for which rheumatic disorder?
Topics: Analgesics; Arthritis, Rheumatoid; Aspirin; Gold; Gout; Humans; Indomethacin; Lupus Erythematosus, S | 1972 |
[Which orthopedic indications are promising a successful therapy using Realin?].
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Female; Humans; Male; Middle Aged; Oxyphenbutazone; | 1972 |
[therapy with oral retard antirheumatic drugs in orthopedic ambulatory care].
Topics: Administration, Oral; Adolescent; Adult; Aged; Ambulatory Care; Arthritis, Rheumatoid; Female; Human | 1972 |
Corticosteroid osteoporosis.
Topics: Adult; Aged; Aging; Arthritis, Rheumatoid; Asthma; Autoanalysis; Bone and Bones; Calcium; Calcium Ra | 1973 |
Phagocytic activity of macrophages and polymorphs in inflammatory exudates studied by a 'skin window' technique in rheumatoid and control patients.
Topics: Arthritis, Rheumatoid; Exudates and Transudates; Gold; Humans; Inflammation; Leukocytes; Macrophages | 1972 |
Effects of gold salts and prednisolone on inflammatory cells. I. Phagocytic activity of macrophages and polymorphs in inflammatory exudates studied by a "skin-window" technique in rheumatoid and control patients.
Topics: Adult; Aged; Arthritis, Rheumatoid; Carbon; Exudates and Transudates; Female; Gold; Humans; Inflamma | 1973 |
[Impulse cytophotometric studies on proliferation kinetics of synovial fluid cells (author's transl)].
Topics: Animals; Arthritis, Rheumatoid; Cell Division; Cell Movement; Cytological Techniques; DNA; Humans; I | 1973 |
B- and T-lymphocytes in rheumatoid synovitis and the effect of cyclophosphamide.
Topics: Arthritis, Rheumatoid; B-Lymphocytes; Cyclophosphamide; Humans; Immunoglobulin A; Immunoglobulin G; | 1974 |
Concurrent development of acute autoimmune haemolytic anaemia with rheumatoid arthritis.
Topics: Anemia, Hemolytic, Autoimmune; Arthritis, Rheumatoid; Autoantibodies; Female; Hand; Humans; Middle A | 1972 |
[Therapy of chronic polyarthritis. 2].
Topics: Adrenal Cortex Hormones; Arthritis, Rheumatoid; Aspirin; Betamethasone; Dexamethasone; Flufenamic Ac | 1972 |
[Mecortolone in topical treatment of rheumatoid arthritis and degenerative joint diseases].
Topics: Acetates; Administration, Topical; Adult; Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Fem | 1972 |
Deposition of osmium in rheumatoid synovial tissue after intra-articular injection of osmic acid. A histological and electron microscopical study.
Topics: Adipose Tissue; Arthritis, Rheumatoid; Histiocytes; Humans; Inflammation; Injections, Intra-Articula | 1972 |
[Immunodepressants in the treatment of the major collagenoses].
Topics: Adolescent; Adult; Arthritis, Rheumatoid; Chlorambucil; Chloroquine; Female; Humans; Immunosuppressi | 1972 |
[The effect of calcium pantothenate on the adrenal cortex of patients with rheumatoid polyarthritis treated with corticosteroids].
Topics: Adrenal Insufficiency; Adult; Arthritis, Rheumatoid; Calcium; Female; Humans; Male; Middle Aged; Pan | 1972 |
Growth hormone secretion in children during corticosteroid treatment. Responses to arginine.
Topics: Adolescent; Arginine; Arthritis, Rheumatoid; Blood Glucose; Child; Child, Preschool; Growth Hormone; | 1973 |
Bacteriuria in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Bacteriuria; Creatinine; Female; Glomerular Filtration Rate; Humans; Male; Mi | 1973 |
Nitroblue tetrazolium dye reduction by peripheral leukocytes from rheumatoid arthritis and systemic lupus erythematosus patients measured by a histochemical and spectrophotometric method.
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Histocytochemistry; Humans; Hydroxychloroquine; In V | 1973 |
Diphenylhydantoin for steroid-induced muscle weakness.
Topics: Arthritis, Rheumatoid; Humans; Male; Middle Aged; Muscular Diseases; Phenytoin; Prednisolone | 1973 |
Sudden gigantism of breasts: drug induced?
Topics: Adult; Arthritis, Rheumatoid; Body Weight; Breast Diseases; Female; Humans; Hypertrophy; Mastectomy; | 1973 |
[Wissler's allergic subsepsis in the adult age].
Topics: Age Factors; Arthritis, Rheumatoid; Diagnosis, Differential; Female; Humans; Lupus Erythematosus, Sy | 1973 |
Measurement of systemic inflammatory activity in rheumatoid arthritis by the 99mTc method.
Topics: Adult; Aged; Arthritis, Rheumatoid; Aspirin; Biomechanical Phenomena; Blood Sedimentation; Depressio | 1973 |
Posterior subcapsular cataract in rheumatoid arthritis patients after long-term, low-dosage paramethasone therapy.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Arthritis, Rheumatoid; Cataract; Female; Humans; M | 1973 |
Histology of the lacrimal gland in keratoconjunctivitis sicca.
Topics: Aged; Arthritis, Rheumatoid; Biopsy; Female; Humans; Inflammation; Keratoconjunctivitis; Lacrimal Ap | 1973 |
Quantitation of thermography in arthritis using multi-isothermal analysis. I. The thermographic index.
Topics: Adult; Arthritis, Rheumatoid; Body Temperature; Female; Humans; Injections, Intra-Articular; Knee Jo | 1974 |
[Evaluation of the oxyphenylbutazone prednisolone combination in patients with progressive chronic polyarthritis].
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Capsules; Child; Drug Combinations; Evaluation Studi | 1974 |
The relative effects of age and corticosteroid therapy on the collagen profiles of dermis from subjects with rheumatoid arthritis.
Topics: Adult; Age Factors; Aged; Arthritis, Rheumatoid; Biopsy, Needle; Collagen; Female; Humans; Middle Ag | 1974 |
'Steroid psychosis': a case report.
Topics: Adult; Arthritis, Rheumatoid; Chlorpromazine; Humans; Male; Phenylbutazone; Prednisolone; Psychoses, | 1974 |
Wegener's granulomatosis occurring in a patient with pre-existing rheumatoid arthritis.
Topics: Adult; Arthritis, Rheumatoid; Female; Granulomatosis with Polyangiitis; Humans; Kidney; Larynx; Midd | 1974 |
[Incidence of chronic gastritis in progressive chronic polyarthritis].
Topics: Adult; Aged; Antibody Formation; Antibody-Producing Cells; Arthritis, Rheumatoid; Autoantibodies; Ch | 1974 |
[Treatment of chronic connective tissue diseases with cytostatics].
Topics: Antineoplastic Agents; Arthritis, Rheumatoid; Azathioprine; Chlorambucil; Chronic Disease; Collagen | 1970 |
Reduced glomerular function in rheumatoid arthritis.
Topics: Adult; Age Factors; Aged; Arthritis, Rheumatoid; Bone Resorption; Creatinine; Female; Glomerular Fil | 1972 |
Total-dose infusion of iron-dextran in rheumatoid arthritis.
Topics: Adult; Aged; Anemia, Hypochromic; Arthritis, Rheumatoid; Blood Sedimentation; Eosinophils; Female; H | 1972 |
Local steroid therapy in painful orthopaedic conditions.
Topics: Adrenal Cortex Hormones; Animals; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Blood Vessels; Bo | 1972 |
[Bone metabolism and rheumatoid arthritis].
Topics: Adult; Aged; Alkaline Phosphatase; Analysis of Variance; Arthritis, Rheumatoid; Bone and Bones; Calc | 1972 |
[Biochemistry of rheumatoid arthritis].
Topics: Age Factors; Arthritis, Rheumatoid; Cartilage, Articular; Chondroitin; Collagen; Humans; Knee Joint; | 1972 |
[Planning of the study group Cytostatic Therapy of Rheumatoid Arthtitis].
Topics: Arthritis, Rheumatoid; Azathioprine; Computers; Cyclophosphamide; Follow-Up Studies; Humans; Interna | 1972 |
[Clinical studies of neuro-Behcet's syndrome--with special reference to epidemiological and clinicopathological studies].
Topics: Adolescent; Adult; Arthritis, Rheumatoid; Behcet Syndrome; Brain; Child; Demyelinating Diseases; Fem | 1972 |
Biochemical factors in the action of steroids on diseased joints in rheumatoid arthritis.
Topics: Acid Phosphatase; Adult; Aged; Arthritis, Rheumatoid; Cortisone; Female; Glucocorticoids; Hexosamini | 1972 |
Factor VIII inhibitor: acquired haemostatic defect in a nonhaemophiliac patient with rheumatoid arthritis.
Topics: Aminocaproates; Arthritis, Rheumatoid; Azathioprine; Blood Coagulation Disorders; Blood Coagulation | 1972 |
An acute immune response to intra-articular injection of osmium tetroxide.
Topics: Arthritis, Rheumatoid; Creatinine; Drug Hypersensitivity; Female; Humans; Injections, Intra-Articula | 1971 |
Further experience with azathioprine in rheumatoid arthritis.
Topics: Adrenal Cortex Hormones; Arthritis, Rheumatoid; Azathioprine; Drug Combinations; Follow-Up Studies; | 1971 |
[Complications of corticosteeroid therapy in children].
Topics: Adrenal Glands; Adrenocortical Hyperfunction; Arthritis, Infectious; Arthritis, Rheumatoid; Child; G | 1971 |
[Clinical study of injectable paramethasone acetate: comparative study on the therapeutic effect of 6-alpha-fluoro-16-alpha-methyl-prednisolone-21-acetate administered orally and parenterally].
Topics: Administration, Oral; Adolescent; Adult; Aged; Arthritis, Rheumatoid; Female; Humans; Injections, In | 1971 |
Chemotaxis of polymorphonuclear leukocytes from patients with rheumatoid arthritis.
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Chemotaxis; Child; Complement System Proteins; Femal | 1971 |
[2 cases of chronic rheumatoid arthritis with severe infectious diseases caused by long-term steroid administration].
Topics: Arthritis, Infectious; Arthritis, Rheumatoid; Empyema; Female; Fingers; Humans; Knee; Middle Aged; P | 1971 |
[The clinical aspects of degenerative rheumatism and the possibilities of conservative therapy].
Topics: Adrenal Cortex Hormones; Adult; Aged; Analgesics; Arthritis, Rheumatoid; Diathermy; Exercise Therapy | 1965 |
[The clinical aspects of degenerative rheumatism and the possibilities of conservative therapy].
Topics: Adrenal Cortex Hormones; Adult; Aged; Analgesics; Arthritis, Rheumatoid; Diathermy; Exercise Therapy | 1965 |
[Successful intra-articular and local corticoid therapy].
Topics: Arthritis, Rheumatoid; Female; Fibromyalgia; Humans; Injections; Injections, Intra-Articular; Male; | 1964 |
[Comparative study of 2 corticosteroids, in a test of double anonymity, in the treatment of the rheumatoid arthritis].
Topics: Aged; Arthritis, Rheumatoid; Female; Glucocorticoids; Humans; Male; Middle Aged; Prednisolone | 1966 |
[The effect of 6-alpha-fluoro-16-alpha-methyl-1-dehydro-corticosterone (fluocortolone) in internal diseases].
Topics: Acute Disease; Adrenal Insufficiency; Adult; Aged; Arthritis, Rheumatoid; Asthma; Bronchitis; Chroni | 1968 |
[Possibilities and limitations of an antirheumatic therapy].
Topics: Adrenal Cortex Hormones; Arthritis, Rheumatoid; Balneology; Drug Synergism; Electric Stimulation The | 1968 |
[Gradual reduction of corticosteroid medication in diseases of the rheumatic group].
Topics: Acetaminophen; Arthritis, Rheumatoid; Humans; Muscles; Prednisolone; Rheumatic Diseases | 1968 |
[On the treatment of rheumatic diseases with Delta-Tomanol].
Topics: Adult; Aged; Analgesics; Arthritis, Rheumatoid; Female; Humans; Male; Middle Aged; Phenylbutazone; P | 1968 |
[Value in rheumatology of a combination of a muscle relaxant, an analgesic and a corticoid].
Topics: Adult; Aged; Analgesics; Arthritis, Rheumatoid; Catechols; Drug Synergism; Female; Humans; Male; Mid | 1969 |
Preliminary results with azathioprine treatment in rheumatoid arthritis.
Topics: Alkaline Phosphatase; Arthritis, Rheumatoid; Azathioprine; Bone Marrow Diseases; Drug Synergism; Fem | 1969 |
Retention of oral 47calcium in patients with rheumatoid arthritis and osteopenia.
Topics: Adult; Aged; Arthritis, Rheumatoid; Bone Resorption; Calcium; Calcium Isotopes; Female; Humans; Indo | 1969 |
[Erythematodes provocation by gold therapy in primary chronic polyarthritis].
Topics: Arthritis, Rheumatoid; Female; Gold; Humans; Injections, Intramuscular; Lupus Erythematosus, Systemi | 1969 |
[Nephropathy due to gold therapy, clinical and electron microscopic studies].
Topics: Antigen-Antibody Reactions; Arthritis, Rheumatoid; Basement Membrane; Biopsy; Drug Hypersensitivity; | 1969 |
The influence of some anti-inflammatory drugs on original and regenerating synovial tissue.
Topics: Angiography; Animals; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Dogs; Injections, Intra-Artic | 1969 |
[Clinico-theoretical bases of steroid therapy of collagen diseases].
Topics: Arthritis, Rheumatoid; Collagen Diseases; Humans; Lupus Erythematosus, Systemic; Prednisolone; Pyraz | 1969 |
[Cortisone withdrawal syndrome in progressive chronic polyarthritis and its management].
Topics: 17-Hydroxycorticosteroids; 17-Ketosteroids; Adrenal Glands; Arthritis, Rheumatoid; Cortisone; Humans | 1970 |
Rheumatoid disease. Adrenocortical function and intermittent steroid therapy.
Topics: 17-Hydroxycorticosteroids; Adult; Aged; Arthritis, Rheumatoid; Dexamethasone; Female; Humans; Male; | 1970 |
Measurement of joint inflammation. A radioisotopic method.
Topics: Adult; Aged; Arthritis, Rheumatoid; Female; Humans; Inflammation; Injections, Intra-Articular; Knee; | 1970 |
Prednisolone-21-stearoylglycolate in scleritis.
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Child; Eye Diseases; Female; Humans; Male; Middle Ag | 1970 |
Leg ulcer with rheumatoid disease treated by systemic prednisolone.
Topics: Arthritis, Rheumatoid; Female; Humans; Leg Ulcer; Middle Aged; Prednisolone | 1970 |
[Treatment of chronic collagen diseases using cytostatics].
Topics: Antineoplastic Agents; Arthritis, Rheumatoid; Chronic Disease; Collagen Diseases; Humans; Immunosupp | 1970 |
[Cytochemical changes in peripheral blood neutrophils in collagen diseases and nephropathies].
Topics: Acid Phosphatase; Alkaline Phosphatase; Arthritis, Rheumatoid; Collagen Diseases; Dermatomyositis; H | 1970 |
[Variable inhibition of erythrocyte sedimentation in vitro by prednisolone in various diseases].
Topics: Arthritis, Rheumatoid; Blood Sedimentation; Hematocrit; Humans; Infections; Inflammation; Neoplasms; | 1970 |
Coincidence of autoimmune diseases and polycythemia vera.
Topics: Aged; Arthritis, Rheumatoid; Autoimmune Diseases; Bone Marrow Examination; Female; Hand; Humans; Lup | 1970 |
Some aspects in the quantitation of inflammation in joints of patients suffering from rheumatoid arthritis.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents; Arthritis, Reactive; Arthritis, Rheumatoid; Aspir | 1970 |
Myasthenia gravis, rheumatoid arthritis, vitiligo, and autoimmune haemolytic anaemia.
Topics: Anemia, Hemolytic, Autoimmune; Arthritis, Rheumatoid; Heart Failure; Hemoglobinometry; Humans; Male; | 1971 |
Mode of action of antirheumatic drugs.
Topics: Adult; Aged; Arthritis, Rheumatoid; Aspirin; Bilirubin; Binding Sites; Blood Proteins; Chloroquine; | 1971 |
Radioisotope study of small joint inflammation in rheumatoid arthritis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Female; Finger Joint; Humans; Inflammation; Joints; Male; Middle | 1971 |
[A rapid and objective system of estimation of the anti-inflammatory activity of drugs in humans].
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspirin; Biometry; Blood Sedimentation; Humans; Hyd | 1971 |
[Characteristics of amino acid metabolism in different forms of infectious nonspecific polyarthritis].
Topics: Amino Acids; Arthritis, Rheumatoid; Aspirin; Humans; Phenylbutazone; Prednisolone; Synovial Fluid | 1971 |
[Studies on the steroid-saving effect of oxyphenbutazone].
Topics: 17-Hydroxycorticosteroids; 17-Ketosteroids; Arthritis, Rheumatoid; Cortisone; Humans; Hydrocortisone | 1971 |
[Tuberculous exacerbation evoked by prednisolone therapy].
Topics: Adult; Aged; Arthritis, Rheumatoid; Humans; Male; Middle Aged; Prednisolone; Tuberculosis | 1967 |
[Lens changes in rheumatic children with long term corticosteroid therapy].
Topics: Adolescent; Arthritis, Rheumatoid; Child; Child, Preschool; Dexamethasone; Diagnosis, Differential; | 1967 |
[Peculiar allergic reaction in prednisolone treatment].
Topics: Adult; Arthritis, Rheumatoid; Drug Hypersensitivity; Female; Humans; Prednisolone | 1967 |
[Diabetic tuberculosis following prednisolone].
Topics: Aged; Arthritis, Rheumatoid; Asthma; Diabetes Complications; Diabetes Mellitus; Female; Glucose Tole | 1967 |
A case of multiple autoimmune disease, lymphoid proliferation and hypogammaglobulinaemia.
Topics: Agammaglobulinemia; Aged; Anemia, Hemolytic, Autoimmune; Antibody Formation; Arthritis, Rheumatoid; | 1968 |
[Necrotizing arteritis in steroid treated rheumatoid polyarthritis with secondary amyloidosis].
Topics: Amyloidosis; Arteritis; Arthritis, Rheumatoid; Cortisone; Glucocorticoids; Humans; Male; Middle Aged | 1968 |
[Serum alkaline phosphatase in rheumatic diseases and its influencing by corticosteroids].
Topics: Adult; Aged; Alkaline Phosphatase; Arthritis, Rheumatoid; Female; Humans; Injections, Intramuscular; | 1968 |
[Pyrogenal treatment of patients with infectious nonspecific polyarthritis].
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Chloroquine; Female; Humans; Male; Middle Aged; Pred | 1968 |
[Judgement of the therapeutic effects of non-steroid anti-inflammatory drugs in chronic rheumatoid arthritis].
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspirin; Chronic Disease; Gold; Humans; Prednisolon | 1968 |
Management of rheumatoid arthritis.
Topics: Adrenal Cortex Hormones; Amitriptyline; Anxiety; Arthritis, Rheumatoid; Aspirin; Attitude of Health | 1969 |
Intra-articular injection of corticosteroid for degenerative arthritis.
Topics: Arthritis, Rheumatoid; Betamethasone; Humans; Injections, Intra-Articular; Osteoarthritis; Prednisol | 1969 |
Posterior subcapsular cataracts and glaucoma associated with long-term oral corticosteroid therapy. In patients with rheumatoid arthritis and related conditions.
Topics: Adrenal Cortex Hormones; Adult; Aged; Arthritis, Rheumatoid; Calcium; Cataract; Female; Glaucoma; Hu | 1969 |
[Experience with a combination of phenylbutazone, isopyrin and prednisolone in the treatment of rheumatoid arthritis].
Topics: Adult; Arthritis, Rheumatoid; Drug Synergism; Female; Humans; Isoniazid; Male; Middle Aged; Phenylbu | 1969 |
Corticosteroid myopathy.
Topics: Adolescent; Adrenocortical Hyperfunction; Adult; Aged; Arthritis, Rheumatoid; Electromyography; Fema | 1965 |
Controlled trial of methenolone acetate in prednisolone-treated rheumatoid arthritis patients.
Topics: Adult; Aged; Arthritis, Rheumatoid; Blood Pressure; Blood Sedimentation; Female; Hemoglobins; Humans | 1965 |
Reversible myopathies--their rate of recovery and the effect of anabolic agents.
Topics: Arthritis, Rheumatoid; Cushing Syndrome; Electromyography; Female; Humans; Hyperthyroidism; Male; Me | 1965 |
[Migration of leucocytes as an index of the efficiency of mud therapy of arthritis].
Topics: Arthritis, Rheumatoid; Aspirin; Leukocytes; Mud Therapy; Prednisolone | 1965 |
[Effect of hormone therapy on the adrenal and liver function in patients with rheumatism].
Topics: Arthritis, Rheumatoid; Humans; Liver Function Tests; Pituitary-Adrenal Function Tests; Prednisolone; | 1965 |
Diagnosis of sigmoidovaginal fistula by vaginogram. Report of 2 cases.
Topics: Arthritis, Rheumatoid; Contrast Media; Female; Humans; Middle Aged; Prednisolone; Radiation Injuries | 1966 |
Polymyositis in rheumatoid arthritis.
Topics: Adult; Arthritis, Rheumatoid; Blood Sedimentation; Electromyography; Female; Humans; In Vitro Techni | 1966 |
Steroid arthropathy.
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Female; Humans; Joint Diseases; Lupus Erythematosus, | 1966 |
Corticosteroid metabolism and rheumatoid arthritis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Blood Chemical Analysis; Chromatography, Gas; Chromatography, Pa | 1966 |
Presocyl in the management of rheumatoid arthritis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Aspirin; Chloroquine; Female; Humans; Male; Middle Aged; Prednis | 1966 |
Cholesterol pleural effusion in rheumatoid lung disease.
Topics: Adult; Arthritis, Rheumatoid; Cholesterol; Granuloma; Humans; Male; Middle Aged; Pleural Effusion; P | 1966 |
[Reduced dosage of indomethacin used with prednisolone].
Topics: Adult; Aged; Arthritis, Rheumatoid; Female; Humans; Indomethacin; Male; Middle Aged; Prednisolone | 1966 |
[Chief complaints: fever, petechiae and anemia].
Topics: Anemia, Aplastic; Arthritis, Rheumatoid; Diabetes Mellitus; Female; Humans; Middle Aged; Prednisolon | 1966 |
[Radiological demonstration of joint and soft tissue infiltration with the "Hypospray jet injector"].
Topics: Arthritis, Rheumatoid; Arthrography; Contrast Media; Humans; Injections, Intra-Articular; Prednisolo | 1966 |
[Drug therapy of chronic polyarthritis].
Topics: Analgesics; Arthritis, Rheumatoid; Aspirin; Chloroquine; Disability Evaluation; Glucocorticoids; Gol | 1966 |
[Preliminary results obtained with the local use of an association of prednisolone and dexamethasone].
Topics: Arthritis, Rheumatoid; Dexamethasone; Gout; Humans; Osteoarthritis; Periarthritis; Prednisolone; Spo | 1966 |